var title_f21_5_21584="TPO and cord blood progenitors";
var content_f21_5_21584=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F57003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F57003&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Thrombopoietin and flt-3 ligand expand cord blood progenitors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 352px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cord blood progenitor cells were cultured ex vivo for up to 25 weeks in the presence of flt-3 ligand (FL), thrombopoietin (TPO), or both. Left panel: The total number of nucleated cells increased only with the combination of hematopoietic growth factors. Middle panel: Both CD34+38- and CD34+38+ cells were markedly expanded by the cytokine combination but the CD34+ cells did not survive in the presence of FL or TPO alone. Right panel: Hematopoietic progenitor cells - granulocyte-macrophage (CFU-GM), megakaryocyte (CFU-Meg), multilineage (CFU- GEMM), and erythroid (BFU-E) - increased exponentially during the period of culture with FL plus TPO.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Piacibello, W, Sanavio, F, Garetto, L, et al, Blood 1997; 89:2644.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_5_21584=[""].join("\n");
var outline_f21_5_21584=null;
var title_f21_5_21585="Mesenteric venous thrombosis";
var content_f21_5_21585=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F70633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F70633&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mesenteric venous thrombosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 301px; height: 404px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Superior mesenteric vein (SMV) thrombosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_5_21585=[""].join("\n");
var outline_f21_5_21585=null;
var title_f21_5_21586="Gram stain abscess 2";
var content_f21_5_21586=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram stain abscess 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 302px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEuAXoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDrmVZQduQvUHPb1qfTz5b4GRg4zinSBY3KRgjd6fw/hU9vbEQZAYnnCk8j1x/hXwjehs2rEj3DOGyAuRwc9frVaWBJUIIwW4bnjPr+NWLBXywkOQRwuM55704x7ZHZgWGMkZ9+v4etL0M/hZiu7xqqWkeXZyDnuB3/APrVPawllaS4R1OThiOR3zmrsMcYug8IWRmYAndgBcHkD1zxV4h9pE0bDJxgjp+FVzWCUk9EJp0aiFsF95X5gc/hk+9W3RHQhk3jbhgP4u/P07fWqUO0zorBhsJGN3APTp/nFXo12kmJwQwHzAcN249aiWpns7lJdH01GMgs4iDzyvT0H+etcz4/mey0/wAiyYRb1ycDHOcY+ldrHJl8khs/LuxwcdMCvLfikt59oJyyREHHPbPb8aKcOaornoYGUqlVKTPN72O+tfMmuQW8xyVy27Cnpz+dOsCQo37QPQgc/wCferEFnf3VrI+4PAnJyau6RYR3g2yuI2PCkkY//V1r051Eou/4H1UdIlrTF+0oVRVUE795559K6SPR57WwW/huFDfdx1IP+NYKgaTffZopUkycg7h/Sppb2R5Y1Mz7QcsB068GuSSlJ3i9Dnqxb2O68H3+rEeVPO8qE5IZs8e5rr5l8wnzQegypGccH+ledeHb9vtsXlcbcblAzx659K9J84OquBuc846jNctW6lc8DGQ5ZmbFFJaiR5XUqWAjRcbY0Ax16ZJ5x7Crmn3TEhmG0ZwPYd2rJWWW81IRyFY7c5yNp+Wquva6mmO0NuFcJ94+3TFRrey3M1QdT3UdiCdpeMfMwGHB+8M8cdOPp+dPClQA5Kjg7M4wPX17V5SfifJBJtCptyCMgnbV5viQbpB5ECucbd5z+X61boVUtUV/Z1VPY7PU1LhDGFJXJ54x0/zxTYZw0ZVlww6n16/5/GuD8ZeLPFFtZabJ4M02O9km4nVow+1uOuTwPeuzIna2SS9eOK4aMPLGn3UbGcA+mc0nCSim7a366/NGM6bpqz3L4hjTDKojyOCODk/561G91JhWC7iOckfePPWmW2AGycqvIJbOKtlSzAeWCAOMcY9/61Oxz3V7MLadbkLvjEncBqla1IuFuVmuT+7Mf2bcPKyCMPtIyG46g9CeOlOtoET5jtUj73Hf0+nSo/OmW4X+IscfN2PP/wBelvsHWyJMMoY/IxAzyMHFShfMjyVAYYY4PJHqfbmraIWgc8Bu/vVWdHMbeUojbIII/wDr/wCeKkE7iXKgFTsHA7df/rVAy+Yx+QAs2AOoHHp3qS3jPkF2lLEnlscA/X0piyFCNyjkcZ4Uj1+tBS7BayiMExoQvTnqB/n0qaANGz+WAMZzHjIB/p16D68c0+KNJsgMqnPGOCaSMC3LhQwc5HXqTwfxyKSYPUf9sLD94ChA3cd/ao45hOiSuGBweH6g4546Z6D27YzUsSLIgMiqx6Yz0NV0sf3oZ5V2MM7VOBz/AD6UCViRSpbbvOSuT3zzjntnNOM4QYB3HHyEjoKWYrA5x8seSNhU4Pr+NVzNB5YZHyxPIIxge3t7UrJq6Ba9CdZHUMHAZScZ9f8A61NkmAAA+XPzZB61AZDIQFJKD1Hb1xTmix1y+D1HUelKw1bqXRcARhjtXHfPPPesieaMSBsfPzkjGM/1/wD11KElciN1KgAqO3vjNJJZwRTG4x85ADep9Pypp2ZXLYGWO5XgLk8fL+VU2tHjlaRiV9iSQfb2NaSQlUVVwrpyAe4/+tUyqxZ9ycnHWk9CoysQ5LRI7rjDBeBzz2qPayqdhVh2GMAe3tVxmZAACzAjI46+ufTtUCFtwdmznJZT2qbiWownAA+Xceo7Z/xqKEyt5ocuQANu7AwfQd+e/wCGKtG23Lv3A565PSjyCuSQTjBGef8AP/1qLgrdCJyQ5DAEY6t0Pr/9eotw/ufpUsrKyqo2lc4X2phlCnATpx0qlIXKupzRlWcmVVKptyoYZz71esb23a3ZZeMFuB3pBDGkZ3YAjXgZwDis64VTMQi7ScAHdwT6Gur4iuVS0Np1ygKtgMc5HU1WulZGkOQo45GMflUNrcSxRlmJwP7w6e2KRnWYv5g2nPIB/LFGxm4tFjSLiI7sMCwJQlO+OuR6jirV7fGJwEiZ8nr6/wCf6VmRQjcSFABOdy9cVoWxO0kfMe49v896NCJJXuZ76uIyPNtMgdQRwPwNPs9ctJiUkbym7qF5/wDrVqTxiSBdqA5II54we9ZUulQFDuiJPLbYhljjrj1PtTTXVFrka1NK3kilkfyZkcEk/MOR2J9qzvE2lDU7NlZASFwrE8mok0RSsU9hdFhJho2U8MD0PPNdDax5tWWbDlV5Y8f/AF81MrLVMcZezkpRZ4JrWjyabGxMjfMT8gPb3rLOBbqsRkA43ZXqCcZr0XxzfWyXp/chjk5OMbTWdp4hu7hNqReX/EuzGOv+cV1xqyUFKSPpKWK9xSkcVbxItwpLM7ZwRXR29s0qI+Fxz+NbOsaFBp6GeNPnHAOOce4rmbW8ka8VSep/Ae9Nz9srxNIV1UjeJ1PhyBEvYtzlVDY6Yz7V6xaRQiNDuVI8fxcdPWuK02ysY7EXNxOzgDOVHQ9qyNR12S8m+zWbbIhxgHnH+c1xSvUeh5deDxEtOhb8e+LrS1jFtYDzZs8yMMc/hXlV5qlxdSOHJDFt3ByBmtrxHpc+fPHrzgms/TNME7uzNnaPkXP3uK7aKpU4XR62GowpQRlCGOXK+WvmHq+P5Vp2kTI0e1sMe3aofLKyldy9Dgjpge1XRF5MYkYkoB3zyP8AJFaylc6pTTR6B4IspbqbfJI6oB91e5rs7yKOKMv95VbHPGB61yfgDVIGBSX5CfunsK7F2jkbaCGXqM9eD/8Arry6jfO7ny+Ob9rqZttv389vQ9PatK4vWtY/3h4Jxnv9aqpC6yqEwWJwMdDz/n61qi2WdVLxgKMseMjHt7/yok9b2OHRblnTn8+1WTGCfuqTnmp0i5ZyqsBgqSOV9cf571AHFsioAdoODgYLZ7GpLmVxCmVJD5GOuPX9azJau9CWGVXYjHzHJwO/tT54i8bDzPZwD644PpWdZQvkybjtHXnlasLLuBXHG4Z4z29aY2rbDpSiowBwMAE4xz61WBXcI1C7eMcfz/Gmuu4lnLAAgDZn9adAVDktjPT5uAOKARbhQLNsRgxJJChe2Oppb1rWE+a4+YdccHBFLHMkcRYEYAx05B7fWqV1L58hXqMDOQME9/zwaXqCTkyrPObjLW52qMYIP8NWY53RSCQfdRjP09qqRxhIxjBIb8cnsfardlDvTlyQOeucDvmhrWxrJpIzrm4kmaZ9u0RsU4Pf/J49qpFZGXcsnYDPOM+o/wA+tdNLaQx5MY27zl/l6t9O9RMkDRYA3c7c4pv3WKNVNaFCwWRU4GBjG7PTjt61rW6lcZJIU8dsc9c/pTIrUbgFJB9D2o2Mko3sSBnaCeenQGpae5LkpPQtODuCoQi46n9aqbczKjYAzgkHpnp75PWklumcqqFFAGASCMfWprWPhpWOWZioA5HbtSSFstSbytkJAHHZc/KMf5+lQlsjI4GApHrVuRSzFQRgHt6/4VDJ93aMHHGScY96TC5AIz5ZYgjjcec4qCKUzxKSjReYoJWRfnUEZwe27tVjzQOApO8EDmmD59kjEYK+tIpPuLGTEFDYYjs2PT9DSby7OjggYBJI6nGeCPTj86RFDNtbOBycnqPUHvRLiFWabIUYJBGcHPBwP50D6lfa28tgYK7vmHJBqPIHBYj2z0p8mXbqSyg52nofekG4gEFsH0TiqWgbmTKiouPvZAPTpUE1owC+W3zEdMcY71ccM0eW+bA6g8VVkaeeCSOAgEAfWuptmcGSWlrm3IlY7sgg9arvG0ch3MBg8c4APY4/L9aZp9zKYPJmRg46jtWqUiIG9ckjjvzS1T1Kk2mUWcbxGR9CKkEjgjy8kHpjp+H61d8qJYuVw2c84ogJVWLqNwGMH/Ci5lzCQSkKVkBT0GTT7eE+YruDn+LHH61DqJLRiRGORzlf4vwqGLVI2AiVz5rdAR0/yKBqLauieW8hjupbfjzYgpcAYwGzjk8dj0/rVpZ1cbflLYIJftWRetvkAQmRh94k5H0FVYhdRsWbYFLdPYdqVk1oaqlpdks3he21LU5Li8I+zgcDt/8AWrm/G+kWOjT2w01ZEdvmxnr/AIV6LYMvlp5zfNWTrWnxO8txNH5pX7uRx3pKbi730OihiJKSUnoeZ3+py3g8qW5RVQYw3+FUtJ0f7fco0RAbOMk1X1jTm1S8MVlFidScoCBVvw1M2l6n5d4rx7OMseK62uWHuPXse7GKjB8p12pWtzp1iPNj3qDnIPFcfi4ur0GCMQop5zxkmu31vV454P3RMgUZbA4x9O9cbqGvbojFaxE9sgZwfesKPO1otTPD8z3Nm6t0nsB5xB7fKPeuNmikSYpGzgL27df8mtNPtEQQ3MzOHblcg4z+laNusUdswkWLc3TPB4604v2fmdK9w5kDAB25buP6VavVluLMRwx88N8o61fFqrsMAbc5BJ5NXrXSbqaeJ7cg7jgke/oK09or3CpVSV2bnw00CUOJbiHAQfKD0avRpba3aMAKFYknHqPw5/8A11V02IW1lBCgymBkEjJq/wCZHnARiwHAB5PWuSUnOTkz5jEVnUqXFigijUnkheSRgY980kZZQRt2nG7A6g/4YqCS5TawVcuexHb1PpzS285JA5z3PX8Kmxz6skwI4zuQdec9B/jTzIrEps+8ecjrUrIrcjO1TkDGfWnqqxtuBB6fMO5+npzSC4ghzGBtwAODjJPHeoZI2jkCoBtPTjGB6Z/z1qTLHJCfIT36n8e9MkY7v4UUk53fj0oBXKM7NIwVDnB25z19qiV/LJDEnaTnJ6e2O/8A9an3MxZ8KpUZO5mpfJBXOQ3oT29/0o1LtbUmQpMhZTICAAM8hs+lRr5XmmKWQF88BTgfnRJeG3GEieVuflXv+ferUdjaTQ7njw57Zxj0osCklqyNI40SXbtdsYZlNZc8kvm4ZguRwQME+1WptOubaZvs+DBxjiqM9o+/lhyM/ez/AJ//AF0luaab3uXYJi/GCoOFBHPPvmtGPb5ke4tlhkYH3j3rHs4iuAcDd2J5x7e9bNqqKx3sADyo9fr2p2uzKWhPDnBcnB7gH+VQXMZaIj5gCDz1Axx/OrBYHbg4Zh3/AKDv+FKIwBuKkHO4E9BSJvZ3Maa3dImZQS6/e29/erWnXHmgiZdoHBI/lVwxmPJXOOO2etIYo1iGeGJ7H9aDTmTVmPjm8wHJ3hR82Bzn+o9qbdghFBBAPpx07UQIECpGOCxK5P8AnNE+FAG5d4Oc447UmmRoVJpRn5ipUjkDofSoDKOhPyAA5Pb/AOv0pt7I6kBc8Ek5qjvAdlLEjJzj07UrGsY3NeLaU3bjx17/AKetOZQATlsgg8ng4/nxWTZzAuBGecngdBxWmysy8qSc4IB6dKlqxUo2I5OYyseFYg7fm/rVQuuep/Imp2PlqhbaCQSPSniZgAMp/wB8VS0JafQyJD5iNE3zK2ST+Pf3pMeSC0R55OM8ntSwFFf52C56c4J/+vSTOrSZQfdznmuow1HykLltoJJBAI6nHf1qYNvQOc7gCODwP8Kp7h5RDH90MbSPXP8A9ekil3E5wSQeTx+YpNaCuXo4QQu5txU8BWxUkcO07YwQCD1x+VQ28uDwQGPHHbjqatyyrk47cFuuaRN+hWlyQVwDxyOg+lcnqkzwXZcBNhOD64z/ACzXX7UbgptJ46fqfrWLrmlrLC4AHmg4B/wpxsnqdNCok7Mo2N4ksqDzPXaAeh7kV0EDoQqscqcYBHU1gaFoTpdB5UYY4HHXpWJ4y+KnhrwtdXNnOk11qNuv+ojACk5+6T+tXGnKtPkpJyfkbVEm7o9IiVUCjazKeenSp5UOzgMFyBgnv/8Ar7V8/wB5+0jEqxnT/DSgj73nz5/kK7z4RfFOLx7PdwS6abO/hTcdjbkdT/I1rVy/E0oOpOFkvNf5nO0k9GUrW80/SPFt8t/mF2LbZD0FQavdaXPC8sLCdj9zbyTXd+JfCWma7Ms9/buXC4Dq20fSm6P4J0WxUfZbctKykAuegIrBzp/HrzfgepTxkEk2zzexu0is23A7z1XAGP8ACs62Sd2aCCFe55HPvXSzeHbmHWJ7ZoG+YjDYOCfcgVR1m1udFvAkWMgFiSDjPbmteZXst2elSqwb917mf5HllI5NxccY6gCrU6xRqryBtw5x6f8A1qraZODqKPenIZgW7/hXoN/oml3lrtjBBkA+buB/nFTN8rSkTiMTGjK0jktI0yfU8JFsCcDIHFekaToVvp8C4z5nUgnnOOtY2lxQaPavEjFnGSXXknHt3rat5Xdwck5OAfUf5FZTvL0PFxOMlVlZPQfdGSSdfIbCg5+YYx/9atOJAEUvJ8/c9unU5/SqipnglRjON39ajmnlS52RxpgKMKRkvnuKjRnI7tFuS33O7EliOSB3GOpo+0+RIpcbSMAk9hTVUpMV5Kg5xzkk/wBM0t5ErMBIwyoxypyfX/PtSEuzLiSiRdyH5c5Jz/nNPiZWUqrtlRkEDqRWbFC1tayvasGZc7QTjmsfw3rt/Lqj2t7DmTnnGO/f9KErp26Fqk5JtdDr0YYKpwcYJK8H1qMRBkAjKAZ6sO9QvMVbLZBHJz0Oeo9qy9Vmum2pajh+Hb1FTZMiMHexdeAOrKZAR1HoKnVFC7F5U9s4z6YPaqtiuLcLu3serMf88VJGj7sIMKfbJ57/AMqGNkd0HhlViuVIAJ9q0LZxjcMc4yo69aqyEhwq55OST3FLbbYnYtjaxHyk8+nH500rieqNGSQheAWzwcD9faq08IUKwVQp6+oP+c/THvV5ZVEJdR06DqTWRqtyYiHyMZxgdeaGlzWuRFu2hA6bX2gDaTjB9T6Gp4CgkBGTyOAOB07Vkx6lG745A9CMZ+v09q0kmXLOGTcAG/H/AD/OlJWehor9S/8AP82VyO4YflVl496R4Y9MYzyOBWdDPvnVChP8Lc8D1rQnAG3J7HA9KlMJKzDCCMkjJ75HX6VWmbevyhcE9jxn0qxuEmGdd2D1xjPfFVZDtfgDYc4Gc4pkruOMkaw/MxypyvPI46/0rNvLwCQI3LFhjvj/AD60X8pVWz82OScc/WqHktPJ5mSM9mP8/Ximl3LSVrj7q7KIZT8m7puGfzFZ9lNvdmXjPQkevT6ipb5ESFsDaqngbufw/wAKbZBDGcKAp7Acke1D2N6fws00D7Vdc+3bn1HoParMT4GGDYIPyr1pFH7pFIPyjqefcUoZUzwuc8DOaghu4bkeTDZKH1GcU4wDPEgA7fMaroAs4kXOS3c55/z2qQpuO7K888kUr2E4+Zw+tWV21/Hd20zEJ/DngZrUsFkaPL4GAMgenbNTyyKYBuAB75OMn1qWMKsZbOB0HGM/T1rscnaxEp3jZiE7gBGdxOc8ZyaqXiqinbtDDsOufarcUPmOSDgBcgoOOp/Wob2MfdwMgE44yAaWzIRnQ3exskHA75Az71oQXYMKjJ6YLdM1jX0TPnZjKj0x361PaYnDKclR0OPp/nFaWVhNdTqLeZXHBxuA6cmrEUTST/KTg/1/lXO2KTicINoweue1c18ZPHUXhDwnc29hewHWbkeQkay5kiB6sRUwpSqzVKnuy409b9Dg/wBoH4i6lBrv/CNaFJLayW7ATywsN0jEZ25HuaX4dfBiTV/seveLZ3aWU+bJZyAlpPQsfx5rn/2f/Dtxr/iqfXNXh+128ILeZP8ANukJ+9z1xX1RblfLUhWUBeAQOmf0r1cXX+pRWFw+jS1fVsqUupy3/CtvChQQ/wDCN2DRIeFMfPPX3/Gtjw94V0Xw+jR6JptvYbjuYoMliP6U3xHfaoigabHtJ+UuGBrmpLrXmdDiV+Byv1ryX7SStKbt5tmkISqq90eiY4JJ+UgHg9KbCFQbo5OuTj0/z0rg2i1x8+ZJOhz246f5xTI5dciYqjSso6Ajp/nmo5PMf1X+8js9QFvKY1vbgRFpBEm7ux6AepNc7420J7kQCAeYoG1uuf8A69dFp07Xlmks/lBxxzg4PqO+adOyum98O3qDyTSWjTRnCrKlLToeZN4XjhuPtEu3yFG7y884q2l15ku1CyhMbAOMACtDVmfDKFHI6g4FYlrAj3TFHZ5McgEcGt43kryZpOtKq/eNnTg/2k5bv94nt/ntXQ2ylHBIO485B6f59KytMsGJDsjZ6t8uefp3NdTa2u9N74VOpOD09qznJGDVtSVIFMSgDBxjb2NEY2IfmOSDy2Cfy9M1JJNEqFX4VR34xVcSknBYDJI3dhn0rK+hNmxTKPkL7fMHIJGTUMpRiAGDhjg453H1p8uI12uSf4uOx7D8ahj2SHcQqsSCpAwAfYUFJdS3Apj2qANoOOf5VOyojeYqqZOm8ryfcU2IADIDHnkEjOPWljDl8ngL6fyqLK4m2MMX7tWlBZhzjHf6fpTHZGwPKCnbg4OB+A/SrUbgh9x+QZyQO1VrghdpVVZV5BLHHr1piW41I9pAJ3Z5H/1x3pY8xyFZGww4+o9B7mo4nd4xlSr+ijp+BpHY78qfrg98e9MbTLJJADPlh0yO49veqd1b3RuFZZBtxwRwR61PEzSgbVZiueV6/gOlWLeNkwC+BgY9MDtSGnyixwN5KiM7e4U1l6oJFU5AYEY64wcf/qrcSQmby2ddhG4Hv9P/AK1UdRGXIOJVIz05z3+nFK1gTuziWMltKuEOduSVGB+fr7VsaW3mnMnVuhxy31/LrShN1wAEKx8dT09OK1bZFj3OF2gLgEgcfWrlJMew+BZYTlYyFGT8vBFW3uBKmTkHGDxx0pDIWtAsnzsQMkKQGPqPTNVUKxFjnLA8465AxWWiC/NqThyEK7ljyeC2CD6miWUfMXJK44fPT0wO9VpFkfAQk4OT8wqrM7bDFuyxyQfcfX09KcUxtJkqNGSyMvA4HqDmq8kO243KreV7HoexzTdkj3fUY7/T1rTcCJyDHvYYHGR+lU3YXwleW1jltxC67tvO/rnJqG3sDDchgNqj7vGfx9/pV9kZYlUZzgghuoFVriXam3IwOTyO/YVLdwjJq6QtxPhgGb5RxgDp71QClpCyMq7zj9B1/CmtOHLF+Wxkj0/yKiSfJ/dklRwcHj8aHG2xSZoxfKpyoUH0bj8u1RPcQB2y79f7wrN1PXItOtHZmXcw4APJrz2XW76SR3RnCsSR8h6H8KqNKU9Ttw2FdVN7Hf3kLFoFQOFbIc5ACADj3OTxUxVVRYw+cDgdMmkZ/MXoS2cDjk1EdwII+97jOPce3FdD7Hm6vcfDIY3VV7HOSOB9Kmu4fOK7MNgZ4/n7UiqZI94yoPPPI/8A1VLFKigqMcYyfb09Klu4ttjJntXwPMAXgbuoxVm2slUAMzCTqcHFX3G7LFlYeuOlRyNHa6fc3MmTFBE0hI7gAnjP86HNopJz0RFd3tto+lXl9NcQQCGJ2USOFDkDIA9z6V8g+HrPUPiD8Qke5V5jcXHm3BOSqR56H0GOK0fF/ifWvil4kt7LT7dljHyxW8Z492b/ABr6T+HXhC38LaBZ23kQfbVjAuJlA3SH0P0Jr2of8JVJuetSfTsVNJqyN/w/oVlpGnR2+l2kNtCvy+XGuFP1+tacamKYFm+XpwOVH/6+KY02w4QFgCBgc/mKsBxMhyCFAz92vFUnfmeplK70G3MJlCmHa2AR6D8RVSNJ0BYxgN0wecn1q5CyRxvhxhurE5x9PX6VRmvlELkPuIPTGMU6k3IdNNaFqG6DAh8bgcEkdPpViTyvKCkBsjqo7etc39qJG7OR6dsVdtmnMiuNxXHXt14rPlRo1Y0rSwhtCzRu2CS3L5/yKoavfLHI6RZcE+vXirgIc+Wx4H8PX/P1qnFZQtIeDtXPzMCD9aE+rJTu7yMC8hlmTIAYMCT061NpGmJHJvaM5PJJ6ce3+etbcltEsTBCuRyR3xU8MaxKC3yknB568ZHP6U+d2sU2LZRbM43sygkof4c9s1ZmnkcMkLFdx6j+HHaqyCVwQpMYxnHTHPWpgJYTypO45HbJ/wAmp8wZBPDKckZZhxg/1qWNZFKqY92Vxjufp/ntT0uXY/OAp65/rUguElYq/DAjb0y3+c0MTb2GZBGJANpPA7cUpjWQK0abMgccE8+v5U5188gKCBnqe3rU0aomPu46gnHJ/wA96Sfclu2244HyVCuBuc9+vtT5HZ48tu9euMjvTGiWSVXL5I5BPU//AF6jZ32hEwSBlRnJGeD+FJ2voStdyVSsZ+ZygHDZOSR6ZPNR3MsW0bMADjkZFZOqTzRK4yeDzt4OD61Yj2rbRxh/3gHPbB/z/OjdGjhb3iwl5FHG0ufmxwPfv+NV7bULe5YpF8objce3FBVPKbhT67vbvVLKQsDGBEQwJYDOeen40X0sNRW/U2ZI3dQsb7eO3b6UyBpYwTIeMfXAz1/+tUMchlby1ABzjNTE+UmHOBkkY69anWwttBwuFPzttLZ456+n/wCqmXDhnXqEPG30quiqzMw4zjHGc49RTHdo4AS5iU5Ayu/J9Dz9OaLXDZliUxLCUGFJPzYHJPp9eKoNchA2WGOuc9Bio76dlQLncV6ED26+1ZktwXwFVdvcDnj1/wA+lUohE2Yrhg4dJOR0wcZ+tJdX7swXk468YHtWPFI6kq21gD945wKsF9xAJDDoSf6U3BXHE245PKKtJw7f3udw9f0qtMuMunzMD9wnrUCu7ROBhD0DD9KBK0f71gA+APnPNStA6lmCXaWYhwR8uck/5+lSm8jaZRvB3fdOev4H/PFUFu4wdjnBPU9BUrrDMzBQN4x7HPpQx2XU0WlVlJ3s2SAT13enNc/4hvWjt28vIlHGAMjFWbu4lS3AiO13IAOwkfTIGAfrVNrFrofv3+cn6/59KFpuXTUYvmZHpkcklkjynNxnKk8Y/wAPrVyOLEnzKSDycnAqaOIKqIoxtAGAMn6Y9KsrHwN7fNnqAMHH1ociZPUyr/R7e/RVkyFWkGiaegCiPIXjjd/jWyGWNMbhucf6sfxf/qqGSQB2Hlk8n+CovLZG0KskrXM1okdJGcK0QyrIw6jHIquH3HCAA44+br9aJiyIFByhJ6jJ/wA/WqrMgxtAXjOP7xrsORGlbPtUEEnd3PGaeEKyKw+8M56nHuarozFFwcMR1H8v0q6m6RWU5V1GeCcioYEiL+7SMsxAPGeh968Y/ab1rU9K03SrOwnmt7e73+a6MV8wAY2n869nSJk53nB6+xrwf45+Jb628babos0FtcWURSQecN2ckZz6V2ZbHnxUWle12aQWjdze/Zr0e3tPCz6lNZKmoXErATOuSYxxgfjXschJhQofmY8YPNVNKtIY7GOK3tkgjRARHGuFUYHQenerrW7HBJ2qOTnqfwrnxFb6xVdV9TOejt2ISpjUSfKwxz3J+opxkCKC68nkAdP89KsYyc7RlODhcc+lJPFlPmJyASuO9Z6E8xDa5lB3YHHBY5x7Gs2+tWZ9sCgb2PGcD6f59K2o3KMUZDz93A4x7n0qhrsybEVFwwIyB1A9aV9TWDd7Ihi04TQq4kO0d+Pz/pTb+VrSwfaecHYAT+v41ZtHaa3aUoUJ4UdAfpWfcmR3AZc9sY4P/wBektXqU7p6kPh2aaSHdK+1CcAjv7c1sxZVyY/u4J9qpIoWNVXaJD0HGfwrTt0bgtjaM5YnpjnNOTTdyJO7uiedFKMUaTBIxjvxjApqIdgUOWwMkE8AAYz/ACq0yFUJbOzgHA6fj/WqrSMjD5Rs3Yz68GouRG/Qy5rua1vFhZd0fTPXI/8A11qeaCN7AZxkr0FKIkduVAJ6s3J6dQe1V7mKYsvzBlUHc+eT6e9G5rdMmjONzcbgcAdQMVYESO+5ZRkgnBHT149OBTFjCqu9sknGBx9B/WpIY137nVuQc4Gc+/8ASk2TqSrGOD8pwPve+akaIhwM9TznOR/jVYnbIVJDAtng5/KrMEqPhS24DjgY5/8A1VImmhGOCgYfMOPc0Sh+NoY7jwPX/JqVkjlUOcnnIZT1x609njXgbCw5yKGSZ1xDIXi37Mb9rd+x6e/HWopEWNmKgllPQDH0rQliaQxbG2xqwYqnU+n4d+npTbiEKfMUHBJyP8KWxSd0c9dSSuWCN1OB2ANSWpWJcPjKn/Ip07xK24lgG/hHII9waWNwz/IvLcnPIxTexr5lmB1FwwYYOdoz0P8An0p96hfj7hByCen50NAVUb9vHIGMDHvT5HG1QMEEYz2GP/rdqVybNbFSaFolXylAO3JAPGPWqs7OSAWweo9/rUt5clHQPwpHBAz+XrUDMJVDbgc/3TnP4+hqkDTsQ3YPl/N82Onp1rKi3bgGAGW+QnjHPp6da0LhC0RLZ56EVn7lDlRy4xkE/wCcdKtCii0/y5KHbjIAHJNSwupO4AYPfd1P9KrMcgbt3I45xTJCVJCnoM4J6nHQ0xtXRqrOhYKFHXHoaerk4PDsTgZHbA/SsZJjuO0/OhyQefwxVoT7lIQsTyCAM4qbE8o1ohLMdjkDPXHHHcVbtXUBVWQkAYBz/P1rLVtwOTjjduxzirVihJ8zaQAc4JyffmhmzWhqRRHfuIyOzHqvrirMm2RhuUZGM+/vz9e1V4pA6kZ2tjjt/wDqpZm+QfMQcduB+dRYzu29RsstutwYWZ1kJx04B+vrVpW2kbjyvbsaryRQSyJK6kuuM7TwxHrT1dZnZyQAG644FSykPgVZJCSrYOMgduaqy/axK48zThgnhoZM/jhqsyN5CZJJ5BxjnH09KyH1NmdjlBk5+9Qlc0hFsq3MblySGCqevXHtUDL8x2rwMdQOPWtdoCyt5bdjnI4qq8DKMDYTj8vSutM5EEBdNrHaNo/E1ft1UKyOCCeSMepwMetVVjljjYkLkHAHcircTuhXaCRnAIXnrUtjJl/1hjYgeoHrmvnD4r3ttP8AGezg1PTgYYmiQtn7wyOa+h7hHaVSnD5/zzXmPxf+Gl54raHVtJuUjvrSM+ZG3BZRyMe/FdeXVadGveq7Jpq/Y1g/dstz1m0t3ggUR7dgUYKE4x7VOZFUsJS248Y7Y9R6f4186+C/jzcaXs0vxNp+6KL92syLh1OerA17lp3jLw5fWvmrrmnKuwN+9kCkZ/Hrmsq+Dr4Z2qR07rUmdPmd46mzGyx4ZSxDADAHBqZlAVicDA7nGOtVreSC8jElpPBdIP442BXb26dTUrM0cJBxgYwf7p5rnT0MpRaeojzLEDufAxkgdcemf69azZmF3dEqOQTx6cUbWlZ8DJ7KeMYos0mjnZm3A49Ofy9KLdjaKSRefEVui7Szj5eSen+NZs8nmHqM5YKcYBYcc+3NaV2ymLy9xR24zjnP+RWY67mYZ59R35NJIjcfEcYbgcgFuoB/GtiDBVGZCCcY/wA+lY0LEFBuw3qeMj6VoW7OrLwcjnA7Gm9RWLaxE+YxBXIxk89P6DimxlY/4gQeCOeRjtVV7uSNGLAjA69QfWqy3EkjqQzcsCB/jSGo3Ls0e0q+8EH7rEHn8KlT54jgDdkBiRx3/wAKSKNyAWcAADAGDSGVU/dzMNmcDnkVJXoLbyNGV3EEk5y3b0q1Ncfu2IJDAHgDPsP5GstbiGSeQxygsWwR2rQh+VsuWIyT8wGcHAwB6cUPsDVtWVN+8SOVK45yVxj/ABqNZXSQqVbGc49P/r1qpCuz5Q20NwAO/r9aRLdWYMoAB4BPXntU3HzoLaVJExkMSOpPf0qZkKhCeB/Ee2OnHfPH86iijREwOR1yp7/4VHcCSZUCuQx6Fu/f+tJk21FlulUnZtJUkfNng+lMnld7b9yNzYBORx07f59acbVGjUYBY55B/mPzpwhEWFX5Tz/PqPyoH7q2KcNuZolEyfOMbjjG3/GrEFulu8bZyp5A7Gqk9xHbORkuSSDk8fTNEMkhbLEYJPIOc/4UND1ZPISZNjbtmTkDnmkKgHeFJA4yp/Glj2GTDnKMCT7Cms6RIqnkdDznPtntQNbmZODdTkMhC5xyuM++PSnSQhLX5Acg4LnvV4mNVYqTnp061RmZmY+YxOecKf5n06UX7Dvcxbm5EDkHkY/L8O9ZoufOkcsPlXjB5HtnNW9Xtdyq+Szc8jnn0FYT202xh5jc/d3ZGDW8UjWMYuNy3PqpeTFuNzjIPv8AjSW+qpu2SjEm7CjHXjr/ACpLG0jt0OW3SbsEjrn0FTTRpIVYqnJ5OPy4q7R2Qm47WJZ3bruIz6/5/WriMWj4OOx7/n+tV4412r5h2r0GWA/In/8AXUsbEy7RyQQRg9B3+tS9rGa1LkEIdM/KGPzbgKuNCQqgYB6tk8Hjiqdqkvlt5YGSOFbkZ9+9XYBJLbwyThoiyA7SCCOBkEdQee9ZMbeth9sdhGAy7QQxbjGasbCSqlgAzAYPTp0+tRoNzchsnn69utSYIiyxyW/2cDH0qLksiuIlT5hwy4XA6D0zTYgoWMEhGYHdt5Hpx3oHJKY6AbeDj8KTKozozDbznDYJ460Fal5QjjbNnHQkYyPYVVNnb5P7wD24qCPUITJyjFufw/z2q7FNEIkEgYvtG4qQAT7VNrDvKJQs7hPKJyAdo4PUjpVOdCL9WBJQnnBOPpVp7dWQDad3t0WqSl4mKbiAORx0Arr9DCNtzVCAgoCATg8dqp3MrQsCcED5gR39v0oE7oMOxOOhH9PWraIt0nzdccgEcUtnqHw6sW1aWaLzGIyeCCP1pLYXAP7xwzjO4qPvZ/yKe0vlcrwq5xke/HPpUUc6NyqsuDgnHX6VNri13MHxH4C8MeILvzNT0mJ506yRMVJ+pHWvOfHXwFs5tMFx4RnZLpCWaC4kyHHoCBxXtbEEKy7W4wdvp/n8adEx27d3zLwp4wcHP5A10UcZiKLTpzenTdfcWpd0fPnwN0Txh4Y8VzxXVvNa6ftKTrKDtJ7FfT8K+jWuUKDzATnGewP49hVTfFLGwYYcH+Lv+tUdPkvGvZludqW65VSRgY/CnisTLFT9pJJPyBpNXNCKYRoypG2WByfw7VNaK2QBk7cYx6AdPypiPF5T+Wu0+hYcmsfUpLuHVodrAW7HL8nofeua13YI66GzcHCvtjyOnqfpWdLEylWO4gsOQM447/y/KtVnMuGH3gTgd8D1rLusvuCFlI4O08/UfnRFslBBslIRmBA5yDWqY/s0TbfmznBH+evv/hVG0tFVgzqexIB/IVdMi7SMsVzlmPX8qUncbMv7RuuikkgUMxAP8J+hq9EojA28YycHqaztQgMrRyxgsdwJCngn2q9G7owDA5zkY7H/AD/KguWyaJjcNAMrklemOtVY4YZp8uCCeOSQAf61bdPNRVZkIGFYgcGpvIG5FJwevP8AnjvzSEpJIr/ZYkkEttCTtIyev0+vetW2kVnCscMDljnjpgZqJpPs9sSiFm4wpHX3xVK2aS4jLyRtGTz0znnH55z+dLXcH7y1L6t/CnHU4H86mdnIJYg567RkHPeqsCO8qgnBPJJ6irKShWwpGCAev5f1qWS0Zqah9nvtkwdh29s+prSLrP8APG2Qc4J7kHBA9+MUslnDeEPzgAjpyDmo4YYlRgMqhIHIIzjA/lS0LlytXW44tklSuVC5BDdPbP8AWkYE712jAIIKnP14/L8z6VONp4deuRntmq87mIsT9zOcDkjAp3uZpamRrltHeHBLKQTkjvTWg+zFPLKkrwWx1/Hv/SnTXDlk8x1dsYYhSKX/AFrK2eB8uD7/AP6qeptzNKw/zvO+UhnCjBx1Bz1FXRAskSlkySSdp6k+tRxSKqklSM8/5NTNJv4GQOuMY70rGbl2K9xAiR/Lk5J5A/nWBdTG1Ty0xwMfKcDFbspA+8dxx/F3rnNWga4nwqgkjJGe3X+lOJrTSb1KUrs2CzYU+voP61SvBul5cEJzyen/ANertsH+YyZyRnJXG72qNrNVDBWO1sHB6Y/rWidi9E7GbM7pCWA3KmMYHPPan2aSfZi82O/zAcnr0/KtO3tQM8jBJJPTJ/8A11YFhGUwDhc4xjOP1qnPQm8diqiLc24QKGx03Ln/ACetW7O15bIOWJ55wcdefWprXT44AVDHOOff2q+sCFM9m6jPIFQ32IcrKyI4N28IOgHUdMZq20YLl/lZTxwT68n/AD6URRqH3Fdw6kDGQKdu3JuQDdnvx09qgl+Q8PtYqcYPGVXgj1qq4Zm7Acjap/kfyp5LOHdxjJHKkfMPTJ7f4UbQ+5mGdvOM46/5/WlYLkH/AC7soDEse3Xd9RUTfIrbiCTnIHXp/kVOFDl0RyF27fkGCvrg+tIqYHAkG0nbjHH1NMtMplEjIEanI7kcUwpgkc/98A1cdVjQsABj16VWaVSxOLbk/wAXX8eaNylMk+14cIpJU8Hnrzn+tIyx5HzAoPvY4A9qga3ypVAOe4H9KcSts3zEFSeRjoMdK3aMLdi0GG3aVxtJCjGT9afEedgbPJwP8+9VpX8wgR7uw3Dkg9sUWquGwpDOOeuOc9f0qbBbQsyo0kg6HHysfXmiKFVbacBScY4FRXLyZAXCkDJOMcZ6mowH8oHIZh/FjPFAW0JJEELkPgoB0K96nUx3MKOEDOMMpwDsPrz3qjZhmlkWUvIC2SGbOOBgY9OK0MeVI6KgwwABwRg/57UMT0KsVmHuN8vKN2x1qzcIYmG1jsAII/pUiHYC64zk8+h/pUTSCWT7o4IwpPJ9uf50PUak2PCmZA3KDpkn8ajlQMuZDkDnHv8A0qaSUDjAAHQdfzzUMpMpO1MEnaSw479fagQjXB+VUZgRwW5yKSB3gDMEZ84HBA2gnBJz2xzUKjY2cjONpNTjLREd8fh/ntTY0i3G7zJtUg4OAR3qcxhMqTggdQf61n20uznO50P3ulWzJui5IJI/izx3qWhO6LBZAmPlKAALkVWeRC+SoGMDluvpT42RkYAcjkY+9VCU7rnAyGJ+b5R6cfjU2HFXJWvVjlVFYcAZ5wfY+1a1tcLIjDYoIIwCOv4dxXOXMawSK8hA9fMHI+tTRaxZEKhlUuBnK9wOwHp05qmtNCvZt7HRCXKnaMBSBk/yp6AFdwOC3OM/h06H61TtLmK6iDrGyDOAcc/hVlXUhPukAdf8+361DRDTQ+KYBBnlV6EY/WmlkYqdvT1HT3qFJ4o0ClcsMnP49KmW43MRJGVAABOe9TYtJouxEKOHVVycA/0qo8qzXcqRYLLxyf8AOO9SLIhUrH1zxwMg+1Z9tZy2V1JOythz8wAyQM9/zpaDit+5fw2GJUkcAgDqfWorkkQ7c9jjjqeuP/rVLBNbXEkjxzAnkHJ5xmo5yZJQFHyZ4J4HHWhEu9zEZgZSjqQhPA6FR7VYRRk8ADBXg8ZFEgDygqVVWBO5SG/GlOFiAAGcAE5wWPQ5qwkTKy5HGxsd+mfrSCRQcnALckD1qtnBIA+Rj/Cck0SMDnLZxxnaP84p2JJ52BUkKrZG3GcZPqTWZcLvIJYMVPPHfn8qtPIoYqdu48fePp+tVBCdrNjGOmOfz/SlY0RWfMjFUGT+efpUSxKwO9QVHvx+H61dbgtgjcvIIGCPXr1z60nkMY5CGG48ZHAH4fpTHcrRMFJ2AAkcrmpzEVUFce3AJP8ASq4idXY9ST+FaEaL5a5AYZORjnjv7UmxtWMa+1SO3dIISTNn04z3/rW3ZbvsoluGAx/fGMfjWT/YkZvjcTDDPwAejHtW88PloRjPGBxwMe1EraWLqcqSUR5Kt0AX+E9jSNCQu2MgEHPHOfb6UyKPcckLtbjn/P41aPQjByOPofb2HpSZjtoUHRBJnoQOnT5fT+tOVRt3Ft2Rkc4pdnzsH5TG0BecfQ09VLqWjUZIxjHvSB3IFcI/AJU8ngHFK0sRiJDIWK8noM+v/wBao7mNhGCcA85PTPaqfl7GRQcgjoBwaZajdXJ7pgMAnc2Oo54PqKzS4B6x/wDfpTV+WzKsGJ544GMj1pptxn/VE/TFNWQJ9mMM4jYAKuCMnBz+FQXdoNQVVdmjXGBwce34U2K3cYcA4PVquo7LtD56bc56/wCGK2emqM/h2GeUqwhCcHgA9xxUlvGEctuAOMdM/wCR1odVdMSZUHIIznnr/hTI2BAYEBvc4qRJ9BjXG26ZEGW64B4xnrUkkUnmqFYxjuB0HtiqlvZv9qM8jsF/un+LHvVzdI/ysfvZxjnHtmnoVKy2GgR25BP3hjrjmrMdxHKsnk5LoRuBGOSMjHY/hUMlkRwRuIGOOgP1pyOroI2zlem2hk2TH20iNKQzAIBgnOBj8azNa1fT7a4G++UfwkbuOuBz29awvGFlq0lwI9NEpgY7W8s89KztF+H19dQyNqMjFHYHkgn8vWtIwhbnnK3l1O2nQp25pSO4ivI5fLZZFdccEdx6VYWQyRHyl3HOME4z6mqVvpkFjbRW0RBRBgszc1fEOxQkbAAZyxPt1rLQ5ppX0GJZymYyHBB6AfzqZZ4vNMZYADvjke9TQidYylwIhIeE8tyxK47+hz6cYrL1KBre2aUMxfP3VHJPp6iluxJX0ZYlAlmKgc8H1BHrTkjdioYFVHIBw386xdJjuRL9onkYZHyq3A61rXFybeMM4YqTgseoptWdkOUbOyNAOFcBTuToDUbBd+5RkZ54yTWZbStcTESkKpxtw2M//Xq9FvRAETIJG5s+x6e/SlYnlsPNos8eyRPNQjBPrUL6bAsjG3to42RcK4GDyegJ+nT/AAog+1fbC0ZIjPVcDH/6q0WLAhJGU4IbBPU9v60noUm0LawO7Bd3PXaFyAf61oxhUChSE565wT61kwmRLk5famMg+nvxWiApcbTucA8f/W/rS2IndgYlKEgspzgKo9+v1rL8R30mn2kLwMcseuRk/wD1q2olKtzuyeRnjiuQ8cSA3McQcFQu4Z4DAipSvJI3w0eaaTKFnrtwL1XZmJ4yDxx/hXoEHl3Vqkwbd5i5I9fp6V5tbpGVLKnTjI5IFdr4QWWeB1jBaHGVb+H86JLsjrxVONuaPQkFhLb35ltY2KMfmXp2reP2cWvKouFwMD26Gql1cGBiNpVwMjnPPr9Kyrq9k81NoxG55GM/5FCbZ57vIq6nqUGmuI1h+TP7vaoG0ewApY7wT25lSJlDcHcOc+nNPeSNk3PHGru3IZgdxHcZ7UySZD8pPyfd7BQfzoXoN2toVbjczELy4XO0jJxnr/X8aiiOyJVC5O7sAMf/AKqZqEEErwuw2vG2YpMkFDnvg8g+hFLC6+YMY3nO7Pb0rRbCsSt8xYzMOOpznFEcR+clicfdZiScVXuLi1tsG6kA59+frToNasJT5cU6k/w46E/4VLv0L5JWukTH5XTccsePx7VGdyqqElxkZO0Lz61KsW4KfkCjnjBBzzz/ADp1ym5hzzjIP/1vypEdRGtg6jBGUGfTrT7YMJJlkiMSRsohYsCZeMlsD7uGyuD160zzW8sMSM7R8vbOKkB8zmNi21gcg9+4P+FILloSHEalsHHPpz14ptzMh2htrA9gKSAIJGaWQ7fUdefWo/Jd5U3OqrtzjPGe4Bx06/8A1qBJLcsQSs+ECDZ1ySMflVhE2ArkBTgbmX8sinwQxlNwTbwco3UehwP507ygD8wB7jjv15qWJtEVwojVl8wHJw2QevfNVzGyhSec8YIA6VfYncc4B9S39aqt5bEjPOTnIPAxxz/hU3GilexBxFMZZF8tjI4UqBjB4bIPHfjHTrTV5JYBScbsjv8AWpJ8PEWOVzyc9/YGoyNzKkefmBwxPX2qr6FIikl+UKxwx9R0Pr71VZZdxxGCM98Zq08WCJDuyO2B/kU4dBmDnvwad0Ul2Iiwjj8xzwADgDp6/hWTJqUc8vyPhVI6+1RJJgNGzMCOMZ5HtQmkRzFjFkls9uh9K6VZbijBLVmrFMkyEJ8x6DPGTShAkW5sj1UDt/Wq2lQPbpt255Pv+FXEaMlR1ZumcnP/ANepemxnJa6D0KTR8AE44HQY6VHEdrBeQeOnXGelR7xAxCRkLnaWzz9PypZbeV2DW/BUYIJxj25oEkie4uEijDM6J8vXsB71wPi3x1Dph22A82UnB54A4rW8R6dc3unPAs218dc4z9a8xj0GS0djduJHTtuGWHqa6cPTpyd5v5HXRhCMeaR3ejeKpbi0S6UKC4xtlY8H8K3G8RqyYD+h57/4dq8furqZJGEQ2gHJAP8AIUkM88kcss07QwxRl5JMnMajPp3rpeEi9UYy953PZLLX4p2BGcdMkfrVw6mkKvINrt2Q5Gc14ZoGsLqcrG0nnXyhuKtkEj1rrtKurmS63zE+Uq8DNZVcJyOwWV7noemvJJcNLIxLvk+mB6VsuZDExwvqe7YrkNOlmZ1cIAB757V0dxdGOxO1SSMA9DXHOOo223oS2QRi3zZOeg7UzWEJjIbaEXsoyKwYJmgn821+fzOGXdkCt/TY3e0VrtGLD7oDduetKS5Xcpw5XzFG0hPnLJvCRj5fLAJ/D3rThbcc54U5/wB3H9aYsBfcUiKH7vHJX/65qzFbmPaAxC+g6n6n+lS30InrqSQSGNXkdAc4zkYOB0Hqccn8aqS3BmlDgMEBIBI71bwJAFOQ4+YYHJ+n+FUbsm2DHhQBzzjFJCiC3TyXWzAEZHzFePpW7bzqU8tzj5c/Qf061ykMs6SM6qVTOWwOD/8AWrXtpfMCsTgEYJzjbTlGwNcx0UT7mDAkDoB6+9ZGq6ULm685XEjbRx2647fStFbjbGC4yMDGOSKYEZU2RFVGCoVcYqE2tSYtwd0Yh8PorKrSqhbj5epPp6V0ulXEGl23kgM3+16nrWY0hhBRyfM5PI569D7VTkuXMqgZxnhsf5/OiMpKXMjWU5TSTZqarMJpGkVSGOCAP6VTjjQxBwxJbgqeB9f0qD7R5r/NuBHU+n+fWntLGdwzhhyCRjp/TpS16kWaIrxWBXDE++aqRThM78k9Oe1aCYZXyPlBweP6VWNuzt+6VSGPOcZH0o8i1ZLUcAGQOYyVb+9+dVorQx7pY0JHTg9+p/T+VaKllhACjHvz+NQKQzbViIOMEdMev+NF7bCTKE1jBqDhrlV3H7uV6c0kGhadA+9Vy/Q4H4ir7Kc4U7ueWzjJ/wA9qigcCTa7EgnAIbAGPrRd20ZSlKxHO7IOEOGJIHp9PwqK7EipG8aKSCWCn+Ljgg+xq/dPtbC5Y4HJH8qgdiVJx7AY7+/tQmQtSvIS7ZG5SCG+UdOOn0q35oDqpjXfg4J6470lumAQ3zHnnOSDSIzsxCxghvu89fendCaHwnMpbceF6571dbkjbzjJLHsO/wBaqs5UDepLcDr1zV2NWIG4qdvVfSpYEsGPKILnd6YyTzTpnAdlU4OeueB9KhhCxgj7wXoT1PpUdw7jbkhmyB83f3pW1JaHyS7OCWB+7nGSB71BJKAyruy/K4PPccfnTJmcgAAgenXP/wBakg3b2JUYHPPQ0mXFaCTswUnBbBxwOppY1BKncpLdwPvY7fqetSKmNxAKgjkYIJ9/f+lSQITGdoPbBJz+fvU3CxGw8wbU4I4wfX0pTvY7lQlTyMMMYp43IrYwT6nselVm80sSCmM9zzQVFXOUeSMjoMg8jPWrlrcOsPOGBGQBz2rOFtI5wWBI5OegPpVsRgQuCW+pyMf59a7ZA0uo832+YGR2GDxxVpPMb7i/PjaSelUdoeMKN6vjqO9S2EuyYrJKQSvCg55yR+Hak9tCZR7GjATG5JA+boQMY+tIsZUk7sDOM5z+NQtcqTIwyR2I7f5OKfbXCyqEbaGB444P/wBfrU6mbTElAnEhxnA6E8j0rlNR0wJMWC5TI3Z7ZrtUTMzbQXXG4EkZH48Cklt0kVtoBYjg46e2KcZcr0KjOx57L4aE20mM8nr0NSx+Ereaxnt7hHa3uEKOwOCRzgiu/SCJo1XdnHAz0P8A9b3qVEgRAjYJIPI6fhVe3nbc05jzjw/4DstCtLtLDfPPcYDzSH7qjnaPStKw0MrM2MhlIAHpXexW0Ui4UjaPvEkYP/16iW1jibKg7jw3TpSlXnJtyd2xOTOas7E27ZOWTJ6Hn/61aYjKgvyTtJwB6entU95CIkLLHklcZxz+dLFhv3K8lhnn9alyb1YrdStb20BcHoSeq8EDOc4rUdCUXaSF4zxg4z7VX01ESRvNlQMexPOKtpNC8i4mjJBwAG5NZykr6sqSkxhEuxFTOV4JJz9MGlR8EKfv/dPamXsksLHy2A3cEEdfwpgkiRS8jrnAyRyT/n2oWpDTRfGWkVQFyefYfSoZYtw+ddoyVxnJzn3/ABqolxhoyGGSO3FXVj+0hslgVAwD3z+tAbbkX2RWUZy3y5HTJqVUMajgIgHJyepHFPEEaMpJOcZ6/e9aW7l8uJ14wf7vP/6vpRcNWx93MkRyR8wGcNUKXTZO9cg8Y9apyFmYsTknjkcZx0+tVYXnkdzIgZSuSAuMH8eBStoXy6Fya8HmEu4IVeT0x/j1qvHcLLKxXaeO9Zl/IGTKFu3XoKp21y6qFCbsHPBwcY9atQ90LanU2+14zs5wOuejf59a5zxH4ns/Dt9HHcqcOM/Lkkj2zWzpLCSPLfIWPG4447g+9c38VtIS80YXUSL5sHJb0FKmouooz2ZvhoxlO0tjprC8W+tluIGPlSDj1/Cr5z5uQOTkmuG+GOrfbNHeyfazxYVTkdPSu33YTls85x1J+tKpDkm4voZ4in7ObiTMh8wgqPKH8QODnrjjtVR/MExbHGf4uBmrSNsAKgZ79eveormWNpFhAPm7Q5+YYAzjgDnqKgxW4JgJvJIJGeaZJZpcYwMP970x+dOijyRvUjHRs8Uy8jcOrRsw2gZ7A0dS7kiQpEqFydvTnn2/KoSy+cw+U8nACjr05qOQSK4LA5BySOePerNvCjMGfIXr6n/P1peomuo6INIpQkD+HB/XmpJl+4CMAcjjt70yNwJ23Ebc46Y/D0pUnMq9WAIySMcn2oJ1Y14fXLD1HUmlRm3Ki/OzkDk8n3/nVeQSF9u4CLk8feH0qyiqiFixx0H49c+tMdrEqsNpPAIHTP5GoQpZiFzsyCeeR6Z+tCSoZMZbd0Ib09qV3G0om7H65+tILDWUgB92MHGCcn/9dI+9ZNqrlVOOPT/IrPiMvnlWycdAFzj0qdpJHkChTg/eIP6j9Kdh8tiy+2TIj3A+/TNSRAkDcRx3PXmoFl8nKkndgkn/APV3pjXgGApGCeoqSlFsu7ikZ2gHk8/X+tYktxcCVwCuAT1b/wCvVyS+xGShDY4wR09q52SF2kZthOST1NNRT3NKUe5LHtV1EqZQnjBxn/61PnXcfLQkFuSf8a8r13xRqZuVitHCAccc4q5pPiLU5JFhmWQS9CR0PtXfLD1Eua6Or6hO12d6xjtEHmS5Byc5qNZbN1855hHE3A3HuOv/AOquNudbijGy53LJnGBzWdq6efaZhDjsMHqP8mlGk3a7tcqOCfU9VhSMlXEkUilcfK+fr+NWn8rflcFuOOmPevJvBd1cwaxCssrCOVsFCc+2a9bdAhVhvJ9cdO2azqQ9lLlbucmJoeyY0XscIbhvl4GOMe1OtbhZJFbB/Dn3x6UscMJjDnGDxj0+tLCwVh5YyoGBwah2ObToTTbNpfccZJJHGDUYliDbeWPcjj8KbcXLF9iYIPDZAxVZZYogWkIBJ9eOP8/rSV+pUYXNUZCDYCox90DNStGigkk8c7t2frWfBqUT5EJ3BOrA0pv44oHknAdByFA559vapbEqUr2LEoM7iKJiBkc7v88VXVfIfe75jVSSTwO+axU8XaekcssQYMg/vDnnoMd64zXfGF/db5EQLETnyiOSPf8Az3q40pzfKkdtDBVJvVDPG3iKBNTItDKGB6g5A+vr2rE/4SERCIwtKZiex5rPnvrSeJnuFKTsxyvT+dVpBDvEkRTkfdHWvShSioqLTPfpYeMI2OvtvHmpRTpbX20x5ABbqo9zXUnxJb3Nr5skkSkDAQD9TXmdtbQywSS3QO4ckYNOeCBsCMN5OeNrfzrGVCk37qtYyq4KnN3sepaFqtrdyBBOgIPrgj3966UyMNrxsMoeeM8YI4HrXidvax2s1vLbzM+cHHcV3PhvXoLeXZdlpi2cHOMDof1rCrRS1i7nm18C4axPRYNsqbixTnBBNVtQljCYPLEc4qmt2JpRNFuaPPGBRbZuJHfzEHGGbAc9ehGa5kup5zhZ6kYZsBpAOScAntWrK6y2vlozHaez8H/GoZ/LIKEEMgx7j6VFFIIdyRgtjJwP6Gmyb8xk6jGUULGcYByR+f5VmaazLM24gnO7b0PPoa35EFwrlAOeWH0rOmttpBiKr646itIS0swfYtwXMZlWPqP7vTOeuP61au0FyTBJGZIGG1gMnPv7cVlJbIJcsCW5HGeTW/YqoiCfKu5ce4xzzWc7LYqPu6lbStA0/TGc2CiPzBlvmyfp9a0I0QgMc4II4PQ/41ki+s47kq06gjIOGzWujxud6OCcYLDkf/rpO71f4iqc28hsgJZdrDI7EcY9aVrZEuFn2rvRSiueoBOcD6kfyqSNtqbmV3I+YKo5574qVwoCs5yM53dl9vr0qbkDkdXVtqhVxnkc571WlfOJFQ4zg44z/hVlVDhWAbGeRtwT71FcO0fBBJI5PXj/APVU3HFajVXeqHIzngHrn6U3GCqkBQpyAB1P+RTguzBjAxtA5P6UvlMwVlJI7kjBJ9jQmDIXiADsQRk8kGnFf3uHRyFGQ2MAEHGPr6e1LIrqxzzkFsgZAP19aC+RtbgDp2600xasVlBjBbGeTtPQe5FRyRb5Bu3FhkbQOMf570khZVBlXOemBT4FYH5mI9weDQtBjhGEc7R2zkjimZAYqMZ75Pb1qVwOqgM44575pvl4fD4AAGcnH60NiSK0mwAshzuPXsfwp0e9snpnoM96b5ZLqcEjn5vSpUOZVBHTgMR+nvQPoC2xLHGVJOMk4qvcxJFGwYY29ec9+TWg5ypfqRwd3as+5w43Fh8vAAPJNIcHqQRLEyBYs5/vZ6U/+z4zyVBJ756060LbOVHbII7fSm/anHHkqcd80PyKblfQ+bop4DNvSR1dflKsepq1f63qKosEZQxZ3BgOfxrW1xNFv9DQ2carepj5UGCTXLbLp/l2nK5zx0r34ctT3mtujPrItSWpvWckGoR+bdq/mggH2PcmtnT/ABHDa2xs/s53gkLI+D+tZfh1oojILs+Wh6Mav3OgQajGWtZxsPOM8E+ua56ns3LlqbGU+UTweLm91VplPKvxwMY9vwr2m2ZzbxmbBYjn2Hf9K4XwBpr2W4SwgeWMggdfcV3ZlMSL5oAToefm3Z9+Mc9uc1x4ianU0PBx9TmlZCW8SOXbG0e+QAP60kIbzyjAMM5JHPP1qEyMkpKSHcffGfY+1XoQSgYjDYBbHP8A+rrWT0OB6BNaq/O4Iu38Pw9K4nxdbXjP5dt8yYwSvXOeorsp5milIAMh46Hn/P1qPyIpstMo78Z6cdj/AJ6U4TcGpGtKfI7s5DRtJnhWM/anUSdcfdJ9c1t3ukz3FjKI/mIHT17/AJ8Vl3GoRWd3LG2/YWzxxiuaudc124vrg2120cEakrGh68cYq3GpUd7pep6NOnOpLmRQHh3/AEeW6u7pgyknYOvXpXJXeoGK7jlLlkTgcdf84rofEOoSf2aJ7knazYZA2OTXMaLHDPfw/aosWw5IbkEjtXoUVJpzqanuUlaOpoaILfVNQmu72RfJTopGATVzVo7C4H+gQcpkbkXj/PWrMlvpT38ZVVYbvmRPT8K6p7a1kVYrEJAhGCmMk1jOraSkk/0RFWryvU5e0kmvrJIY1ifbyQRzj60trbyJOyFd27jaOx/z3q1dWM2l3ym3ZdmcNxgHiqMcrS3riV9ybhu2mje7jsONRtXLUlrb20irC5edz8qqcgf/AF6tSpLA6LdRhX7H8uf8+tZ9vcW0Opb0RhHkDkmrOv3r3sgmhBMUQ4JGKVpcyT+8mWrOr0DX44ZUhuR5kB4AHau6Xy3i85MnIBBI6gds9emPwrxrQYi/J+cKcev6V6ZpM9wVVXVtg6A9q5q1NReh42NpKLvE1I5wJHR04GOp5/A96TcrFmRWAI+7/TPcUlxA7jcrJkcbR19zmi3mUYXaobHcday8zzfQjktHZyUZc8fLnB/Pp3zTzbiPb8yMSOvQZA61KpBYlOSw+8p6+xpksRKkgruIwfXI7/lQF7sp3JJnVo2DY/hHUdsVawPJ+cYBGMA4x9PeqttH5Eskshy/I4OMn+lXVfcNsYJyMbj0PoP8+lJlbGJa+FohdFzzHJyCeMfWuhhjSNFgigYxJ0+XqR3FWEjPHJ2nAxnj3wauJgKCuRjkgc0pScnqxyquW5VBKxkPIqqOdzdPxz+VSzxhgDgggYx1z0qR/Kdwr/MrnABXg45pZVfGeijoM8f/AK6kz6jbZWVM7QFxgnHJ+lJKA0gQgBvc4z6c/rToAyR4k5c/3QcA+2ef/wBdRNIivuU5Y4z37+tIPMUJtVRuBIPy5OR+PtTXTg+XtVTwMdKY5Bm2szFt2MAHBPYfWidvLXCAKSeB1JpBa4sgxGrDJC54HPNVElAlCumTk9D1+v4VLAso3mQPgHGPTikfciDjLEdOM46jH50wWmgB/mYuOOnX/OakZiMkcg/Lz0+lV440PzNyQPmGe9E8jOwjTcNpwSD1PT86aWoyywMcQYnew5Ht+FYl1fEuI9hGQMgDGa2AcJ5aMBgHkgnn1xWdqVm5k3qQ5zhgcflQt9TSna9mJp18WDI5cEjbk8f5FacZXygV+6R69PrWQ2nzOjCQleASAMg+1WoE8oqu/eSMHnn8qHZ6hNR+yJcXJViS3HOcHBx/npSwoHRpMhSD0PX/AD0pJYnbzCeFxgE4x9afEjYO3JbH90Dn1FGxGlh0reTGcuxPdVHX8PSmeWTyrjHb/OajcgHcCWY9h+ualIyc+W/NCB6HiXjCKz0rVLkCJk5LL1GPSpfBJtL0SecnmO5wAAc/h+lbvi6w/taGKQxghV+ZgOoqXwrpVlYIr25ZZCcY7gV6MqkXQtrzHtrEKMLMwPFFhaW8uJpvsqEdl5z/AFrB0Rr6aZoLIv8AZ15D5x6V6Nr3htdbkjllcgLzg1o6R4WtbeMs5wOcrjr9cUQxEYUrPVieNgoa7mr4dhkisIQ+HkIBb159RWhf3ltAoa7ATn+IUy0RYMLE3yqMDvTrqG2vYNl0iuAcjB6fWuNW5rs8Oc+eV2UpZo5WikQkYUZUH9PcZrSF+qbSxPzcYyRWWk1pBLjfhFHAPGKdqckDR/uZASRn1x703Z2TL5bu1jWMqOoMbKSRliOx/rVa5vLaCFvMkXpwAc/hjpism1ukidnaVDGBksTgf5zXM+ItagvLpliTaU4O08EnFOMOZ2NqOGc5eRY8RtHdgm1jVmOTnvg9/auP09p4bt4JFYF8gZbr780smqXAmWEvtVevbP1q01p9raK6iZwYySOmGHH+NdUY+zjyy2Z7lKDpxsQanbJfaatntywfIYY/Kuj0/wAGW7aJ5rQyLL0VcccVzkt81je+cAojyPm4wffHrXTJ421FCsDRiSHA+cDoKip7ZRSp7b7jrOp9gpQafBYqsy23zZx85PGPSmC4IuFkjiUZHGP4T7flVm+1m0vZGginVbjjcOgH51m3MRt9jQPI7AHIIyBSjdv39/MnllJajNbeeaEb2254B9T60mk6S7wI3nhywxtHJqvILq+QuUfYpG7Hb3//AFVo6S72u0M2MkADoa1d4w5YvUJNxWhal0NCqRtgEgZY/wCe5qhqmnvp1tudtyYzjvj/ABrq5t04RwDnbncRx+JrP1nJtWcqu5QcAnrWEakrpNmFOvK6ucjpV4VulaBSo6spHU16zpkrGyilJHTnA7+/+e1ePxCSyWW5lAL7yAN3OP6V1mi6/wDa4VijGZh1jU89/wD69a4im5ax2HjKXtFdHf29x56kJ97kEZ6inIVj3AgFuxAI/GsqzlkjkjaX5GBzjg5H5fjWr5iHLcKpAG4+nbn61yNWPElGzGq8ikiNQARgAHpT5Jdkap0YHBHp6/jTYVIBbef5VA67pwuST19T70hWuWI4i4c5yMZUnj8Kp6mL+3EbWaeYuRn6+1a67im5AM55U5OKjM0ohJhCPIVJVWbaGP1A6e/pSvqOEnF3JdPlmnhDTDbIMfLjv357VfhbBPmEKfVTjjH8qrRSOuN2GYnkgYDH1A9Pzq0cMnOFY4HTFS0Q5XZZ2KW28fgMke1JKCBliwGcr6g+lVfNZJiAMnGMD9TSGZ3Jwx4PcfnilYmzFum2jEZJUn7xJ6VRlineVBABgkBxjgf/AF6syhTtAyQ3U9MinA4y/rjjOM++aNi4uyFJIEfOG6EjtTSwmZQpLDrgHJx7/wA6p3GoJ5qQx9W4I9f6VLEpVvkDklfmG3n2z0pcttws9yWd8hQRzg8g5FZzxzG7VxIRESM5Oc/nVgSHB8xADzjB449Paqd1cqsYVckk4GTj8QO//wBeqiuwJs0mmTzQzsu3jqM1GjLJucZYdOOfpWamZQOTk4wuM8/41oWcqBFCbUGcEjpnuKLWC1gSNzOeuTxgHr7VYZ1UMdvJ4Iz054o3EvkMpA444xUJO5APu7QTjPJHpSYascZN0ZOX+YbcZ7ev6VWnkEUQBUbc5Pvx3FWXCHqT8vYdvxqqR5kYUZ4wfw70JAmKk4CglRlsAZ9P607zGZUDjI/h+bv6U0oiRH7hIz7YxTIHVmy54ySDnAPFOw/MUjL+ZnIAJIwR+HvUXnE8hAR2OaSaRinzlgO3cgdvas83e0kZzjjO7H9KfLcqKuYnhPZcaHG5JYFercnH0q9LbeRLCYoQ0Tn95820qNuQQAOSTxg4xWP4H3pplumCImUct1FdPcXKQKQ5BH8uf0rokrTaNcTJqo0hfLCwcIGcjPIxuPc1lz+JbS1RQ8hDg9CcDjP61JrGorDa7lXG7ABxjArhPFkdveWpAkUXAGcMcZqqUFJ+9sVh6HtH7x3MmuwhVeInyiOc/WsrVPFqiB1QLGuMEBs9eD/SvKbORZVP2ieVoV4ChyKkWCOW3HkTOyMSf3n3lFdSwcYv3melDAQjujt4vEryRmLy88ctnBYe1W4riaU70/dwuOoPauJt5Y9NYPFJ5qSHgMo4PtXQTaqttaCVfnUdV6e2D+tTUpJP3FuXLDpP3UGo6w2mXAV5nYFcc81g/wBpvc36LFyZj8qkY4qPVngvdkqSbVU5MYGcCsSUsl6Jo5mBXmMgYz+HaumnSjbzOujTUUbms2gjVnnkcTkZ2g8Uyx1a9lsBHFs+RuOeaw5pJpZDJK7OeRk9qjVZoJQySY7jBNaKl7tpO7OxQT0SNe41FnnzKzbh75B/Co7jV715t1rMq7edg6VkGUSyspGWbnI60rhB5ckMbh0PPPWrVOK6FqnEn84pLJMxJuD1OcD8a6/wtcyy2E3nyM0R755x3/pXnk6maTzXfaTzgGtzw4pR3DTsVYfdAor01KBnUgmtD0q2SK3jkWJ5GQ9ADz+datpbRyhd4CnG447j6+tcXcag1q8KK4YjHPTPpW7p+tq4QISrdCw5FeXKlO3MeVWpytodHPcvu2JgELzgcCobtUurXy2YKxHG04I9axLjWo7VCZjvcnAx3+v+Faml6VNeGG8uJyqZz5a8lv8AJ7VDp8qu9DjaVP3mYY8O3N3eRxu+y1GWLDv7V3OjeH9P0i3UWiGSc9ZH6gH0/Cq9xqMcd+kEYZlIzyuOfeteJWeDzCMdMjOBj2qKk5yST0RhXrzloZM7OJGeRFAViQQf6VJHdzQqqyY8snjB559auS2CSo778OORjpUVrpgmYGZsgEgAADBqdLGKnFrUttdYjQ7fl6lc1ZtXEo+UEgYIz2qOGwhCEZJC8j8O+asAxxgAAAjn5RnPvioduhjddC1ATKQBgqOOfX29Kl2GSQqo5XHPpxjNZ0bshLZG5jgYPp/L61ea5WNF2su4jOKmxDuTgeUGZ8enPOfcU9ZgGRcZx0GeD2/SsiaeRT1YdeSM/rUIuhnaXIBOOOxPpT5SbNm8+WGMAqOcjr/+qnKqqoAzkHqD04rC1fxBY6NpUt5qDOLeMgsVBJ/Kn+Ete03xTo41TS5JGt2YptZSCCKXs5cvPZ279C+V9TWmUKykjBJyMVSDOVO2QgY4GasykHC9cdccA+tVpVLNkK2c9+v4/TNSJaCbF3YKc54Pf3/CpYmKKfJHLqCuemKiBGGIYkMOozwRUsT7j8vbnI7CgCKR0UZboTwPTH8qpzW4JG5RgDsf8+lM1BWLcMck8nPWmG2mjJcv8oHOD05//VVWNI9yV9sccjEgr645HtUtgAYwSenqTmoCoYKpzznj+vvVxSsMAGQFAwW7j/61KwN6Fp32kbUyMhd2SD9DTWP3izHI4JPB6dKxbrxBaQStCdzMvcc5/DtVuWZp7Teh4Y5DZx19DRytbg6bVmyZ928NkkAgAetNMTNjBwuTt5rNhmcOfMLA+uevtV4OJCVT5t2OSP8AOKLA4tDiuCBuJzx0qRyAgQHIx0Bxkev59qgdgpB+4ck8NyOaUqHiYO7JkY3BsEfQjp9aPULFV90zMC3GeAO49Ky9sPfk/wC5/wDXq7eu6JIqPuA+6R1H0rGNzgkHGe/NawjcbRZ0W0+x6ZBCSNyqAW7/AP66ztSnP2orIG2jIznoP61eMs53E8AnPbFKtpE5DTH5PvdeT+J7Vr8OrBTvK8jk9U1J44jk71YkdMYH+e9ch4intpLRbj7Ri4PG3PUe36V1XiO5iluHt4jENrEYAwSPf3rzW6s7ibUJihDW8R6jtXfhoJ+89D3MJBWvYuQxW4twTKwlwGyfyqTT7zylMUwQpnO4iqcdmDNFESRnuD2Nej6d4T0saeo5lmbhiWzj/OautVhTXv63OyrUjTWpxd1HIrpNBOrREgFTyOn86uXFq08aT70SNR93Peqer2v9nSyoh6HA56Vnytvs9xkcNjPBxVJcyTTHH3ldHQWtvb20yFmUQsMbgMk1X8QywWk0JgClGGeR1qtpHlzWgEsziRR8vsKpa1CyskinzBnHXOBnvSjC9T3mOKsy/fW1tPYyNEWD4+76k1jxRRRxM1w0ivnAz3rRsZYjE26Ux/3c/wAjzWfd3zXKlJPmQHhttaQUl7vQ6IPUy3uZFmj2YEQ6HuavG6BjKOSCTkbf8/pWSysqlSSuCWGeadFJJM0ZYbcdcjmuqVNMuM+hdkIEyliRg8lu9aOmzxrfoV5T+LHeqaQx3TAsd0ankVbjEVtKTbgIBzyc/Tn8Kyk01YctUejaXptu1u8+1ArAAccj3rUtNC0wN5jIN7f7R6+uK88h1i5CpEswwPcDn0rQttcaG7jSeQqwIz6GvNlQq62keXWpSezPSLPRIiMRwhhw3zAEAZ7Vui0j8uSO4VipUoyoSOD2BHIPuOa4jQfHlus6Wtwm0HC+YEI5xXcQXttfLJ5N1uZRwnf/AD3rjqRqRfvo8XEQqRfvBd21u+GCDzOmaEuACFlBKgYGTz7CkuSxPybTjsTkcU5SrhQVIYn0zg+n/wBelY5L6aksiuyKRny+pOepFQ2s4bAyCdp6cDGetALCQDnbzwKF5bG3gDPTAosLyLkpKx+ueenT6VTk814ztOGP4d+KmXezAlvfGcjNSyEjOFAOOg6fpUjTsZsS3Pzk4QBuCPU9/rViSeWCDaTukPXPUj/Gp2B8tnOMhfTv/Wo7HLhyVQjuWzx7n2p36sb1KrXkkkT7wVJODjvVKNZzORK+V/EH/D0rTuMCZsAZztHGRTJEBxtXK+v/ANb86pPsJpbkfiCwTWNBvNMMMcrTR4UN03Y9a534J+GNc8K6PfWusqkcM0xMEatn8fau0hTykLgfL1NWWlcYOVdWA+U/qf8APpQq0403RWz1E2PLKEPJJGMilkkAjPzdOmTUQuBIW8vpjBJGPrUVwuSO7Dpgen0rG1wejJI5Y5UkUkgrwWAxg+3+NCu2SAwz936D0qqGCjuG9v5YpC6hCQDuAyR/9b8aLCsSTBXZWUdOmOdxpxMTRnYWz2yfx/xqvNHI+wxjKtzzxzSENGFD7iXyAQD29fT9OlOxasLI5WYYYhB0x1H09qfvMcRcn5c8Ke+Ov86rsoiI2Alm9ec1Oh3xlHPBOOnfNS0VpuVrRLC5cMsALbsHAHWtbyhsaNl2kD7vaqcIihyY8BT19TTpJWUkI2eARxTlqwk2yGcIHCrnduxx0zTo0IJZM7iMdBwaYyMHLNgHHOOPxqaPJyD2A2kjp9f85oBvQm2EqQxYAYB7Y4qvdndIwDZOeBjrx/OrkjeXHgMG4H/AqoTsmSQx29QSDQiE7mZflyW5KnHFYDmXccqCc8nFbMlwGkbacHPJ7CnBMgHyk59QK2UuUuzYx5dsB2Arxgd6ztauTDbxoz43jBPp71PIDOqNEQpIJ5HXkj+lc74ra4hMLtICpUAY6itoQu0iqEU5HI3T21pcSfaWcmQ8Edqyb6wuIoJpraVWiY5YA8n61uahYw3MPm3GWUYAA6jisq50mMoFt5pIy3Bz06mvQhNdz36UkjDM9wGVyQGXofatfSPGF1DPEjriIcMVHNV30gRSMjy7ioAPH41BDpbxtvjlHy5xkelbyVKatI3fvmx4j1T7Qu6KIouc5YZzx0rGtJwsokljbJ4AFSHV2uLcQNEu8fxDjH0qEzn7VFBtGOP6UoU+WPLY0jZLQ6G002/mtpr23RdiDdtUc/lWcl9G7v5kbGUfeHQVuTa8dM0eNYYsmT5DzwcVzcQSUSXDgh2OQFPArKlzSu5rToSr3N+HQrWfT2lg47ls8Z9KzxZwQgRvl/QIauaBaXOqSvbw3Hko55Bziq97YT6ZeCJpVdgc7gO3PFJc3M4uQKaTsRT2ECXcX2lhLbDn5eopurS2gWNreNFiA4XuPrUl3O8sLxQqiMowSa5mK3kjmBmYSAkleenNaU6bl70nsbRqNFn7QtzF5UcLCUty4NaMGnPsSVsPj723sPSs6xk2OFVRvJAJ7V0lvaT2qZ8xSZ2wMZ4q6j5dEEp9yDy4nlCBB7DjFbVxY2iWqCTaZAo59+OtZVlb7irK556Zq7CDcRsXYjGc49a5qm612MJybMLUbRkdfJnwCflJ7f413Xws+0/2tcNPIJkVMbjXNRpgOZlR0iICjpnPTPvW7pN46yrHAoiYfMWWitJypuH4nLiFzwaPS7aWQ38m8FYxkYNW0wmSrbup556/4Vm6Wzm2xIQwVa0EYk+jZOCOOAK8xo+eno7IsfKz7hjrt+vGc03lcYGQOuetRKAApIznpzjvinI6squN3z85bk8//qP6VLRncsqdyDBXjgj0p8blICFAG44w3X3/AMiolA3IOTzge2amklPlqVVRxnp0GcfzqWh3M+6LNKFYEIDnjpiozcJEV2vtXII9DU946+XkZ39c/TpWJcW1xO5PnKqRjc3HPWrikzSLT3Okt5YZELqAMkdanBiVhtxgdCf84/GsaxLQmPJB49KvCYOoQL1POf5VDj2E9yZyWXCcAg/KD796r7Hzktnjrg1MgDAsB8o4xnvUdxIFMYQlc8DjPFMi5NGAis0eSzcZI5H+cVE2wO7kgn2702LEYwnUg/hUbOzucgbQN3+fypWZSHM5kwW4JzjPB+lNKoOCPmzg8cj2qTcEGQNo5J2+1NADIZOq5zyOaQXsTwswX5Rn5cjnH1qNWMpLkqoBBx3+uO/SmqzO7KAMKOc+lVL22kmlUNKV2jPy+maLBHc0JyA4yAeD7jB9c1BJGS+7JzjHJ9Omach8sBH+Zs9e3SmGWNMh1JIGSO2M/wD16LDiyNpNszhCTx1A4NS2kcu4spB684zn1/pUsNuJJCeMHPPfjmobq4jgUYQ43bQBxzS9CnK+iJSpUswwwwNxI5qWJSoDNlS3r0JqrbXf2mJiVwsfb9KsvnywpP3hk475osTK60JywIJJXP3fXn3qheBsM2QQx52+vQU+PcckEBScD24/+tUd5ttAskwLqeQF/wDr1LajuVCDbsjNkiSD96WAA447/wCfWqZ8QQAkBo+K5TxP4jluJ3gto9iLy249vauX+2g8kHJ9v/r12U8M5rmkepSwfu3kf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_5_21586=[""].join("\n");
var outline_f21_5_21586=null;
var title_f21_5_21587="Diabetic neuropathy";
var content_f21_5_21587=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Diabetic neuropathy (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?21/5/21587/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/5/21587/contributors\" id=\"au7393\">",
"       Eva L Feldman, MD, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?21/5/21587/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/5/21587/contributors\" id=\"se5269\">",
"       Jeremy M Shefner, MD, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?21/5/21587/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/5/21587/contributors\" id=\"de6967\">",
"       John F Dashe, MD, PhD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?21/5/21587?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      DIABETIC NEUROPATHY OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Neuropathy is the medical term for nerve damage. Neuropathy is a common complication of type 1 and type 2 diabetes; up to 26 percent of people with type 2 diabetes have evidence of nerve damage at the time that diabetes is diagnosed [",
"     <a class=\"abstract\" href=\"UTD.htm?21/5/21587/abstract/1\">",
"      1",
"     </a>",
"     ]. A generalized type of neuropathy, known as polyneuropathy, is the most common type of diabetic neuropathy. Other types of neuropathy can also affect people with diabetes, but will not be discussed here.",
"    </p>",
"    <p>",
"     Signs and symptoms of diabetic neuropathy include loss of sensation",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     burning pain in the feet. Early detection of diabetes and tight control of blood sugar levels may reduce the risk of developing diabetic neuropathy.",
"    </p>",
"    <p>",
"     Treatments for diabetic neuropathy are available, and include several elements: control of blood glucose levels, prevention of injury, and control of painful symptoms.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      DIABETIC NEUROPATHY RISK FACTORS",
"     </span>",
"    </p>",
"    <p>",
"     In people with type 1 or type 2 diabetes, the biggest risk factor for developing diabetic neuropathy is having high blood sugar levels over time.",
"    </p>",
"    <p>",
"     Other factors can further increase the risk of developing diabetic neuropathy, including:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Coronary artery disease",
"      </li>",
"      <li>",
"       Increased triglyceride levels",
"      </li>",
"      <li>",
"       Being overweight (a body mass index &gt;24) (",
"       <a class=\"calc calc_patient\" href=\"UTD.htm?41/23/42366?source=see_link\">",
"        calculator 1",
"       </a>",
"       and",
"       <a class=\"calc calc_patient\" href=\"UTD.htm?36/47/37630?source=see_link\">",
"        calculator 2",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Smoking",
"      </li>",
"      <li>",
"       High blood pressure",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      DIABETIC NEUROPATHY SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     The most common symptoms of diabetic neuropathy include pain, burning, tingling, or numbness in the toes or feet, and extreme sensitivity to light touch. The pain may be worst at rest and improve with activity, such as walking. Some people initially have intensely painful feet while others have few or no symptoms.",
"    </p>",
"    <p>",
"     Diabetic neuropathy usually affects both sides of the body. Symptoms are usually noticed first in the toes. If the disease progresses, symptoms may gradually move up the legs; if the mid-calves are affected, symptoms may develop in the hands. Over time, the ability to sense pain may be lost, which greatly increases the risk of injury. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18551?source=see_link\">",
"      \"Clinical manifestations and diagnosis of diabetic polyneuropathy\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Potential complications",
"     </span>",
"     &nbsp;&mdash;&nbsp;As you lose the ability to sense pain or hot and cold, your risk of injuring your feet increases. Injuries that would normally cause pain (eg, stepping on a splinter, wearing shoes that create a blister, developing an ingrown toenail) do not necessarily cause pain if you have neuropathy. Unless you inspect your feet on a daily basis, a small injury has the potential to develop into a large ulcer. One of the most serious complications of foot ulcers is the need for amputation of a toe, or in extreme cases, the foot itself.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      DIABETIC NEUROPATHY TESTS",
"     </span>",
"    </p>",
"    <p>",
"     Diabetic neuropathy is diagnosed based upon a medical history and physical examination of the feet. During an examination, there may be signs of nerve injury, including:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Loss of the ability to sense vibration and movement in the toes or feet (eg, when the toe is moved up or down)",
"      </li>",
"      <li>",
"       Loss of the ability to sense pain, light touch and temperature in the toes or feet",
"      </li>",
"      <li>",
"       Loss or reduction of the Achilles tendon reflex",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     More extensive testing, including nerve conduction studies, nerve biopsy, or imaging tests (eg, x-ray or CT scan), is not usually needed to diagnose diabetic neuropathy.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      DIABETIC NEUROPATHY TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     There are three main components of diabetic neuropathy treatment:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Tight control of blood sugar levels",
"      </li>",
"      <li>",
"       Care for the feet to prevent complications",
"      </li>",
"      <li>",
"       Control of pain caused by neuropathy",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Although there is no cure for diabetic neuropathy, use of these treatments can improve painful symptoms and prevent complications. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12986?source=see_link\">",
"      \"Treatment of diabetic neuropathy\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Control blood sugar levels",
"     </span>",
"     &nbsp;&mdash;&nbsp;One of the most important treatments for diabetic neuropathy is to control blood sugar levels. Symptoms of pain and burning may improve when blood glucose sugar improves. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"      \"Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     If blood sugar levels are not adequately controlled with the current treatment regimen, a different regimen may be recommended.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       For people with type 1 diabetes, this may mean taking more frequent insulin injections or using an insulin pump. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?34/31/35317?source=see_link\">",
"        \"Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       For people with type 2 diabetes, this may mean taking an additional oral medication or starting insulin injections. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?35/37/36436?source=see_link\">",
"        \"Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Care for the feet",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with neuropathy do not always feel pain when there is a wound or injury on the foot. As a result, daily foot care is necessary to monitor for changes in the skin (such as cracks or wounds), which can increase the risk of infection. The American Diabetes Association recommends that people with diabetes have a comprehensive foot examination once per year, and a visual examination of the feet at each visit (usually every three to four months). Foot examinations are described in detail in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/38/43618?source=see_link\">",
"      \"Patient information: Foot care in diabetes mellitus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h3\">",
"      Avoid activities that can injure the feet",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some activities increase the risk of foot injury and are not recommended, including walking barefoot, using a heating pad or hot water bottle on the feet, and stepping into the bathtub before testing the temperature with the hand.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h3\">",
"      Use care when trimming the nails",
"     </span>",
"     &nbsp;&mdash;&nbsp;Trim the toe nails along the shape of the toe (rounded, not straight across) and file the nails to remove any sharp edges (",
"     <a class=\"graphic graphic_figure graphicRef80053 \" href=\"UTD.htm?41/51/42814\">",
"      figure 1",
"     </a>",
"     ). Never cut (or allow a manicurist to cut) the cuticles. Do not pop blisters, try to free ingrown toenails, or otherwise break the skin on the feet. See a healthcare provider or podiatrist for even minor procedures.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h3\">",
"      Wash and check the feet daily",
"     </span>",
"     &nbsp;&mdash;&nbsp;Use lukewarm water and mild soap to clean the feet. Gently pat feet dry and apply a moisturizing cream or lotion.",
"    </p>",
"    <p>",
"     Check the entire surface of both feet for skin breaks, blisters, swelling, or redness, including between and underneath the toes where damage may be hidden. Use a mirror or ask a family member or caregiver to help if it is difficult to see the entire foot (",
"     <a class=\"graphic graphic_figure graphicRef77032 \" href=\"UTD.htm?28/40/29313\">",
"      figure 2",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h3\">",
"      Choose socks and shoes carefully",
"     </span>",
"     &nbsp;&mdash;&nbsp;Select cotton socks that fit loosely, and change the socks every day. Wear shoes that are fit correctly and are not tight, and break new shoes in slowly to prevent blisters (",
"     <a class=\"graphic graphic_figure graphicRef79305 \" href=\"UTD.htm?24/41/25245\">",
"      figure 3",
"     </a>",
"     ). Ask about customized shoes if your feet are misshapen or have ulcers; specialized shoes can reduce the chances of developing foot ulcers in the future. Shoe inserts may also help cushion the step and decrease pressure on the soles of the feet.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Ask for foot exams",
"     </span>",
"     &nbsp;&mdash;&nbsp;Screening for foot complications should be a routine part of most medical visits, but is sometimes overlooked. At each visit, the shoes and socks should be removed and the clinician should visually examine the feet. Do not hesitate to ask the healthcare provider for a complete foot check at least once a year, and more frequently if there are problems. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11464?source=see_link\">",
"      \"Evaluation of the diabetic foot\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Control pain",
"     </span>",
"     &nbsp;&mdash;&nbsp;Neuropathic pain can be difficult to control and can seriously affect your quality of life. Neuropathic pain is often worse at night, seriously disrupting sleep.",
"    </p>",
"    <p>",
"     Fortunately, only a small percentage of people with diabetic neuropathy experience pain. Pain resolves without treatment in some people over a period of weeks to months, especially if the episode of pain developed after a sudden change in health (eg, an episode of diabetic ketoacidosis, a significant weight loss, or a significant change in blood glucose control).",
"    </p>",
"    <p>",
"     There are several medications that are useful for the treatment of diabetic neuropathy and have been approved by the FDA, including duloxetine and pregabalin. Other medications are also useful, including tricyclic medications (eg, amitriptyline), gabapentin, tramadol, and alpha-lipoic acid.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Tricyclic antidepressants",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are several tricyclic antidepressants available for the treatment of chronic pain, including amitriptyline, nortriptyline, and desipramine. Clinical trials have shown than tricyclic antidepressant drugs are effective for patients with painful diabetic neuropathy. The dose of tricyclic antidepressants used to treat diabetic neuropathy is typically much lower than that used to treat depression.",
"    </p>",
"    <p>",
"     These medications are usually taken at bedtime, starting with a low dose and gradually increasing over a period of several weeks. People with heart disease should not take amitriptyline or nortriptyline. Tricyclic medications can be taken with gabapentin and pregabalin, but should not be taken with duloxetine. Side effects can include dry mouth, sleepiness, dizziness, and constipation.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Duloxetine",
"     </span>",
"     &nbsp;&mdash;&nbsp;Duloxetine is an antidepressant that is often effective in relieving pain caused by diabetic neuropathy. In short-term clinical trials, duloxetine was more effective than placebo. However, the long-term effectiveness and safety of duloxetine for diabetic neuropathy is uncertain [",
"     <a class=\"abstract\" href=\"UTD.htm?21/5/21587/abstract/2\">",
"      2",
"     </a>",
"     ]. There are no trials comparing duloxetine with other drugs for the treatment of diabetic polyneuropathy.",
"    </p>",
"    <p>",
"     Duloxetine is usually taken by mouth once per day on a full stomach, although in some cases it is taken twice per day. It should not be taken by people who take other antidepressant medications (see",
"     <a class=\"local\" href=\"#H15\">",
"      'Tricyclic antidepressants'",
"     </a>",
"     above). Side effects can include nausea, sleepiness, dizziness, decreased appetite, and constipation.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Gabapentin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Gabapentin is an anti-seizure medication. It is usually taken by mouth three times per day. Side effects can include dizziness and confusion. Gabapentin can be taken with a tricyclic antidepressants or duloxetine. In some cases, gabapentin can be taken at night to prevent pain during sleep.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Pregabalin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pregabalin is an anti-seizure medication, similar to gabapentin. Pregabalin is taken by mouth, starting at bedtime at a low dose, and then gradually increasing to three times per day over a period of several weeks.",
"    </p>",
"    <p>",
"     Side effects can include dizziness, sleepiness, confusion, swelling in the feet and ankles, and weight gain. It may be possible to become addicted to pregabalin, and changes in dosing should be monitored carefully. Pregabalin can be taken with duloxetine or TCAs, but not with gabapentin.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h3\">",
"      Anesthetic drugs",
"     </span>",
"     &nbsp;&mdash;&nbsp;Lidocaine is an anesthetic drug that may be recommended if other treatments have not improved pain. It is applied to the painful area in a patch, which slowly releases the medication over time. Up to four patches may be applied for up to 18 hours per day.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h3\">",
"      Alpha-lipoic acid",
"     </span>",
"     &nbsp;&mdash;&nbsp;Alpha-lipoic acid (ALA) is an antioxidant medication. Several short-term trials showed that it was helpful in relieving pain caused by diabetic neuropathy. Thus, ALA may be recommended to people with diabetic neuropathy who do not improve with or who cannot tolerate other treatments. However, longer-term studies are still needed to confirm its safety and effectiveness. In the United States, ALA is available without a prescription as a dietary supplement. It is usually taken by mouth once per day.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H111721506\">",
"     <span class=\"h3\">",
"      Narcotics (opioids)",
"     </span>",
"     &nbsp;&mdash;&nbsp;Tramadol is a pain medication that can be taken for breakthrough pain; in severe cases, it can be taken every six hours (four times per day). It can cause sedation, dizziness and confusion. It can be taken with pregabalin, duloxetine, gabapentin, and TCAs.",
"    </p>",
"    <p>",
"     It is important to note that the long-term use of narcotic medications for non-cancer pain is associated with a number of problems, including the potential for abuse, addiction, and fatal overdose, particularly for patients treated with higher dose regimens. Because of these issues, some clinicians have stopped using narcotics altogether for the treatment of painful diabetic neuropathy.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2287309294\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H203569923\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/44/33475?source=see_link\">",
"      Patient information: Type 2 diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/47/20208?source=see_link\">",
"      Patient information: Nerve damage caused by diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/40/22144?source=see_link\">",
"      Patient information: The ABCs of diabetes (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/42/8867?source=see_link\">",
"      Patient information: Neuropathic pain (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/52/20292?source=see_link\">",
"      Patient information: Diabetes and infections (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H203569931\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/38/43618?source=see_link\">",
"      Patient information: Foot care in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/43/39603?source=see_link\">",
"      Patient information: Self-blood glucose monitoring in diabetes mellitus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/31/35317?source=see_link\">",
"      Patient information: Diabetes mellitus type 1: Insulin treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/37/36436?source=see_link\">",
"      Patient information: Diabetes mellitus type 2: Treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/7/18551?source=see_link\">",
"      Clinical manifestations and diagnosis of diabetic polyneuropathy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/46/8938?source=see_link\">",
"      Diabetic autonomic neuropathy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24985?source=see_link\">",
"      Diabetic autonomic neuropathy of the gastrointestinal tract",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16934?source=see_link\">",
"      Epidemiology and classification of diabetic neuropathy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/12/11464?source=see_link\">",
"      Evaluation of the diabetic foot",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/60/41928?source=see_link\">",
"      Pathogenesis and prevention of diabetic polyneuropathy",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/43/12986?source=see_link\">",
"      Treatment of diabetic neuropathy",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/000693.htm\">",
"        www.nlm.nih.gov/medlineplus/ency/article/000693.htm",
"       </a>",
"       , available in Spanish)",
"      </li>",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases (",
"       <a class=\"external\" href=\"file://diabetes.niddk.nih.gov/dm/pubs/neuropathies/\">",
"        file://diabetes.niddk.nih.gov/dm/pubs/neuropathies/",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American Diabetes Association (",
"       <a class=\"external\" href=\"file://www.diabetes.org/\">",
"        www.diabetes.org",
"       </a>",
"       ) (800)-DIABETES (800-342-2383)",
"      </li>",
"      <li>",
"       The Neuropathy Association (",
"       <a class=\"external\" href=\"file://www.neuropathy.org/\">",
"        www.neuropathy.org",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?21/5/21587/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 30, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?21/5/21587?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21587/abstract/1\">",
"      Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006; 29:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21587/abstract/2\">",
"      Duloxetine (Cymbalta) for diabetic neuropathic pain. Med Lett Drugs Ther 2005; 47:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21587/abstract/3\">",
"      Meijer JW, Smit AJ, Lefrandt JD, et al. Back to basics in diagnosing diabetic polyneuropathy with the tuning fork! Diabetes Care 2005; 28:2201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21587/abstract/4\">",
"      Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21587/abstract/5\">",
"      Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004; 63:2104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21587/abstract/6\">",
"      Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc 2006; 81:S12.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f21_5_21587=[""].join("\n");
var outline_f21_5_21587=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           DIABETIC NEUROPATHY OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           DIABETIC NEUROPATHY RISK FACTORS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           DIABETIC NEUROPATHY SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           DIABETIC NEUROPATHY TESTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           DIABETIC NEUROPATHY TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/51/42814\" title=\"figure 1\">",
"           Trim toenails PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/40/29313\" title=\"figure 2\">",
"           Foot check diabetes PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/41/25245\" title=\"figure 3\">",
"           Shoe shape PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        CALCULATORS",
"       </h1>",
"       <div id=\"relatedCalculators\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a class=\"calc calc_patient\" href=\"UTD.htm?41/23/42366?source=related_link\" title=\"calculator 1\">",
"           Calculator: Body mass index for adults (Patient information)",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a class=\"calc calc_patient\" href=\"UTD.htm?36/47/37630?source=related_link\" title=\"calculator 2\">",
"           Calculator: Body mass index for adults (Metric, Patient information)",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f21_5_21588="Dextran: Drug information";
var content_f21_5_21588=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dextran: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/27/22963?source=see_link\">",
"    see \"Dextran: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F158641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      LMD&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F158675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Plasma Volume Expander, Colloid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F158644\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Volume expansion/shock:",
"     </b>",
"     I.V.:",
"     <i>",
"      Dextran 40:",
"     </i>",
"     Infuse 500-1000 mL (~10 mL/kg) as rapidly as possible (maximum: 20 mL/kg/day for first 24 hours; 10 mL/kg/day thereafter);  therapy should not be continued beyond 5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pump prime:",
"     </b>",
"     <i>",
"      Dextran 40:",
"     </i>",
"     Varies with the volume of the pump oxygenator; generally, the solution is added in a dose of 10-20 mL/kg (or 1-2 g/kg); usual maximum total dose: 20 mL/kg (or 2 g/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Postoperative prophylaxis of venous thrombosis/pulmonary embolism (Dextran 40):",
"     </b>",
"     Begin during surgical procedure and give 500-1000 mL (~10 mL/kg); an additional 50 g (500 mL) should be administered every 2-3 days during the period of risk (up to 2 weeks postoperatively); usual maximum infusion rate for nonemergency use: 4 mL/minute",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F158663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/27/22963?source=see_link\">",
"      see \"Dextran: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Treatment of shock or impending shock (when blood or blood products are not available):",
"     </b>",
"     I.V.:",
"     <i>",
"      Dextran 40",
"     </i>",
"     : Infuse 10 mL/kg as rapidly as possible (maximum: 20 mL/kg/day for the first 24 hours; 10 mL/kg/day thereafter); therapy should not be continued beyond 5 days",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F158645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F158646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with extreme caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F158647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with extreme caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F158627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W [low molecular weight]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LMD&reg;: 10% Dextran 40 (500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in NS [low molecular weight]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LMD&reg;: 10% Dextran 40 (500 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F158613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F158629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not use if crystalline precipitate forms. For I.V. infusion only (use an infusion pump or pressure infusion). For volume expansion/shock, may infuse initial volume as rapidly as possible. For nonemergency situations, infuse at 4 mL/minute.",
"     <b>",
"      Monitor closely for anaphylactic reaction; have epinephrine and resuscitative equipment available.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F158681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dextran 40:",
"     </b>",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Enalaprilat, famotidine, nicardipine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Do not add any drugs to dextran solution. To prevent coagulation of blood, flush tubing well or change I.V. tubing before infusing blood after dextran.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F158628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood volume expander used in treatment of shock or impending shock when blood or blood products are not available; also used as a priming fluid in pump oxygenators during cardiopulmonary bypass and for prophylaxis of venous thrombosis and pulmonary embolism in surgical procedures associated with a high risk of thromboembolic complications",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F158683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Dextran may be confused with Dexedrine&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F158674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Cardiac arrest, hypotension, tightness of chest",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dermatologic: Urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestional: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hematologic (all dose related): Bleeding time (prolonged), wound bleeding, wound hematoma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hepatic: Liver function tests (abnormal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Renal: Acute renal failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Respiratory: Pulmonary edema (dose related), wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Anaphylactoid reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F158632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to dextran or any component of the formulation; marked hemostatic defects (eg, thrombocytopenia, hypofibrinogenemia) of all types including those caused by medications (eg, heparin, warfarin); marked cardiac decompensation; renal disease with severe oliguria or anuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F158617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid overload: Administration may cause fluid overload; use with caution in patients at risk from overexpansion of blood volume (eg, very young, elderly patients, or those with heart failure).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic: Large volumes of dextran (doses &gt;1000 mL) may cause reduction in hemoglobin concentration and excessive dilution of plasma proteins due to hemodilution; transient prolongation of bleeding time or an increase in bleeding tendency may occur with large volumes; use caution to prevent a decrease in hematocrit &lt;30%.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Severe and fatal anaphylactoid reactions have been reported; discontinue use immediately with signs of hypersensitivity and administer appropriate therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal failure: Has been reported with use; fluid status including urine output should be monitored closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Use with caution in heart failure patients; monitor closely for fluid overload.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemorrhage: Use with caution in patients with active hemorrhage;. may increase the risk of more bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; fluid status including urine output should be monitored closely. Excessive dosing may precipitate renal failure in patients with advanced renal disease. Use in severe oliguria or anuria is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombocytopenia: Use with caution in patients with thrombocytopenia; doses &gt;1000 mL may interfere with platelet function and transiently prolong bleeding time. Observe for bleeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Not a substitute for blood or blood components.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F1076314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abciximab: Dextran may enhance the anticoagulant effect of Abciximab.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F158623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14446431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F158651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Hyskon)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     32-10% (100 mL): $3.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (LMD in D5W Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-5% (500 mL): $26.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (LMD in NaCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10-0.9% (500 mL): $33.16",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F158625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate, CVP, RAP, MAP, capillary refill time; if pulmonary artery catheter in place, monitor cardiac index, PCWP, SVR, and PVR; hemoglobin and hematocrit, electrolytes, serum protein, coagulation parameters, renal function, urine output, acid-base balance; observe patients closely during the first minute of infusion and have other means of maintaining circulation should dextran therapy result in an anaphylactoid reaction",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F158634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dekstran 40000 (PL);",
"     </li>",
"     <li>",
"      Dekstran 70000 (PL);",
"     </li>",
"     <li>",
"      Dextran 40 Injection (AU);",
"     </li>",
"     <li>",
"      Dextran 40 Vifor (CH);",
"     </li>",
"     <li>",
"      Dextran 70 Injection (AU);",
"     </li>",
"     <li>",
"      Dextran 70 Vifor (CH);",
"     </li>",
"     <li>",
"      Dextran Spofa (CZ);",
"     </li>",
"     <li>",
"      Dextran-1 B. Braun (CH);",
"     </li>",
"     <li>",
"      Dextril 70 (FI);",
"     </li>",
"     <li>",
"      Dialens (CH);",
"     </li>",
"     <li>",
"      Eudextran (IT);",
"     </li>",
"     <li>",
"      Fluidex (CZ);",
"     </li>",
"     <li>",
"      Gentran 40 (LU, NL);",
"     </li>",
"     <li>",
"      Gentran 70 (LU, NL);",
"     </li>",
"     <li>",
"      Hyskon (DE);",
"     </li>",
"     <li>",
"      Infukoll M 40 (DE);",
"     </li>",
"     <li>",
"      Lacrima Plus (MX);",
"     </li>",
"     <li>",
"      LM Dextran (ID);",
"     </li>",
"     <li>",
"      LM Dextran L (ID);",
"     </li>",
"     <li>",
"      Longasteril 40&deg; (DE, LU);",
"     </li>",
"     <li>",
"      Macrodex (DE, NL);",
"     </li>",
"     <li>",
"      Macrodex 6% (GB);",
"     </li>",
"     <li>",
"      Onkovertin N (DE);",
"     </li>",
"     <li>",
"      Plander (IT);",
"     </li>",
"     <li>",
"      Plander R (IT);",
"     </li>",
"     <li>",
"      Plasmex (IN);",
"     </li>",
"     <li>",
"      Promit (CH, DE);",
"     </li>",
"     <li>",
"      Promiten (LU, NO);",
"     </li>",
"     <li>",
"      Rheodextran Infusia (CZ);",
"     </li>",
"     <li>",
"      Rheodextran Spofa (CZ);",
"     </li>",
"     <li>",
"      Rheomacrodex (BR, CZ, DE, EC, FR, LU, NL, NO, SE);",
"     </li>",
"     <li>",
"      Rheomacrodex 10% (AT, DK, GB);",
"     </li>",
"     <li>",
"      Solplex 40 (IT);",
"     </li>",
"     <li>",
"      Solplex 70 (IT);",
"     </li>",
"     <li>",
"      Soludeks 1 (HR);",
"     </li>",
"     <li>",
"      Soludeks 40 (HR);",
"     </li>",
"     <li>",
"      Soludeks 70 (HR);",
"     </li>",
"     <li>",
"      Thomaedex 40 (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F158616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Produces plasma volume expansion by virtue of its highly colloidal starch structure.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F158631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Plasma expanding effect lasts 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~75%) within 24 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Niemi TT, Miyashita R, and Yamakage M, &ldquo;Colloid Solutions: A Clinical Update,&rdquo;",
"      <i>",
"       J Anesth",
"      </i>",
"      , 2010, 24(6):913-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/5/21588/abstract-text/20953964/pubmed\" id=\"20953964\" target=\"_blank\">",
"        20953964",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9339 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-110.137.129.113-3D84CAA1B7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_5_21588=[""].join("\n");
var outline_f21_5_21588=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158641\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158675\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158644\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158663\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158645\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158646\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158647\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158627\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158613\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158629\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158681\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158628\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158683\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158674\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158632\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158617\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299161\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1076314\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158623\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14446431\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158651\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323102\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158625\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158634\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158616\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158631\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9339\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9339|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/27/22963?source=related_link\">",
"      Dextran: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_5_21589="Post ablation WPW";
var content_f21_5_21589=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F73726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F73726&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Ablation of accessory pathway in Wolff-Parkinson-White",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 370px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown are three surface ECG leads (I,II, and V1), and intracardiac electrograms recorded from the high right atrium (HRA), bundle of His (HIS), the ablation catheter (ABL), and right ventricular apex (RVA). After radiofrequency (RF) ablation of the accessory pathway there is loss of preexcitation with resumption of normal atrioventricular nodal conduction; the PR interval and QRS complex have normalized and the AH and HV intervals are now normal (74 and 54 ms, respectively).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martin Burke, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_5_21589=[""].join("\n");
var outline_f21_5_21589=null;
var title_f21_5_21590="Ziprasidone: Patient drug information";
var content_f21_5_21590=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ziprasidone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"     see \"Ziprasidone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/33/23064?source=see_link\">",
"     see \"Ziprasidone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F235894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Geodon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5498099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zeldox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10023587\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700570",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a higher chance of death in older adults who take this drug for mental problems caused by dementia. Most of the deaths were linked to heart disease or infection. This drug is not approved to treat mental problems caused by dementia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10023589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692053",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat schizophrenia. It may take 6 weeks to see the full effect.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691952",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat manic low mood (depression).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692186",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bipolar problems.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Tourette's syndrome.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10023588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ziprasidone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705285",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Long QT on ECG, recent heart attack, or very weak heart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10023593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697190",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have breast cancer, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a family history of high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697268",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high cholesterol or triglyceride levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are overweight, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697320",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have Parkinson's disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697141",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a slow heartbeat and do not have a pacemaker, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10023594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698139",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood sugar. This most often goes back to normal when drug is stopped.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10023596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness, trouble moving around, or stiffness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More trips to the bathroom, more thirst, or weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10023591\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow capsule whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10023592\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10023597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Capsule:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10023598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11154 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-4838B967EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_5_21590=[""].join("\n");
var outline_f21_5_21590=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235894\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5498099\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023587\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023589\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023588\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023593\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023594\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023596\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023591\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023592\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023597\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10023598\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=related_link\">",
"      Ziprasidone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/33/23064?source=related_link\">",
"      Ziprasidone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_5_21591="Emphysema in AAT chest Xray";
var content_f21_5_21591=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F62580%7EPULM%2F79789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F62580%7EPULM%2F79789&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Emphysema in alpha-1 antitrypsin deficiency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 308px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior chest radiograph demonstrating basilar emphysema, with a preferential loss of basilar lung markings, characteristic of alpha-1 antitrypsin deficiency (AAT).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James K Stoller, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Normal versus emphysema chest radiograph in alpha-1 antitrypsin deficiency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Normal lateral chest radiograph.",
"    <br>",
"     (B) Lateral chest radiograph demonstrating hyperinflation with flattened diaphragms and increased retrosternal airspace in a patient with alpha-1 antitrypsin deficiency (AAT).",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_5_21591=[""].join("\n");
var outline_f21_5_21591=null;
var title_f21_5_21592="Azathioprine and 6-mercaptopurine in inflammatory bowel disease";
var content_f21_5_21592=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Azathioprine and 6-mercaptopurine in inflammatory bowel disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/5/21592/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/5/21592/contributors\">",
"     Yousif I A-Rahim, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/5/21592/contributors\">",
"     Richard J Farrell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/5/21592/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/5/21592/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/5/21592/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/5/21592/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/5/21592/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunomodulatory drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (AZA) and 6-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    (6-MP), exert a steroid-sparing effect in patients with steroid-dependent and steroid-refractory inflammatory bowel disease. While azathioprine (AZA) and 6-mercaptopurine (6-MP) have been noted to induce and maintain remission in ulcerative colitis and Crohn&rsquo;s disease, their use is limited by concerns of toxicity.",
"   </p>",
"   <p>",
"    This topic review summarizes the pharmacology, dosing, monitoring, and adverse effects of AZA and 6-MP in inflammatory bowel disease. 6-MP metabolite monitoring and thiopurine-S-methyltransferase (TPMT) testing in the treatment of inflammatory bowel disease, indications and efficacy of AZA and 6-MP in ulcerative colitis and Crohn&rsquo;s disease are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44566?source=see_link\">",
"     \"6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=see_link\">",
"     \"Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=see_link\">",
"     \"Immunomodulator therapy in Crohn's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=see_link\">",
"     \"Overview of the medical management of severe or refractory Crohn's disease in adults\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACODYNAMICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    (AZA) is a prodrug that is quickly converted to 6-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    (6-MP) via a nonenzymatic nucleophilic attack by sulfhydryl-containing compounds, such as glutathione, present in red blood cells and other tissues. 6-MP is then metabolized in the liver and gut by one of three enzymes (",
"    <a class=\"graphic graphic_figure graphicRef72170 \" href=\"UTD.htm?5/34/5664\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thiopurine-S-methyltransferase (TPMT), which catalyzes the methylation of 6-MP to an inactive metabolite 6-methyl-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"       mercaptopurine",
"      </a>",
"      (6-MMP)",
"     </li>",
"     <li>",
"      Xanthine oxidase, which catalyzes 6-MP to inactive thiourate",
"     </li>",
"     <li>",
"      Hypoxanthine-guanine-phosphoribosyltransferase, which converts 6-MP to active metabolite 6-thioguanine (6-TG) nucleotides",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The absorption of AZA ranges between 16 and 50 percent in healthy subjects. Absorption may be reduced in patients with Crohn's disease and ulcerative colitis due to increased intestinal motility during acute exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Following absorption, 6-thioguanine nucleotides accumulate in tissues where they are thought to exert their cytotoxic effects by inhibition of purine synthesis and ultimately DNA and RNA synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. AZA and 6-MP also inhibit the proliferation of T and B lymphocytes, leading to decreased production of cytotoxic T lymphocytes and plasma cells. They also lead to apoptosis of T-cells [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies suggest that erythrocyte 6-thioguanine nucleotide concentrations, which are inversely correlated with the rate of metabolism via the TPMT pathway, correlate with therapeutic efficacy in inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. However, the precise mechanism of action for these drugs in inflammatory bowel disease is unknown. A review of the mechanism of action of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    is also available elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=see_link\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no pharmacologic differences between the actions of AZA and 6-MP, emphasizing that they can be administered for similar indications on a dose equivalent basis. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Dosage'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DOSAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of serious adverse effects mandates that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (AZA) and 6-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    (6-MP) be introduced carefully [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. There are several different strategies for dosing AZA and 6-MP. These include empiric weight-based dosing and dosing based on thiopurine-S-methyltransferase (TPMT) genotype and phenotype testing. Initial genotype testing for TPMT is suggested but not required by the United States Food and Drug Administration prior to use. If TPMT genotyping is performed before the start of the drug and is normal, gradual increase of the dose as discussed below is not necessary and the drug can be started at full dose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44566?source=see_link&amp;anchor=H2#H2\">",
"     \"6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine\", section on 'TPMT enzyme determination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The molecular weight of 6-MP is 55 percent that of AZA, and 88 percent of AZA is converted to 6-MP. As a result, a dosage conversion factor of 0.5 is used to convert a dose of AZA to 6-MP [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/1,9\">",
"     1,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest empiric weight-based dosing: AZA should be initiated at a low dose (0.5 to 1.5",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    estimated lean body weight daily), and increased incrementally to a maximum dose of 2.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily. The equivalent dose of 6-MP is initially 0.25 to 0.5",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    estimated lean body weight, daily, increasing to 1.0 to 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily. Severe toxic (as opposed to hypersensitivity) adverse effects are generally encountered only rarely if the AZA dose does not exceed 2.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily or the 6-MP dose does not exceed 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily.",
"   </p>",
"   <p>",
"    We generally start 6-MP and AZA at 50 mg daily. If the medication is well tolerated after one month, then the dose of 6-MP is increased to 75 mg and AZA is increased to 100 mg, depending on the patient's weight.",
"   </p>",
"   <p>",
"    After three months of therapy, the dose of 6-MP and AZA may be further increased to 100 mg and 150 mg, respectively, if no obvious therapeutic response is seen, provided that the patient is tolerating the therapy and the white blood cell (WBC) count is &gt;4 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      3",
"     </sup>",
"     /L.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H391261686\">",
"    <span class=\"h2\">",
"     Dosage in patients on allopurinol and 5-ASAs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients exhibit dose-limiting, preferential 6-MMP production. In preferential 6-MMP metabolizers, administration of AZA or 6-MP leads to high 6-MMP levels while 6-TGN levels remain subtherapeutic. An increase in the dose of AZA or 6-MP leads to increased 6-TGN concentration but also results in overproduction of 6-MMP and side effects.",
"   </p>",
"   <p>",
"    The addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    to AZA has been suggested in patients with hepatoxicity, arthralgias, or nausea to decrease 6-MMP concentration. However, this approach is controversial and may be associated with high rates of opportunistic infections [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     Allopurinol",
"    </a>",
"    blocks the metabolism of 6-MP via the inhibition of xanthine oxidase and shunts metabolism away from 6-methyl-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    (6-MMP) production (",
"    <a class=\"graphic graphic_figure graphicRef72170 \" href=\"UTD.htm?5/34/5664\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/13\">",
"     13",
"    </a>",
"    ]. The addition of allopurinol may correct an unfavorable ratio of 6-thioguanine (6-TG) to 6-MMP by reducing 6-MMP concentrations and increasing 6-TG concentrations. As the addition of allopurinol can lead to supratherapeutic levels of 6-TG, half doses of AZA or 6-MP should be initiated (25",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"   </p>",
"   <p>",
"    Theoretically, oral 5-ASAs and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    also inhibit TPMT activity but the clinical significance of this is minimal and no dose adjustment of AZA or 6-MP is necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H969623537\">",
"    <span class=\"h2\">",
"     Split dose administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another strategy in patients who exhibit preferential 6-MMP production is split dose administration of AZA or 6-MP. In a retrospective study of 179 patients with IBD who were preferential 6-MMP metabolizers, dividing the daily thiopurine dose led to a significant reduction in 6-MMP levels without adversely affecting clinical disease activity or 6-TGN levels [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/15\">",
"     15",
"    </a>",
"    ]. Side effects associated with 6-MMP, including abnormal liver function tests, leukopenia, and flu-like symptoms, improved in seven of eight patients. After a mean follow-up of 42 months, 12 of 20 patients remained on split dose of 6-MP with control of IBD activity. However, additional studies are needed to confirm the efficacy of this strategy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H517304416\">",
"    <span class=\"h1\">",
"     TIMING OF RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    (AZA) and 6-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    (6-MP) are both slow-acting drugs. A therapeutic effect can typically be expected after three months and may take as much as six months in some patients. As a result, these drugs are",
"    <strong>",
"     not",
"    </strong>",
"    indicated for monotherapy in acute relapses of inflammatory bowel disease.",
"   </p>",
"   <p>",
"    It has been hypothesized that intravenous administration loading dose of AZA might shorten the time to a response, but evidence to support it is limited. An uncontrolled pilot study of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    in nine patients with severe ulcerative colitis suggested a possible benefit with a clinical response in five of nine (56 percent) patients and clinical remission in three of nine (33 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/16\">",
"     16",
"    </a>",
"    ]. However, a controlled trial in patients with Crohn's disease found that intravenous azathioprine was not more effective than placebo in inducing remission [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/17\">",
"     17",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DURATION OF TREATMENT AND TAPERING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who discontinue treatment with AZA or 6-MP have a high rate of relapse. In one prospective cohort study, 87 percent of complete responders relapsed after discontinuing treatment with 6-MP [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/18\">",
"     18",
"    </a>",
"    ]. Once a desired therapeutic effect has been achieved, studies have suggested that therapy be continued for anywhere between 12 months to 5 years to reduce the likelihood of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/19-22\">",
"     19-22",
"    </a>",
"    ]. However, another study found that duration of treatment did not influence the likelihood of relapse following treatment withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether a slow dosage reduction every 6 to 12 months (rather than abrupt discontinuation) reduces the risk of relapse has not been evaluated in controlled clinical trials. As continuation of AZA and 6-MP is associated with maintenance of remission and there is a high risk of relapse when therapy is discontinued, in the absence of side effects, our approach is to continue AZA and 6-MP long-term in patients whose disease is well controlled [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/19-22,24\">",
"     19-22,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no evidence to support a dose reduction in patients in remission in order to prevent long-term side effects. Furthermore, a dose reduction may put the patient at risk for relapse. Thus, once therapy is tolerated and remission is maintained, there does not appear to be a compelling reason to reduce the dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects occur in 9 to 15 percent of patients with inflammatory bowel disease (IBD) treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (AZA) and 6-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    (6-MP) and most often during the first month [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/25\">",
"     25",
"    </a>",
"    ]. Of these, 10 to 20 percent are severe enough to stop treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=see_link\">",
"     \"Immunomodulator therapy in Crohn's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=see_link\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The side effects of AZA and 6-MP include dose-dependent side effects, such as bone marrow depression (1 to 2 percent) and liver dysfunction (0.3 percent), and dose-independent side effects, such as pancreatitis (1.4 percent), allergic reactions such as drug fever, arthritis or rash (2.3 percent), nausea, and pneumonitis. Individuals on AZA and 6-MP are also at an increased risk for infections and cancer (see",
"    <a class=\"local\" href=\"#H190342717\">",
"     'Neoplasia'",
"    </a>",
"    below). There is no evidence that switching from 6-MP to AZA or vice versa can mitigate these side-effects.",
"   </p>",
"   <p>",
"    The most commonly encountered side effects are anorexia, nausea, and vomiting, especially if the dose is increased too rapidly. Dyspeptic symptoms can be minimized by taking the drug with meals.",
"   </p>",
"   <p>",
"    Patients who develop hypersensitivity reactions to either AZA or 6-MP should",
"    <strong>",
"     not",
"    </strong>",
"    receive either of these drugs. Studies have suggested that 6-MP may be used in patients with IBD who were intolerant of AZA (including those with hypersensitivity reactions) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. A possible explanation for this difference is that the majority of hypersensitivity reactions to AZA are thought to relate to AZA's nitroimidazole moiety, which is not part of 6-MP's structure. However, the proportion of patients intolerant to AZA who will tolerate 6-MP is not known precisely. In addition, those who have hypersensitivity reactions to one drug are at increased risk upon exposure to the other [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190342717\">",
"    <span class=\"h2\">",
"     Neoplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of six studies estimated that the risk of lymphoma in patients with IBD treated with AZA&nbsp;or 6-MP was increased fourfold compared with the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/31\">",
"     31",
"    </a>",
"    ]. A retrospective study found that the risk of neoplasia was increased in patients who developed sustained leukopenia (defined as a white blood cell count of less than 4000 for 20 or more days) while on 6-MP [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether the increased risk of lymphoma is due to the medications alone or the combination of medications and the underlying IBD is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/33\">",
"     33",
"    </a>",
"    ]. Alimentary tract lymphoma has been described in the absence of treatment with AZA or 6-MP [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. In one series of 396 patients with Crohn's disease or ulcerative colitis, only one developed a malignancy thought to be associated with treatment (a diffuse histiocytic lymphoma of the brain) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/36\">",
"     36",
"    </a>",
"    ]. Despite the risk of lymphoma, a decision analysis concluded that treatment with AZA to preserve remission was associated with an increase in quality adjusted life expectancy, particularly in young patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple reports have documented an association between treatment with AZA or 6-MP and lymphoproliferative disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/35,39-43\">",
"     35,39-43",
"    </a>",
"    ]. In a prospective cohort study of 19,486 patients with IBD, it was found that patients receiving thiopurines had an increased risk of developing lymphoproliferative disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/38\">",
"     38",
"    </a>",
"    ]. The incidence rates of lymphoproliferative disorder were 0.9 per 1000 patient-years in those receiving thiopurines, 0.2 per 1000 patient-years in those who had discontinued therapy, and 0.26 per 1000 patient-years in those who had never received therapy. Patients receiving thiopurines for IBD were at an increased risk of developing lymphoproliferative disorders compared with those who had never received the drugs (adjusted hazard ratio 5.3, 95% CI 2.0-13.9).",
"   </p>",
"   <p>",
"    Hepatosplenic T cell lymphomas have been described in a significant number of children and young adults with IBD (ages 11 to 32) who were taking AZA or 6-MP plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Hepatosplenic T cell lymphomas have also been reported in IBD patients on AZA or 6-MP alone as well as in IBD patients on AZA or 6-MP in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    . Therefore, biologics are now being used without concomitant AZA or 6-MP in pediatric IBD patients. Future follow-up will be needed to determine the relative roles of immunomodulators",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biologics in the development of hepatosplenic T cell lymphomas in IBD patients.",
"   </p>",
"   <p>",
"    The use of AZA or 6-MP has also been associated with an increased risk of nonmelanoma skin cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41350?source=see_link\">",
"     \"Skin and eye manifestations of inflammatory bowel disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41350?source=see_link&amp;anchor=H6#H6\">",
"     \"Skin and eye manifestations of inflammatory bowel disease\", section on 'Miscellaneous skin lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MONITORING FOR TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the risk of serious adverse effects, close monitoring is required in patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (AZA) and 6-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    (6-MP) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/10,25\">",
"     10,25",
"    </a>",
"    ]. AZA and 6-MP are safe with long-term treatment provided that blood monitoring is continued at regular intervals to detect the development of the serious adverse effects including bone marrow suppression and hepatotoxicity. Several studies suggest that",
"    <span class=\"nowrap\">",
"     AZA/6-MP",
"    </span>",
"    induced liver dysfunction is dose dependent and is generally associated with increased levels of 6-methyl-mercaptopurine (6-MMP) above 5700",
"    <span class=\"nowrap\">",
"     pmol/108",
"    </span>",
"    red blood cells [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. However, it is important to emphasize that periodic monitoring does not always prevent bone marrow suppression or hepatotoxicity, which can be sudden in onset, even after a long duration of treatment. Patients should therefore be educated to pay close attention to unusual symptoms or signs of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/1,48\">",
"     1,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H517303942\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that patients should receive weekly blood monitoring (ie, hemoglobin, white blood cell count, platelet count, serum aminotransferases and total bilirubin, and amylase) for the first month and then every two weeks after a dose increase until a stable maintenance dose is reached. Monitoring should be continued for the duration of therapy and performed at least every three months once the patient can tolerate a stable maintenance dose.",
"   </p>",
"   <p>",
"    If the white blood cell count decreases below 4 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L",
"    </span>",
"    or the platelet count decreases below 120 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L,",
"    </span>",
"    the dose should be reduced (AZA dose should be decreased by at least 50 mg, and 6-MP by at least 25 mg) until these parameters normalize. A repeat white blood cell count and platelet count should be checked within two weeks. If the white blood cell count decreases below 3 x",
"    <span class=\"nowrap\">",
"     10(9)/L",
"    </span>",
"    or the platelet count decreases below 80 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L,",
"    </span>",
"    the drug should be discontinued until these parameters normalize [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/11,49\">",
"     11,49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=see_link\">",
"     \"Drug-induced neutropenia and agranulocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mild hepatitis (transaminitis) is usually reversed by lowering the drug dose. In patients in whom the serum alanine or aspartate aminotransferase become elevated, therapy can be continued by reducing the dose of 6-MP or AZA by 33 to 50 percent, while following liver function tests monthly. If serum alanine or aspartate aminotransferase exceed more than 50 percent of the upper limit of normal, treatment with",
"    <span class=\"nowrap\">",
"     AZA/6-MP",
"    </span>",
"    should be discontinued until they normalize, after which",
"    <span class=\"nowrap\">",
"     AZA/6-MP",
"    </span>",
"    can be reintroduced at a lower dose. Both 6-MP and AZA have been rarely associated with severe cholestatic jaundice, which may progress despite discontinuing therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21592/abstract/50\">",
"     50",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     AZA/6-MP",
"    </span>",
"    should be stopped (and not introduced) in patients with an elevated total bilirubin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Metabolite testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The toxicity of AZA and 6-MP is related to their metabolites (6-TG and 6-MMP in particular) (",
"    <a class=\"graphic graphic_figure graphicRef72170 \" href=\"UTD.htm?5/34/5664\">",
"     figure 1",
"    </a>",
"    ). The relative accumulation of these metabolites depends upon genetic polymorphism of the individual enzymes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44566?source=see_link&amp;anchor=H2#H2\">",
"     \"6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine\", section on 'TPMT enzyme determination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been suggested that direct measurement of 6-MP metabolites could be helpful in minimizing the toxicity related to 6-MP. Such testing is commercially available. However, although bone marrow and liver toxicity of 6-MP generally correlate with 6-MMP level, other adverse reactions (such as pancreatitis) can occur without elevated levels. Given the low predictive value of the metabolite levels in the individual patient and the additional costs compared to standard monitoring with blood chemistries and cell counts, we do not recommend metabolite monitoring to predict toxicity in patients on AZA or 6-MP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107701887\">",
"    <span class=\"h1\">",
"     AZATHIOPRINE AND 6-MERCAPTOPURINE IN PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and 6-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    in pregnancy and nursing is discussed in detail, separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25834?source=see_link&amp;anchor=H521045305#H521045305\">",
"     \"Fertility, pregnancy, and nursing in inflammatory bowel disease\", section on 'Azathioprine and mercaptopurine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (See",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?41/17/42258?source=see_link\">",
"       \"Patient information: Ulcerative colitis in adults (The Basics)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=see_link\">",
"       \"Patient information: Ulcerative colitis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      (AZA) is a prodrug that is quickly converted to 6-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"       mercaptopurine",
"      </a>",
"      (6-MP) via a nonenzymatic nucleophilic attack by sulfhydryl-containing compounds, such as glutathione, present in red blood cells and other tissues. 6-MP is then metabolized in the liver and gut by one of three enzymes: thiopurine-S-methyltransferase (TPMT), which catalyzes the methylation of 6-MP to an inactive metabolite, 6-methyl-mercaptopurine (6-MMP); xanthine oxidase, which catalyzes 6-MP to inactive thiourate; and hypoxanthine-guanine-phosphoribosyltransferase, which converts 6-MP to active metabolite 6-thioguanine (6-TG) nucleotides (",
"      <a class=\"graphic graphic_figure graphicRef72170 \" href=\"UTD.htm?5/34/5664\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pharmacodynamics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AZA should be initiated at a low dose (0.5 to 1.5",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      estimated lean body weight, daily), and increased incrementally to maximum dose of 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily. The equivalent dose of 6-MP is initially 0.25 to 0.5",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      estimated lean body weight, daily, increasing to 1.0 to 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily. We generally start 6-MP and AZA at 50 mg. If the medication is well tolerated after one month, then the dose of 6-MP is increased to 75 mg and AZA is increased to 100 mg, depending on the patient's weight. After three months of therapy, the dose of 6-MP and AZA may be further increased to 100 mg and 150 mg, respectively, if no obvious therapeutic response is seen, provided that the patient is tolerating the therapy and the white blood cell (WBC) count is &gt;4 X",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        3",
"       </sup>",
"       /L.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Dosage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AZA and 6-MP are both slow-acting drugs. A therapeutic effect can typically be expected after three months and may take as much as six months in some patients. As a result, these drugs are",
"      <strong>",
"       not",
"      </strong>",
"      indicated for monotherapy in acute relapses of inflammatory bowel disease. (See",
"      <a class=\"local\" href=\"#H517304416\">",
"       'Timing of response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should receive weekly blood monitoring (ie, hemoglobin, WBC count, platelet count, liver blood tests, and amylase) for the first month or until the maintenance dose is reached. Monitoring should be continued for the duration of therapy and performed monthly initially or every second month once the patient can tolerate a stable maintenance dose. Given the low predictive value of 6-MP metabolites in the individual patient and the additional costs, we do not recommend metabolite monitoring to predict toxicity in patients on AZA or 6-MP. (See",
"      <a class=\"local\" href=\"#H517303942\">",
"       'Laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Side effects occur in 9 to 15 percent of patients with inflammatory bowel disease treated with AZA and 6-MP. The most commonly encountered side effects are nausea, vomiting, and malaise, especially if the dose is increased too rapidly. There is no evidence that switching from 6-MP to AZA or vice versa can mitigate allergic reactions or other types of intolerance, such as dose-dependent toxicity, dyspeptic symptoms, and infectious complications. Patients who develop hypersensitivity reactions to either AZA or 6-MP should",
"      <strong>",
"       not",
"      </strong>",
"      receive either of these drugs. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As continuation of AZA and 6-MP is associated with maintenance of remission and discontinuation is associated with a high rate of relapse, we suggest continuing AZA and 6-MP indefinitely in the absence of side effects. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Duration of treatment and tapering'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Studies in patients with inflammatory bowel disease and solid organ transplant treated with AZA or 6-MP suggest that it is reasonable for women to continue these medications during pregnancy if they cannot be managed with other types of therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25834?source=see_link&amp;anchor=H521045305#H521045305\">",
"       \"Fertility, pregnancy, and nursing in inflammatory bowel disease\", section on 'Azathioprine and mercaptopurine'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/1\">",
"      Nielsen OH, Vainer B, Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther 2001; 15:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/2\">",
"      Tremaine WJ. Refractory IBD: medical management. Neth J Med 1997; 50:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/3\">",
"      Yatscoff RW, Aspeslet LJ. The monitoring of immunosuppressive drugs: a pharmacodynamic approach. Ther Drug Monit 1998; 20:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/4\">",
"      Lennard L. Assay of 6-thioinosinic acid and 6-thioguanine nucleotides, active metabolites of 6-mercaptopurine, in human red blood cells. J Chromatogr 1987; 423:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/5\">",
"      Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996; 91:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/6\">",
"      Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol 1992; 43:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/7\">",
"      Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/8\">",
"      Weinshilboum RM, Otterness DM, Szumlanski CL. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu Rev Pharmacol Toxicol 1999; 39:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/9\">",
"      Cuffari C, Hunt S, Bayless TM. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment Pharmacol Ther 2000; 14:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/10\">",
"      Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995; 123:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/11\">",
"      Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/12\">",
"      Govani SM, Higgins PD. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. J Crohns Colitis 2010; 4:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/13\">",
"      Keuzenkamp-Jansen CW, DeAbreu RA, B&ouml;kkerink JP, et al. Metabolism of intravenously administered high-dose 6-mercaptopurine with and without allopurinol treatment in patients with non-Hodgkin lymphoma. J Pediatr Hematol Oncol 1996; 18:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/14\">",
"      Szumlanski CL, Weinshilboum RM. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol 1995; 39:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/15\">",
"      Shih DQ, Nguyen M, Zheng L, et al. Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism. Aliment Pharmacol Ther 2012; 36:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/16\">",
"      Mahadevan U, Tremaine WJ, Johnson T, et al. Intravenous azathioprine in severe ulcerative colitis: a pilot study. Am J Gastroenterol 2000; 95:3463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/17\">",
"      Sandborn WJ, Tremaine WJ, Wolf DC, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology 1999; 117:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/18\">",
"      George J, Present DH, Pou R, et al. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996; 91:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/19\">",
"      Vilien M, Dahlerup JF, Munck LK, et al. Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following year. Aliment Pharmacol Ther 2004; 19:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/20\">",
"      L&eacute;mann M, Mary JY, Colombel JF, et al. A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology 2005; 128:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/21\">",
"      Treton X, Bouhnik Y, Mary JY, et al. Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 2009; 7:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/22\">",
"      Bouhnik Y, L&eacute;mann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/23\">",
"      Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/24\">",
"      Kim PS, Zlatanic J, Korelitz BI, Gleim GW. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease. Am J Gastroenterol 1999; 94:3254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/25\">",
"      Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007; :CD000478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/26\">",
"      Ardizzone S, Maconi G, Sampietro GM, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 2004; 127:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/27\">",
"      Bowen DG, Selby WS. Use of 6-mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine. Dig Dis Sci 2000; 45:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/28\">",
"      Boulton-Jones JR, Pritchard K, Mahmoud AA. The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment Pharmacol Ther 2000; 14:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/29\">",
"      Lees CW, Maan AK, Hansoti B, et al. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008; 27:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/30\">",
"      Korelitz BI, Zlatanic J, Goel F, Fuller S. Allergic reactions to 6-mercaptopurine during treatment of inflammatory bowel disease. J Clin Gastroenterol 1999; 28:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/31\">",
"      Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005; 54:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/32\">",
"      Disanti W, Rajapakse RO, Korelitz BI, et al. Incidence of neoplasms in patients who develop sustained leukopenia during or after treatment with 6-mercaptopurine for inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/33\">",
"      Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001; 121:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/34\">",
"      Connell WR, Sheffield JP, Kamm MA, et al. Lower gastrointestinal malignancy in Crohn's disease. Gut 1994; 35:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/35\">",
"      Greenstein AJ, Mullin GE, Strauchen JA, et al. Lymphoma in inflammatory bowel disease. Cancer 1992; 69:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/36\">",
"      Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/37\">",
"      Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000; 118:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/38\">",
"      Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/39\">",
"      Larvol L, Soule JC, Le Tourneau A. Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease. N Engl J Med 1994; 331:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/40\">",
"      Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/41\">",
"      Li S, Borowitz MJ. Primary Epstein-Barr virus-associated Hodgkin disease of the ileum complicating Crohn disease. Arch Pathol Lab Med 2001; 125:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/42\">",
"      Calaminici MR, Sheaff MT, Norton AJ, Feakins RM. Ileocaecal Epstein-Barr virus-positive lymphoproliferative disorder complicating Crohn's disease. Histopathology 1999; 35:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/43\">",
"      Dayharsh GA, Loftus EV Jr, Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002; 122:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/44\">",
"      Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/45\">",
"      Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011; 9:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/46\">",
"      Cuffari C, Th&eacute;or&ecirc;t Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996; 39:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/47\">",
"      Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/48\">",
"      Ardizzone S, Molteni P, Imbesi V, et al. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol 1997; 25:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/49\">",
"      Tanis AA. Azathioprine in inflammatory bowel disease, a safe alternative? Mediators Inflamm 1998; 7:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21592/abstract/50\">",
"      Shorey J, Schenker S, Suki WN, Combes B. Hepatotoxicity of mercaptopurine. Arch Intern Med 1968; 122:54.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4056 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-15E18CE5C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_5_21592=[""].join("\n");
var outline_f21_5_21592=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACODYNAMICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DOSAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H391261686\">",
"      Dosage in patients on allopurinol and 5-ASAs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H969623537\">",
"      Split dose administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H517304416\">",
"      TIMING OF RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DURATION OF TREATMENT AND TAPERING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H190342717\">",
"      Neoplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MONITORING FOR TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H517303942\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Metabolite testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H107701887\">",
"      AZATHIOPRINE AND 6-MERCAPTOPURINE IN PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4056\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4056|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/34/5664\" title=\"figure 1\">",
"      6-MP metabolism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44566?source=related_link\">",
"      6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=related_link\">",
"      Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=related_link\">",
"      Drug-induced neutropenia and agranulocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/14/25834?source=related_link\">",
"      Fertility, pregnancy, and nursing in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=related_link\">",
"      Immunomodulator therapy in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=related_link\">",
"      Overview of the medical management of severe or refractory Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/39/10869?source=related_link\">",
"      Patient information: Ulcerative colitis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?41/17/42258?source=related_link\">",
"      Patient information: Ulcerative colitis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41350?source=related_link\">",
"      Skin and eye manifestations of inflammatory bowel disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_5_21593="Biopsy eosinophil gastroent";
var content_f21_5_21593=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50254&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 490px\">",
"   <div class=\"ttl\">",
"    Eosinophilic gastroenteritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 470px; height: 351px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFfAdYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDvPEPhrTItSh1pxMmoRQfZ0KSEbVJzsAPHPrXO6t4xm0J0+yWEJtII2ieOUNh25bcOexPXpWtZa5fahZi/u8SC5aVV+YHOzgbfRe1cz4R8Vpq+vyxavbRG3T5mbyyDFyB8ufvYJ/Ot1B772PpPar2fLLr2MXW9L8ceNtWLpp6Whm8qeyS8ISONMYbnuORx7cV1MfhDXdK1+OfTCt3amVH+0mXYNgGHUA9uMDJx3r0K5nt4NKvEj3zRu2d/QkY6DPTPBz2rlLPx1ptle/2XfNsljABESEJECONzdBxyaI3d3FEynKSSk/dXf5/5nb29lazSCJ4FCMVDbf4iRyM98EVU8YeJz4f+y2Wm6Ok6AgNKyr+O0HuKs2dzZxKUkLLGOVcglsk8cDoM96ztZ1K3vtNv01S8t4raTEJWTapbtu3Dnjrx0qI76mE6cp69Ec/B4vGp+KbSDTWZrCZMzSSxfMhHXPPrjGPpWnc+KIrf4iW3h1LQSLLp8l5NNuOYNvCjHfdg/oK5fwbawW+qLBpDTzWjH/SLqcMVIXIVU44zyc++TXRSeGLe38W3njGW6dnOnfYfIZflRQwJYH3AHHbmqsk2jetf2cOmmpzHjPxRb6izyz6bHOISERg3ltjOD043egrC0ux0zUZGSx1K/tJY1DbHjDBgTyQ3UY9K09b1bT5L6TzdCjnYZG/lBwPvEjgirnhqa3kiWe3szByUBY8ED+6cZx6VvstDnpx5pWNqOdLe3EcUj7c/eLc578+vtUmHjdLiCQpKjb4yDkA+lLa6FqmvXDyW0SJEoADynavX6ZJ969J8O+F7PTUV54hPdjjzpMEE+qr0A/WsZSUToq4ilQj72r7EGn3WoXFnFIdPnEpXJUMAGHbGelcZ4ol1O7vY0vIJLQRDMMb+/wDESOCa9Zt0dEKuScHhickiuS+IrxfZ7ZFBa6DbgFOSF78e/wDSs4S12OHCV4uty8u/4HBXc15badEyLGULYcsMso7Adua5XWNNj1GWG8vLmOGfJIlZjls87VX+9jHtXXW0we3na4uDCAvZOCff1rl9euEim8sxRzNgM3GQ+TwOT/8Aq6V0xZ2Vo3Z2vhCTSI9PuHsLa4tvLHlvLM+7fGBksvOOvXuD7VFrOradN4oh+2W8d5EI/tERZujf3W9OlZN7rVto/gRry2itiJLz7MquSYpZHwOe4Un9axvGVzJ4XsJdQjgjup2VY1lYHNuejNjoQM8Hn1rGSk3odGEVKKlKbs7P+v6+Rn+J/D2q219F4qvLmOK8vg1tKsbttRC2QHXooIwB16ZrvPHGhzzBLfwjaQxQwxhpY7dfmkJAwSRyxGev9ax/DX9ueLPC8t9HJNdL5oDbNu4OFGQCvBAG0e1ej+GWiudNs5URdyL5eEY5BHoe/wD+undxfNcwxM4SpqMUk43289fw2Mua21iDw7bjUJp7HVjHskFlLuBVW+Uk8fNt68GuLXxBqVr4wh0GyvnjIDSPA4ys2efMJ9Tnkjgdq6P4nahq+lrFfaUqyWrSeVM3LNC3rk9vY/pXnfjfxNaac3g7Wp4JrrWb23PljT3EYYDKuSed3+769aTWnMx4SooxcHG7e2nXp/X3Hpp8L2l6sbS3phvY0MscQkDeYf7xXrjPHHWqemaLZjWotQ8RQyKdPKyWyI7FXl5ABUfeHQ49axLe68OWPh238aSz6jNfxym1tQx2TTP0aExg7eOefxr0PwzqMGv6YtzZ3Ah80CMADDLkcg57j0p8+l09Gc9SnOKlzXVnZ+Rxl5oWneNfFV1dapajTXSILHf2qhS/PRiRhmwThu3vW5ommXmoadNY6jaTJBb7Y4Wm5kdei72zyeB8w65q74htL06TcWtnI8GpNC0aXBG4IezY/r2rJ8HSeI4PDOp2etrDBcGQLat5/nO8ZHzZYDA9u/XOM0NX1Rca9SnTVOOvby81/wAEg8R+D9F1zTpbC71BLZgnlvscjC55+Ye/eqnhXwNFp9/C9lrFzeeSxdS5xuXGAo/vAf4Gsqx8Ia1feK7q/vpEt7EOGt7iOdlZE/hRY+m7GVIPBzXd6na2V/ALdLaSH/nm6yFHDjpjP48CnJJaXNI4itdtPW1vkXLnRriws7qeyRrdmw4baZpYyOu31JqMnVL7T/PvLezt7MKpJkUb2TOW9x0x+tamm6iumRwWsv2oQwwYIuSC5fOQM9Tx+VXIL3TNdtAnmCMpIpeInYysMHaR3rNtnF7WcfjjdX3tfQ5rVNPm8U6pLpi6pFY2CQx/abCDiRlPXnHTPQ/mKn1Hw3o/h34f6nZJK1lYW1vJMZh+9kjABLPzySR26elauv6MLiZri0zbyhCvnQL+8B69e6+3evKvAuhePYPHFydZ1iDVrDyZUMjvmJdykIJIjhs5A7Edeal20Z1U6kqtNclTljFXt5r82+l7vocF4R+JumWFzbf8Ix4alu2vnW1kupbgNKmTg4THy7s9AcVY+JsM+h+ObeLwZpbTWS7Q8eDKgct+8XcfugD1PU8VQ8JReKPB3jCO8vfDGlRGW+23iQrCY3Tr5kWMlTgkgjH9K9tafwVrDQP9kmAuDvllIcFQD0Yg9z6U6F43utPQ6sbXcnGUJN8yu2m326PXTtrvZGLqnirQtC02wsNFtJpbC6LS3dyjKGiOPukn7zD8uK6ie2g1HRdMkgusWiDBmdvvg+x9eOK4v4p+FtO1DU9K8RaOZWjVhb3VtGD5Yjx8p2j7v1xWXqHjC50HS9Wm8S6DqM+kwzrbW0VnGNys38O48Djv9MVtyppWOGFXlj7Rb6nXePtZuNH8LTx6Ezyyy3C2cA+80YAy7/7Xt7mvLZ7XVrS2judbu/tTNKES1jlyy9wGPRT3yc/SvV9UUXOjabe6XZSW8FxbpNBBcLteNWGSZB2bnpXLzST2/hS4WaBLqQyYUEEpGcewyf5c1UHoaxfu3W5maFqF1rUOo6aoSxVEbyblX5+XqMkk4IPB45p/hRdX0zVIJUvZZE8zdiXGEQjAT/a/HmoLe7ex0d1kjskFyfu7VByOgYA8c8DJx3qrLq0Bjtmv5tOspGTatmkoGxh95jk556ZPHHFXYlu+53Wm+JNe0/XpVk0q/u7dm3C6gieZRn+AhRlSPfio/iRoGpa5eW9xLaSQ3NzgL5A+baOx6EN/kVUj8YXPh7warvqMaXEzSG3iJySvqD/+uq/gjxvrOqXF2hId5oSkby4URZ4J65P1rOzT5kZpOMnJJHEXI8ReCb+0im/fRXjt5fmgFJF6EAfwke/PNdno2orCYXsJY7TeMbZpMbgRyOeuD6VR0rwVq+qSym1vdKvra2kUec12JUJ9AFGRx3PNR/EXQtSY2yT29vH5GW/1e6Mo3GeOnTr2NU7N2OqnVvdXudYmqXUs0vnlZbraAwj4Cr2x/Orlvqgt4BHMm1gAQpPBz3964SyupdFs5FuZx9ljI2OeTtI4XPfB6e1a1rqkMscTStuQjdv6Z46exqXE0XLJHUPeJc2MkcAKefkzE9F4x8v1rB0rStO0q+Eup3jRlXDKFRt3PoPr3p91fWdrYrcSSCGLHyyE/pgdeazYJlv0aZZfPHl4ZmGWUc9c/pQkRKK6HRLNbx2kzTvlpiR5jnLMM52j0rHvGtZ28qV0WNxjEpxnvg+/vVK1dUs3EkqTOoI+ZuhPTiuLvFv2vkkllfdFkfM3ytz39apRFKdlZGhBe2s12sV5p8xgAbYY5ArMB2z3x6detegeB7ey1HXrRrQbrVhvIPGQPX0xgVy+jaHb3aQpeQy7pmU7EGf3meGXHevTvDlg3hqIibyW1GaPaIBhfLi7cDqfapqPSyIbcE+72Leu3bT37tEEKoOPVSD/AFxXD/ETxdf6PdTyEsjzOsNsvRVPB3tj+7/WutuxJLD5gMe5cKUXrnrz/nioPF9vYazrenadqUMF5LFbgPbNn5HPUBxyDjBx6Vj0si6LhTnDmjdL9LM8/wDA/iW+1r7Rd6jdvdzWs6wyybdqujAsCccfQisq08fePdZ+IbaNDGsehzI8QdVAMUQzyXPRs4z+ldm9pa6CV8P6ZYRWRCM8USH5JJByfmPLHbxntWfrMEaW9wyqIgFAOTk5OOfw6U4RtZXOvE+zqx53FJ9LWsvl5/I4K68OWUGuW3/CS62/kLJ5zvbTGRkUdRkcgnp+Netaf8QrS9eN9Cn32EGIypHzKMcbvwryG/8AClv9vSd7t5iZFkEpJIbjO4DPA7fhXV6WmlabbqXvlWSQrI4wQC3QEnp3raSTOGMFJ+9sejXfjPBOyeMAnIfeenp0oriJYfMUF0Xdk4B5BHqPais+VHQsLS7GUvi+CHxbHa3Fi1vYRSR25hlTO1W7/L0B3ZA6cGvR/EOg2mt2NtaOkcUFuP8AR9i706EHPTIIP1HFeH32s6/deEotZ1bwvdR3yXpgXZalDMmPkcgjcMZI44zXfaV4ouNI8DWmqz2d9d4iPnwbSzxSA4YcdRyML1XvUyl71luDwyqU/ap6P8N+/o/6Z1NxeDwvpBktY7q6uLOyMMKKMvcS/dQ88KBnOfbvXnHgLwxJqHiG61Tx5Eb6yCLLbYfa7y5+5KF4YDsevAp+keKda8Q6xDc6jpottJB/d2zNslulwO7Y2+3r716J4i8Q6Tp3hyNxYy2EKYn81wD8x/h9+OoqneBz2jVl7OKve39d+v8AWgmpmwmYG4ieOOU5UK53vyDtJHNZfxM8O/b/AAroUmjNZxWaSulzG38UbYzt9cY5FYEWu2Gs3E82jtLNKYjLIm8qiEfxqp6n6ce1ddpviTS7SxtbbxNPbxQ3EoUPIwSTfx8+3oAcgZqIyTalDU3rUKkKS9pdJPY6Twx4fsLXwpHbw7pYAN3nbvnkY9WPt6D0qKKOJ47tJ3PkBCTuPDDPf2rmPHmp6hoUUem2ky22mFy7En95ycBSehT8e9WND1T+1dCM0EatPCrJtOcMexPqOmKV9fUzpYeTpSqp3jf5r/hzy3xB4js49QuYtMkDTiVh5Rk8mNlBIGwHrzx1rqfAviTV9Kv9vi/SrI2cg/dTwThivGQpB5IxxwcZrIuNF0i+mlvLDT4H1K0kab7Ps+VXb70gz39V6Aism5eV9Sk+1TO0y482ZmwR+H90dPxrqspKxg0kr30Pd7Dx3ZWdoq3FrMeOsa5GfQ+lO0rxrtvrh7mJxZyHMMYIJQD+ZNeX+Ebid4rhdQBkgkOFjQZZVGOMngD/AOvXUW0dvdtI8ZC4GERugHTg1i6aQ1RoO91udFqnjq4knEdhEsXcB+/1rAubm41S6e4leVpY1/eyMMBFH8hWJqGoS6ZqgtljjcswCvuGWBGCAPp39elQeJNTj8tIYJXMYBLLyE354Lf3sc8VSh2KXs6S/dqxc1q8trK0KG4kjd3+V9pYH2P+NYcJvbzUoIoo4rkrgtHMxwEJ59wMc8Vc1rTptS8JvFZO6apaQGdElO5J0ByV9VIHIP4VR0lgNGtNaji/07rb2kj5R5RwX3n/AJZKMtg8/wANaLRENuTsd5qeg6XdLpUl1mKws5TcxKQFRCFwG2jqRzj3NTGddZs+LeS0gctHbG5UAkdCX9M+nTFchFa+LbzSQ1jE+rRyzRAsdu3ax+bZnHAHJ9BXRazp1/qusM/mRQ2EQEMIRskFepLHg55A9OKytrZvY1nKEaatrJ/h/wAP+hueGdLXwtYQWEkkieUXkeRSFi+Y5LHHAHTmnajqml6RZRSXs1rYKxJTa4Cn12f3uucjjmuK+Jnw317XNNiuNP1W93xw7RaxzhV2jH7vn7x5NaOpfD/+0dL0y8uJI11qzsktJJw3yTHOXA54IAHIGeKlOLdmyJxjye1Uk23/AFp0/q2hoeJNWtZPBy3KXlvd6XfjyMwNu81WJ6D3xjPY1z2jfDe31rwbGJysV5YzStZzIARBuwG3DPGcDgelOj8GXGleHtE0zRtWSKO3u5LvUSy7TLu5CooGMEnoMVg/D7wL4n8J6/fTDUbme0m3lrS1dpTcOT8rOG+VSBzn8KbpxlfX+nuawxU6VNRpqzvdv02/NlzWfCZufDGm6HYyNPdaXLNLLwP37SnJKqOcYOOemAaTTr/xR4JuNLgaySSwvjGtzJIR/o8WdrS7wcLtHPIOa9MsrbUrcQyXtksNy4Odu35cdMsOvH5Vwes6hreqeJ1tofDTyaOItonEyxS+YBlgMn5uexFKKjGyWyVhupUrQlG6953b83+CX4HaWx1u2uLia8ntrzS3IaCQOH3oeAQV7EYI+tXlRNSe6i8M61F9qiwJbaZWwGxkYzyB+YrhdA8Z6Vaz6Poul6Fez+ZKLVrSSQR+SWP3lXuO/OMc1uaz4h8K2uqfZp7W5tdQjPEiOcoc9iM8cdaaTMK/MpuLVmuyVvuv+RsaNY+IZkuhrkdtb4cBJYcl3Pf2x79avDRLyYggrtib5DMuTx3A/Gq0HiG7j3b9UidGGEE1tkrxxuZSB+nNRpqmp2Wnx28NxFdAFv36S+YzEHONpHA5x7ClZmd6y7Fy60m/IBnmjfcD8jJ8uT1OevNVX0cxosr28WzhEZpcEseNqjrXNeIvis+mwvK9vYSLGNsk8UnmIhHLZPQY/Wsrw98QtK10yXV8zRX1u6kyRqz7x2JGP3ZxgZ4zRG97HQqWJjT9pOyXy/K/4mn8ST4p0XRLdtB1GTdZuJbi1ik2u9uDkhXOQCPcdM4q/wCF/EEvjLw9Y391b2ytKHtzI/EjDdgcjp2OPWueW/8AE0eu6vrNnDBewjfLAJJAVMffaM53Y4KYH5GqOm3WrWskFu6w6LYv/pERghXyw5OcMg6jOBgHpmr0+HqKNF8nt3bt539CLxX8M7ex1r+0pb2dCZ/PAOScg52q393tg8V0FlptnqunT2OpahPpyPb7ozEwQjsGHHzYznFburXKT6CmvXItkuCAAkkh2ADrgHt1rzbVfHtpJZ3jywu00aDeiDym2sMKxz91fb86bm+W7exFCk675EtT03wRBoWjaf8A2b/bKagBFsnaQ43djx6df5V0WoajpF5AunpPCyjBWJCcFQOORxj0r5i+GNzq+u+LIJre2/0NlMbKiF2xnqT/AADjOO9e5+E/DrxxyXt2ymON2EMaHadwbnPYCs24yfMncKuDVFKVW6fb9SefWrwLcRanHYWumKAsNwyMuzHROvX9BXI6lFD4lhW10W7Z2j3PPNGP3cfclxwM4HA9O1db4hWx1XRpbCKZgxbzfN/j298ehPQGqsSaH4b8KDy4Y5p2YFLWJ8qef4yTzx1Y9atO2xMVyx23PLTeXmls62tvHMSSBNNESrAHuAMAHqMkniq0/gPw3qtnJexi/mnlUS3SIx2pnIZlOMlAccZ4NXfEHjbU9UvrsQ6SsdkxXanzdugGBwR3JzTNDutIuobjS4XktNY1KIMEkYldyNkglRyOM+pFbarUbi2W9NFusUeiQ6XYXMKBV0+eSHIRsZKpnOM9C38609Vjg0eOO1msUha7i3mXaAG5wyfQVh3upQeG9XeK1vINQuA22WWMGOOIkciMdQV9Sagij8Q3NktxFcwahpzfvIpNQITyl6nd3OcfeHX0pWBXa0Ltnous6Ncaf4j8L3T2dnP/AKPMrReYhRDgqVHUdcEjjmvedLudJ8TafiJhL5e5GB6gnqD6ivKoNfl1KSK2gu5LXAWOKJFMceRxhBxxwfeuv0aynuWU+cIbxOVdBlT7EDn8axqK+r3IqUrx5r2a6o4r4heGV067W2uVMVg8oeKVDgAHg59x6elYQgurCA/ZJBJJIURiyhjH2BA6Y5r3S8xc2D2etQrMgPEqsOcfUcEVyl1o+nhjFbuZYHGTvHb0OOtOM9NTSnNzWu/4M83tGvr+xube5yr/AGgBNyAvuU9BxgA/1qnZme11+9jZykc8O1mA+UNngY/GvRX8HfZ4BNGJvNDhixfcjjsSOo7VfXTFvtNkj1TSi15GhKXkZ2sAOmR/EM/zqudFeZ5wNPe2vWkZtgdQslsVyD/u/WtzTdJNw8KXdsqJgmQnDY56kn7ppfD+v2Opa0NNS1vrnychhbpnaR1wD/Wu68M6j4d1nXpdL0cC6FmvmTNJxjnHp83PXNQ6nYutB4fWot1f+tTH86Lw+63VnDI9zN8sPyliinvyOtR2zXNjbXeo6ndtNMUMs0zDaFAHP+6MDpXV+NvGfh/w1PHaagpmvGXzFhRASq9MkngZ/OsyKaHVdOEotRPZXyMJ1Y48uN88kfxcccc1N76tGdGvKScuXcxvDmv2fiaMXumXSPbtKIGC4AVuCTn2BzWPolrqEXiEXhcahaWd+Xee3O5HXn5s9SxyQQe/qMVBqOiad4Z02PTtEZ7ezkOQEHzMzHH58DrUieJdI+HPhp9U1Waee9upRaR2dvw0h7H2wO/areiuhzd0kcr8XtduvDHxJ0nULCfzyLXzraGRA6ujsQ6n342nvWx40vdVGjWup6PcS29tIAphhI3xzOchpO7Db8g/hB5NN8Y+MYtVtdN1Wz0OC8tIiSftUYaW34wxVuME8Zx9a6TUI7LxJolvdWKwv5lt5kEYHyeaowAcVnGTfvJ3O50lCMYVocrW/ov17/8ABPO7nxLFrfnw6ZClvdRbBIRGG34+9t+pB69Kit4dQ1u6jS6ysJO+TzSAy9uccdqm0i0fTrSae8s47PVLpsmGf+EL3Y+p7Cquk6hf3Gptj5oTnIVQCQAeR7VtF3jexhWhGNVxjK67ncyypbQxeZHHwoRWORkAUVF9pFzAssgVWPdh2x+lFQbpHa6jq19a2s1/cXMixxoQ6FQwKnnGD1Pv2rirDxjLe3kFgLApbzhljf7yYHJwq45ORyepPeotf+It1PrZg1CPSLqGGIbLOxkMksJbOd5OFJ24yO1P0fWb7SdQN1aaPYSQKPMCLC5LEjjDdcjrjHP4UoxVmranC/aU4qTiknf8P1Kt5qNzZawJbuO7k08vtkhkjJ59zjcPwNO8RW2kalE0+pXcfkwgswD7tgI5Xb6Y/wDr1qt4w0O71wy63qcVnIApfe+0xsegH4/lWb4f0WOfULb7Wts1ojMluocM9xubA46Dk9/1qlpuW3F25V/Xc841ewgaOyh8BaheXmmCI3G+2hd555C+3awUBuMYAxj1r1zXdC0vV9BtF8WafdI1uqAwhgko6FgWz25yfrXVXAi0W4cKsVu6oqM0KhXSMDhcKAfyrl9S1zSdaRba1lmN2uTGZIcrsz83Xhun3etJPaytYUpSno5Xvbfv/kVfEpsfGlxBbWyyxFSQkaz/ACyKB93IH3cduhrbl1TTPC/2SKTT7lbacEiFY/JjDLgYBJxt64HeqWn2MNjFFPpSmV5VJQkYZsnkL/dUnrXKaP4h1TWddm0HxBpkt9osrkSxXQ2CMgZGx+o5GBjtzT5brTZEqXJaM1fy2/r9DX1+6h1TVLeXwlIy6rI29rMD5QRySxOBkAEehzirt94duNQhjnuHt7VDGZLq3dV2q3cMTyQDyPriuC8Y/DjVtX8U6cfDIe201JN87i78tkUsCoVjyxAz0HX869K8Q6i/h7TVtb2Fr1mjELrLEWaQcDccdcnH86lSaSubTownVcKL06X9PX7zJtrC2N0LOzMV1a3GCxefZucYBG0clenAqoyak2rLpulKxlSbayiM/Imc72boB1P04qTw0+n6n5U82jajaSpMUDSMSp/21H3gn+eldfdXupJfBYUheHpIY8h9v0x/WrcrGHsW21dL5nCf2Ne3Piy/vmKbYywQq25WwDtVfbODW1Y+FdRv7RDJYyxxkqcuR8x7/gOua0BeazvddEOnW8pVipuLeRScZz1GCePWsOS18Va6V06TXbtbsqZHtY5BCSgOGbhcjqOnNDk7lQoOcXJNWW//AAx2d9a2NnZXUayM126hDt4GzjccdQDULSWOmTQTPp6XDGFYoI3H7tBngFR0z6dK5PRfCv8Awg+oGXUJp7rWJIvlmmmaZkTORg+5GOe1dpYRadq1r5iziS5/1j25JUBs85zz19anoTPltyxd/P8Aq2hyF18RtVu9UeBdMtYLIfufPEjAx4OD5SY5Pua7HRo7W7tUiudzQjEjLGh39crweh4zzVyH4fWU17HNcsXTblYsdOfUdjWz4g8Q+GvDMJW/ure3dF5ijwXwB3A6fjWak72Q61bDRUYYdNy6la+1ecOs0TQpaqxDQMv7+QY/Lr6dq5bxR9u1vb9j2WcCptbuRz2PYkVl6X4gh8QzmfTdRt7uzMpjZISWOVGSBx79enFbU13FbRZkJ27tqRlgeffHU47VaXKzX6vTpxvdF7SxbWGlW1sySXMyqFN1Ie/rg5q7q0d1JZzQx3MtlI4IFxE3zISMA8jBI7Zrn5tYtSsjBpGeNMgDgDnpg8/hxVjUNRgt1ilt7mSVJkV4kIPz56j2NPldzBuFzCbw34rv9Nure58dygFgsRNlnYmMMrfNlieuR0+lZd38LLia+FxaeML97pYgiiWDEYkA/wBZ16Y42j8eldRJriIn2nIMKgfOnGPb65qLW7+11GyS3j1KSzmkAZHQ/Op9wOoPp3oSd7mqk7KMXp8v8rnK6P4Z8Rt4w0678RaJaG/sY/kv4ZNq7VOA3HDvj5v0xXb3OnaZrurPd3dgkWpQHLBgWLA/xdgQQM4xXHRvr/h26F1pw84Z3v5eXEntt65P6V0lvcJ4pitb2Ka707UJF3FSpHKZ4Zs8DPf07VTT3uRUb0ul6m7pfjrw8YRaT3MKISVlimXb+XHI+tc7eSaRdWep/Z9aOm3UdrItvceWZI0D5WOQt0fGQCKranoljeNazwRC1vF2yTSiIeUWJ4K5+8CQc4HNZt74Me58N6rZQ6kscUkDeSsaeWhYksck9Ac49qVkthU4QTd7q/n1+5/1qHwi+H09nZ6jc6/q2mX8t0FDrbuZIWBO7eRtC5PoB9aTWND8MaXd2kOi3EWmXl+32ma3VSscwDYGXGQjBuMZxg9K3fgrp+qaNpS2WrLdJDdQ+bmZlYK2AAoYcH5e461vXvgvR7vyzqMm21glNxHuVQVY9QPXOOeKXNaT1IqSalao+3n+XUxdY0rUvD+l7bfTbadJ1865kUh1hVQThh1weQW+leO2vjGPU9Vt9JkkiV7yZmH2bO1SB90qSQB7D616r4RspG+Kt/4k1a4uJB9iktElc7YjHuGyNVHDYAz+JJ5rTtfAnhvStRvNa0LR7OPUbpvM8zlioPZUJKrnk8AGonBuS1+47MHj/Yw9lKmm7rV3/L+rdrli/tNMvprXwvPKkNzdwM0MO0gEBcOM9jjn9RXGaboHhPQ/EK2Wqyi4ubseUBJEZEVAx5PPJYjv6VueL7HVXv8ASr7RrZZrvTgSbhiMJzkZDdxyPfNS6ppmi+SPFmrIssmn2rXskke7CEfMRt/iIbOBWvS3c44ylCble3mjF1288Vy3baRps0ek6f5+yKzsLfyCU3YGJByeOSRgda9MaLUEeHSzGrWoVfO8lfmX1Offrke9cj4S8e6Z400VtT0lCt3bRl5bVnHmxn1J7Z/Kt3R9S1rWLO8OpWgtpPljt5kzh+5JXoCOahu/QUqclHm6X/Hv/wAEpeJr223G2sJIYgVCkyDKqq5Iye5J/nXmOvW1zqU2+S4jRckSK37uL257H0ArpfGU0MOry6dpUTG7+zG4e4ky6bgcCNfc9T7VxviCebUtI0uV2MNxbh0uYlXMbHOS646+ntW0FY2vFKyuTWflaW5lEjSpHhCU4Vv6kH+db9pb6bd3lvqVnZw2kzMR5jx4YMOOvb61k+CLC78hxqcEV5ZRjdmUZYvkdh0H9a7eG0e/gZZg00yA7FQ4EQ9AOnH60pOxUH1Mo6VYySyzvCC+VEi5+QuM87e9cn8RYPF32xp9K1ArZwRhI4I1XZ0wVZSMMMcDt2ruFjRVWJGeG5f5ZiRgFs9/emG2lmlNjN5ZUZYGTAL+vP8AIUKVnccoJnB+ErrU9TjSfWbXULQ2RBW2WEiKY9R5THpg9VOfY9q9Q0DXQ10JvJmgGQHMoIIY9zntXm/iS2ubnWHuINQaO3jVVW33ldigYwD0681H4fsvEFlrEFy80Ulux2tul3F4x2A6dOufwpyipIySWx6t49ju9J8Nalremw3eqyW6h2sEOWK5GSvqB1I68VB4Be48QaLHf3Fq9pKSQoJxvUdwDzW34R1TzY3jYBY14VkkyR/d+tbOr2t5ETLbyQeeseYi3BDeh7EGsLtaEOtOL5G/QisrWa2hdJAxU/Ku0cr+FWoPPjRJLkiJR8hJAP0A55rPtLq+nsYX1YGCdn2tFHwSnqcdz7Vj/wBsSXPiny9PSGbT1iaORm+aRXP3WTnA5wPzqbNmbUpblzxJqlloGm6hcWkQWS5OZAqYMjkYyemOP5ZrA+DWgWmltd6rZmRYSnkNJNL5ryj723cey5/WrOs+LPDgvtT0zX4Gkt42SGW9d8xmb+6MHcCD3HpWv/Z+n2uhQHQXjGlyjeEtzlGHcjOefWq2Vu4WTXJtfqZfxD8HaJ41kju/tUltdxuiiSM5Em09GU+nr2q+txbaNpaW0aOUt0RPLV+WGO/ueprJTxBZW9wtsX8+6CssUWQCQOeP60lv5l5HFc3EDLc5LCItwM+p7/SnZ7M3hQ5VboN1zy9W0yW7uYDJOuWjhh+V8hflYAc4Brxm6h06a5XUr+2mv1tVdTH92HcSGxu6l8jH4+1elaxY+I7XxlYT6NaRXEboHa4WYReR2YEdTxggd+RXUpo2hOsU15p032iCT7S8LAIjSf8APQqexJJqk1FWE3JNcvT+v6ZzvwaNtr2natpmtaQIc7bpbdkJhRHz8gJ5LAAZ7dK6iPw5aaNo7aZo9qsdsjtLDGh/1eTyAfT2rFufiTp08s9pZ28cZSQIxlBUg5xwBW7q895LpcMVll5ZipPkc4B78mskuq2NK3t41XKtdN2dn/XU8t8UWzXU0i3CyHbncOpzn1rlrW0W01J1kt5WVtuzD8nPJAPYDAz9a9vbRbhpYJ7mKC4uAmJI0YoM/wCyfXHFecavpjLfTQCA2wJO1cgkfj3FbxlfQt2m7oowXF7d/vPN8kfwsuJAR6dP1orLvZpbICMgtFCfKSOMY4xnJoqrE37naW/w48P2ukahYyL5898QXvWTLoQQVC+wx+NPttEvdEe2mtri4uEiZZWS3/dO5X+EkkjtyMd6zoNeuxaQ6ttleBoy5jkbI3ZwFUjr9e1ZWi6/rOr+JZUu5ri3t0y8u0hIEjzyQD09Mnkms4wcY2T0JqVY1KnPUV2/66GL4lvvBV3rckWqaPqum3OqTbpjJCFXfnsc8c8fL6n1r2TwRptlpzWIuYGgnt90UJxvi2n7o/D1NYXnaDrf7udk1KWB/MRJotuD2cZ5rs7GaEsqFFSQLgKoz2rOcFe5t9Ycqbp9Onfr+Gp574a8aXeveM7nTPGNmkTxiWLzIYjHsAJ4f2IHB/xrbsNOsdL1iK5ihaFo2fywuQwB/iXniumv7WLUdPvZoCkVyqFQTFhz/s56nFeeT3Fzpml3d5qBM0EzLawxljjd1aXn+ED5fqarmVm9kYUozlakld7I7TxD4h07TLKK41NkCAFwfunA9D/hWboOr+F9ekN7ZTtPI6E+U4KtGw457EfSsDxG8Wv2OmXZuUWc8RxseZCDxgAfdHGccHik+Go0LQWm0/UtLuJbi7meU3CnCRk8hQOMZOfbmkpQto9TethK9OLly6Lc7/S7KKyleZZxK0gxsyWA9x6Cr2qlHjWTUXglRdpQXIGP+AmsafV9KtLw/ZY3topXBVZcAJgc4Oc/hzXP+LoruTSruezWW6ulXfCWO4Z9VB46U+VtnPSjFvmvb8zuLbUDIl0YIWMEJEcjBeYyRkbs4OCCDnpzSjT4Ly6yt2UfaARvAyfbtXK/CCx1m90PWdTuzcGWa2+xWv2gNhtm452nqMnAJ+g4rK8F+HvGba5OuqXMsVqYjNPNfOreTJu5KqOoIz6DinypX12Of2sbtP7z0FPCxjuBNBPJLIG8wbpehz15yOfpViXVJNKEt09rFNMEZN0a7nbHOwY/TtXC+Fvidomt+J5PDejHUL2SOJ5TfvGI45Qpxx7Ht2NO8d69qegy2/2W3WayZvKdySBDL/tMPXseemBS5JN2Y4tTXvao5N/HU/i/VdSmstK1e1uo4d8ks8aCFVQZCqcblPHQ5yTyKT4W+KLnxfrN1bz29xBLZyeSkgXHzvnKvgdiD7e1ej6RDY6hYW97ql9diKSLe0JOXYnsT6fhVOTXrHwnepongDw5asJW828uGlEaxcElmzyxA9+OlU3d2ijWNoR5VG8u+y2/T0NDxKtoG/4R+51LV4r0wCdjA7RoydCob+n0rgY/hJ4Zv4jJI2q3Ekj7wsupmQgr/CQB39+RjqKTQvFl9r3jSaJZI5LV96mEqFd2Pz7wx/h4HA4xXcvq6abp1xfTWzTbI1eJYjtDuxAUFvqRn2oXNHQbiuW+7W5k+IYW8G+F5NN8I6bbPqN0VjEESM+OMjGOW+nc9TVBluotL02LxVp4/tpVWWVbX5U3MCCMdnwVPB65pY77Vp9Ehu2u4LfVZkYOYPl+XJ+6eoxx+ArL0GbVTdhb23JhDh3d16cdVJODn1B7VaVkZtNvcfbaMbpZLKOS7aO1iKefOmwgAnAHfcc+/Sl8QRT2ej6ZmWW48sbHePnHJ/lXY6dFda1LBGh2qvy784LrnPPpVnXtEu9JtDOyq8LP+9ZRkEEdx2570ufWw1Ze63qcTokbzaZLHcSMwkbzEDZVtvqRXLW80Eut3BmLC2CnaCCrE5OCT6cHmt6zv3fWrRbmM+fcyF4iQcPGwOVJ7EDtn3qnq+g3X22/u7yWS4KlYrdgfm8s4+U9ht9atGi0SOs0zU7URRYZUXHyBSVOfx6GsfxJqrwajLFdz77W4jBCHg7e+W9cjv6Vxlrr1zJ4rt7FfLubVZNoWOPBfjG48YAz0967zWNMTVbR7WSP97FnDcDcO4IBpOPK9TRS51puW/8AhJzbW9rNeW32q0m/diZH2iIg4II7Guhs5rbVdPCxKjxhSnktwufoOoOK8w0ySXTYZbXUoY2tZ38hkHYH7kmc8Edz7YrrPhzA8EktldzRFmPmQlWAMgBx8o9Bwce9ZyVi+SLjeG6NfXPHCaZ4l0jwtpltKbi4Rpyy25ljYDlkX0wOSR04FcJrdz4j8R/E/VdIjN1p2n2aEQRlSRMCvzyB+mRn14Ge9e4aTEbO7jGFEsrAM6qPmGDj3HTFZepyR3WrXWn6XPbQ3RQyNG2MyOONp9CQCOlSpWehzU5rm5UtN7/5/wBbaaHmXw28L6v4bTUf7ReCK1d828EEhmGc8vk9MjgDrjrXo+lCaOUuHWISQsgkJwRx94ep5ri/C+pXCalqFrJEJ3tVe4uxG+5gRxwh6c8c1ofDTVNZ1TU7q4v4QLcRCVEMe3BPRRxzx1qnJzuzTEYf2HuN30OgWxheyht2lku2LAM7HEbDPtyazfHPhC71HTE0uwKx7f3gO4/PtOSD9e3bijS/Huj6j4qm8OxabeDVIS5E0IUKwQjcq85JAPTHY118UlzBrJj8zzWtjt2sMb42AP5is5ptOMiKOJnSqKpT3jrqcx8KfhtD4Q1C91K6eKbUryERNGpG2JM7ivvknritLxxqbCCPS7I4kDHzDH16ZCim2/w28P2XjObxUn299UnuHuwZbg+WJCm3G30AzgHOPyFeZv44nHxIFjZ2zNp6TMlwzQ/PLIRkGM9gOOvXn2p04X26GEKrrVZV57vXyuzO8W65HaXcNvFC0MQzF5xbYZpe4UDnPXk1Hbw2+q2sdza3MkNhGChVV3tG46gjgg/XORU2uPZPdvvlGWbJQxblznJIPUGr2n6aqJb29k4kkmnEmeFyxHBJ/u47muhuyOiCblqdHpdhb3dkW02fMcYCKzjDHgD5setdBpFhLYzYjXaXXDDORu7ZqC20Oa0ZUntopHYYjMEhzk9uR/Ou3g0VLax3BTc3yx4DysfmbH5VhKRNWvGC1e5w93CZ4d7N5fnzYcheR2O01Q1bT0S4zaxytbBB5m/+8PQ969A8O6Q6W1x/aqRTSGUlMpgoOw/nyKxtcsrawuttyZbqJY8orkYj56YHX15pKWthwxEZTcI9Djb62tbmKa4MYlndT5kBG1jgcc46cDOK4mbXAZIh5hW3iyJBHlVUKPmwuPXgnrXeWkaSTTsGJiViFVVJ2gnrisrVNGt55JW27DkvtK7A/GAWHr/StotLcKitsaHgfULGWUrbyj7NvEbDqpDDqD2NejptisjaIzGOBtpDsD8p5xu/xryvR7RdOijhjKxRArM0KgcuOrA9SMY613Fj4fnm12XVLe/VrSeIpLBKNwAYcjB6j8qzmle5FRpxTbIPFfiS08NWMmp30bGKNlWG2gxulbqeTxjArB0H4k6drfiiHR7HQrnS5bpRMl2dpVsDcQyDnbgHPoa6i50qC8S50+7gQ2qx7em0oBwGX+77VUsNG0/RLSS20aKWHBDSvI2WmbtyeQO9QaqNGUXe/NpbtbrfX9PwOE8ZeHLbxPqckvh6Vm3SvcSQzfIm5xgkY9Oo6HJrqfD9laeDvDdppc2oSN5JdnZ1z8znLY9u1XI47PTbqW+1VhaxSksfNfHmELnoO3061i6T4p+HPiyKW8upZ4ZoMRyRS+YmCM4+7wSatyurdBSioWaTfpqWtLPgmCSfU3l33u0+YoBMg9gPp6Vf0m9ufENt5mjI5swW2748fjk9apaT4d8AeIrrdo0bs0LAsqzyIfqQeSK1vEn23RfDrQeErS4u5oFZo7SE5Bz7nn396lvW3XzI9rbo7+fQ1bgSafps1vFPHCY0V5AAS2SO57GsUaNeai6w6m0V7BcIfvPj5D2Bz1qj4HXxhe6Xd3ni+witgzKsELACZ0xyXVSQDnp3xVDxiTHJZzW4eAgsssiA5jQjg49zQl0HRvJ80Xr3JPEp+GnglYE8X3Ns96/7yFX3Sy4zgEBegGO/WtI+IbTV1t7mwhnt7RiXtjKmwyJgfMo/umvPl0fTdZ1aC88Q6NFqU1vmO3mlVlO3qu4fxAe9Zuh+Idf0XxVdRaxpk979rcQ/ZiGZUXd8rRN0VVHbpjrzVKBvClJz56knK57l4fmW+NwJVdyiDaAeSO+KmutCtdWPkXmxnChoLhVxInYq3asjSpTARLaALu+9G33cenqCKZfWt5DcyarpyXSxOwM8agsOn3lx1GevpWdtTnrwlGbcXbsYWvfDS4W7L5e+hb7rR4RlPoR0/GivQdG1maSANcIzJjhh3op+0ktDH6zWWjimeU2Flb2tnFDb2q/Z4V8so3OTjqPWsTxdpxOhpbaTEscIJeZIANzHsT3P+Fey2vhC3l00rLPKWf5gEI2rnsPX61wmq28emam8aRbvKOHBOeT2/CrjO70N4zhVvGPQ898Px3+gWsurSRmMt+6gEhAYMRyxzwOOma0/Beoatf6rdym7D6dHEzNczKQqbR2J59ecYPAAq/4otNQn8uGGKP7DODvmdsofXK9cg47c1kxz63plqbG00u4a2yGWSAEs5/vN6D27Vpug5eU6Hwb8TNN8SXV3ZtHew3luwdjIpV3jXIDqPTHbrWrp+uXuoeMb/StU01Y44N01peRRHa0W7C7yflO4cjHfPAxXIeHtIksbh9UvbWHTWlcYdiqvI+eWfHIB7V1sHiyCzu7mw2uymITRwuBkn1Rv7uaycbXOhJVOXk+Lr5+ny/Ukv7YWWsLJAFSaMtLbblBQqfboRnr0wKs67q8en+HJdXlsZL1xC0yQQAbmb06crnofSotcvP7QhtFkDLaNH8yNGQVJHIPGQc/mKksZLhrK1tbrMt1KzmAOm3MY5QSAdPlFPomYPm5mpM4Twz4z1LxHo91ca/osOl2cDpClwkRVmmkbIi2t1+TJZ+OldTp3jG+t9Ohj8N6fZXMMEnkzx3BKyxHBIAA6oeob0+led6B4Z15vFmsjXbeXV49Rb598zEJh+JVI4BXOAAcY9BXsGi+DhoOmSWNiFghnfJ8v5ixxgkscnocdaqThsTOlKnb2ltfNd/L8O5T8U+OJW0A28l62nrN/y1soyZUXqQM9PTI5qn4L8T+HPEttdQWUt++pIuwxmQhCp+6z4J5AByOv51yfxAk1jS/ENpY+EJED2iIHJKsDIT85Ib73GMAH9a6vwF4bTStQZ5jbx6qItt3bQnMMcjHcwXt0xnHfNRayvf8ArzN5QpKKUIuPW70v6aDE8EzadqYbQ47fS9NlIkupIv3ZYg5LEYO7qcL711ssct6/lG3eRdhysgBXbjgNnqe/t0qzPLNeOqQrlQeE7NjvXknjzV9U1/VpNC0S5vLRIRJJLcjI5yPT+HHA9qLuQUaetpO39fqegapJcWVlFLLEsziMAxQqCpAzzg8+nbnpWdpt/Yz6TBqv2cBpVI2owbf6jHY9iDyK8nHhvx14i0G9t7iRp5RqEMqi9l8l5I0QggEdEDFTjvjI5rqtR1G/8H6Dp8cOkNezzbTNdNCSk0oAUuy9mPvxjk1fJfRPUnnjF2qL+v6/pFHVdPu/7JmvNB015LQ/vEnklLGQbgPLwBnA74645rY+F+g6tqskt54knvWcSmKK3d9oUdQxGcLkcBRnAGc812Xg/VtS1rTkur/SLq0RVcyl0Crgd19B7fWuTtPjLaT6isFtpN/aeX+5jLIsYTLf6wKRk8ZPNZuXs03L7zpUp4tqjQjteyT/ABfVu3/ARo6tol/DcG60vbFbZA81sFFABVg4PbpjHerui6rp4RIJZ1gb5V8qSPaq8cjJ+6CelWvEsUOstPbQXiCzDiSWKNxIFJHGQDkA46jvXDeIpF0K4jmihjur6ZVSIMp8sBB0f+8MY+tbJcysee073PRtPkS1kN3btIrBgxXfsJ9AexxWnqfiia90yWyezVZ5UZSd2Rn2HX868i8IzeONe1KznvM29mJW3oQPnU8BSB6/0rq9c1vR9CZRf3YjmCiSR0Ussak43NjoOD70nBXHaE2pS6FzRvC1xfNDPAkqyq7lllJ2RnqQOw/Csm8mu4IZFuo5I95ZcMuCTxjg9B716f4R1+KZPsN0VSZcMkitujkVuV2t7gjHrWzq2iWOqgfa4FZgMBscis/aWepnLFeznyzjofLs1rdabquQRLrE5UoiMStuvRVBHVjk9OlMbxXb+GdUEOFknJxI7ltqnPIA9QeM16r4l8OSaBe+ZaxCO13AxXBG4oeyj0ry3xPFqy3DtpljGMzM6zLArebzncSMt+B4roi1I3SVueLujsNSig13w9He20E8HnqA0bqCpJPUemTWT4N146ZqTRXrvtiYN5GzPltyBz1/vc+1P8F6n4h1AxDVIIpCxIZN68AewP8AKuuTQbRLzfLFhG42H5gR/XH6VnLROJ1U7NqXTqdv4a1O2vrBbtWjnZG3RbeD9CD0OD0rzLxJ4a0LRrLUNR0l9Q1LxPeOxgRL0xtGXf52Ujk4POCc8Y4rrtG8PCLTbzT9Mu57ae4jkWC4fD7JGU4JB6gHBH0rxeEalqV/A2uM63dvatG87R585kbBYMDgk8578CsbyirrV9h0MNSqYhx5ml3ttva/9dyv4K1+eHWoG0p5kuZbhf7SDMzFvmIKuTyR1496+kVuHCx3L2zKqEIPm+WMEdce9eKfC6KXU4fFGsW2iWhvbBBGbtQT5yqdzRFMA+YAOG4zxk16xpuorqOj2l5Fby20UqeYsLPkrgYAf8KErMeNn7VaRVo6XXXtpvsUNN8MaXH8Q/8AhIYIo/7UMMiwsXOF3LtLYHG4j2zirWhrrtj4tka7heSzYBJJpHG1ZD3B6nPp9Kkti2oSWsgeK3kkUptAIyw7+wA5rl/FHi3VbHw/fLoelJcmWQAXEpMgVFI8xioOR0BB6dT2q7Nnn8vRbvRnr+pPutpkRBI2OU3YIB7n0r52htY7PVrqe6SF7u3aURSPkeWG4Ix3PAwT0rR0XVNc1nxg+rWd1cz212ip5cLMy2rLhXhcDpzkgkYYHrW5rFm1trFxA0cL27v0MY+Y46n3AqoLl0FQpOleD3R57aRxXmuCDUZ1m3/IJBEAyqf4Rg8ev6iu/tbW0t3trNZmS2iCmMqQCCPunPXP1rnLmWzja7lt/sy3EalvLgxvXnhgT/KtrS7tr/w/F/aEkQuAxDbcZbHXGKuWpvB9D0TRZDHdxzXV20kGNoYhcbvqP6Vuya9pylgLlWK4zgHjNea2HiCXT1EE6m5KoERyNhUenp+NW4r+GWJZ/NBlZwfLQghP9msHC71MqmFU3zT/AAOxvtfO94raPJK5Ri2A3/165u4+x3Su8rt9ob76tnJPuBxWS13NIrIUOF5XaPujsD+vNRTvAiP5z+RKc4yPlP8AjVKFi6dKNL4SO1kVImlBC5yS5HIwfbnFYPirTxqNuoilijMpwdzbsAfdYqPer2p6o9vDaiKwM5bJd4hlVGO/t9K5yS2OsW1zqumqzSI3mtGrZww4yD3Ht2rVLqObTdi1oulzaddHfu8kDl2OCfQ5H+cV39trmmx69ZwzSswvHNnbW4XOH/vFgcbCejd/SuN8KSnxde6l4X1GaQXlpYNJN9nVSIQ3AjZifmfB9Mdcmq3g34ZX0N1o6C4j/syJ/PkOGSWMq+4YHOCSByD3qJW6si8eR3eqO88fanLpEa2lgpkvJSskxAyypk84PqRVDwVrN9rAuIrsSXEEQIS5ZdrRue2SPm9qXx//AGZ4fEmt3lxNJKCG+zl/mlkz8oD9hjjHoKwPhZ8TbjxVDqj+IrKCAWZ3QmAERjJwE292P9Kz5oq0erLjQqSpe1touv8Al/X3nSfEHUPD+m6RHceNb6SC1YiCBtpZi+O2Bx3rM+GeqeBJ5bi98PwPdzxuFa4nXGPTAwBnA64zWnf3VhrWi3FzqlpCLRDvj8+NJ8leh2ngDPf9a4y21i8n0+8GnG3juXjzZxmERRsfUkcDHXbT9mnvuVCrPkdJyfK+l7HqE3iKyhZ3tobaBg3QoFfnvxxWLffEGDRU8xkeWzL7JLk5YhvRj/SvIdH1XxBqv9oWesoTqNvA0qNKDHslGNqsQMMGzkUuha9q8mmHStUaDyrmfMpgiI37eCkmenqG9RjvV+ySM3TppaI9fsfiNpWuOEsJVlcLvIfKMBn72PStSbxdapA011bRzgDLBQGP19q8UtkfTGuDA0VtdOrxM+MmMY4c+/aq3g2TXrM6hJqWrS3WmFBsBI3MxPGCByKHSXQFTptWaPd7O/8AD+so11EJSCR5mGA2H3FXLfRdHnYpC9y0jd5GPy+4GK8v8Na5byH5bNG1NhnCx7PNX1GMhjWx4y1XVj4SlOmXDafqJw8ZyG+UHBGOv5VnKLWxapOTSpyav5nc3WhNZwM1nJKyjr8vzf8A1xXz94v8Q+ItH+KU+n6Rf3b6w9wnkWCSkRmIgMMgcYxn8K6rw1411+5khRZJry8kHzmMdGHB4759Otd4uiaPfa/ZeKdR0nZ4hS3MJkyUG0ZAbb03gEj1AOKzcFNJyfnoawq4jBTlCpFNtW1V/munQ1fDGoaZ4ognngtHDRSFJVf5QW7lR6dcUUzz57KENp+CZCS+RjPvRT5X0ZxVoyc37J2j2uykPEl9NGLWC/sbR0IVYiuZGBHA64Ue/WuOkguvt8iXjs0hYlvmyD75Hc0adotnY38Uh864kR9wYknee+7PbNeg6r4dj1WbTL6222jqR5jxqCOOQcDqe2a0uoM0Uo0XfZM45dPMty8itJKq/wAWODx0P+eKSOF4o51nVHnZsqvUBfTHf3+ldvr95Yw20llpqRieX5nZVwOTyfqa40xCGOdVcmQY6nO4/wCfwoi2yoz543ascv4u8O6p4m1m306CfZbNEJCyngDqc9MY/IVUiTSZvDAvdE8QQa1eaOsitb2rjzBGc8YOMKT+BHQ1h61YTWOoT3OqXkwMm/BiZjlSCpBAwSCM966j4f6HoEdrdeVFcQyGyNrDbhQISGGDK+Pmck44zgY6ZrV6IxvLmTRVvfiBqdh4Bj8QaZbC7mmO8u0ZCCM8FsDJ6jB9MeldB8LpJte8K22r6ij295cxssu3Kgrk42g9ARWf4LstS0rRry013TREi3pNqkbfKIioGVwThWIJCnnGc10Ws6vLo+i3VzbrujgUlIIly0jYyFAHr+VZuyXKvvOqzqVG49elvyN6wtktrjzIvkjh+Z2UZwo5IA9a5K++IE9tqQlMUclsz+UlusRZyexznPvWL4H+KjeJrea0bT7qzkjDvLFKNysAcHJAyTz0IHp2q143ubbRocaZpE0V9qCbpLkyAhFx8oTfwGxzwMnGKcYa2aOeo7PmlqVL+wg8Q+IkuphcwxPIv2o7QXGRkMvYL7fpXfWenQ2N1PFGZnjLbgTjfIMcEn8q5TwLc+JLB4hrKWZtUjMkZ8nzJmc8DD9+Mk7hx0rnfHF94o17xdaeG/DVrJFb7PNuNQkzs3nuWHQL029zUuCUnY644itVglUfurRL+v8AM9Tkl3J5kT74k3BliIO9scDPbrS3XhC4sdG+06ZdxRTlA83moHyvUgMf0/lWLa3v9iWpsdFuEijtObi9uE3+Y38WwdMg9zwOnNZ17c3ElxdaumqXM+o3EC24glmKRKu7hvK+7kf3qUU3qZV+aHuxlZfi159vvuddLqMmgxtNqj5t3KiIyoFHI6HuSf0FXrHxLYXXmQQ20KzxosvlyMGEgPTb9fWvJLDT725b+zr6WWa6eRhlnYgtjrz7YFQ2XhO21eXULO0SVLnT1KqZNwHmDrHz0JHOPxrT2cepySUZfEesat4tnurR7Wxt0tLqQbEe7j3IjEcZXjIzxXDHVvGdneqfFvhvStVjtxvju9PQCeHtuVDkOoHbg1g6vPrEOnaYtxLPHLbboYlLnK/TP3umOfTitLUtf1G18P6VJFcILqRiJJgudyrwcD3zzTUEtEioRUX7uhDHoupza1b6lpLx2iZLkFPllBGfvdsnseBzW7q1uWuYIxbWzXJj3+Ts3Nz1ZBmtHw/qLajZJHLaxtcTp50ezrFg44X8CQDULpDr2oz6X5sMmpQfv4XE4SZMHOVAPJHcD8aLu+pqnFJpnNeKbTxPD4ZuG0+cW1yw8qIlxGip0Occg4PX8q5jwfodvY6xHc+IGg1CVoUt5LRlaW1c9tyOMse2eleh6tcWkyHT7+7Gn3kyGIm6JCz5/usDjOccfyrnrXw+LDURe6pJHHb2xV1WFs+Yc/LjP3ffvVp6WFKNnqbep25k1dtReN1IURi2jYpHtXGAQOwwMcfSuy0TxrIkMUWoQNMcZ81ODt9x0z+NefaNrdzqwvpJU3Qty/HcMcIp7ZAx+tNsdQ8v+07y7JggjcNsjGSmTgInqB3JqJQvoxtQqR5Zo9O13xNY39j9ltQZJJU3HevC+gPv7V47rl7rIufsMVpJNb3StGJLdArgHsH6g9sdsVuaBPYamn2uO/KwtctbmaE5aHjmQj05AJq9qq32hx3cmlbbiWNtr7VJWVONxUdMkehoiuXRBCEILlicrpGgQwarYldYzdxushWJCM45KqSNuTgj869IQPPEHETwgt8qNXlWnNEdaikjvZLWAyh8FtzDad23ZjIOcgHtXrOnarb3uoW9jp/mMsw81GdcFe+AD29aKly4T5EYFvrc/iKK7GlubaSyn+9GcEhWwOffHbjFXINFku/F7slu4sZLWRZVVBtLup3yKPYkdB97pXLW2nal4Z8Wazd6HAzaE05W5SZg+9+ACoByFBIx6itTw9q/iI+I7ex1MGJ4VkAHDOUJ5YEdQMfhxSa3cdinOSXItG/+HL3gHw5F4fW7stSkubzzpFSYbiInQDIOOvBODn6VX8YeMn0vV4rNLd5LRMCXIIXk8ID3O0/ToK6HTrdFa6+yBYS8mdndndvnbB755P1rnfG/h+K18VXGqJbyvbxXEc0kTElJJCowR/d5xntxSha/vE4iV5eb6dPu26nR2xD6VEzF4i8bhywIAOcL+YriDpF3aeN7/G1g+xIwgzF5e3lCPXkjkV6HJJ9qjtQyCFAm8R9QmeME9+a434hWeq3Wk3P/AAj8jSzSMC6WuPNIyQQM45zjpTg9bEyvZSa2KvhLQH8J6rFqPh/7QlvNIIpopH+Qgk8E9wCTgnkV2vi7RZL+3luLSEtHIPmO7nd3B/L9a898C2PiaDRZkeGVpFuArRkhpmXoygA9Ac5J5/CvR7WFIbG9kt7ncFmWOSJXyjkcAj09/X8KUlyyuip1facrdr7et31/zPKP7Fv7q9ylvHMI153D7rehbuOPrU2t+JJLS+Wz062iMqBQdoGF/wBnntXT/EXxFpWjT2Z2XML3DEF9p27h1HAxwASa50eHpNTmF7awNLDjzGKjcFGf9ZgcnB4yKtST3LjCShzov6DrEl7EJr2OGNkLLsZscjp/U1pPr1v5Ed3+7uVztRVUfOW/vDHY9KyNY0CQ6RDBbBJoGILycxkMpzu57HjNPt9NuYLKC6UoxkdhLEg6gDCjPp05osjOU3uXB4hEltqE6lBPbkQtH1Iyc4A757VVt7q31jQ7z+z3lW7j+VftC8glsHGee9VdN0+ORr83Alt5LnbtR+W3DoQO3JqTTfDuqrIGcQOrsCHZ8ELnkN2B9D6U9ETeTM+C81XTLiNp1VEL+XNuf5eDjeo7HBz/ADrTvYNK0aWXUb+8FtC6tGkUY2tI55widz3yeB3rpofC2nvI1xqV2oUHJAUuzMeoXP5Z71BqXh+fVLiG0EMNrptnve1uhn7TvddrrIDkMGHU44wMdKlzVyowbu+3fT+vQpfDrTLTT7PV4NMs/LkvpFe4kPzu24cANnqTknPc1T+IHxBuPDljZafo0dzBLKXNzdm2Zj8vRFAzjPPJ44OK7ax0Y6P4Zt7DSrtAtqFgV9n70tn7315Ncr8RfiNq3hfVYYdPS3S3ZcOXhJZnBxjgfe5z9Kle9LYyqu0bRtv/AF0MLw9p+p+NLW3uNYsbuewY5c3KGBZIwOCFOCCRkcVd1XWdP0e2l0+y0a2/s2NlRLZTtQSDkE45Jx6n8a7jWtW1fUvhytzCiW+qXMa7SVyE3Yywz1xXIaHBa3NktvdRf6TJhXmkcMJ/9or65yaad9WaQlKVO8vT/glJ9RttX8JDzIp7CWdcC2YgeV8xA+o4xj3qnYaY97vaCdGkyNwVQOR8o5PYdh2zmtHX7DQ4dQt7K8YGCJSVeVCC4PIGPXIOKy9PGnpFM+lsttpcGRLOSTHEoOWLnPynn65xV9NBR3LeqptsItLuZJJAJS2U4aNv6j61PZ6bbQhGvhG8gG4sxG4gc84/CtCxksJ9MtdQs5luLeZXO8x8gHjJzznnpXF6Ppmsr8QLi9uGT7AN65dsh1xhVA7f0pI2K8elan9sjDBSS2BIpPK5yCanvluLSWexdmljQB8pF8zM3pjqBnoPeuvXb54jZW2sTjOfl/8Ar15/res38nieCCAkIX2QbeqnPY9zTTuTNcpHENTt9eihsUSMs5AZDtCoOu1hwK7iKNp7RLq9ED3Tlsw8jCfwsx7GodQ0b+zNOurrS0d9RmQfMGz/AL2B2PvXOWV/e2VmIpFlhWdDHNCfnZgf9o9etHxbAvdN7T9Y0nULiS2sUurbVbYkmaEbfM4yDj+Iev416p4auW1TTIo7zypHVQZHVx83+2vvntXkvhm1Ok28Btk/flWjk3tl3Q8fUcV2OmSQ6E0l6RNHBGhdYxhiAOufaspxXQcuapHl3fQh+J3ivWPCGn28ujaadUkafyWO04RdpPQev9KK1rbxBY+KNMXVdFLNG0hjnhBDNDKM8MPccg0UQlG2quJ4eTdpaNbrzMMXy3KF/NBOQV5547Y7elTtqV58kUUs6qRgIrkDPpXndtBeaTqWtX15vnaElQFyAwzwT7e9Udd1rUb3RmMdooj3rI8ce4Hbz05JIBxkfjWnJdkxmktUenmSaSc+c5jUfK2DuJ/H+tLqE72mhS31vFIvlZOJUxkd+Ov+NcX4PkbTvA95qySmed9zWaPGcwFcYbaeWwSfY/hWH4M8UeI9Y1VLU3k14WdfNF1yzKxxknpkDr2FLk69iZVL2R0+oa5D4g0uQwaSLvU0jCRC2zvAY8kh8fKOnPC5JrvdO8O6fpNhBciOBdWkjRLl4JGdd3dVycAZ7gCuK1250vw/q0V2dOV7hAFKxvsR1B4JBP4/XFX/AAKNWvNX1m71i4ikUuv2NoCB5kJO7DjJKsM4I46d6zc4tuMXsafVasFGrNWi9h3xB8THwtb2sclqZzLllkO7ywR0X5QSWPYUy+S3vfD1zcXsTLGbAyTRSArJGpUkjPUN7da6rW59Tht4odCt7RpoSTvcZMfGRk5x1zyazbS7t4raWa4gF7fOxK2qtgO/csx/hz37009EOLlrY8Rt9Mv9XGnad4BF3Z6auGvzPJtMc5YOZGY/MQVAIC5/U17/AGGmJDp4lukaRnYfZUOd/HVsdvpWF4T8NLZ2V7qEdvDAbiRi8K4SNCeqgd/Tmsjx/d64s0FjpUd7HcSR/LOpLeS3Ylh9wD37ZpylzOyK9inqn/XY76Jl84pcDbcRDKhlxgYyKNFNg9jcywhFRJGMucbi+ec/UmuT8DeFb/Sbcf21ei8v/Kky8bFkxy23J64Hc1rg6fZ+HIk0y7t72bcXmaKUPt53bWwT/j1rPfQdRRikovexj6g1/Nr8y3ysmmSqS8KryEI69Ovf9Kr6XFFPsFvtPlQlo4exj68A87h1wfesi8XUp9Sk1bRdRaa1iby57UjEkYbsVPBj7Z9+1dH4d08SrHqEMwhkQg/Z1j+83Rhu7gdQe9bvRHHe7NTSIfKtt09qDO+VibB3sp6YJ6Dir8ouHv4rmGY+YAA6YzuJ/n+PJpkirFK5Cg5beIy3AyOlMSAtbNM7SKecDHX3qPMrkurmfrWlRX9+/nh3jdP3jlipUgeo/KuQ8faJPc2lhFalkaBtyx4wr5+8rEevBH0rtWS6nChIS8icglscHpgHrULLeFyWK71wvl5GScZIweM1SbRajpqZumwz6L4ctZ1u/L1BomtQ6LzEvIYg+pzx6VxumW/k6vpl096/27SS0kSxReScngLIT949yR1ruNVtv7T0yKIvLbtE5mAjbYXJGMZ/rXPXtiNI0+Wdyr6hMdyrvDbQO+OpP1/CrizOVPW7OpgbX7jxff6bq3hqz1bTJ2gYzRjZ5G4fO5ZuMdwo64xnNaut+HrSIS2iLC8MWBH5jE7eOB+H6VneHLrUtK8OG81+4uLia6INjbyMQ6e4X29/WqWnaqNc8aWujQeaLibc80zNzEAMsRxy3GMnjn2rPW9+wqbcbuT0L3h/QYba706xdbgNLJvu3k+VZWOSCh6H5ePWsfVte0e71PWtKsdGaKwtZDCZ/lVJZBwcknPPqcZ4rofFeo6RpOsRaNaWk8ly5VGle5bEbvwo5PXuSOlZf/CH2rasXuLkzREEvHIDuf1AZeGGeMmmn1Y42lrH8TnfDPhe5e3vLkSJY2VkUuI5bqXyVAJ+ZCeigr68ZHStm18U2klrPptm2nX9y2WZDdbikYGAyovJGehHFLNqWneKtA1SwudLuBa3UoguI5lJW2khbaORxnKgim/Y9P8AALX+ujTzdXd6FgRoLctHaxgcxR+mcZJJ5P0pt333Dlm3ZLczbvRJ212K2s4T9slZJY5imGgDYzyByqjPWuqGmakg15LJTpdpbRfZbSZ/9fdE8PNn+EEnjHaqWg+LLy91K0N8INGtplAijIZp7o5OBnsoxnsPrXZ213YTX13C93GTZFGmDHJjDAkE+5xUSmzSUZQ1mrL8/wCtjxTwZ4f8Q2N/cQSWl2Ld1eO8vME+eGG3IwfnPIwR0x613cmk3HhTTNP+zPMZ1t1headiztglgq5HHHb14Jq63jNLi6uIoJre2cowtIWYecrfwsw7Z64rK+FF3rH9sa0niyOYWp+eKS5y4Zi3JB54YenHHQVTbfvMUqklHlt/mdf4ZmM9tZvdIwupULEOMFRnjr0PfFWNT12wF4YLm6gW4dzGUbqMcYz0z/jWPPrFubloWMS5mYWyhsNKPX+lcN4217SNB1n+09Ue2gvi6vBG0LSlcjG7Z2OD1PXGahR5mayo8rUqnY9WCQgr5JkKZzIAM4APWk1JbXy9kTOskqsiOoKlAep9M9x71ztrqVxqfheeZgkdy8ciRyYIQSgfKSOoB4PNeUQ+O/EsVxdaLqnmf8JAkTQmG3w5OVBV1wOT3BFK1tTSlh3Vla9mvx8vX7jr9A8PX/g/w9r5tdSb+0LqFEhlhjOyF1BHmkn+JgeT/PrUngO/1u3E7ak4u7Uug2swfKn72SO2eQT3rZXxHqD/AAp1t7SzS+8QWkQtxbXq7g7dNpU8MwXccd+BXDfC/RJ72N/EK3smjWkEBjudPtpT8xU5G5P4Cc/d55PbFW5NpmNOEeaUZpq1vNeV/wBNzsfHUOk6vrtz4RvLie1sVaC4EqYYJITuCnuVYZBPvXJWfi6T4a317b6rc3moDUrkQqbRebRRnD4I9/ujjj3rXv8AX7HVpLUTWD298gY29xIqyRFgOELKck5HIPv3rpPCVrean/bseq2QmuNUiVZJ4cBkTZgHJ6gH+lKXupJl04x9lJzldK3z1tfztv8A8OcjHqfiiHVrqOOeG50+dRLBcuPNJYHhsDJXuD/Ktjw1qfiuO1nPizw3AswkC28kPMRQ5+Y4PJPHNcnP4Sn0F7f7LeahBFBOVuYre4CB+gwG5wQTnnivXPDc88ulRPcO6MibXlkO1go/jb0xUtNLU6q06b9+KvFd9L39NbK1kW9KSG8gjSa3t9OkI/exsgD7gcbcnPP0rZk0rTYrUySxvGkfRsn+Xf6VjJqtheoMy/aomXJYDLAgcHJ7kdKwdD8Qa5fapcpJpwttJjbaZGLbx6Zc/L05PYUuVs8ycZyd4uy/rr/mdUN8Vq01pDHHLg7nXqf8OKo2l1uuGMkyQRY3GRpAQWA+7VOz8UaTqMMy2dwGNsf3hRsAZO0Y7sCe44rjviX4Su/E9vZQJcWtvYwsZXVhzI2cdV6j247UNWRvQhGbcZu3mzs9TSe401o7OeNJ7jKrMwy/Tr6jHWsLXNXtYdXt7LU4JppIYlEl2AAxbAw20/eyO4/xrL1Cx1zwX4Ait9NmvLy6lmSBnQ+ZJBAf7h6kkkZPYVaPhVr2y0u61J3P2RTJKsr5YjOdvv7+1DTSujeh7GU+Wq/dV9vT+kdIbqSTTVW6n+0sDiNsbVEWBt4Hf171554iFy4mnV/3aP8AOUbPyntkDI5rW1DUXaCW0tYHlaYFN6zAJDnjCgfzrkbTT2v9SYxyyxXQB3RiXYqFeN27nPXP5VtCNjmclf3UU4NdbUdYFnPM8kwAVFk+YMB6E9MV0GpaPaaj4UutH1B5baK4u47orCBuJToGGMEE9j6Cr39nx5t572CP7euG3qoUGT+8CB3HrV23C3+oRiRAIWfaQvUHGVJ/Gm2Uqaa94reF9EsLO0+w6ccRZO9ySS2OnsPwrRurYwTZUKUGA3PX/wCv05rqNP0a9DrLHYMMgrIflG70IzWdrlvbwWLkEx3isd6E4I9iP61nzXZcZRb5UZenTHa7YBJViB6DP+RXLGwh0u/a6g3yzBmHnNgGAHkgeg7etdBa3C2zRExbi2VPmHjJ7j3qC2srXUJpLxZ3EBIkaBlB5B798dapaEz1ZmS6jeSa0lqwkiVYxls4VTgcHsSc1Z1LT7iRTLbgiaRN6hmAUdiB6VrsqTIzR/wyE428g1V1q0LW8hlmdJljBCKN2ST1Pt2ouO2mpyFsFstSQ+ZKjfJGMj7zE8tu9O2K7bwz4q03TZJJtQnt5NMZXSe8l5CHGCMY+6Dwa871zT7lYYpZ5iBGx/eBdoOei/UdM11XhrS7O90q5guIIVe6iP2koT8+eeh+6fbpTkk1qQ48y5Tl/EvhHWPh5rb+IfAl097ousr+6e1O8BThlBHQ8dGHUUV6f4U8Gr4S0FtK0rULi6sWnM5WQ58tyPuqvQDHcdaK5FRitm/vO6ji7wXtIxb721+fmVYNU0uy8PG/1+aGwGSuyf5Wcn+HJ46evaqvgnVdB8SxGbRbYRJtMe0rt4HBI9yKtanoth400EpdSI1u0xkj3Lgh14wx7jFcN4esrvQPFf8AZMCsIPNaXalviFVYZDB+uT+WeMVok3ovmYv2TUpPe+iV/wDhrfierDRrMRtJA42kbdqr0H90Hr+FeV+LvH2jeHNVvbXw1Z6Z9qhVRI8rbS7k4I4GDjuueorbg8YSSeKH0RrcRRiTyQuclO+4nvkZIrD8KfDrVLnxFJfP9ls/DltK80TtGvm3hDEjahzgE/xfXHNOUnTaur3FSowqQc5T5UvK9/6/q5L/AMIVJ8Rbyx8R+IGu7K3kCyTaZ5RjEjjBDDn7vGCOoHNemWmglru6l091h2jd5SsACD6GmXMNnolneXl1qBZdwaSWbONpPAHfrxgVh/F3UtQ0zwfpureGriVfNlxI1uvzSfLkD2BwfzqtZOyOaUuVabmf8Rk8SHSXXT7e4ieYqbiOCRRLKvI2g5+hyO1Yc3gbxJJ4U0eLUdUb+0I5pHntYbgoVRivlqZB951HUHHBPWuq8JG+1HQrS6u4hbanLFluOVyeCQe+MZ9Kr+JLeeO/0s3Gu2tpYzSARQSzeVJLMDlmUfxEnjmrUmtAcdm3udPo1hqFroBtZrlWvSuBOOQW7E9NxxxmludKludKW2kuo4ZC6vdXEhwGRTkKf7xzjFWyRaGKC6u4jcSrujgPBVMcgZ+9XK/EFtUg8LOujyCNhL5kpZPM+TuMnpx6/nWVy6cZVHyx6mt4gvbLSfDk08+6eG2QZCEgv1HIA9+hrmPDVrpGn6Fcy2gjZZH3yQg/MzHPy47Hng/lVHRbrUdc0G60qZfNkZd8JQ5EyZ5Vj3OAf6VpaD4Ui8K6c82yMafeQ7/soy5hBJzluvOcjv19KUJJ7HdiaDoU+WW/4/8ADPX5mVpQlaeObSrxJookKnzR5Uxx2IPcdMjINdm0y3EEbedtWNQQkf3EBGWGegGa4mWTSEmiezu9ishXbdDbs+b72Rwfyziug0+3tr+0RLfWLY4XEs6jCg+g9c+461vI8tHRNcQWyRtLIUU8bpWHfoc/0NXjeLEqx4ikQnO8Hk59vWqVwtlbWqxTTSyRlQoAAYMAO9Q7baCOOeFPNKEN8xOPbArO1zaNmd/FocLW4Z8+cyAA9NtZuoeHVH2jyhs83qV5A/z19zSWHja3ubyyt5LWWL7QSrSE/KhAzz7HB+ldRcXMFvbNcXE0UVug3NK7BVA9STxWV5Rep5sqlejL3up5TeWrRXAjWN5CpwibTyAOv0rR/sm00qA3+pvG9/jzFSRAfLC/xEcY9s1NrurxT6mbiy8xoNoTeBgMQeo9v51heIbqEWSJMDItyhLOeS/X7zduenHFbK7sd0lKSV9DitZ8R6je+JtOkE7s13KsEduzHClmOOB69T9K7nwNo0uh+Ntb1HVI5YktbcW0LyAD7QWbcWQdccAZ9/aue8M2MVvfQancM1zJasfJXytoVj91jnqfYda7S10+81aNpUaR5DIWkYn8Mgf0q5tWt0M3C6s9EcZ4l0u5utfuL9EzNeFdkqOALcE8hvw59zmrV5b30t5GtqxSyt0wBNLtEagYJI7k/wBa3r/RrqwkjEojVCSw3/NjH9739Kx78KbGSGVZCu4ZGcMzf0A7UKVzTlVrxGX6XGq6WkNtfiGXftjxlA3+9jkn0B/GodFs7iOy1Cw1x5Ee5zFZRG4xubGN+e20d65PW9QuvDXmTwNIg2faJL25UuIiDgfKPvNjjdXoPgLV49X09P7YiZ1uoR9juHg/dT7hklOmBxjnBzUzhpc3pYiVOMoL/g6f10IvCXgq28PwW8urXkF/qtuSI5lBIXPA2gkk4GOW+tUvEFgnh7Sbq60WG48y6nDXMpcySkDP3ieoyc8DvXJN41uLTVbq4jt7eKzglCm0kyrkeuT19jyOMHFer2d/ZX32G3m8pl1JDsOOox0Y54PuKOXk1M51ZS0k720PNNJ8JRwibxNealGyRP8AalsZbfElxMD+7jaTOAGbjPXH51peBTrWoXuqXmu/amgUYaCSPylEjcYjA6IB+Hf1rtdX0z7bZW2jQ3dlDYW8zNeRO5MzY5RkI688nNWtOhW0tVs4G3IsjM0rdZF/vEe44xQ53RnTh73McP4u1W18OS2Ly2gun52+WRvARec56Z4HvXO654fl8cuniDTrj7FcXMAima7Qt5W044wSGwMgMK9Dv9B0vW0glvo4bq3Ri8ZQ8buQfmB/DFXbSxt7VIzawoqpgxRxDEcajjGOnrnNTLllGzO2FWpTqc6e2np/kYHhW0tNI0DTtCtr65ljjkeRpZhuknc9XIGSFHbPault5hZvO9klnAZV8t5BFtlYdiz9fwzgVUu5IICTEBEZGzK0eAwX8fasjUNW07Vbs2em3JLomdiEL7EkEc07X2Mvdv72pV8bae+oz6WYdRhtIk3vK0gbdM+QQwI+9jHfvWJputaZ8PRfaXqGieIbltUcme8hhEkZJ6Hg7lJznmofF+tJd69HBHbySWWngW0UbsQJZOrScdBngeoqh4s8QXmraTbjTWubWdVYzyK53OF+6mep9f0q1TvYn2zlFxe3z737+R0Gh6v4W1HUoGvbyZrmT/UR3VobdY2PBHH8R45J/nXTQeI/sniKa11FZ9JURARtGBvYKcgsfutkenUccV5oNZf+xYbaW2ivdRVEluLq6+aTceAE7detbV19g0jToNC1PXrXTdRcI8ulSyNOgYjOU67M+meORScJO/My5ToaRimu+z+7T8H95S+Nuo69p/iCxn8LRyahpNyfOkgigMheRjzHIR93jkA4yO9eqah/Z+vaHdaTdborhoEeWJANyKoBJ9Dj09q5XwNqU1lJdWN9F9hunVVjkR8LOmcJtf8AiyDkZ9xW/d6IDqq39veyWjw4Y9AHAHRs4A4HJ6VMnsuxkqUVu3bp/wAE09C0+w0zSoYNL3XETKQk7tuZ/UsRxn2qW5htpmWwmv47eO+V4XQEg5KkYHbNcMfCmrpr0c+m+JGt9Ou5TIECblhGNxVQDggngVo63eJbRMmqBSznPkxKS+e7kdAPela70G6cYxtzd/67f8MN8MfC230W6vF1DX5r+aNQiu6CHy1Y55I4J/8ArVuLp2iDUpI7e985lVUaNbjcA54BC9APUD8axUvIdQ0OdTPcyQeXtZpyQuDwhJ74PrXM6Wbu1spba5s/s0sbZD8+XjHBUjnOe1VZvdmMYSXW56zJ5TGSJJiDAu3YzYeLnBA9RxnNUNaZG00RxKJCwAU46YOSMVxh1ASzSa3MUjj06EGfzG+82Oo9cnGR78Vj+EfGt5440i6kuYBZMl00aJGcBYsZHA9xjNZxtc654SdKN+2r8tv8195peJdOVXaVJ44mnJke3VdyZI5OfQ+1Z2gzTLL9kt7NbaVUIZpSG3rwSFPXBqjq0G6V43MuN20iOU7iO4HtzWr4XuJGtfK8pbfyEEau5LZCk9z0Nb7I5oIu3qfaTuhYhshghOAR3rvfBGhwPCt/KPMzjYemceo9q4ext5JLsMmC+f4hn8OK9b0GW3XTI0idAUHzgHoaxqOyFi5yhStHqabZ2nbjPbNcD4yvo3urhI41mkaLyRxgBgTnJ9q6jV9etLBAqyLLcv8AciB7+57CvGfGWrXayxKGhWN5CXkB4Y+gFRTi2znwVFq9SS0GyLJdLHEx2ojFnJHHH/16uzJGoT7HB5KBQGAP3j359O/41itr0Olrb27RSTXM8YdyrfcywUdevJ/CvWPCfh8LHuvtkjxEJtx8ue/1/wDrVtKXKrnZOpGmnKRwN6Ta28bAMjsN+48c9j71n3l7Na23nmB7mSTo5G7B919BXpXjbQ408q7tkjSNj5cm7onoR9Twa89uI5vJeGJgXXJzu5xnp7UoyUtSoVVUhzRMS8Se6sY5QX8uJy7sGxhj3x3HHIq34GtJo2WaENNGoMbSvlBI3IyfXn8hWRA+qPdN9qaaQngBDgj6Dua7fQGaS4jjEpk4QfPyVbufy4q5aIlP3iL4A3M+tR66t8DDdWVwbUqxJOFJ6Z6D/HNFaj6ZHoOu6lLp1y9tJPJukIb7xIBJP5D8qK5uR9BYuE8RU9qpbpfkRaM8Gn6MnkYkgU5ViuCFPQlR1Oakv7y2sntVvrsfbJzgReYCcHrtHpVjSrq2vba4SzVoUhIyGAyM881xviLwNf3niSC5mmAtW2sHBO9QOwx09Tz1q4JPdm9eXvXa1bNK9TSD4ysYGsrUz3aHyi6/vHKrksD244z3ra8Vak1hDZyzRrDbyYtmlI+4ONgC9ABVDRtW8PPqh0me4kNycRpc+X8sZOcAP/XpmuVvvC2tW99cW93q+oajamYvF5h3RxjoNo57dfrQ4t+ooVafOk17q3/z9f8AgHpN/o8WoaRDbzZuIzhi8R449D+NOeyE9lFAjlYYhnZGM8dOD0zgda53RGksfDqW8Uf2eOLPmRyTFQFHVtx7EVwL6vF4g8S3eoeG9X1hg86Zsfs7rDEccbG4BU4yBjoaEn9oPZuT5abv26P7vT/hzq/G93r+6Wy0GydrOWHiVFAbA7F8/K5PGO4+tcJ4x8J6jrlhokvie6n025hgEFzHLCJCULlsqeitjHPsK9VkEwMKJA6yMAW67Ae/1b3NVdd8c2fh7SbrUdTtxq+xxGtsrb23/wB1v+eZGM5PGK0hJ/ZRFWHKryV0L4r8NnVPFmj6vo984t4rSOO3mY+Yk23gknqGA/A55rvWRSFUxqZI+ocZXbjkGvPfDPxH0jVbPTtQvLSPSLS7naAgnMMcuOFJ6AN0DcAmu+WYMkqxsrPjcGXnIPfP0rOSasmYRXupI4bVtZh8M65Z20uleTa3T4FxAoWOMk4wRjk9+McVsS6ss+n4ljKWqHarqQQyliAzd8Z6dcdelc58Z0vY/C7arpkPmzaUy3I+Q7duQCceuM0eAWbW7KG3uFSCxDiORjyQG+YIR2JzjmhW6o7Kkb0vaJ3atfy3/wAvxItb8MeH76Mx3stxpojPJjUmPKjIJAPXmuHv9P0jS/s8Nt4nsdQjDh0kWRlkz/tDHB969k8TaLDcTpbSI4VvubW5B9CTwTjvXDax4B0yzX7VJp0rI3yHAIVl6nkHGOuSK2hNdWcbWt1saHgzX7OeKHTrnUPtV0CwVfKO0KOfzx1Na+p6tbRW8wWWFLeHl5WO3bjpkdMmvPtTtZ7iCaKxv7TStLhH71rX7856Km88twPXHFVrHwhJq8ETa0WTSITmC1WUu8pHO5/X3J/Cnyq92axTZ1+kXUesX8MwDXkG4FVUFFY5+7z1r1nxxCLjw26giNCASjrkEcfLj1rhPDF1p9rDbhUgQ/KFZlwsIHb6n1rf8Ta499p6tEUSAOdyZ+9+Pt1rKSbkhVYylUg1sjkYInj3yHIiXoDJgfr3rN1jU7K7spQNss9sik7W2Myk8dOGHH6VoxFbmGQSoY48/MV5x6Hb3Hrjms77DpsmoTJsVpfKaNiEKqWIAJJ/vY6DpmtF5l1JNsoeFtdu77W3sdnmWygOWz8ikHgqfr1r27w1IBEMPuRR1A4/OvOPCekWWh2LPbQyNNPPuLSHJZQOBnoMe1dboeqtEGiKoqRgs2R1NRU12MK0XOHKjq9T02K+ZDIoOOufSvPPEsEAuXigUCJOcLwd3qD3rfvvE0s1mVjeOF3yu1c7gfTJ6VzWRcSM+4BVHy7zzwe/YZP41ME1uZ0ITpq0mcv4ts459KutOvI3lt7uNUVoydysDu3Y6HrjB4/Ot7wbZ3MHhPUNNN1IZJnaWESj5bdtoVdo5KjIB+uawpfEckd1PLZgCOPJkjIy30/LPPbFdvf3UenWaNqNwIzKUWLnlXYDkn24H1rSTaVjSMeea7nmmjeB9SsgbXUbeB/tEpY71+0Mh/idWPdsAkZAHpzXRa9ZytrNrb6fDOYIoV2JzuP97B6DJ79ql8ca9daTDZvDGRbEObiReWZ88DPvXQaK6w6bYX2oLPmQLOLVCNwOMjdnt04pXe7N5y0S6osWVsVtbSK9RY5yvy5IC89s9Sf/ANdOhnhN2YYkdtqF23Ahfl9+hBqjfX0OsXhvY1dUhfYFHzBj7Dp9TXO6hNdXviTT9JsbhIdOLF7qRCflIG4gnuR6dOalRuVdpXmO8X+P9J0HUoNNureeSTegZLOLAVn5CgDknnnFdO7My7tsghbCo/l4Zz6Y9R0965Xxf4MW88UaH4lXVGSEXG4QbMSSOoI+VhxggdCPxrqv7QhsxAWkEU6qWQSfOobP3gPSnppYzcnGN1/Xf8f67ZXiHSbu40+aN7dlu8BkEnA69CO2ema8qlttTXX7Z7O3mguEnU58o7uvXOemM+1b8lvqCXV3O+pzSHliySEmXPPmZP8AKumXWLu50m3e7Lo6JsMoQKWX3Hof51qrxM1eT1MvWPDUHiC68+zSeKZiyNs+4/YYHXr0/OrX/CNyWVuvnWEsa258oyt8wZuOuepHOK7nwfaPp+mNc2tq9zNM4XZ2UE5LZPpXaR2rvatDelZxISW4wB7CspVWtCKmIVKWx4eqwaRY3uoWVtGLuLGd0e8bs4DsD6dcV5VrGh3+s3gullF3cySNO6u6x+Y5Ocgnp347CvdNc01EvZmtGAifIXj5W9sGuQ1/VLnRdkGl2ZSWbEcryw7ySepDdvQkduK2hLsa1En7xlQ6JrEvhNbW8aeS6jYrhVLYj5Jx/unbgj3rprP+328HXNlq0iTW0DRtHdMQxQnqpB/h/Pk1haFq2tXN7BZ/bwL2dWWPMhO0qpOB3AI4AJxwOlbCQ6lrvhW90mctb3aXcDZucFH5z82OmOQe3Ss6kX8S3Rth6qf7ibtFta727tedvvOy8G6fdadA0upxq7tt2xROCinbnfntniobvSI7q9Sa5SS0vGwG2YZdmeQR0x7io/D81rYStYyXizMys2wMGcIhxlcffwSd3pWheMDY3DWYEz2uS8RfkA9SrcZHfFRfUhxcXaRyWkeIJLC7uIRDC0Ds6tACpaNVbGQuOQPf8K6jW1tnslmv7YTxMyHzLddrf7xHYeteX6T4ov8AWfiXNpN1DZ/YZY5XWSyjUHy0UYkZ+eScgj1xXqY1KOEJFcWpS1YBAzMMDPGCOvOcVVSOoqLcXzdn8yfVbCLWNG1CxEqx219bPb71UMi7hhXwOPlOCK4nwb4JuPA2h+Q92mpu+BLIDtBKngA/jivS7b7OlvHbRokSooVVRflC9h6VSv0jazu0nCoilSCOdjngEVmt02CqSSlCL0f+a/4B5tfbbrV5/s9pFFEi75HOSWyOVH04rT8LFLjT2BhCyKSF2jCuD046E1Nq1vZ2NkZpHIIPCRD55WPGOelZFnqSm4t5EhMUf+rCqcZHUgA/xds1tutCIuxt20rJL5TqY3Tq2MD8xWhcatPBARDIi88Mq8msXWNSjsxteGV1IBkGRlQehPr/APWqaMSbR5ihojwZV9Pp1BqWjoi09y46RPcBodzlwWYHjLf1JrBvLaXU7n7HcKViJ2Mm3G0gZ+99e9bc0TvbskW9nBwAOp78fz/CoL7WfMCxSqqTD5WuFPLDp8w6f40LyInJmFd+H4XQi71CW2WWNIpcKCW2Ef6tj93tnP4V6b4d102wxcs85lOXYfwEd64y9soL17aW5nWNfJ2CJ+ckk9c/yqW5/wBEgQmZI0i/d7pH2jPHA9TRJcyszNxjNNSR2mveJLO/spLBY8rOfLZn6AetcNfaeF1AeUsjxrlmXqqn0z9KLxoYh5txKY7c8mQHhhjIH1rNt7u7vo3tdK+Uk/60OVHXOQD/ABkcZpRjbYIqFFcsDA1G01G8v57dnSEu4ELSg4i5zkLx2716X4Vt5JLy0iKBRaRlZHPAJJ5I9setcXpsMd/dMt5JIUSV4JknzuRlXOVHv2P1rrZtSu/COmWs6W0VxdXiEtBIT+7jXo7H246+tOeuiJb0uiTxXpcE2oS2gnEESsJVYHO7Iorl9I1i4v2lnvbf5HO5VjPKnqRx/DzxRQrx0N1ay1OP02bxDpnxQDabOU06+Ci8gcnEmByG/wBoALgjtXv7Af2aFZA/2iMo8b8kg8Hp7elcBrNnYW+tT312Ehltx5yTsxU4xhs9jXbW9/FqWj2OpWsqS2ZXCvGOOO3/AOusZczd2PEqnaEYfO/fy8jmfDvgfTbC6d4PMe4DYjefGV9sjsPWiw0rV9K1u6j1C8a6sbgeZAVYYUZ42/3ag8QeIp7X4haPoNsnkW8q+ZeO3O0FSVAPZu/vmtW4laYzSMQsUa5YzkKpHQZY9Kak5NkypypxjJ7NX/Ql1XUIrctDM5tlRRiNB5jOfVuOlc3rHiSPT4A8EC385GI4ySERugJA5/Cm61BHqusQvY3UOTIqrNKxeKOQDadpXlgRx9auaLpljpsTx3aQ3IL+a0zgqB1HGOQKtJJGHM2rEXha/n1XTp5LmKO3uoJvJKrJhSccn6dvrRf6BputtcJJaxC6b9zNNG4VmB/hYjnggc9RS2unw2UF2mloDKQ7wqxyC5GRg+ueefaua8OyXl5Av2JibyIMq8ZbAPzbx1Ld8nviqtfVFczizSt/DthpunxaXcafaix3sPKZd6TMx/iA65x17da7XQrSy07Gl6aslvA4x5Mrsxjx1wxOce1cp4f1K41uO70jV2dZBGWS4wFYjHzIe+ccg1gHxRq3grUEh14SajpMLt5l0gzLFHwFIB6qB1PPWpkm9GbwgqqcorVI9M1w2r2k1vfXiwWs7hQZ5Nod+i4HY8fSvDr7TtW8HeNluNOlkeyU/wCkh32o8ZJLbkHJI3ZQjoa9PuIrbxHbQajc3MVpDsdUukYSI8WOXTPsQPrXBfEWLTta1DRZ9Lknh1G2mNrbtIA0U8HAKTDtuHRuenOOtJJuPusulJUp8tWN1p1t1V7Pv/wx6BY+INK8UaXcIHaAj5WSf5WAPCjPcH2rlfGGn6jb6bb6LaSXI03zDO4lfzAxx8qqvYfpWLb/ANmWPxGTTIfPj+xkPdxh/wB3ahlyWdh1C8DH5c13k2oadJBLa32om8WVSkbxN90HneOM47f/AF6VNSjbm3Nq7haUaDfs79e/rseKP4Y1rV7iKTXba6stItlMrTzDZhByyxr/ABMemeg7ntXT+FfEt1qXiGJY41j0wIy/Z05SKMDg56lhgZJPOasa54Dv28QWWpabrF3eWww0cYutyjH8Tc8Z/u4GcYIroLrw/cLpgS1NtY30pxcGCDEcp5xuH8I55xW/tFJ2MPq8oxU1Ja+ev/AJL/XNPtbWCK1MUjs5LPjPQDJHtnA9K1tOuIb2yS4aQRyTtt2tgdOeD3GfT1rmYdAmh0eDzolimSUpGS2/tyvHGCAO4NTT2z2rQwxItxemDbbxRfPt3ZBIHYlz0GenPSiy6HO5tbl/XtTfT7GFoolDq53GRTwBwFHp9al8K2TapObmGST7HMNzKx+U9wwPfuCa4y3tdSmu7m3ky3zNGqpLulJTkkj+veu50G/vNJ0qCx8iPj5x5q4LKeSC/brwKGrKyFJvc3Zru3htvnkSWNOm0nj0H/1h1qtaXFvcae10tzA1vIuZHL42c/dbvnPaqz2t1rVtPLpkPmYTcYWbaXIOCuegYZOKytK0XUW0vUI0sfO+1sQkDErJESMNIuf4uBx7VNkTc1rq4gisDfWwS5R32BmPygjs3+etSWTQazEVCJBLB8/lu5JGemT1wecZqbwlobWHhu8g1PapvpCwtlO5o1AwHb0Y459K1tKg0jQNImjtmZ2uW3TM5LOzAYBPGAoHQdB+NJu2wuZydoq7MmDwzoulXq6jftK2GEwiGGRm6ZwevqBXHeNob7xTrsQZdmlKdigscEr1z/tc9fXiu0v77TBpIaW+typbKSyDeqnsOOpqhYatpEsVja2dxbzTop8gGQAqo6k+nXpUOWurPSw1Dki5OLctvQ1rWyMs9tbIhkhXa0ZlUEYxwT6MDzk1wfibxDqFz4tmsLJbhbaNwheEEvI2OTjoo/n3rtLRX+3SwXTAMhVk29QMdB/eBPJPb3qzaxadbXczLFBHcTYMhU7S+Mkj3qlKxzyhbS5U8P6feWXhyKO4EgmkAaUq2Ap65564zWT8Zr/UPDPgq0n8MQJ9qu3SG4uvL8x7XPO4ADjceM46munjuluw5jm3qBlOnHPTFcp478a6h4T1VoE0ZruKW2zAxY5kY8EDjHBxweSOlOCbZniLvWW50MN/dT+GfDa6gireyFkYr91JSgbkeh5+lcp4yVLHxFc2skkm4NEZCp4Usm4Jk9QQCePpXe2QX+zY31WFUnMMdwI8cibbyF9DniuZ8fW+m2WlW0usQf2hf3Y3xgtyoXB6egJAHuKIPWxlLS1tv6ZkeEI0Qz3Czm4g5RY2G5xznoegB4zXSRjfcxuYGIY7kLDAPr17e9cPoGp6IHe9s4NQtb2J9sqyOGAbH3vfPQiutGoNcE7CSjKM7OcA8/IO2fSrktTSF2el+FU3WPmxORG7H5T2xxin+Lr9dM0OebzViZiFBIyTk8498ZrL8M3zQQpCB8iA4JbblfXHYVg+OryLWZmFtJgWyjG8kK2TyR9eBk1zqN5HH7Fyr3e25gXF5HcrscTBEbKDOQR2x6/WsjxLePBHaRparOl5ysm7KoR6jPXg1W1iOddJmtLPBneRT5gblQAfl57ZPNZ2ln7ULa3uIFtZ1XbIobgknA4966Ujsm+h0Hhiwiv5FuEEZ1AZRGVflVSOfr0x6DFdbfaZNqmk6jaWUsUE32dxFchgCXI4G4dfQGszwTo4tdRWzt1OxHJIB/1efb09apfEzxNFa63H4f0uS4GopiS7WKPbbxoB8i5PQnOePSobblZCSjzqLdrlD4eeDtT0XUpLbXQRbnLQqHzIzn+NSPujgZHer/iPQNSnsfEKC5a3t54HWGYMASGHXH+z09fSo/FMl5N4j0m/Q3qSR2sK2/lr+5AIyzHnkseMHoK7PVhZtY2y3Uqr9rYxRxgEhXxkjcOnrSvy2ZblOq/e3/yPNfhR4Zk0LwarP9ma6ubgsoiTHyrgADvgnnJrvrPRTJfQ3WoSiSSA74YP4ImP8RP8Tc8HoO3NZseoXOm6r/YdvprLZpbkm7JywKkYA7ENnPFJqiaxObRbN7ZwZh5kLShGb059O+KU29WXSgqjUU0vNm1cMyagI42YpjJTONvPDD/Ctu4KJcPLaPhtgaRG4Yj3B61QtYYr67m85lj8sBXYnb5fHUn+VeS2mvL4j+Ndxp+nNLHpliVWfU1YtFIkIywHGBk5HFQ79ETGFOcrTly2Xa9/I9A8XWsC6TezRQyyyNF8kasMKSepP+eRXn2oW4t9RtbpEE1oUzxIQXJxnG7AwO9esXAxL9otVWBXLMqEZ3x9D19a4bX/AA0nizS7W8ijMdxD5qCzkztQc7fqpx79xWkJW0Zk6blHnicxq7ae9+I9Rvb2O5VER4Y3XYpI7g88jB4rbXX7eCT7NHciKCIDcT8oKDgYJ5Nc7ZfD68jEH9p3Uc97Ezlig7H7ir7L0yfpUv8AZ09hdlr4LK8SsxyBjgD5QOnfNaaME2lc6c61HcxSyWaPcY+VCVI2gemOvHFYl1MuqQeabV4LtCIijncYycjII6rx3q3osbNDcPGxEbKoVFHKcZYAemDmtTStJCJN5UTQxyt909ChGMZPJJPOetLRE3bOR1C+vmvJLZl2FCjwHBw8eAT8x/i6/lV/V7n7Rb2N3dRzmzmiaK2mVxs8zP7wk9nPA6dK7m/8N2d2ttuvB9otkIKRzKA0YHTaTnjPU1FNoNrDbtaw2s7aWG3psdWeOQ/xjBwP5Glzol3bsjmdNs5r21nsiy/uFjm8vPALDHTsOPzptmbhJ4l8iUS7gzb0KqoHXOa6G20gWNxPLaNLIjgbpJ5NzBh/npV6/wBZitxCLuRA8p2om0/OcckD09/50nI1hByaRHoOnW9xcm6+ytvfhHAwzgdOv86yZfEekeMNZvLHTbz7bdWnySiEYA57E/eXsSOK3YtXt2WFjLK13MHiEYUkgEFd3TAHPFY/gzwPpfhOSe4N1HJcyjZ5r7YlC55AXryahNblVIOMuVoW5ux4dsIIo0cySsz+XDEXdV/DtRXaxNpqorreK7kYYAgY/Gis25NnVTxNGMbOnf8Ar0PFvB02v6r4amg8TNKL1LoiBLmMLNNDjJzjquTwfSr/AIo1jUvBHh42WgRGR9Sn3k3D5S0YIPnT1G7rmrGpa7oej+JrNJLaaG5a22JHu3E+pH68dcetbd5a2viDS4reeJZojLlHx8pPsfUHHFNtu5cqcIqHMm0n5X8+5mfCa/1TxU9tqHiaOO51O3la3+0lSgmAXLErgcLkLu781ueNbC7js5hJIzwSuHcDmPZzzj2/OqPw0uZ9E0bULu/RpJIHkgjhb7yrkYOffJqrd6jJ5eo65qt28y3JkhhtWUqsUeMiIemOScdT3p07y95Kxx4yDp1vZ3uoqyfkQ+FdKEKPeTmV4IZN0UZUhHcj39Bj6112madLqCRMuHic7SicEd+n9a53w9J9u0iUWzSBFAZlfqmRkex/pXbeEb2y0+6CsAisoQs/3t3HUVU2zNvlg3HVmRfactjLlJcJjdtbqCPWsXxzq+qaBYWUmnGG3urr94l3MoG4DHyA9iR3NdDruoJPcXXmFYjNJ8sXGVUcc47nrXI+M7U3ekQywPG8kbEJGctz6Y7dKcNWrhJScVc6bwXqD6ra2moz2lul9JK8crqo/fJnljj27iq3jDQI764niSKORYUZkilHMkTD5o2zxg8dazfhjJdXSw/b0NpNbSrst+nyc5I/u49K7HxHqMOn6ZqeoTbDAvzsZB95emD9aiWkrGlBuElyHkngXWpdJ0PXLW20jdJo8bG2g87zrc72/wBWWP8ACCSSAelXPCeh2/iLRbSfWbTyL0TMx+yuUVsHIHBO0c4qnJe21rHpN/4cgWDRJ7kw6jaFt8Tq5AIYeoU8c8c1fvPF0Xhi6vdF07QrOwsYVZrJbdmy45zlcElm65PPStbfy7g5NyXNtt5X/L+vMxfEbR2fxJgn1q186wEkbGOCM7rlMbWDMuTw3Y9ce9TW3h/xe/ilrrT7ONFFw8iyMq+VHGzZ2ZOTtwRjHOa0bC+OpS2NzBCyvJbYPkMcBl56j1JFdl4fmlW1uWu0eXUkDCGIAjLY4JI6VCqrouh1YjCzhFvme+39fmP0rSJtKadvImlRiJI5FQsd5PzBgOvb8K0NP1e2uJvIvLKdJQceYYtqA9gTXnVl4r+JUWpIun6Wk8bu3n7Y9hEfTIycbgc4Pcdq77RZvFF+jN4jeBPm+RIYxu2e/v69qUlZ2ZhySlC+ll5tP7h8Xh9LmRlMli0ufNIimI3MM4OG449afNplloki33223tb2UFWeV1Z4wfvBD2+o9a0ppnKiEKXhBysWVOPYNjr9a4+/07UdZuYxreh6dJZxgkIX8zHPALDvjkkYFHN3Jp0JVL3krLu0Lu8MaC01+2qxRyXgaHapM7yA/e8tVBYdsmo7vxL4f1u2ne3vfMaDMbQpAyMrAHAIYcdD1610Wjabp2nWippdhHZSGIKz7i0hTJwu49F/nT9WtI7m28i5VFWVTul8ncc9PvjkceoxTcu246cI869psY3ha40+bTJI9JJCKRHKG7uRuI98e3Suo+1eG7Py4bi4MjkMJGcncpHY+nsK5ea3vxprx+HL2wNyXEUbRW5B57HI9ByTxXlFvZ+GtA8T3llrmuai94cC5VYXaGJ2OVVienPPGfc0cspLzLqU6Dmrtxi38z1DV/EMdgWltbUTxxNmRA6tHCW+6rvnCZGDxmuO0/xn/b2uXelWtvBBNKrPtgmcok2PuM/PBxk44FP+IY0zR0sY4dIt2gmjL3E0zv5ErIcKhVSAGweCeo+lb/gmHTrrQ01GDRvsHnFgqBBGBjjHQEpgZB6+tXb3btAqiU/3btby/wCCczD4c8YateLFrMtrbaYn7qKytQSqnGWf/aznGWPX0rc8K2+maNc/2Tb2Szz8iS8PzMSD056elaQ1LRob0LaaohLjmUI7GL/cz1B71lePtT1rTbWwPh21jcXMmLu+trYSuZMZWMKOcEYyfalyKTV0OVaUYOMJNp6vvf8Ar/M7L7LHc6qt5HvNzEpQLn5Rkf4cVxkaa2/iuW6voZjZI8k5+UbATgBV/iIyOwrvdGjmttOtTcogvpBuuAv3Yz1IH61W12HzFW4t2LM25rdSuC2AevtnFCfQwulJeRU0iS3iEOyLy55/ubTgZH3lVvTjpVu21yKfULi0EZcWzhlBXPzdyvuPX615t4Sj11damltLm/kWNPMu0uImEcMmRhVVuB35XjH1r07Q20uy8WXEUEJFzOqkhmzHlhlsDt1oklEqpJ1byir2Kuq6sgiUo0cwclgWYqMjk4PY/wCFU/FdiniWDRJ4J4Ymt4pUfdGWLlsEEHouDk5rUPh+HT4rqJC0vlyI4jkI/dh84TI4bjv9KguvL09Y4CHWErlVzjgnrn60JroHLCpazMq08CWospHVmEca5meYbTKQMnGOP/11Vt7h0uEjVF8kkbSBhgTxkH24FadxqF7bHZbHzIGyQhG7A7hT1+tOtYTfO90lmVltvmby/lAPvn+Qqk+5LpzhvsXI7y4iNvbbFVjuTcBnk56/l0rJuJ4Y7iVL6RI59okjUt8u09RTbm4uY55GSQNISGVQegUZ3Y9O1cXe3lxrUolCxRGRg0ck0ZKZU4IxngU4xJbtsVPHNzc3tw0ccUaFcusUR+ZgBjcDnk96wdC8UQWTW7SJJcqlwsM0e3c0ZY9Q3UEetdrHoz+IXWW1geK5t3YwuOELn74Q+hA6e1ba+ANJ8+G7l2rfXLBHBwnnEHcQB1bAGeeatySVmTHV6ne+Fjb6VdtcX0oBucxwblJkfHJJx04xXnvibx2NW+Llrolpo1pcx7fJ33UW6RmUlmK9gF759a9AOow2GnzvPLAtzJOBGrKwWMDoSRyf0GTVrULK1PmXFnYW1vdzMgmuymPPXuu/rg+h61zppNtoU4fvFK3l5f1/Wwy0hjlw0exl2cruwFJ4x7gelSedZrIYI0eYhR5isMooPBOOn415fLpXiYeJ4nneexRZ2aSQPuiniycKqg4zjGOmK7W5e4hihdmRgdzbpPlVgODj6ntTcfMrdu5Lq92RFfTwbv3agQJnJz0H14rnLuBr54tltGJTGFMsbnIPXdu7YP411EcaTqtwl2WuFG4Px8voNvp2rN8T3d5/ZrQWEUMd3cMVMhBVIwBywx1b07Z60R7GktbNbIZDZSahb38N3cSyQ6hbPDcMvUsRhcemCPw5rF8G2GheEXl8IyzRf2jMyySJGDgk8qhf+8euDVXTNeg8IQC2vEnZp5PNiBbcwXGD9Sx5/A1v2mj6Nd6+viGGzzqkm1nfzCA5C/LvQ8Ej1oa11GpT5XFbPf8Ar7vwOp1LAQl0BQJ5JG0nC4+7jrz0rl9Ns00u31P+0NSFtopXCKfl+zufVjz83Ax69K349ah1DU7exntjBJMjOl1IwVCV7AnliT27DmuGs7u88Z2+sad4mt20yzsl+1i4RSWtnjc7VIYbXbjP/wCsUo3sZSvTVpaM0x4s8P2eo21vealfzmQqr4TeluCOPnX17H86l8Vw6dZ6bCNStFuEuJTGnlHaoYj5ev3j09K5yPRNEv7HTp/DcWoXMcQETrcfKzvnO9wPc89uldvqunO+mafa6xHthdC7eW+SJDkYJIwBz6VVkmiXNvc5HQdPkvtyQah5dqreWxWIpJHjkgr79jnmt/Wbnw5dLbx6obmO0tpFMVwj7cvjGW/qKqeG9S0Wzmj0LT5JIJrlneJ59zi5lHUByPvAcjoPSofEWlvLJ5Ekr2zbjLkAMrE8E4x3oer1He/U5r4u/ZdQ1sPZT/Z7GWGMrKVC7SpwWU9wRgY5zWRoHg/TLS3g16fUZ4LVW2zQC6xHNz94ODj8COOlemaXpllb6G1tdSyzwxBTGThmU92J7DPYVj33g/S9eEc8t3etZ220tb/Ki7j3xjg1SnZWBQitjihquqapqM02nzaimopclIYbVmNtHDnChm6MCvU9c5r1aGUJZxNfwqzxDCAgBgfqe/X3rQ8L+GfJ08rprx2yqxHAOSexJ/KuJ8Wai1nJcWsTy3NzAzI7svl5x1IX27Y61LkpuyLpKPM0ndo6PxDNLpOjw3bNHAZTiKMHJIIzknr+VcXpviZL1JZJVjkIVzFIRgOR6r164xUVh9p1K1szdzTSWglLN5yhmTIwME/qOlWE0ezsrjEUKsY2wABjvnn1zTSSVg5ZN6nJ6Tq2qM8kt1cQzFx8yspGG9cUV109tYmZ2ihW3MhLtlQcn6iiqvcuMGkX9Z0zw14g8YafDeXdrb6q0QuLZtwJIcfeYdPoCeRXmiXOpaF47jivtYupJLKZk8hJN0V0vJ4x0656Z4rsB8NYl1HTfEOq6xHFpNhbBrmFMtJI6kmOMdsYx79qtTI9z4j+0HTrSE3W6eQGD95EN2cIe3HB+tc07Je6ztwNR1L+0ScF38vPe9v0XU7HUtXsdHhha/ZIvtHzttXdGM4HJ/TNYvizXtDvfDsuoRQXF1b+YqQR2biNkYdmyOO+c0eLLKw1fwlc6bfwXC2rL5WxDtdSeVcHuAR+NeK+FJtU8B6zeXmrebqWnPCjTwxvu81Dwsgz0AxkA88GqjF3TRxS9m0+a9+j6fNHXQeIjbOlxCrRW2/bLbSsSzMcbVGOp9wOK3de8UJaXMdmlqGuVJMkjP8A6sn+DI5J9+lbmk3Ph7WbOGCOMWJz5kWwAPGWAJIJ7nPf1xU914OtDKxF3NbRybPNQxq5lI68/wAJIxWiqRlqTOnUpPlktUUQ0t3pK3McJc5+5nnjr9a5HU9e1eyMIEssgkYloyuFX1GCOK9b1XTrS1jtk0t02BP+WZzx659a5PxEtnpEsc0lsl3qUg3RoQR8oP3ie3PGaIyTKUuZXN/w5bCKEXMivFMV+6vJye31AOPzrE+KOoRTWLeH9rCS4QO0u3coPICEf17elXvCmrXv9nyajreBBkeTFFHtH0Hc47sa8ju7HVvGfj4ahYxSTWt07tFOZPLSJR8vI67QO3055rGabvY7MIoxqqpNe6vw/wCGNT4VeF9UskvIvFE4ttFkm822BcM1xJ0wPRMAc+vvXYeItY8Iv4mh0PUropqEG3bDHnMbNzt39d23t6V32lWcWn2cNjFCJ40iVDJKgYyf4DPOK4jXvhvpU/iSfW5Lm6fUXO9Ebb5UIwQ5XocngA9quDTblLc561WTtTp/Cr2T7Mk0AaJa+fBpduhhncqskbshIzz16YB49a6/RreB7eSS03PH5hJcklmPTJJ5PSvCPFsepRa3oun2Spb6eV3yyYOImDYDjpnbgfIOfTivaNA1ZpdFMmnSW7W0Gd0k5K4VR8zsB0J46dzSkktjSpzuLu7tWvrp/X/BN6NEVuB8oAJxzz9PpWHr+o6nH4futS0exmumjUlI/LznB5yBzkYJxRpesmfQ5bwwtFIjuoQHlyDxj3Pb9KxvEV5/aOlWWn2eqzW87TfaQ1sWARwOFdlOTj0GOetOCu7nNVhKm3FrW9jF0zXNU1LT5Ly/to9DubhfL0+W6nKxTtg7iwAyOOj9Aay/CPhDXLfWILjxF4mg0qEP5xlOoq7zkHPC52qOMZIOa6PVtC0/X7e3fxNPdTX0UYRZ48855Oc8AEiuF+K/h28ujDdaVafa7JSLeRF5aMAD5tvXB/vDvW0ddFoZy5mtT0Pxhrc2mT3H9lu6qWDK88eEyRncF6lT296peGPF0+oCZb6OPzkcASRkpuBGeUzgEY7etcx8OrXV49DuIdaila1lI8mK7O8jHf6YH51b0nTxa3kkSRtCjA7wBjzCT1B/zmjlWxaTsmdtaeKrKSUxPL5ci5DSJ91cdTu6fjWN420zS76Fb6+i017WNfMS5MmGm46ErwO2Cf0rDksTBePbiJZkcMkMnl7TjHqOvPUGuj8LaNOdPm0rWLeBrWUiIRxTBgwP8W4fgPz6VMo8uqKpzXMvaK6KmjePraexY/ZbcYASPL4aV8dCvbA6VvR3eq6kkRt2sVaVcLbbi0hIUlsk9Biuavo/Dei6dcRWlnCVs5l8wHgdeSpySdvQE10PiPVtI8IJYXU1lNqBvPkjijYRgIVzvZu5YHA9ajld9DadWlGL01+/8zh/iQuneFR4bMM9zPeakrNGJBtWBAB8hPUDcxGecV6RoCLBp8CxoF8uMBJInym30DfrXHeN9d8E3llot9f2skMQYvAZCd0L8gjvhuMbTxkCt/w1qGmz6ZFFpIN3Y+WfLjWT98rjg8fTPWqbujKKkotNefS5sC+gnt5ZbSQyxKSrFVx8wHU+lcv49stc8SaDYyeHFjM6hRc2/wBoEe9Bk4D9uwIrrdLsdPtdPmW28trWePF0JH3YHU5H8IFcJrfiaLQLnTtTspANOSdUmIPyNG52h2zxjgcdcmknZ6DUOeLtujuPCOi3GjeGotN1O++03UyFZiCXCLkkR88nb0zxVbRNHvdMun8gGSF5PNcEjK46DJ5x2rI0jxM2peK73TWDYjWWQyYIIx91s994IPHFTa342tNL1ez0h4rm4uJWXzSo+SLd91c9z3I9O9Di7ihNwi0nvvobvxP17+wdBj1KKBJbt2SBYZCUxk55xzxzz71nnU7XXPAEOuOXsZLOEyu0gBMaEkMp+mD09K0/GFhHfWelrPIknmswZJeQ4Azng9fp0zXO2HiTwv4ie78IRssVpPbvZyMhCoCB92Mj72P196IrRHMouMFZ3/4BP4Yu9P1bw8JLO5iubWX5UkTOACec5wVI79xmqf8AxMNGkEb3A/s+IiLeoLhlP3S3+1/9auO8UeHpPBWi7PCWovdalYTi7ugg+SfIAZSo6cAZHvmu7sPENjrfhmyvQiGzulEpLjhQOCW9geKbXVHZTmn7sttP6Qye0gvYblraWORgAqSROPkcDocdiOCKr6Popju4rq6ntCkJLKkbZDHGBnPYegquPh7a6jqFxJb6hcWkdwfPPkEHp6H3yfwNaN34bh0PRoR4fuES7D77i4vF3vIvfIzgHHcDtUKcr2saVKOH0Snq/Lb1f+Vy9qmpxac9nvktw4BPz3AiWNOmcdSOe1cb40soNG13T9e1zVH1K+t2+0aaluvybG4HHT1/TNV4vC+h/EDxBHrN1Pdi905Et3OPKDgk7GVf7vX345qfxjo1h4QsU1QubuHzvKWOMeYyvnhtrcHjI9zTfMpWSHQVDktKXL8r6aPfp8kavgnxNdeM/E93JHYTafpFk6vA/wB8LKvUFiMHJzwK9Gkuvs88xuULiUFgoyy89M+jd/pWdoM1q+k2sViMwiPcgC7Se7EjscnkevFOmcfJKGgijEhfa8oRFYdsnuanc5aqTk4vZd9zJ1vxDa+HJNOTVopf9KuFiB2/Iq/3yOwHGT3rj/HHhPW9Y8bx3NhftJZ5jeK4S43JbqPv7gDjt+PSu/8AE621/pNhNHpsV/LM4jmmZsiFeucDryBj0rzbS/DGvabfTzpIptCzozBvKRIjyWcE8DAPA+tawelzC7m7vQ9LRIAokRlbnHmFcFwBjIxWb4jvNRNvHb+H7W3ub1jjbcybEiUfxsR1Pt2qx4UVdS00fYiLqBADHcBgFk55Jz1+nauR1zVJp0um0yXhn2vFHNyhU+oHPQGpirs0c1F26nPG61601/Gu+LrC01ADzRHBbbkHGREGYcsfYCvRbW/jnht5bjUPPjZcCQQ7HLdDvA+7z2715xPHqGu2j36Ye8iUrKJlKvNweWz39fwNb+kW1zYaLGiPGbnyASYhu+Zjk8nrj1rSSTC8t7nf6jotlc2T3E7xywxx7/KnRSOuM7uoNcxLp91K/lW2pPNpTSbZ7SeQsMdCUbqCOwrImbUgtkkMkqrHGXlEj5884wAQfu+ord8LXWmxpIl1b3I+4DbodxJPGR7jkmos4omM2vj1N+wig061jtLfYYVJcNE2CAeo47+tR6kl9fmytvIM8Eu5ZJJXAeMYOcevHP5VOJ7SLVJYdGuo5EEZJVXDKG/uhvX2qh4i1G+03TYZYZbO3QTLm4uGJWIdMcdvr0rM0hTU2uVb9zG0fwN/Z13Bfvey3cdtJ/o0R+XfIPlGQc5Cg8Yxk9a53TvHEmpa4La+iQ2VxdtB5cW5pbVlJAZvyziunbxSdb02PS7S8WNIZA1zKqMrSR5OFXcM4LfxD0HrWFoWpeGbnWLq4t4II9VZmilEibZjjjzCp7H261qru/MZxjJHcJaW/wBkZWRmiPQljlv/AK1V7Q20RvI2ciVT5jFV3lV919ah8Rag1josEsKSEOVjyBgovc49P8aydDMd9bx6rbvO8sbm3kCsNrDIbBB56df0rOztc3i76M5LxJ4/8RR6xc6JoUf2axmBD3UEwE0eTwFz0PGOOgNP0vVfskMei3VvbTz22ZZZmLtOS5ztV2zkLnv6UajpzX+sXuqxaaNPeOVpV3M24RgZb8BjO6k+3x22s2QjL3rzAKQ2QzY6hG54x0PfFXCLS94Vd0nJOjdKyvfe/X1NO3S7tJ1tmV/sbjLhsbXHUE47/St21gSeVRDCuA29VxyB/UVVJkiUq0RCkkgde/Q+nFTaXcPDc4VpVUkDC/eI9Bmhji3Y3Lnwbd3dtFdwxKsknWFjsZR6ntRXpFtJ51tFIA671DYcYIyO/vRWHtGed/aFWOlkeG/D66tdc8MyN5KvdrcNDLAWztHVX/EDoemK65kgfdLccqeNy9jj1Fef+HL1NKF3a3Nqbe1W7luZHj4M6tjaRn7o4I5612GlTxLqax3t/GtuUYiIkDk42KPQ9fyp6atHrV3KHx9R9zbaRd3EljczRSXMuNsckmwrjoB7/rzVTVdA+yWwRdFsr64EBijaWPc0ajJAJzk89Pep57HRriRrufSla4hl83zrhm4deQ+3O0YxnJpdB1G41mS71KaaJtHjidxNGxLSOOAo9arXoc1mld6L8Tl/Buhi807zIoVjnVgJoxMGUMM8464I/EYwelaGj+HtY0zxC11Fcrc2Ezt9pgnZi5Dd19CDjB6YyDVG68bJYan9mNqsEsnzl4UAOcZ5HU8d66Wy19buNJMod45+bk+hp2cdEtDpnz1XzTd3+JpW2DMfMVEOMtk9/QDpVyZNMJWa8SD5fuvJgkD8a4zxtret6ULSXQtGbWVYMZ40RgxI6KMfd4ydxz0q5rl/Mvh6SaSFYVaON3R4t3kscEjI++RntwMUuV6GL5ZOz0E8d6sLT7FDpmbsM+57dIfMEpGNq+wzRbWMHhzTLnVk3m8nRy0LggRMzDYijpgc/jWfpUNtf+LUhs9QubuNLdppLlNuYhnlTjoCTwOcVd8bajbNZNpPnH7RgGNghI3DkE47mi12lY05koctOT13NPwlqE1/pMVzdFsI5XOfQ9Pfr+NS6zme7hm8seXbiRiHICuo4KnP8q4Xw5420rT/AAampR6iL2wsn2yhWzIucjc3HdgSD3xW14e8eaX4gma0YLuuAGt0jIlErE8YI7nrg+hpuD1diFKMHo7nH+K9S0/UsaR5bJrW4rAGjZQ79gH7AjuO4rQvtN8RWfwvkhsrILd7y0otyHkeD+A+m7qfyrSvfBmnv4qbXoCy3kbCR42GCWHACn+H1I713ds9xaxKilYwiDd5cgbr1zjpzxzTbSskaucvj2f9W+7oeY6QvjW58I3qad5Vtcw2qraWLw7HMqnJkDN3YE4B6HFO8C3kWvlZrJ2tr6DP2y0dsuspXO846gkH5j/OvRr0xMxuC6yiNgC+7aAcdDnvWJZ2mmHxGviK0L2115bRTHACyDG0LIvQ46g5pqStYzmpP30rr9f+CXp9OFjZRi5kzJJgj0Bz09zUlp4ZudTuQmWt1D/OWBUgD+v+NZ1/4yXT7y3S91G2imb5kMiBhGMY3jAOFPY/WtiPWdQlto5rG6VGkXeJmw8c6noykf0/Gk+YzlKpaytc15PCMNtAiAmYqzHc4xgHoK43X4JLK9WG38sxKeRnJU46Cug0jxVNaRs3iG6ea6YBBBAg2r6k+/04rD1a8i1C/M0MRDmXIDDjA6j2PtRG99SaPtU7VNThfGlxrX9nSizAjsyoaR0GMDHLP3GOua0fgzcm707WJ3aN0g2BZ45g0Ukmeir/AHgOp4Pzd6yvifrN5pcpSa7nh0qeACS3ijBjbcTl374BxwK3vhxZf2B4Pn1S7WeJrwi8mtJoRDsH3ImUejdfm59q2l8IN+9Yo31pZeIL/wAaaPpdrItz5EiRgnahmVl5HcZYD2/Ous1fST/wgWiW955Yube2igVt3zJIBggN0Jz/ACq5Y6rp8Vhe628cVs7MYnkID8gdTjk9eB61nazpr6npS+U5tp1QlBESI33YAkdSeCB3HrWUpPobUKUZyTnpHvY5/TvhTb6lc2t5q19IbOPfstSmY527MV6HnJz7CuvhsLPRNPhi0G0ih8rdsfZgnHJziqFr4kOh2gg1+6kmwqpJJKeUYDHy442ng888Gq9t4phn1W3fT1kuLZwrtIrZVlzxx69+SKjmvudX1arrfVK9vP59TY1ZWXw9IrxwwX0qkgquNy9PmPY8/hmvKtf0+WWy/wCEfa3uBJdgPKVfDRYOMNnjuDmvV9ZvrbSvBOqa9PavqAhEkrxXAKjIOM+gXoc+lZPgTX5/EHhx73VNHtLXEqi28iPAmQDrgknKnjPQ5q1fcwjXjBOFji7jxBr/AIKt7iSSWwfSN8YaWWL9/G3GQG6YbrtP503VPiHo9nrQlupbZtW8qN0aOD+8MqQxOCfw/Oui+I2hR6tDbvq0lxDYwje9i2FSfPADdwfft1FcDoukeHrvXdGsItAhWy8875EkeaUhRwp3dQO2B9aqEFa7CpiFKV4pJP5u50MHxR0q58VxaNdvMEv9s1veSuBHAW6KFH3QTwTk9au2XguPw/4gg1bSBKIWY5hIAERJO7PGT3xn9axbLWPDB1RrLU7OXUmaffZwyxqI4mTJPlsuNq4XkHjIr0bw/raajFcsLt70k8rKQ0kRP8PToBwKbvHZaGWkndvX7v6/A2b1LSe8t7+do49QMTDYzBfOI+6x9CM4/KuBOs3v9pS6dqOlpZ3ESmNbYIUjkjJyFC8DPcY6g461b1rRz4r1u7tLu4ksYxCscKNGS4wfmJxgE9+tdN4sj0Y6RZveNdmdMWqtIv8ArfLXONp6+x9T1rOMkjSeH9nyw7r7upkeGJpGsZ/skjxpbTFYlX5dmVz5ZHYDn3Gat/21dTWV5fS2z2l+8axtbvGZYUj6dT97jk+nWpI7W11EWt5bMbeKZAkqMMPlTweOh7c9RXRwRzMWlt7WMmMfMp+4FxjGPpTk1uZK6i7nlvhk2On+KXlnnkWKbdCdgCIXC8L7jryO4FdTB408O3ltcDSbqz1EQyJ9sCtvMSlsbyPbn16cda1odH0uC8W9g0u0+3AErIASFOfQ8dMjp3rxyz+FNpoXibWpNP12zdb63mht7YYR4TIeVfnHy9B746VTtIVPmU4qSur6mlP4s8S6D4imtotLe7aRl2yNG5imTdwY9v3SykHnkd66jWLm98Q+Ip4L21NtpIUSPtjAe2wvVSeHJPHP14ridbl+IHg290lbB57i1hhWPf5JkWfAw3mgcgg8AnqOleh+B4NZlmm8QeLCTJdxr5dtKuwKo6uVzwOgAqnoubQzk/3jWpR1rwbqr6fGmm3TyW0EaxI32jyWOTnLAcHr1B9qs65BfaT4Flh1GYXFytu0Mrxk5ZjxnB5OAQMnrXWabbC/v2FvMiuQS0e/ggc9PyrB8bTzw6p4beW3gGmzu0d3GxAZyDwUz97I7cc1m5OWh0U5RpVE5a23Rz2jyw6F8K9J0/Tzcwo/mm5lYMyuTwXAHIHTHY9D61zVjf3rX9sL+3F6zL8zQpsRx0G0DpgfhXZ6zePp2pLFFLPBb25kSIRQ8pG3zMoX1z68VP4f1PT74PDpV/eGTjzIriFd5XHVOmPXFXH3Y6mM5JzcoqybLVtZLs8izKkgFg3Qg+rHv6VZTT3aDKQy7g210U4Cj0/nTrfaboxwyRbRjcF4yAe49e9em6bDD9ihZVVgUHOKznPlIrVvZRTaPJp41cNH0L7QR0VSOh/z6VVsdB+0Ldw2k0N1cuP3aSM0K3CjllB65bgZ9veu98eWlmkMDIipcbs/KP4emT7ZIrkZRCtoTLFMzg5jZDkhT6enQ81UZXV0NSVSCktLnIaFGumXaFY3tb1SBmZGQABuVcdMd66248UW0d3Jowg+03MikiNwCj7gf3ZB4KkZ/lXM6f4w1y51GW3VrZ4gTtSUFlUA4PrntxU2v+HbfVYbHU5rt7OWNBCqwbf33JYL1yCD09KmtzJXS1OvAxpVZuFbRPbyfTQy/CLWN5q1zpltNOiRRLIIGxITDuAMSD+HB29ScDitq+8J6d4aa61/SnaO9k+9cXD48tM8hR0BPGW5zXRaDfWtyZbqXSbCPV5G8u4yvlsxXn5nH58965fxf4j0q5e80i+06/kXIDMJVjeP1AJ4yM/jVptvTY55+6vZz3Rsy2Vnrmlpr93qRaVVSGVIpg6zjP3s9mx6elP0XTdL8NIsaa1GbnUmMsEV04RnUDPygcE84P4VkxaLoPhTwMb7dO0DfvYpJWC7WAwAQO5z1rjfCpu/iVrW/RGXTb/T7QWzTMvmA7WOTzwMAj61N1s3oOFOXs3OPR91t/kj1S6tUSWG4RZI0nOW5G0qQQwPqMZ4rlpPDcmmot5bXpjhR2KPGc+UDwpCjt2/CvQH0uJPDkMDObw2oEd0gcFm4w3T7rHrivEdU1HU/hpqi/Y1bVtCuHMkcc8ijykzjaeeD7DOcdKcG3sZtxl7yNm2kmj1aBUicxgYmneYjLg9l6AY5PXmutQw3G6YFVAyfvccfyPerj2cN9BaiG3ayd1V2jmHzLuHQj15zmtLWfCUMOgXBiu5I5ioxlcqy45GPU+opOSKUlBq7OVk8X3UQEcV5fCFeA27g/T2orM03wzceJpBbtdW2npbqW86Y/f5AwBn8faim+RblSqKLs7fcRWvhHT5dZm8Xa1FJLJIwaC1kPylhwpdf4gpHA6V08OkCVotQup2YsAfJWLaCRyCc89+n61xVro81hq+o6/4qvbm+1ObEcNrZgiFY8/JFGOrOTtA6D1711fjPxpP4b8PRW9xZwTazODNhXZkiOcbWc9SPy9Kj3m7XuaTcV7yja7vY85+I2o6l4yWwi8L297E0TmG4s2kwsvzAeYfofriuzvrkeEvDthp1pELgFfKuJGkITzAMtkjuTnHsKqeD1fWrZrixEdpe3TlLgclUII3Fe4BPb3rsLCMacbi0vZY7lgu1hJH8o9DzVuXTsZ8rXXU5LTbTTvE8pd7fE6r8r8/MB/Dx3z60abrWgQ3k8KahZN5ClPJdydo/vDvx6104sbB7v7Xptw8WNry/Z48DI/piqw8FaW1xcz2+m2sMt2C8jxxhZCW6nJ4B56+vSlddTT2kloywl+dQ0120CaKZ41BQxzb1bjnJHUsPWubuNc1GWW8sbqKOL/Rt9zz8kanA2qfX2HNbnhnT7Twpd3OmwxtAuFZwZN6ggYBHvzzXBfHXTpZpILvSLrE06iR4ZG8sOVOAc9Mg84qXpflKpSUpR59vvO08FtaaZBd6lFqCLFNti37QpmJzwT3b6da5ie2Xxb4p1CyaKa2ORbSI1xt8yMHHmK3YkenIJ71h6F4T8RReD1sr64Mdxe3Yv1adhjOzbs3jO0FTwwzzjjvXWeEvDniSLxJZ3us21rJbRDM3ksFyF4jZsfxkdccdDTjP3efqFSjGL5Htrro+9r+ZQ1TwLZfDW2afR7aPU4r+VUaxmLELAHXmTnDsOwwByTXrcdhbQTJJpVpZWrREBXjgVGX0VcDgdsV5L4k+IetadrBi1DTWuY1kO2DIEsYycFePmxx1616nZy3Nzo0d1aW4kW8gDgs211U43EdwQM/rSnfRMxp04xgn52/r5Gf4omtdNhkvLhpYmaTcXX50jUA5BHcHA9+a4zwpqunfaRrFpNJNFdfNcKg4DL/AHx6DOc9fyrKXRfGl34/eC9jmu/DlwWMzq++Bov4dh6q68YHBB9jSaXaaf4N1CbQ5obaa3v5A0vGJD23DkkEjII9zUzUYWvqejhJzq05U4PXqnu15enZ/Lqd1eeI9P1jSr+80W6s7i7gUO7Qzj5I8jgr13E8f15qHwjd2mq6TcWKRNDLtLPj+LcTkj3B9K467+HEek6smseFhPBIrO+wN8r5QgKfUEfLjoevWsrR9V8R6TcD7Rp9tBqAk8piirhAw5IHQ4A5x/OlJNPmjsVQjCdJ0ZaNvR3/ADNW1+F7bdRM2qrIPOE9juBG0YxIpz2I6dgc+tdLoUFt4Y8PW9rf3cEWxnXzJTwdxydqjqAMcitXzI4dPutV1a4jhsZESVFkONhPGMdcn/8AXWPqGlHx3BaXnh28smihQxzedIVWIA53cjoe+PStlPm3ZwTpexvbZb+QviR5odF/tHS1iudxIjlyHXb3ZexPbB71neAPEV3qc0lleyRXEpUujEBGyueBjg+n1rpNE8N2emaK1rFqsGpySTGSeKOTC7/9kcYUDoe9XvE/h+PSfhbq2o+DbGKbWjCJZDAP3jqrAyIncHbu4HJ9zT5lsc1SvyJSZ57Hq/ii98VwWWoaVFJCJN3lTxhoUUnknIyMYyM5/GvR/E0M+raYVFwx+1TRLPI/CoA+Rn+6CQBWR4CXUr7w9aXmrSvJJJueIyOzN5OBtJ3c88nB6V2iyw/Yf3Sq1uqbZi/CuBzz680pPXRFpXjc4PWU1DTfh7cWnh/TJL/VHZnWNCAEMkhy5J4AUdM+ordgK6LFpGitMr3k0aCUFvm5HTPYfjW3o9u08slwgLDbywJKsOu0j06Vn2uj3cvjG9ubyMGzUloS7A78jgZ64BycfSpunuOVRw9xPQ8z8RaPJe3B0zXhMvnyYPluC0D/AMOTyDjrXVWXgeKHTIdJje4jtIHDrIG2iRsZLEDrnuO1T+MZrKx8Y2NzdytHGsPn7wmULKSASemODn3610N/e3j38ckHlCxeNXJTkNkZ69uKmDabVzvxsvaQpz5bXXb8Dl/CVvq2hR67Z6rbI+jyxlRA+14mycZHbbjqWHfmk1o3NnYyyQKLe3eBbeDygFEKH7xXHAbp+tct8QtVTWrmGCxvJJIIWkM9ujbUc9gT3IGfbNT+Hru4uPDNrbXPnmxkJWOM8YwcDH0Jre3U87ltdI1NJA1LQXsdSnfzmAaK4Q7vl28D/voE+nJFN8F+GG0fU/tlzLDdhYyi7x5ec91yck8jkelatnaxW+20jLYLbpJGOS5xjr9BwO1ZnihGku1hWMyXTsqW21dzDspTHfPWi99CuW0Tn9R8AnTba+m0x55biQZEc3UR7vmRR6H+91qt4GttQjaGaWE21urFCZVKjI4x83LEjgjp3r0vxPJFBYWyRS5vUgVbmXJb5h1X0zke9eWXd3rPiK3kuLN5H1CGcSNG7+WJEHWNc8LnIJHGaqLclqZ+Z6pZ3lzNc28VrJL5rt5e3ytxQDkrt67cfxCjx3o41i0jsohK95CN0d0Ts8vJ55OcKOv1p/gexvbLSdLOo7pLwIhmlI5D55AP0IB9cUeLPE0FvNLHGztGPn+UA7uwOO/Oaw5by0N1VlePLpbqZejaVF4W02WD7UZpZZN8j4+Zj/nmt3SEvNXgY6cJGtWJjMzApG2OuPUA9+ma8a+K3ia40u4tbO0lLF4xL5hHLsedv0A4Oa9MuNafXfhr4Yn0S4NsHjAurJG2M4Awyk9ucnHfNaSi9H3JlVkkowR0FzizSXLJL5f+taF/MPXHY8Guf8WeH9Lv9NfUmhnKn91Ld27KrA/9NeowPUj8a8+uBeWGlyadax/Ymv5dkkaYBEKncN5Xg5PHHOAc9a6ix1GTwnp/MFy15coZRD0URgck5+9n06Yp8rWzE6kmrTItNXWfC09ukN//AGppckW9E8xmVVGMndyB1Bz3rqLHxFZXdtN5pS0eFgrxXBBUFugyOoPOCOKwkt7DVLWXU9MsJ9OvRgNDZTARzbeQpByq5JI6fWregt4f8ZaHrFpY3DLq6oqPbXsAhlgZclSUH3kPI3DI9KUrbsmE3HR6ozdR8K3Fz4h3MZSkmZLeZG+UMCPvEHjGevesG/g13xDdeKNA0oyX1xouoxatpd35wfztoAljDAn7wyQPVSK6XQPM0uOTSNVuFltrk+U9v5mHt5GG07D3GD/I1y/hv4X+J/A/jG21Tw3PHNAjlwXm2mWLvG4OAcjH8+OKmc3Gztc6IUva80eZL1drvpqWvFHiSK/8VLZXUS20ckiKrk5lSRgNwOD2JxV/T7Y6dqU8sm2e5uGILbmLEEYIGOecDmvRdd8I6dcayniK202zuL+Jy2cnK5HB44b5s8HjvXnet5h1DUXYz2BiUbQBtcKR97PRzuzxx0q4yUlocsXfVGzBbm1ci6uGUHmMSHle+0n0rVg1m7tFKW11JbsPnMYO7cP1GfpXk1trbWtnHDHf3IZrjdFLcAEsOmD16nPA44rrLSTW7yZoZLWS4SFfOURj5oD0OT1II7UrJ6m1SM6b5aiOmvNYk8wz6pM7l1BGTz16FfTrxVO1tL3VBOPDtyJ5ERmEjkKoHXH5/hXMXyzw6wkV7DLiU4Jcld+Omc9RyPl+tbfh22v5raf7VG9layqdjbhGVQHnkfeGeeaLWWhm59EchY6l4ofUdsVujzyHMZMCMF5wWPp9a7v4j67b+GfCVnb6lp8F7c3EhWN2/dxxhcEscDkknipE1C2toRFY3C3NtCGLtkZKjrgkZNYfiqfTfiNob6HJdO91dQSXlsqwkNbhMcKCOc5AwTzz0xWdROovd08zeg1RqxlUjtrbZ7aa9P8AI0/BmqR+Iora8htHh82Vbbyo/m7csWPUE9G6+tWtT8N6Jf6tJqOoHUH1CL5DBbzLtuAnH7zI7e2OlYvwRtbFfDOg2EE10Etb145DMuwyuGJwRngZ7Z+tY3jLwpq1x8VNT1e1nCQ3Uqsq/aAs0QQAOgT+JTjIx1yQaKaa92T1sTinGdXmjGyeu+3z6m/8VbWbUfAlymgaXLcXZCiGC1kLMjdDJn0C5JHT8q85tjY3nwuXTtASeOTTrs/2jYiT7PNczvjy5Cc52BQwz2PavV1fWLC1s7jSbW7jjRzJ5pTCEA8gk9j0qh8S/Ddrbiz1PwtpMYhuZStybaMBvMIyNw756VcXZpHPVtflT0NXwJZS6J4TuvPuTJqWqQBBFbruSEhSBIzdHbkc98Vz+kaRFo8Udv4ovFvEI3zqbQygnqrYP3fU10j6lbRabbMGJYLiQxsQFdMBwvbANefa74kiu/FX9kyS6nDciJCdzBRKuMg4/i4I+tJJyNoSdNu/U9KvxqMhGoafqQn3qGSGQjypQRwScZX+Vcvqfir4hxW6R6L4amlu8lVjaRJEQe2SOD61p+C7zV7pLhNWtsQWzbI5zD9n3r6YOORxyK6Oa5si6eQZDJ91sDdz6cVm42Z0OcHDlcV5O2q/T70cBBd/Ey20I3V7oGlTatLclTbedGixxbfvcE5JPvRXoUtvJEcvbIrng/OFx9evPtRTRztxfX8jFsUdNKa5RklfllkJyDjj9OaxzoQ16IQTJkAl9x+9n1HtWtoaF9Lhhn2gqC3ychs9+fentqEelwyuieWwALSSNgDnj9ccUK62NnNO7LHhvwULeVLeGMlFyTLv4BOOeK6fVfDMUcJllczMAFCg4wOuffmqWk6+2mpsk3XOQAhQDa46gqfxNN8TavctEolIhgmdUVyRlGPr6fjUe82ccpVXUWtkQWVxtnMBCC2KkSYjwSfTjtXEax4iXRvE97ZTztNYTkKiFsqi8Y/+sateI9ea3sr62tWVtQhiz50bblzxnGOvGa4OOy13xRMILdriOYRjzLqaLbEqDJUBsd/61tCPVlPyPW7ubSPEV3a3SKba5t/LhWNcO0zP90YXt/tHsKzvFHhme81SwsWEUiQXDSMXXP7tuGHuR+VeVQaXq3w98V2WraHN9utJAYriW2R5IC7MP3T4+YEZOG9fxFe4ak4s9Cl13Upgss3yW6DgKOeSPzqZe5s9CqUXJqK66W8zP8RRWesaRc2UrzPbwJvVfuxx7BjBxznjitbw3p7wWNrCrbrhYkLuXLE5UHIB7AcV4n48bUxqekanF4itdLiWPzY7RwzfaV3YMhVcgIeeWxXWeB/GuuWGof2f4l024tlt1AivETdHLkbhgj27dKiztodlWFouEHqnb+rfrbXTc3/i7Zwaf4Ov9W+yiW6sjkkYD7SMYB6jJI/nWX8LPFFv4p8GWGm29td2tzAWgbcxUYU/wt3ByBnr2rsdSlj8S2txBcwNNbeWGnVgcSRnnauOpPT1rxX4Z3V/Y+KLCezSL+xrmSe1SK5uB51qquSYxGOMjjGPxqlFSjfqjCM6kbU5vTe3Z9z1Np7XRvFkNjNe3IN78xty2URvuhh7k4GazPEd18P7vX5dN1W6mt9ZDmJmaJ12OV/56YK55/PvXT+I/Ctnqut6brV/HKlxYlpY3WTaGz2YdwO9YutaPpPizW7q3mgki1TT0BQrFtB6ZIbuB6dM0KzQozlKSk5W80QeEUmXSjY3N0rx2+yGOYNlZDyUUYyd3fnufeqPjQ2cMst1LG32mOIAusePlXO4rnA3Yx6frXJ+JItZ8P6xE9o9wdLRwv221gLlJuoYBeeRwcjnmuhlaw8V+G2junjDXqbzn51iII6r+m3g80OGiv1O6NW1SUoq7W3n5/5/iVfCdnpGs6fdalGkwuLyMQSDOGGxsgdSPxH8q1dIh8K+D/tiXmpQW1tc48+S4lPDtzhT0A64A/SotB0/TtGs00bRLyG4S2hk3RbhvfGScDqDyAMkkADNcfrHgez1PULm8vrlINIuWDfZLi4w4IHJVxwRng+lNJR93ZGbjKsnUVnJ/K1/6/W567pmk6YWS8s7iC5UrlZEmBXB6YA61sJbLZ/LD+6U8lVzlvrjrXD+A/BOhaRZyX2mS3TWRbYslweBgAcY4PPANa+sa8ugo9zqu+KxyyRCFTI0rdsL2GOv60k3JmFSCj123v37HRzRwtbNGkiPI3zDYwbOPXFQXcMrWJKOqKMPvYfLx1/LmsrwzqNvrVmdUtl8qMjY3nqE2qvPb61xXxAuPFE+oprVlqNxbaLb2iCKyt0bdMd3zll6FsY24/xyJa2JhzaHtEGHtbeOBRFD5Y3sOhbHBFVGxGSFBdc/M3X5v6Vz/gbXrrUvDdsdXgNtqMheMLImAxXsccK2Pwzmm6r4i0rTbGY3N/b5KnCKRuAHJc56YqbWIp0JuTVjkPjL/aC+IbOxsrZ9rWBcyJgggNuJ9sYPvxmuI8H2Eth4Ev8AUtZvp4dQ8Rb1hSFiHW2XIMmT0XJPvzgV6bZ6vaeMrLTtcgSDcjMsEp3Esqvw30yMYPTvVHxPoy6rJJexyXkGqxW3krbhV2TouSoGfuty2AMZzitafu3uaVql6VOPZP8Ar5nJ+Fvh9f6HqNveLcQvawkMA6lnkUjAwTxiu6Yp5KbyWZfuhV+6wHHH0rh0vdVkFg8d8JmkGY1QlzGAAAGz6e+O/pXfQRK+BAVL7dzMnGT3Bq5X3ZnDUitkknn3bDgZPtj0zVlnnOZHYRKAVyp2kdjjviu78IaTDb6X9pkQtLcDJVxgADOBiuL1vYt9NDETuD7VJ6j2rNSu7BCrGpKUF0Ob1u8lhgRYLgW1wAx+b5Rx0Az3qp4JvzqWsRW+o3qGeRSC0iBZGbPA44zzwfSsDxdDLqOqQJdg+Qh2QsoICnvkj+PPHPtV6bwZ4n8N65AkNtPPplyDOl3aAGaL5ACJG67wTwQMYPatrK1jKpOzNnxFr+o2fjTTbGC9l8m0cSXIJ3ebu4CY4H3efrWb8QMaXLLf25lwVZ4BKcE+n1HNa+rae1trljdXNxI1xKUeUlQMOBgEnvnGSKf4ut1mt4ptRaR2lyY2jUSMIO7FScAA5245NKLV0VsjxXQb4+KHdtVjkkniKjIAJVQeeDwRnoeor02+U6Xb6dHp1s0tkiCMbeSCOQMfzNXrXw9BpEEcnmQXaXhV4J0f5WjGcED+EnJzniu18N+Hxq12XZNsUXWfHBz2A9aJzS16GiajDnb0Od0GOJpo5LmNWCD5IZhlTn3ParviLTTrsUMtz5n2qDOGhG4mPHVh0+X1Hb1rrdV8LmzTfasJI1yx39fzrCsrqNJF3gs6qVjVZCgHHcjtUKV9UZtxqLmjqc94PjstF1ozXOoefpyRfv5CSd0gU4GQOPoPSqN1oEuteI213RpoLLVlcZCHCSxE5XBxkAHP1zzWV4u1O7tLiHTLNRmaPzZJQnyoQ3AHbnrnpXUeAbh2sVSSSO6a3bE7pjKh/wCEke461bulzChFc2p2bAxP9pkaD7SqhZWdFJHHOH6ge1YfiDxRLoN+DLEBFJEGxMAdje3PIYduK6GTTReahbwRTLBEAZpFJw0g7KP61xHirSItRnntJkV5vNcxsoy0bKeo9Bg/lWC1Oml7OV1Jf13+RBcfEGQ+IrfTrOSSfUZUSdba2A27TyFz1JOPoPWu5trG+1fSRdeKNKjs70hiscLiUKpxjeT3PcDOPWvPrLTJNM0hpodQjQyTm2WUoqPFGxOAGxnBweR/eHrWn4MTUNR1fU9Kg1Oee1W0SWCWRyPLYk5BPXlSOvORxxVNaXWhhUUYStGWne3Q0rrw/oGnXwu5ZtK+1sFPkzy+W0TDoU7qfbHNatvbWqr59oiqxYtuFyJEP0YdRXJeEvCcMeoajca9pdhd3c0v7lpSZJDtPUnOCcfSuwhks4oMXUlrbRDICuVQKo7D2BqddjWs4PWTbfn/AMOVSYprn7K19CLh2wIQwLvjvjtVXXPDMOs3duLnU7mJrVfM8uMgZPr7j2pYND0P+3l1qLUVMiNuBjkVoiTxvbuO9dHNrmjMY2sZrKaWMES+W3QdCT7Upa6GUMTKjNSprU5aw8JW9tqN3dO73n2iBoREwCrGGHJwOvsKsaBo6abcidvKWe3XagVuWG3bkDtxxV2z8WeHL6KVxcSSvbD95HCpyFzgN2yKhv4fEE/irR38Pwwz+F5iftEzMoeMj7xcMNxz0UL369qEnHTYKuJdWXNV3LZltrRjcWcDn7OchCgDKTknd9Sc5rkrPS7+68Ypr6qPs25ZA8o2bSOMKP4s8nPTk1vzyxaXLc3F3OBiUADJwkZOBk+megPvU2qaoqy2qyMUinkWPcoJIycdPShOxvKlzWSVzFvPHOuabp+sy+KX021s2nWCCSbCIocnCgfx8c556GuP1Px1rmm/EXT/AA/aaLOdKeeNIrtSzGQMNyzAj5cHk49BzTvj5/whmsazpPgjU9XvdP1O0Y3EdysO+FHmACpKewJ2nODgfWua+EGl+JdE8R3dvrkUuLQSQzwGQuGOCFGRw3OGBHYVPOoWVr3/AKuKhTji5TlBKCSvotHbS2+jf5v5kt94t8S6l4obS7awNvZ2srOIGRWMzbjmQNjAU4ziu8e80S8driWGxk1aG3LKShO+RRwiHtz+FUPEnizTLS8McWnm8jYKk5icRM+Op+pI6d8VjXdrNqzy3nhSVDHIS+yb5JIz3BHTGfQ1rGDu22XVrr2cYRjZq931dzuppzfeHvt0iyibYS8bEgKe5UHtjNcZeX9zJcOlosiMFAV2PDA8fka2vCNtqNvZR2+rTRF5OHKEnaGz8v8AnjmtCzsfDpvon01VW/jbPzBgGx3QHg/Q/hT2OV36nBRX7CSWCd2gaFvL2AsHBHXdng9sGivQnk+zSH7LHDLknogJA/z/ACoquYr2c3qhdAV43uUuMcBShB5VRnj86i8T2LXGnxNGR50J8xQx5cnjA9/Sn+HtTt9a0qG4hjaJnU5JGCMdj71r7Q0Swzyb4kOYwR8yf/WrHmszd07wsecWTazpwuYLVbqOExj93MhLJ/elUkcemAOa0vD+t33iWO9sNZg09IIE3/axmNTtP3mHY+4rsv8ASYF+1p5k4A2KQeFHX8Dmuc8Z38R0pbSC1gtprh0a5EYRJJkH8Ix3z61fNzdDmcJJnLx2ttf6s9vpE0T+YSdzEokZ6Mc9So68dc12sWn6lf3DRxXkktrCoRDuJDfLgEDt0zWL4L8L3F28OpqkcVu4YW9tuDSsSSCWx0A759a9OsrCa12w2sEBlAxI7vgJxnj1xSnPXQpSUVe5wXhPwpdaPq0d9LeCFIldWjSRmEuc5yDwo7k/lXFav4rPivx6+maVuuvDejwr52octGCDyVHQjPyj1Ir074hw3WteHrzRvDmqR291cfubm68s/KDwUTHr0JrA8BfD2Dwj4SuNCurxru4uXDTzbNm1f4UUcnaDz7n0qJWmveNMNOdCanHR/wBfPrv/AEri+G9B8RX9trF3Yx3kyqvkvJyoUcKMe3p0q1438IW2v+KdAvJJZVSyTEhU7fOYHcAe4A45H0ra0HSI7JIoILxhagn5TjcT3yPetS809GVp/tcHJ2/6Q2CPpj+VHM0xTlDmV/6ZQt9WsPtYg86OKZ/k2M+N0noD36V5v4q8JWtnrtrq0Eoa3s5/tE0cGAxkdu4HPOPvY6HFd1p/w+0C98WpqU07SzWciSpB9qYx7x0bYew7Vpar4DmuNVmu4ruI71YNCy4Eqnqhx0HH6U7xWzM4YmEKlp7aX/ruYfgHxMfFNrfafKqie1O+OP8AhK5Pyg+tcx4u8TSeEdaMNpbTXTSRC4knd9jGIk/KPUgA0xGsvCOo7JXu7OdmdFjCFo1O7OcjkHr169q7bWtP0nW4bO/e0tbqVIt8au+1uuSMjqD1qk0parQ0q0pw+F7/ANfiPsFu10+C/wBElFrBOEKmPkMpGVLBjz1rzbS/BGpeHviLftbT7tKkiEa+Zlu3I443Fi3zfSvV9KltdQjWUaXFaX8oJQSMUCkcfMoOB061gWOoQWtzfG8+R4bjy5yZMlnb/lpz1GOM+1TzNaF4aEm5Sa1X366fPseRaEI7Lx7p+ieVeWc0d2QnmwkMWTJ8wt02EHGR2r2fW/Dun61Zm11GPzLWNcxsjGNlPXK7egzn61cW5067kSRLW21BUO2OZudv9efSp4WmnuJFkQYIwH3c5/u47ACrlNydzOMLLyMWGz1a00n+zLc+TpIXeTGqkqvYAHvkc57nNVNR8OS6vHY2l3cK4smzI+CWf+8cdM9gRxXVXqB9Mmh81iylfLVW4LA5x9Omc+lZC37Wtrc3V2fKTeEkCttJB7g9ssaSfVBd8rTL+jmzsDHpcEKQxMpKREbjtHTjvnuateJbCefR5kjIn+U7N3BUEc7SOeB0ryTxHceL4NXttd8H2cWqLEXUpKchFUcpgkYHOOuc12N947s30YXcJmluQifaLO1UtJGSvK4OCdvqOvWps27Gs6bi41KeqSTbton6/gXLHUfK8LvBcrNLcSj5JnVQUYfxMB9MZ/OvJNa8F32s+Io1v9YMFjdblaWGHzztZMdjjaTk9sV0+r6bqUlnGY4p2srs/aDGgJd0I43DsQeSo9j7Vc8NSz6B4du73UkSHT4w0i4A3MnToCeS3GO2TmtVG2qZMa1k0o2T1/r+reRreHdGXwhpFjpFhdC7jiLsJwPL464APcnArkdT8daxb3hMakzu2QhC7uD95lwRgH17GumXWoNU0CCS2kltL+/jZ7dMeZswMct/CfSuPtrPULvVraCGzknvZQSJVAyyr1BHJHfk1UV1kYTR6BpGpWmuWhv4NOis7lyI7iAKNodfvNwOhzwfwp8M6wNImNqhiccDd7VT0+50/Td9ql5DDbqQJkBzgnBIZh3zgY9TSeENebX9SutMitPKvEaaQTBtwWLgEFGAxj1FKwKfKjvtN1drTShauAzIhIYEMB32/h61x2tZWYzyKW3/ADAgcD1/Cr1qFEeI9hUg7XPH4HPpWMZIrq6nheZEFr8jqrclj/I/pUxjZlU0otuPU4/xXrDLYyyaRPGLkOFYEnknBGV6EHse9ej/AA58XXWu6RPca5AIbiBDawyQqVSYkAsQD0I4J/SvOYvD+rQ3CCFJ3WOUrgR4Ep6g+30Peu48OlruzvYLlRFcRkpPs+TcWABP19MVc0mrESjzuzMiK6PiHxHYlNhto5Nkip1RQcDPqTjP4is3xBeR6j4mkhv1zbGXaQV/djBwoyOcAAYAOfYVs6LotlpV8IYdYjecN5Yj43bO4YZJJHqao6jpyi+8wL5127kJbhS/mHJ+cnpjvx0ppq+gTW1zovsiQ2sEPkq0cKBdwAww67h6+ua77wUix6YyIMjIbOOpIrhoEK6fAS3SPy8sc7So6kj19BW74P1pYMQzthD1B7VjNXRFaLnSaR21ypktWB+ViO3OK8rvrUrdvlGO07mAGOT/AEr06a+tHtyRdQqGBwSw/PFcLqV6J5bmLejAjAUgjzMHr7Gpp3RlguaKd0czf6Gmo2ex4YvOR3Kuo+ePPUbu6k81xumJqHhnXZC+nuyzIsKhwQqnPr0I9/Udq9SsVjkMcLoydWd93IwMj+lclrfia8hvILO1ggvnwLi6e6BYbCSNiJ3X17+lbpt6HQ5Wdj0TRpUubZJ1JLqMZbkk+34VyfiHxLHpPiSK0F3bWtxdFi3nJlnUHBXPbPr14q74d1GIysmnr5Xlt5hg8zfs9QjdSvPFef6totp4r+IU0erXglj0m4K2jQyHeOAwD+ikZGOox1rHldzpo8iblLqtE/8AhmerpDBcLJHe26TQk4ZGAkjbIxhh/FgYqjYaTa2c0ltoVmlnFCGZ5VyCoP8AD1yTgcCtTSRE+lSvaNH9ngc4Iy3zDt9Kwtb1s6TohgCSTzajunUrwsEa43Ox9D0FCvsYSkle3oYviXXHtNq2VtPDb/ZyxnjwZFkzyVIzjAHSuSm1JfEFs16xa5t3O2U7Dlvl4OOoHr/tVLY2U0My6hprvbFZPMmtWbdtB9V9CD9ORXQ6fZWkUM00KFJpuREP4cNuOPrW2kSUtTm9F0XUr2wvWt3KWcjFVkmBVnXGCFA7E9zUmj6fdxvLDdK6HYVR2HCtxjI7njrXXXM0sug+XYho5HPyk8Ernp7cVUuZpxCY5CPNABPGcHvzS5maKJjx2s2ki+5gWZ4RFArOCDk7iwB6jrx61t+GvG1xZ2Nvpss+wRcPOoyyEnPQ9VA4H0pk8f2vS5YI/wDWNGyI6/MQW78+nJxXBHRdSsY5EvZbdioPzifPy/32PqKdlLcylDpY9W1i1Mto11BdFknjaF5eqlmPBdfUHoR0zXM/DbVotX0me3N4LqbTZWjmkRWLRYOFPP3hnjd+Fc1o/jq1/tCCxaKQWswRTOWwDt+Vcj39a6XwXYXOna94qUyqNJb96AkIQ7mIG0nqyg85/HpWcoWOunUagovuYfj/AEWLx14qXUUszHqFmnkzEOAJ1U/KTxxnnvXW+bMbBre2k8uUP5Usi4yoCjdj2HC0eN9TFtpYttJRIZpAHnmUYJC/wn/aJz+FYPg621CLwhbrLEFurnzJl2tubLtlW/LtUqCT5kU6z9j7Pa2xmTeBdcnYQ+UsirJvVQVLBeoLNnI9xXTJo8dqsvnQMGADl04UnHUCuQ0nR9SfWEeO4vWuZZQXaSZjjHBH+z+PWvSjBJe3xSObcB8uI146YOB2rWTsctO97sy7u/dECGBVQx4V1G3OPTPcfzrl5dF1BtTtLcCefeA8XlgbZD2bd29wehFet2vhS7awRbmGF4lORGzZO329D+NYGt6e9nLKIG8u2XG5TwTn39DiojNbIfPGbtFlnw7pn26edRN5JUA+ZnAcfT65opNGdraEIkSOGG4EdQPSiod76CnKV9GeKeCryPw5qt/FDd3k6PIWS1n5ZMnA6cYxivbtJlsNQH2XUFlgmOCHjPzAH9MVWvtDibaQkKyB92Qg3AelY2oRX+nW1zNpsW98ExKeN/qMnvQ2pu51aOFk9tv66mx4js7nTFVLaV54GJKtFndntkDp/LvWfJ4Y0jxdFBe65pb/ANqwbU+1W8rRM+OiuBwfyrjdP+LeraToU/naXDfywy5eQ/uwEB+bJwefQ11E3ieK50fTNQ8Ozi1h1INIs06nCEE7l+uQR/Kq5ZxORyjP4tbGnf8AijQPAsMdmXttMi+6IwO+MklupJqt4e8QXnidtRhFldQvEVYFgf3qMMhgcYHGOPeqNh4Y0fxTcWGq+IUS5aBdzhgSMHoAO+cV1uu+IorW33QR/wBnWUILyPnAIHAB9hx+fFZ2103Oq0Y+7BXut+xSskjtIZnuVPmyEKkLEglf7xOeD/hVXUdXg0qBby/gluEZiFgUnEhA/iYcntgd6xdJ1ez1kyyWd19ocNsdeQyE9MjsTXUXPhae9tbSK6lV1BDgIwLqf7w7cVeifvGc/dja5Qs/E39s206waeLaZY9u3dlCB1256HpXnWn/ABI1KHxF9jvbF4FkIjjaVdzoScDKsMFsA89q9V0zwwLK5nd0eXb1JOZC3YsB09aytS02NrwNLpsEzFgXuXiy+4f3T2+vWqTjqrE01pZMy9Sv9B1rTfslxq9p/a4by7c283l3BfP3QRjdjniptMg8TW0UNh/wkF5JNEQ8c80X7x4/7j/TjmsPTfA2i6d4gl1OG6MsiENCXjHmq3bOewz174GavWlhqEWrvOlwzRwq0jSPIcYHJPp0HT2ptJqxUG4vmf4/8Efq1x4guFkt9VsYJ9Y81o7aQkYlfGVC44JPvXP/AA58dG/8QRLqNsbK5jjZpQB5iDacNuA5zyARjHX0rq9O8S6T4o1sWemag9zfwJ9vhW8smt2d1b78TH39QOPasjxloEcN9BrdnYray3l1vv2twYZGcKcg87Qd55wec5wahRUVyyN/rDrW9jZJp3SX5HqViYLgJd2rrICpICnge5B7HtXnnjm2N3qGqW+lrsubm33FnUiILja3zd2z29+M1PrPjO2s9Jnn0yJ42hV40t5AXycfePuOfxrnfgbq+tX1hf2+uPOYJoXjAlULI247coSOOOQD6VGjVzaFOpRk209vw9e+1iz8ItH8S6JqVlpcgt5NNLmKaYKGTg5LZJHzngd69S1CawsXbzoxbzljvd2ba4/2QOa5mHxHo+l6xB4dtdNvTJZBUNxsLZbsjMepXuR0+la2rGLVGeV3dLg/KsuOvGMHse4q3dvU4mrycoX5f67GvHLaSacHgdJI3baZEcMmc9B+PWsrXre01nw9c2dlJEvnKY0k3hk8zcDuyOOCDXLabPqPhbxBZ262thPo15Ii+b56h3YD5yUJHbqAOwrjvC+o6LonxF1fw0+pzJZuHjs4XtmjV5CcoD2IXJAxjIpqPVENWaUuv9bHrPhKyutP8OJBcGM3UcrPOY2ByD0zjv61zsuvaXq/iqbQLFYZJ4kYT3SLiS3YcgA9TgkZ7elXvBF88moaxa3MySMGBAQAAdQwwOAPun8au6lc6Dot7cyzCzsby7AjkuVhCyNgckt3AB6mktWzWUXRfKU/MXRfDt5KEkurm2O8xE4WYHGGHdR1Brl7/UZJNImhtrRZ9P1FTC6shIyw+UEjpg4JrrbUR5dorhZkKFUhzuBUjIOPQ55PTmvP9A0660LXLKF9TvoXu7hnmt7+T5ZYgPmSNehH3cYHbirSumVCSpytJXudXA2h+FLuCLyFFzbQrFNKZeN5+ZkUnjIYjP5c1r6Lqp1F7ySwWS1kVTEzoo3DPqwGSPcVz+oeEm1aeS7tQbm7s2Msdvb4Ecjj7uWIwpAPUjn61pWtrLoFmYrd7zSpYYvMeW7jEi3EjZJT3BPHHfFJtfMj2Lk7Jp/123/B/mcnb+EtQuJru3mtFhswpBlcjaDnLEtnkH2xzya7TwdpKaaL7Vn1CJleIxRgEyMgJBZt3GeFx6etPeL+2bFIZ4J7O2O2cJGd8bODgnHUcHOCKpafosbXO9b2KeGOUxOirsQHsG9vUYqnPmWrMZ0Jq6aMrxrq0kUkc8N00el5M5jjOCxPr+WSK4LwPqFxP8SXEV8LpXWSMpINsbN1jY9O+Bn3r2W70i1u7SSw1CGK6tZVYgLICUIOOMfdzxz6CuP1P4fsdHum8PLbrfuVaWSSUK7RoSdoPHfH5VcZK1iVpqW/Cj63eeK7S21C3vIJBOVuxKhjTyyMkY6egAHOa7C9jksNSjNy7P5IwM9WJJyT7cDGah8Ba9r02nKPEelPLew/u4pygWRlA4L4yOvGRz3rYkiOoRyrfEh5yCwU4K+m3P8AWs5PXUFzp3kef6PpNjH4mluYL6yjggufPK7D9pJ+b5Ac7SPmOT1wMYrY8Rz2WmeGjqDK9xeB/LhRAVWPOdpyOoOM/hg1leJdP0jwc3/CVX0yXmn20++4jiiKTIZBgbQeMeuenbFWX8TeE/G8C6Pp92puJIg8W4kRuDyoBPKuD2PvVN6p9BRXOnFJ3Wpl+FNTub26eC5Esku0MhcBSu0ZK7ehH8vWuoh8uUgWs8Eiv87OCDs4yRwa5bUrQeC/D17fafJdXs88XlNIYsfZoCfmUgdDkYJPGBWZ4e1FDYRzkokUykSSqpAJ4+7jqfb0qmr6ocZNHf7ZZYXRH78Fzwf61fs7d7mCWQqPKQDbEg6AHnk9siuZ17Vp/CHh7TpNStgbiVXfy2Yx5BOVXvggdu3PpU/grVovG2k6gmn7o7pk2+U7k7cg8H2PrUNaX6ClUurnTWUUN0sklndxujDaZUYMoYH7rY5Gc9elclqjWeosptw8Vxp7mJbwDEZTPzI69xnJDdqp+ENQEWrWukJDJbagCbQxdRtwd4I7qFyfwzV/QfBt1NcFpZ47axtHZt8TDdIGGOBnAz6nij4XqyL9y3pWh3ei6jNulU4HmmZWBDg9NoHrWd9s0vTPF2qX1zZmXav7qSEACSXbymP97HPsa6LxLrNholuHnkRLK2ACLA2+V8DAX/eJ5J9K8s8eaX4nKWWp6VZtcxq+bq3tjiWHHKzAdCMdcDgjnrWbbep6OGUfZv2jtdW9L9dNf+HO08EavOItTtNRBjmUKC5XYHyx4A7kYOD3FJq+ka7qQ+0xWt39mEQh3qFPmR4+6AT06kYrzyXXRN4gj0o2ty89zH9oN9vVDIcEqpiXmNT685Jr2jVNFvPE0ei6hpcuUhtljkRmKqrDqMHjOfbNPnSkYYik6VOMpaXbvfp/w5wGkX3h+znhjvLqSyu3hKCe4gaIFd3IkOSSc8c4AxXVQ/ZjGZA0UkbblDwH5SRXF/EXxB4YvNXutP07UjLrEbi2ZVty8JvB8rY7nHfGRmuW8OeKLvQ5rnS9T88SwXDRy28iKfmY9scjI/GtuXmV0c8Jp9T37wvp0VxqHk3GTGI94VTjn0rpLvwzpr2ckaWis2Sw3HJJ9MmvNdK1AW6mZjcC7DZhljOVVcdPp6mt9vGd9a2lsfMjnkl4O9OnXkEfyrnlGV9BVoVZSUoSOX8QWEWmzPGrjz2OMRckAfw4FYt9EX09RdQz5fKuiRhXIHOcdSOnFb76mXklluLnMrNvlWMAuRnrjsevHvzXNXGtJfyq97CGlWRliLsHbb2yR0OPw7VrG5vKdlYl0Lwjo15fpb/aI4tXdfNitSwJkUHJx/hXR67dT2tlAwi/0ZFk3BhjEgHygAcnJPU9K5K38F3l/wCMLDxHBqAisHeOUs7HzU2Agxqo7HB69MmtPxhqcsxSOCFIYBdLaLJnf5sRO5i4xwN3AGe2amo7a7muDhKrPk7/AOW5U8JC0u9Bgm12Yfa/tJZlklCj5jwjH1JHArs/E0rReHt1gJIb2JegA3R4PG0ng9+PauH19HfxFBY30VtHpEcsdwmxNgnYsF3cdSvHX1r1qfThcWFvFMzJIqnG84BLclSPbpSelmxVZwk9Fb/hjzDw3r2s6hJJHfX5nj5Ado1DKw/2gOgrrPC9+9hN5lxE8y9ThdqjnqT2Hua5nxNcal4c+bT9Ps2feEZ5QQgA9h/F+hp1j4ruLqyluNSghs5IF3brSYsrk8Y2t1z/ADqmrrQjSzjY9W1fxjaWULLErNdlNyow4Ge5PpXAtfXOpXRW4KksxkBPc/3R2rhvDur3+ua35cyHDhvK2MSw2/wv6j6YqPUX1GLVLmZDI4gkJjMR4iAGTntSjT5SIU6dGPu9T0Zrc3AYqGBU43ZPPFFcN8RzPaa5Zz/ZLxrGexheI26sVRiMsCB3PXPtRTUboXP2PTIy8k8YjXzFbhmHO31/EVX1iN7hoVtLnyY43WUsqbiyjqB6E9M1wnxF8QeIk0S2n8O28TRs5PknYBJxkEgkEjrwOc4rrfDurajd+GNJutTtTY3l7DmW0c4ZDyOc8gdCAeeaycdLm6qcs9tUO1PQrC+guRcWEDQXLhpLZl2iT0JI6/zzVOXxP4G1bQodLspI9Kkt5Ba28F1GIzu7bcn5quJdSfaVjdCkaAKrDkue4H/1q53WvAumavqEF5f3MCxw3BnaNY1DTH+6zdSDx9MU42+0zOtSk7HYWNp5UMcUSkRQDpgfMMVyvjGwk13SJLB2dI2KurAHbuQnBPrXbafHI+nLcuwjj3HcgIyR6/8A1vxrzOG08eW91rF7e3N1b6VKrILeSNEig3NgeWerMOOR1yScUQ11HUqKL5d7uwzwf4YbSYZn+1RXF3LhJHBAwM8L65zXRW0/2e5V42kSXJ/extllI7gV5n4Te90zxbuurd5La33omV2yyE/3n7/4e9WvGutahfalFDZPJYW1uRM7oeZHznaT1wAO3XvWzi2ylU0sz1/QfEH2KOSPzpbuWbb5jSnbISM8lsc1fGpSTX6b7dI4pxhpS+7nsuBXnekaiuv2SyRsFdMbiR1/2uOSc8Z9a7/Q9LeYO7kCI4EqNwFPb8fU5rGSS1YpRhFc4l/aQxTW80qJ5UmQVZc7sdvpiqOn2sSXrtBPHCscgcbjkkHsoPUDpUclxDJqAt5bqWKItzLsyF9ME/ez03VH4n/s/TbaO6u5W8tm8uNEXcWYckcHjjH4nFC7D20bKdtpWl6RqE93ax2sd8VeLfGpYqGOSFJOBn07dq1ooDrNpJZFvKnYBox9794v3WweMmpbyTTY/Ccup2CwNEq5jIXl89iD0P61zngPxBJqGswRlYEZZBv2JgDB6564IP6U3eSbFCSjrDRo831C7lv/AIqaLp+pWcf2QA/aWjwowvXAB+7nHXk54r1uFbe0kZbOeO3VP3yxRKCCp4GGPOR6ZrnfEthp0fjHUbw28Sz7pIYmA2/u2I+YZHI4weo54xVmLTbnw54f1B5RHexurOlxgnZwSijPUg5yemKlanozSSvJv3tUunTT5HKeKbzW9P07UNR06awmvmdCZG+8Y+d7gdNwUAY9OecUfDrxJqPipp4LCW5aS3AJun5tSDjgn+/xkeozVL4d6T4m13Vp5zqT6S8DAzSCYXGyEAs4EY4dXUn/APVXf/DLU9P1rTL+HQdHg0q0Sbz47YRkeYrEjcxHRsrjbRKk0732M5ZhDVRitbPVfkunn38jn/GHw/8A+Envo7sXYF5LF9nkkuEOIVU5WRf1OBirt74Zi/4SKC9bRpLi5ihXyr1h5sZZRx8pPDZBO73711F1q8FpqaadPd6XDdSsFS2mf94T155/TvVttSWwniSY7pr1yqiEksWHoKvnl1MvZ8zbit/+H/zOM0RvEVtPrmuNa2stq8W+WHzPLmgK9cKAQ+AvIBBORWD4rs9T8Z3dhK8s62N04K3EMQ3xoR99ozjcO5A7ivY4tEt5rC8ubrUG0+2bl5o2CSem7d2yfbmtCCCHUNLuLjSppb2W2jPlLMAHlZRwpPHBPGaXMk7ow+txi5RnqrW9PnqeeeBtAk0G+0e2ikkubKCEpKWGN65+8vcY9PyqH4h+F31u6sr83oh1WwlMkSBwFnj3bkVQRgYx7d81i+E7fxr8RLi7sPFGnwWMcI+022oWZaGayuAeApHByDgqa9Hn0bUrPTFtNXeGVZozFJKqgb/U8cjPf1qpaPV6hTrwlOO2ltH5GhpWmT6ZoUE3mhWuGDTNEcp93jH1OeajMzlkzcMdh3ATfMPcYPWvPNK8S3vhy9Oh6zLdyaUUEcTSqEJPYq33cgYGAcH2Nehaasd7YLcaff2d3FKvyKW2NweeDxms00bToSpe9U1v16amF4u8G3Gs239r6PqjaZclwrCRm8kMrABxtOQO3pXJR+J9T8FazHpviSG+nS5ZhF5EYmQMTwzyH+EnIwSSPSu318+KrW4tE0S2lazDk3flsCd3GOvBXBPTv1q34r1CPw5oS38OnafcahNKAY5fljDlQXfdz0A7dTWibatucXOlJ3dzE8Sx+PNS+xX/AIasNPisGb5reRlglkOeH3EcrjPy8evNUbvw3441Ust5caWqsn7kWTvEGI6qx6Z9CMZrutMu08QaPZ6tBK6K8eGhDByrjggHuKzr7xHaadeDTG86STAaTYAQmenPr3wKnWS5bGlKtKlL2lOyfbt/mcT4Z1DxvHf31lrmn3sSC3M9tdvL+5kiXAOSOjgdAa7rVdSlg0oSTRu0su0R7lDAg/xZHBxz061sTOzQFkmlEci5KtyGyPT9MVxPjS0bQ7/TY7Eqtvflg1vIS4woHzIP4eSc4pKyNud13qlzatWXbX8EZcsNl4s0/VLK7nMdhLEYr6PG92BPySpnptODj1FcVqPhFvDwsrXSYA91bKdpI5vAW/1oxjDcjAH0r1rw2um/ZZksrJYySDcHeXcnHQk9PpUnh280i/8AF8Omo8JurYn93Im4naN2EPTHP6Vqp8t7HPN+7zPojkfBGt6rqNpMuoRSLPFI1vIskTKzqexbox47jnit3VdW0fw1bD+1rsWthb3KKwePPkknIyoByO+fbrXL+L/GGveHvjHDYXNglxpskiKqxQsftKOfnYn7oZe4wPWuo8c/2bfaXHaXdgL2zlVsSySbZYwrfKpbsBu4J7cUNarsyU+fbX/MwPizpn/Cf+GrSfRNYtLnVLSf7SsccgxsbjZkd8c8/hVT4WaRqfhW8lubuFVd4trRQEuuR1JIxx2wOmfatH4f+GtF8Oz3N/otm0c2zyne5mZ9oODgZ46966uTWNYurr7JY6Y7BUytyMDHHQk8Z/GlKdlyrY0hh3Zr9UvzsUb7xRpq6nNJpGmXk11ONklx5YVwCOVUvyfr3xWRJ4p1KW6tLTT9Cu3tlzHKrcmIj+8wGMD09zXU2+l3F0YLi5ZbdkGJY4gGB4yAxPv6VeitLd1cPllhAVwCSSRkjGD3z+JqeZFclOmtNWv6+Z5H46uLDQvFOiXerzvbwGZblY4QAJXccqQ3O1eOvSu31LX5LbwxNrtmiSacwMqSQ4cyFjt5Yfd54PpXB6r8OPFfirxDDc+IrrTE0kBvs8d1JultAWBwAo+8MD5ST9a3vC3hW/8ACxutNuNZhvLK93C5t2j2pMD0wCcZx1ximopdbl1K/t0ko69X36HnXhvwTeeNU1vWdM1iDQr4yIjW7Fi0TEhgVc4bacfUHivZfB/jzTrTVP7It783sSEr+8TY80ijDPGejZIJK59xXMaFrHhzSvHn/CJ6RYX9pqm8qWlAZJMLuCgkkhACccY61J4m8J+Rcxa34Rjto9Wg8zbC2Y4/Mb/lohPyiQDOAwwabhG7VrXMalSdaPvvm/pv7xfEN+ul+OrbWrjwdb6vMsqype2lsUdznAJwOXXPBYf0Na3xE0N9c1G31iz0eNHdfIacRr5rsO0hHI64/rWBaeJ9d8OeBWvPE+m3l9q0cxGbPkxRgDltvAY5Jx6V0Vl49tbfSdK1C1lu5bHWQ0ixyR7nRxwwbbjngZ4NDdnpuY+x5feX4lS2QabpkKzwPK8SN8qMRjHPy+vpzXIWPifV3vowZIRbuBtiEICp6gsRnOOa9O1DxDYMralf2yeUJRbO0e5x5hGQmzGcgc964rxPHFFJZ3nhnwvJqml30m6ZBeYjlfqSDj5ehLAcfTmmpLqjSMZydl+aMzR45G1F43SMec5fzLgEEDOd6MOpPpXTXHg2yngS8a4TT5QA3lvnD/7S9MZ688CtPR49fS3guNVtLK2S6XEMVuu7yscgsW6cdOOoqLXdL0TUoRZ66Lye3kXF3HBK374Hoq4wRzznNJzb2G6fLu7+mo7SLqx+xXNpp00jzxwSMGAABwMuVc8E8g56Yrh/CV7Jc6k+lee1290GWeZGKeUcfKY1AwcH7zHua6bTNFm0TU7vw/plqI/D89oIl8qfzXhQnjMjDO7P8JGAOOa2EisfC1pHHBaCJ1JAdZNzyvnJz/Mnp2xSvpbuUm+ZSjohs2hLf3sJ1S0mMNuyjeJQJCx5K8dhgZ+tdlY3V4I7hYJcop3BpcEqp7Ad/auF07VLm5vWNy5VSGkJzhEXn5zntnuaxrbxR4ku9TubHR10t7SYqsEmctE45LFj145x61nN23Oj6u69+VKytdvb11O91PT7hxJHcwLcBuZBMdu7Hfjoa5PU9F0uK3kjltJLYSjYWD7lyfQ9jW/c+I5YI4kLSO6KFMzjJkI7txjk5rLutWMuYr21MsD8nDDGexqo8yIh/fRB4T0rS/D00klhIs0ksTQtcebvZMjswHGM5x60vh3wppmjaMtqlwLgWaSSu0rbpJF5Zgw/iPtWtDcaZbaSb+3vHihVfnjeEYzjOD9Ko6Ze+HdVKLZXbO7AN5ZQqMg5wNw5P0NJz1s2EqTlFypxdl1sziYvjxYX1uZbPSGlkikaEW9wh+SMY2uCOBnJ+Xtj6UV32saBo2pwQxXtpbzeSWKq8BjZM8nAXtRWclK/utW9DXDvCxppVqbcu6djhvHXw5m8RakdRs76RLeK3SIgRF9pwA2FJ2r3HTrzXofhfQYbmxtx/aEcKQxhIyPnfAGPmPc+prgPjFfeJtOsNKj8KPfIt5O7Xi2Y3FVyNoOexreih1ab+zclUtZNpuXQhXR1HzgAdiRx261q7uK1OTW7Ud+4fELxJ/whWm2NzcaRqFzaJOIp7mJgYkjLcP0JBI6CuZ/t2Wx1u2ZNmpaDfqz6ZdtJgMSeFz0DA9QfQ16eL+S1b7PII5YHAL28qhlwRxkVyPiTfcTrH4btEli81LW90uOECDy3PzShcfKBzkjp1pRts0P95GXNfQzPhZ8QR4lu9Y067jKT28pyGbgqRjcox8oyMd+tdF4ugvE0F2t5pXW0jcQwu25A4GVJHf1P0rzzwBpOh6d8TNWFjNdi6lifyllbcnlA4zuPJbgAA9q6b4p6vq2jeDhqGkSkXEN/F567Ad8Z428/wnoT9KfLadkaO7p+0nuuxz/grWdQbTtQn8R3S3KRgKbllyzux5VcfTp2q54T0yx8cXV08sl0radIruigRyIp5XA7r2Oa3NRsrTUPDr29kiwJcx/abXyflETEZHB545rnfhpouq6F4i1PVZ3eEzxtHJHJFgu7H5WPfjk5rS902tGZPm0ij0BtPt7CdI4Y0jhPzNk8g46e4roLfVbZNKh0+MqsRjYyOXyzHvz2rkN/najHb3O6a9nztiVSWfjp+XNMk17TNC1W4siZvtkQZpVliyhCjO0Nz8wI6HFZuNyp8qSUmY3jR9QSyePTLudLlsGJ2+X7Rhvukn7ox69ai0rS9Y8TaBZS64jWa20uI3dQdx770ByQMfe9as+HPE+oa5qkb6va6e1tdDMVunJQryd3sRn8qv29pMdfkiS+jaJ5DLiP70i5yFC+gHetNVoF23c5jxS0nhfxXb6TbTfbbCWCN5LaZ9okJJ5AHRj2I/GvQ9A0JNHtzdx2LWkDBTGj8uR1HJ6mqmo65p6X9nHNaxG5gbMbGASTRHBBGT90dfeu30F4LzRzFvmklK7pGl5CjttHYVE5OxLm4K71OX1i6j1DTJlljxKiFodwBC9yB7HGce1czr8w8YeHNBuvDupW0QhueWblDGRsbB6ZVuce+K7XULKKW3eOzbLyJIFbGABjBI/lXCfDTQk0aC/0YAzxrc+fkrlHLY3c+p446VK7o63OMlZK0Vr8/wCrm34B8Ef2FLdXqzMJ5VC2swUEx4+85HckcDPQVf0fRPs/iDUdXgykMpYrbQnZGGPJA7HnJrU1TxGY/GK+G7SxcQCESPds3JypPyjptGACeuT7VS8Ua5JoXh2S4tbF9RkTEUVmpIVpHICliOQozyRT95v1OSnO8XO3/DGdeeDdP1W7W8vIQt3gq8kZ+Zo+uw/0PWvQNOtI7WKK3mWIHgjcBuB7DP06mvINR+IereHdPsY7vQopb2QrNNHKXjj25x8gGScE9+PX1r0DQb432nNqV1CWmkO8gNznGNv4HvRJStqKpL2l0ji4bvWfFPja8sbmFxYO7hFXA2oMgY7enNd54dni0W1ls9N054JN+2Se6fcXfvkDp9BxVbSfIs7i+Wf7JDPcJ9oeZQch1P3Ce3v9a5nxVrOpSXNxJaPHHbW5WQ7D98kjJX1HWqfvO3Qya+w9jode8ayaLatNqssNmjOwTyiCHcDLAHuQOeetJ4J1nT/EMU1/58sypGcpdAiReeWI/u+hHGK4vU9bt9aaTSBb209jModmuYuQwGQVJ6DP41i6Pq2oaXr0Kpt/cwusquhwSB0DdNvTB57U/Zq3mLltpHQ9Zv7bTr6b7HG2YpUPmA4fDH7pVSMZP6Vh/wBkT6Os9vdvDdwrkWcgiEUkZA+6xXgZ4xx9aw9N8UQDxRp5W3Lh5kibb1YE53fhVj4l+OdS0zxHf6VpUduLYusLSPHmRpHAyEJOB1GO3Wkou9i/aSpySTuiDQfGOmXesnSZZNR07X4mG/Srt+JD13RngN647jpWN4ystD8Z+NkjutZWB5hAPs6q6yIYwxOFPyksCRtPr3rbvYvD/irw/pdh4i04T3zQLJBcxDZLbyBiCBIOcjAI7HNTxeBrK+ls7ie6uJbnTE3NKUCyXB7O46cYGcfe602+V3RtBQmn7T5P+vwOQ0D4kf8ACJ68PCUVh9p0uG4MQublzHPI8nzblGMYGcYP0zXrb3mgS3SXC/YZrtRvGCvnKOASQecds9qy/Ekem3k6QS+XJqoCPBeyAbot3ACueVLdP8K8f8S+M7LRrS4/tDTmvI2Jt47m3fy3tm/vg4O4cYxWFWooyV+v5nZh8LSr05VJacurt29PL5N6nsfiX4i6LpVpJJbNBdXK5Qhn/dKR23AZJzxxXkHjXxncXfiPwpqFyx2MZo1KSgRMuV4A7AZ/EVydpPDd3JhsIkaylQTBM+Y6joenctk4z9a9o8P/AAtsr3wbf6Bq2oWt81+qHzNoSS2xyrR5HDZ68cjitJU0t2ZwrQwsbwim0923t6dE0dR4d1bw81lqA0GeymubcAXFpFLhtzYBOf4uvUZ7U3w74P0TRPiHceLheTNJe2zQRxsPkiPBbJ/vEAe3WvNfFfgfU/h5aWC+FdNk1S6XYPMuZTKs6qR+7AAGCTg4Hp7V2d14n0We9TSRf3VldTnIaWNkBbGTGT04OV/Cna97bHJOkpwTv8Xb7rX/AKZ23iqz0rUYptSgvo0u4YiBskUBiOQH/l+NfO3jjxSnizxPJ4Sg83TtZgcQo9wuLeVlU/uyo5A5JBORnrXvGhRQaALgxhJo5iFlcjeT/dxjg/j14qh4r0i0u4pbiewtZbwgvFeR2ym6h/3T244wetOEuVmcKclaHTz7HM/DCydNF0/T9ZmtrpiZI28pmwQCNidsFex9660aXdOWimtrpZQN6GP7pIOBz+FeTeIDLdeCrbSrE3n2hbtE8oRF7h0bo3y4BKtgY6/lXpvgHxVqH9jafputRrHrCK8N1HdTfvUKEhGbAwSygHHalJ3XMjrqqtQm4Ri9P632/qxyHjXxLregatbW0Wivd2uwSSTM7IN3cAjIBH+11zTnsfFmoeI7DVdA1G4trByJGjl4CjIypXkMD0wa77xpaRNJZ311LFmILFIxmChCeV+UcHNXRbyDTZmmu/L4V4lt5CEbA6uT0U+nHSnz6aIz9rGcVd7/ANf1c8n8Y+N/EWqfEmDRPCsNvHBboouSsymNnz85cnoFAxsHOc16Tdaml1cst/5HlImHkQfcTH3v8+uK5LwPB8JtO10S2OtWkus3swDKZG2l8k7RuHAJJ+td18S7hP7Cn0nTruGzuJSkbqiK7lW7BPQ4PPbFKVuZRSOeNVJ8sY3f5eh4lq3ja20rVrjxLaaVHqE2mxi0826zFcLAx2ErglS/cZ7ZFb+n/HHSoPDfie8fS5Wh0qWO1s0eQEXJbdgNx8p+Vietd94S8FaHpWlja7QyPMszyzOGaWVRgSEtwT6AYxXkvxl0KDw1oM1v4W0+Kd9S1IXssiZ+eRQcFVGVIAZhgcc5NNcsnYqo/auy3S103t1LPiJtN8VHT9eGswaGbyIKFikbMij1CkYORgkjHHbNa9j4bSayjhgi8xrNf3d48gUlgwIOF454zj+GvOodX8MQJa6XO9xo99aQGPzri3EyzZO5kkU45DZIYcDivY/AunpH4Sufs1wL3ULqAvbKXVQ6k5OF6Hv1+lXPRI1UnFS7adX/AFoUPiLardQppVxGssT+VdNJESrLKBgeSy9OpB55rS0qKWzS3u9NDJJaWwtLfT1YhIsnLMeuWPOT1rnLDS9dt9aLRvdJpsS4aJmGAh5G5T/EOceldbC9lZW0l7JcRQWx2/6TPLwgzjJA7dQO1RK1rCpR5bv+rHMfEYa5LLp1ymo6bYwvJ5McxwZjKRnG0jGAMkD8a2dLsNSECTxXCvaxEETzJjzB/GM8EE9h05qDxDHY+IobOWG7ikitWMsUqpvidT2XHc4/CtF9daS7TTBKxfeCofkKvXDHoM0nqkaQquGmmv8AWhrQW7cTRAgFi4R33bAfX3rJ8SwzXGpWo0rbHGtq8EkjLuIywOcfxHj6c1ha1rWq3urrZ6OEitnlEaBAMsc8liedvXjvjmvPvDfgvxNcfFGG71HULx0iuGzIznHl7ueewxzgcdKlvk1ZdOn7a99lvr0+/X5HVePbK31Hw3f+H7OWbUr12jkvYrOYGeJVPCMehDZyQOBit3RPDNv4N0Sy1LUZ1utQNrgJajclsmPlCHuexY9cVQ8JWcKQ+LvFVpGhutTSaeIkZRUVzGjHvggFsdeazfCd28QktZZZJIi2JUJZlPPK4PIA7Grim0Y1WuflWlt/P/hv67vdtNfk1ub7JeW6wmVSyGJ87u+HXr+NLrUSR6NPHsAZPn+Y4w/oT6cVPpejiWUR6bbKrMCcIPur6kjvXRzeC719N3SbWblmUj5mB7flQ5JMd4wXvOx53HPHqvh278I69DcGx1IjyruFcSQSjBVwO65Az7Zrf8C+Hrnw7HDcaq0dzMi/vX253f3WwO3f1IxWUtqNH1NjAvmtAC0XnZbaO4xxn/61dFp/io2tqI58TLcAxIFG5k4PT15I45pSV9kTzTgpRi99zmrm6+Kc3ijUruygSfT3OIo7OaLYPRmB+YNgd6Kx1tL681Gc2F01xKw8w+WNu1eOCR1Oc0Vdl5GHsn0f4HRWWjSPYyWd99peO3kCXO6Qlxu6Z9gPX0rpfC1kmk2BtEunv4Ii4DTcMqE8D8OOlcX8Y7nxXbalb6hp9zLbWs8QkNsqrtmKno79dvIIHpmptB8YG7u41E00j3UBjhnVB5JIGW2jqoyDyR296zabjc6Ie/o9GtDu5rC6u7uJ4GhNsUzNuOJCB29v/wBdVbX+z49RmuNOu4ZZLgmN/JcPsx1Bx/WuS1TX9M8XW+q+FbPUprTWbmF4PPj3LHHIBkrv6HgcqOxNY/wZ8GXngqe9F7HarLJIo8xX8wTY/wBnoo5OO5z7VLi0tRqUpS5Vql+Zo+NrGz8J3MfiU7riG3J/dJiNhuznLHjbjOB1J4rpLG50fxXp4MbwX2m3qAtHICFdOo3DqvT9Ku+L9O0/WbN7aJENlcoyXdpcjAfI6x/7QPOM8dq848Orofw612LS9T1KWK1ktg2ntIpUAgnzg5xg5+Xb6ZPrTXvK/UqMnbbR79ztJbFW1GIEpBEB5aqThQB/QdMVz/jy+mtozDaTyzsSI2lVzuVBzx3GTXRafq+j+JIxHYXBW9jBZ45F2sy/3wp59s1zQ8Lapa69b+YkuXclWViUc/3j6nHaqi9dRya2NX4O6leWtzqd14gSSVnhWG0nAIdE53KSeh6NkelZ8Hg2Hdeo+oPe20jMI2nbMoVsZ3N1LE/nXpa+HrxtOzKS0wHCDggdq4jWEns1SC2SaSaRskRxksq9yAOmDxmnGV22jmSpuTe7MrWXbw14oXwx4Z0ieXUrqzWaW8QB5XeQkBACNqoABkjHJ56Vd0m4stI8RWkT3J1DUI7chokGxVzhXcnv82QCP5VveGv7VbTZBdTnypo/ukEOi99x9+OBXIeIbvStI1pLLSQJdYljWN5CN5U56L+nsKd76DpR5bubNHxjeado+ow3F9MZLm9lLQ2seC5AwGJPoPzNenaGHstER5HeJ5VwGIw5AGSefasTRtEt7Wytr/XVjnvII2kM9wgkeMdwv+10H1rjbbxlBfeOWk1A3KxWm9Ni5McbsOF9+DyQOuahrnWnQJtP3eh19jJdMLmeXc8U/wC7gU/wR7up9M9PoKtTII5IjbbftO4Pk9yO5HpWjLL5bC2nSOHcVVJQchyRkkfT3rkLvXdNtPEcWkrc+bdDI3yDPOMjce3H9KlamsXpZ/8ADnU6jrKSRlUszFcTAwjkFST6H+lcroniWzuNQv7CCU/b9PdY3cYZVb/YIPO3oT65rHk8cWegeInuNfgaXSolaaKFYvMcSoOJQOw7VzPgvW9BaLU9aVr5jDKUjtWVc25kYvsYjG5T2I6AGr5VGLbHRi5SVGC3+9noHivQDda0Ip7O4v7e4jV47lh+7JbqNw5BwPpirusaoNKsLXT9I221kigEldzcdAD2555rzO3+MGu+IvGclrH5enafFMEtbKE5kaPOGMg6Mccjp7V12r3bQySmVefM2BN4y/Pf09TUwmpu3Yv6pOFOMqttb+qs7agbyWZ1lll6k5kI5PuRVqPT7CaAGeVUmKECTnILdvbiqOnOl7cpAYY0mYjcVbOcfWvQtK8PaRfr5UsTrJGuDzgv7n/OKuUuUzqzpxhzM8XfRb19UWKKOVvJ+bzVwVIH8Oe/r611N3otlNFaXcV7OFjBN5EU3Iwxn5SfuEkYPX8K7DUvh1OZ/MsNQbaScrLnIH1FQ33hvWvIe2ktvPgkI3+RIo4HpnBFP2ifUyjUpS2l+h5rNoF+2r/atPELQ3UnmCKE7ZFwc7TnuBwPaunk8Lw65axalqZb+0Ek+eMkfOBjBbrzxz61qWfhfXYZY5UswrA8I8vPp15x9au3+havBHCI4HRcYdYm3haHPzHLkbsmvvPNb3TL7T9X+0AhraNHKPnCliDnaPr1HtXZfDzxBJqF4iTQpFKqiIE5O5geuD3PpVXVNN1KCBYb9GTJJUOPlIPX8aseF9OWwkia1jdlhwXfbkEnuf5USd0dCguS3Qh8RbNb+II062aOXTpIxG8nAZWRyzYPcZ49ua4yb4e+Hrq51PxFBrGq6pptnI4Fmi/uWkVeik8lc+ldb4R077V4w11y6v8AZ3NiskakhQ2Wf+g9q2dEvdD1S+lsdHinS2sIyTaSKEibHBcH+IDpt4z1qdHquhk5Twy5LtN2f+V/k/xPKPBGoeIddkuVtLCxbRLSylMKiIIyDI+WNurvnOc8cV0elP4i06HUb68a6udMjj3xLKvlyxyHGzYepBwx2nkCvTb+NZ9KikQrBJDny41jAXggAY9OnNNuLWW505RfAyyeZtGz7oPOMj1zz+FVzR6KwnWqS1lJnn/g/wAa3PiiSW21NJALVDNDKXKqMHG/n7rDOc+hrsTbW13CW8izYv8AJKzADeP7wI5JPr9az7/w3ZOLm10xIrNriL95KoyJCvTjtk5rl/AEt5pWqT6fqUkhiZX8pckhSO4+o420NJ6xHGq1ZM7rWvEUHhLw5d6q9pNdxWyBhDA38XQDPYdOccc1leBPiFJ4xh1AXWmSaXeW7rHMkku5lRhkFTjHbmtZLl2sGjkjTy9wQo4DJcBumc84A3ZHWmaLaaLoVhd/YYIbW2izLNtby41X+9j8h+gqNLbainTSk5SNn+yLOytvtMs8dtchhJEisFJI6YX1xwD75rHGkXt7qX9oDVNPfc7OLWZxvQHsXxz61U07X9I1S9aK0mM1yudyupXj0XNZmra1pWsxy6XdaNdJADse+hkAZGB67eDjOcg9RTUWHM1rfUwPidqOteGn8nXvC8t14aM0ZOoWPMkb9A4OThh2yMfw961bL4dXi3t/9ovtVuLbU4Q6XVlIySN8wbeQ33T0BQ+vWsfStF1zwZqaR6V4iAtbkZFhJdFxKh6EK5O1h7deBW9o/wARZrnUY9IvppDMAyxTqpRHYHKpIOqMccEEjPB9Kp832SI8zer3K2ofCHVpdVsL13t9QjhIdjdwotxgfeHmIRvyOMMDg85rgtd0XxzovjPVvEVlDBd3NzMpjt7iUmRIgfljUyYyoXAxmvefC3jie9tHl1a1lsXDEKkpHzr/AHs4wBmt1PEGn3KwpfCAl1LKTggj1Ge3vUKpLdq4qiq0ptVI6rqnr+qZ5N4jv9PbSbe48WSabZxXDJt+1yBmiYjO2MZxkHPNc58VdWj034fQz6NpY1S1wYkmM2Y7VCMrLGEwc7u54z14r2DxL4D8J+MrNrPUtPik3ESHypTGYm/vLjjP4d65bTvhRqPh7T73S9M1BToikmzVN32mMMcsGfoRn0pqaCNeLbivdb6nz1PpFhr7aRBc6heRXN/bLLKLiZWbcP4FB5x6c+teqaxqtlpeiaX4Z0LUrG18SW9rFb2M0inawLYVGfGA2cnB79aq6X4Eh07xzLrut3Ut7FEQwtUjwFkXhdwPXHXH41P48/4R7xB4m0Y6fqUMGsW1zbrIscW8SANkKR/Ce27mqitbN30OyvJy97lSu9+rXnbr/VjBuNC8bXfiLStS1CFo7eVlS6VLrasWxwJXK9/M5OBnn0rT1fw1q/iTxdrWgaFqFnP4dlgjukSKdRJY7D8scgzuGGJyRnORXr2oosU6XXkgzI7P5bkkE+tec+GPBn9m+LY/EOmXjLLayyOsWzBlMnDRyN/EnocAj8KfNfXsck1KKai99yXwCLLRtNi8PHV7e+vbYu9y2TkK53FR3IByfWty+0W6Oq/a5LfUIVcAzGBfNidR90kjoMd64PUtCtvBPiS6upp7i7tWmmlijjI43nLrvOM47eors/H1vqPiP4XJpOganNDJ5qPcJGxjbygM+UcHuDnHQ7aJb3XUTc3FcqN8RQSWfm2CxLJMCDsYZA6ZVuhIPb2rL1u/0vwxaXQvnutQvJoiyeQNg6fxc9M9a406xq3gbwJY6a+jpqNxfOz28HWOFlKgKMch3Bzgfzro7m90O71z/hHtTdG161gimk08yHhmQM0ZccHAbHXmptZ67D8k7Mr/AAnuJJ/BaLqNqkc8LyBoWGwphs8r1Awc4rVGpaELpLe2uD85JDW6ALv7jceoq14kvNN0WKDVJo3tZr1vKkaAFkQlcgHnuo59q4HxfbaT4fEmo6k19HZznzBHZhXLknk5PbB7c+9KNrG03OtNzWt/6f8Ameu+ENTs7H7Ss/y72ChmIBX6kcYrr7fXNOFqd1ygMa4YZ/WvB5/EulTWNrc6PvutNdFKzODHntggfxdq09M3X2l3VzDHIphAMybsgZGR/jj0FS6Sepz1aMKj5mzY8QG21fWH+zo/kthAy9S3qK5LV9RkgvYZrdbOIQPhbdhwq8gkd9/fPal8O6jez6syx5Z4W3R4XckoPQj1rU8QaVodi9tfaktxFdeYeIo9ynjlinfnvWi00LfRI0bCzHkh7WJbdHyzFUBLn3x6c0VJFd2sJ857o3vmjK4ypx68fy+tFTqaPm6HK3uvy+LNZuNKt4JbbSbdf315c8R7hwEXPLE5J4rN8KXOkReMbnR7CZp7iOBs3EaDyux2hs8tjn0zxXZeIfDlvqYs7a4nuUeaEw7UA2wxnuo6qxzjP410Phj4aaTpNov2KEWqgBFZeuPx61HMorUdStCLutEcTaad4R0LxC1zsto9au2JbEmCXbvt5C5z+Nd1aR2U4CPK0MowNmec/jXMaN8P0s/E7x3jQPblvMEzdZCTyPXNM8fatdxfEF9OiItI7aGMxBlA8wt/F/tDAx7HNU/edk7mHtdeWOhs654w0Xw889jfT2zKqbo2Kktz1CgAkmudg0jSvEtr9q+3Pqlu7ZMF0qlWOeAuQCMdOoPrXJeK44U12GWeCZCqFiwwQqk8g57f41Y0i/0Xw1Ot+bu5uLWSKREiVPlVWbLHbk4I6U+RJaGsOZO6NGbwC+n6xcar4fu5bfUYlKxQXvzRoT98eYOW7YB9BXa+H9V1jTWiGttHc3AUSsIyAiKeGx/QkVzMXiXVPE2gXtjo90lvOR+7uYQPMiTPGDjgEcbuozV74b6NqsWhyDxLPJPctcMIVuPmeOI8ctnkE5IB7UpJ294tcrupR0O81DxrZ2No9yVv5XbpHbW5lk/Adx61wF78VXvdSt4bLwb4nnnjYjzPsRVWUjkeuPr6Ve1fSp9FimW1AksUYt9oYbzCp7bT24rmvB/xHnv/ABXdaLPNcRziN3iU5zIB75wAR3qI2XS4PBU1HnpyXz/r8Dub27voLOCS3s7nZIA4WVRGUPUqRzzUug6Vodpb/wBo2dnHBJOPMLOuHYk9CTyAD2HFeb7I9U8Q31ppvie8ttQtiCyTQkqg6jDAjdjPXvXrWiTww2FtNqGppfeRCB50pXM/+0QOn06+tVLRaMzlGcdJInXZqVvcRsjFEG536YA9PWue0zwt4f0yblHEUspncynOW9T9a6OTW7WdU8vaRINpYHCj24rB1Uw3FxHHJJEsTHarluAf7zfjnpUpvYunS5n76sdfcR28lszSSRhAM7n6AH3rxVvC2leHPEmpeKLrV3k0mHekcSQlpPOYHkk9RgnA6e/Suo1bVfstnDpGo6na2sk2Wt2kkC7gD79jwM1DD4TRNDvtP1opcpdvvniWTcmMEDBB685PPpitIe6tXuY+zlGXLc808UXF94m1m+eCW21DTbtFhspkYbhFjBVv7rAqQR1zXRaHaaVoNrZ+Fr2OL/iZRB3F1AWaSUZXcW+8rgZVRngA10ng7wXpvhHSNltcKzEmWKZ8A277cK+DwcE9889e1ee6Lod3pWoyat4iuJdQ1C2O/fMxkmdM5aXBOf8AgWOAeazUVGUmtb9D1Pbe3p04tcvs1q/6/D+meg33huwtsJoGlLHfxKHg1BnG9jjlG9uw9O1dFPoUV3oK3MrgMR8yjaQjYwQxHOeCKoQ3eneIbKabTtQR45lO142ztYj7rAdGGehrmPAPgHxPpkOvQP4gtZ7yVFls4G3lZHBOd277ueBxnFVZ3OarKPsvi89vvuzpE0u00qyhnjLhpFKjL7iuOCPb+tXbDxTd2BVktomBG3Lkhj7Vx8PiSbWSW1T/AEa7iby5oDFsMTDglh9e/wDSmXU9xDeSNJkJG3yoTtQAdyf1q3HuRTjCULSVz1rTPHdhN5cd9ut5W4+b7pPsf/1V0sGpW0+BHICT0HrXiOmXlhq9tmzuYZmZ1jfB+4x559OKSLVWgv2i2MiR5hjuM4VjnHzDt/vVDpLoclXB0nrHQ95WVGGQwwPelZgoyxAFeMx6u72V1aSXMkyzoUZEk2ug6cN1JI7VkeINSntbGVhe3i2MSbUjmuWcp2HJ5peyMo5c5P4tD0nx1LbSwW8dvNE7mYyOqsGOQuB9BWP+5tNEu7oTSLJLGWVF4ViBuwSeAOPzrifCmr2s1sGVkmJXG2Nhwemfeul8b6gZfBk1pbMTG0Ai3AYyp+UlT2PPeqtyqzO6nQknCjB3uzgvDmq3Gl+GdDWKe9ik1Im8kMZDTP574QMMHIH9a9GsfCf9g667WhU4j+ZSpOeeWGeABz+tX/DvhvSmstN1W5tEmk0oCKwZhgxqoABB6E5zjOauXOo3GoNK9rEqBDiQSEltoOcke/pRzdInNUqSnVbZqWumfbVkgkcLEgALw9Seo5/nV240oW0Uk1vMS4+Y+dyv19uKZp12tuSJWbZgsGYY/DHaofEd680ItIXWMTRM5cjcCByV/Ks9bnNeo5pJ6GFMLO4kdXkE0jEM0ikdR1B+ntXAfEgSwzwq2Ii3zDyXySvQFf6/nXfW99aatuhuhHbXsB+dCoCkNgKQfy5rI1OeyutZg0DWEW5wPJM8AG8O2cRnHr+netYOzOl3WhQ+HJu9S0XSoLnP2i5LSNPIMlwuVzz3wM/nXK6xrq63Pf6PbQltKa92M8fDEo21S/sSOg9BXouj2kwmlFpMifY5dlvjlVxxtPtwRWPN4d0jSdXkv/KkTfK05h3B4xITuYgjrzyPSnFq7Narbna/QxPDmly2F2sk0iQbAyxB+WPOB78c+ue9bjWdqLiRpbeMzk5kK5HmED7xH9DW3CkF8zwui+dPja6gc9wRWtceFIxaYgjInAB3FslvXcaTnrqS6kI6S0ueReI9Pul1z7XbsrWk+GhkaTLRAYyCv8vr7UzyLHxfewWUkq2viBpy6R5AaQKw5xxnjOcemcV21rp6yamkCBHDNtkDoGC56HJrgPA8D6x8WNMnihdhY3UoMgG3ygqspQ+/titL3TfYcnyPQ7j4n+HJrPwpLqN1Pc6jDp6CS60+AiMvESN7Kf7wAPXPGa5X4SX1p4tna/1KKWG1Fx5lnYJ1hgUlFDvj5hx92tH4d+Otf8a694+XWLaMeE4FmtbeIRbZS2SoX3ygJbPQke9aHgu6svD89laWqsiW8PlKGYHbuGRnvjNQm+VrqYQlOSbbFvfENnpfiC9hsrkrPKd8lqd21Np7ehI6j6V2+heMLO5TmcAEZEcgww9cetea6XorW+tre6ozuxM8ssitt3u44J9SScj6Vm/EC7vNMvNMhikt7e2aEyGXaJGAB6c8deSaHBS0LcFJWkei/EdjbyWmpWFoJoZVzJKhHOOn49etcBfeG9Pt5pdf0qKOTVVXzLYyELIq9gvYkcjJ9eK6HwBr8MmnR2+pTRnT9QbauwcCQfxgfwg8H0zUPi/wUG0/Vle3luZlVvJiQnDJ1JX147CpXu6HTQfK1Rm9Oj/rsct4b8balqWrW1vLHM73DMNqrjBHXpyeh5HAr0O40t7e+kvba8hjtfLWSEyY+fIwwAHHHPNcR/bdlongqx1O3s5Lm6CBM3H7qdBjDcn+AAYIOTV7w9rdlqnw70/7BbCx0uAmSO1YktGQTkAkkkZJ9ulU1dXQpX5+Vf0iPXbDWNQ1CyGl3H2XT4zulDhGEvX+8Dz6Yq34e01tL0gjVHLXJbfJJvyvljJ7Dgisr4K+J77x5faxZX8Udt9k+a3Mf3ig+Xbn1z34/Ss74ZeM73xpeazaXNrFawwDenlM26NQxUiXPQjg5HBocddehSxWjpp7m54Q8T2PiHUty2pEdmy3FuJyp3gNw2B0J/OsrUvAJvPHtz4m84ML+YTywFMtuHICt0CjGfWtXQ7Cxh1iWxstLjtbd5CWuoI8ifaeS2OME9Mmt+C/tIrz7G0oinlcm3j8wBio/wBnqfr3o5rN8pM6dmnLcwPFN9bBNQs7iJzEsCujseEkP8YB5OPx60uiaMuteGUt9Rla4WJQ1vMrBgR3Ukdx6Vta3Y2esxvbXLSKM8PC2xlPfBPY9weKk8L+GNL022kt4Lm6Ku4m3PJtCsOmdvf19amVnGzKjOdOaqLS3VFGw8F6fdRW1jFqH2SQdP3ADPj/AGeBk8/lXd+HPDEWlaLJp0DB7WRi0kh+/I3uO30rmtYgnW3dLdoBLyYXkJYRtjg5HOPrXAeNNfuobW3GqajrekNC+Ptlk+xJHI6ZIOaVnLqZVKTqaqW57otrb6doLw2vkRJErSYI6Y55/wAa8i8X2OsapqGnPZxS58jdOHHKZOSRn+HBqfwv4rW50ZPt2urrAi4RyVLNjnBC8k9Mg11tt4km1GyN9Bafv5o9qxFSHiGeBtP581MXyvuCwlanq0c1awHSLeG2ciWZVO4KeBk56iitCW3srtI557lUuuUlguD5bIR69j7EetFaXRbpT7BpN5eTy2uoahEX1G4jjllgHAAxnYPTj+ftXGeItB1LXPFl1qOs3F3cwvNutDFctBDbp6bc8EcDjr1711mvTS2WlbraUxMxRBKfmKDr+JqTRNQk1LS0lvsGRmKgRqMHHG4Z6cdqUW1qiJ005JW2NPSrC+vLKGZp2dkwFaX/AJaAY646Dim6ncT6g8U1zpwubi2YgSyRB9ntuxV3TFigjkLl1i27hIrEHA9q6fS9YtIbCKLZIsiJlkxk/n0NZuVjKpeOqjc8fvNMh1ed01aDzLp2Mm4EAjPv6dOK57xH4csYNLS0huUt5GbAeaVULEnoM+/GK9iuo7XULxpCrb2fcVGBtU9vf/69eNfFvwPPqmpXF9ZBGEUOzbKQdgA7fj6VtTkpOzdjV1H0RpfD63k8O201pPcIgdzIdnzCP6+w9PevU/DDxavYTPaTh/4PMHGG9x+teS+HdJ1RvATC6+TUZrZk5cM0a7xg7uhO2u3+Fml3mm2FzJeDKTndy+5ickk+noBU1Fo3fUqtK693scYY9Y07xfJHaOdQ0+JyZ5GfJibOBuz1Uk8io9V8O2Oj65daybBCPMxK0EZ2ohGccep444rq/Gq6noFtp2p6dDayKxcyK6gtLJu4LZOOmOnpVrw81/qeim+1uC3jurvJEaHcnl4OC31549Kbf2jSjWaTg9un9f1ueV+JLTSdS1XTzpNncyyXJaJjHMV2N0GB1zjIweMVX0P4e+JLe5FvcalA9kp8yKeSXDxR5yyuvc+o5+tdXpWv6Npfi8aOttILmULcIFctuY5B5I4GOgzXW+O7nUNMsVufD0MDzKQZpZz8sSnoQO/9Kd5J279ypzjO1+nb+vnqYyWOt6TpWywlj1KMHbHNGoYDfnBx2xVvwz4fv7VDL4gvpbqferQQBAv2dhknJ/iz/drR8GarJc6ARL+7MjMhZORwcBh+v0rVaY2wZSvnzRASIzNjjp+dQ30HHnk93/Xc4XxT8MovEOrz6ifEMSzTqDcQR/vGgVRxnnI/3eBmuw03TLXTtLtbK2muWht4ljRpMbnwMAt/hXEeBvhlZW3iLXdVg1dtQjvCyPazRMhX593zMPvHI6ivU3065gUyuiIu3kq+cDp6U5y6XMqclvLcydd06yudHuYtaf7LZyIqpPkMAx+6dv49K8q1/wAKX+o+J7drG6t3t0mhQ6pI537QACgHXkAjbjBzzXovjfS7/U7Kzt7FjERK0oZWHZRg4Ppn9ap6DoV1ZTW2ozGCAJH5QhRmfdg/M75GM+mKqD5VdMXK27vY6ZbTSNB0Iw6Tp0VnawK0sixQhVmbbyWx1P49qx/DPiCw1iG6e2mme7tGCzQkZ8tm+70zlSO/UGuuvN32VHfHl8ggcgj1xWH4e8N6Rol9ey6TavC1yuJIw/7sdztHbnnFQmrakxbitNilqNhYaprc8V5YTRyQRBUmZNq3MZwQd2M/h1o8Q6b9s0q5hiUbniEY2nBxjp78CrniTW4bG40yzvjKEeVhH5Z+UEDI98Z4xXC2fxIXW/Feo6TpNsZZNP3tdCYbN4H39p9jx05obaVzegnJpaX+4X4beFNVtfE8smq2yjSRD5KPCdrMSQQTj+4e9VWstRg8UX9pbNJcWzytIhkHIAzgAjjj9cVe8dXelSpZXOoX2o6TcPKtpDLbMzFmcZGQDjHvWppXhu702CO6fxZqk6ABvLeJApHvgZrRTvqZzoyjLYztLtLm1lDyRpGIzxtO7OB6++eal1LTG16wutPkRis/zOycNntj/CtvUL8hjFYIs8aMVeVhgKwGSADz361s6YVt4YHghgNyw8zzlBXHYgDpik5dQi+WNkcR4S8IPo0oklKP+6WIBhhVXspxyT05qLxzdQJqENu00dteXc8Nutu0i5jiTJzjOQGPftXpOPsoN1JFHJcEkqg+6DjPfv7188fG3w3qmoeL01/TIQmrXMqy+YZV2KUUKAAemAB2waV+Z6mtOdSKcqe6+/foetfEL4g3XhPwhpYk0gTq0otp4nYqMAZxnsWHSuu0OWHVvCNvrOiB3tLhTOVkH7xwO3+8vP1xXHaRqI8T+GZF8W29pdM8UUd2vlnaWA+Vxg8N0II6V3lprujaBoVlY6bA+xUEUNui4GfQk+/U89al2SSS1OHEUasH7sd3/wAOZVnfB7G5l2ybWDEy4++vXJPbA7dRVO61GPXNFcabd2l1KjbopLZiWGDwMHkDtg151o/hfWZLq9tZC8UyPJLcXAuTtyzZwFB5446dKfa6Drfh3V4b6/aK3G0/Zmily0hIwrHA4xnvzWvJHuNbqxy3xI8a6ppniiObSZ83FqEBWUf68MuSGHp2r1vRv+Ecv9I07xDpunyafq97HuECu2ARw0m0nA5Jw2MmvOfiDYa3J8RfC/hzS7LT5YI0jluJpY0Y3AJ3SBi3zbR0A75r0fxbNp+l+I7TSrG2jS5TbNOsS7BEp/1aKenYk/h0pVZRikbUKbxFVRjfS7+S/QtaqZbDwZrcaZNxdRmOJos7lLqwJ9uxrzr4J+HrrTrU2Id7mGRRN5cUgdIWVSC+7pliTkY7V6hrLfa9Fv4/Lwlx5cgHTYxwAeOR+FeQXNwulaumjRvKbhm39duGxkYI9R60Qu1YJ04vmqN+9c9Unt5bFkbeoaDhQv3gDzyeufrXRW/i2b7Cj3tq6qw2eYq4DMOoHviuG0/X7650y1lvQiRDOWJLyKV4xu6kf1q/ZyyajdQ/ZwoP+sHJwh6ZwevWpcb7mbpqa95EEGvwLq0skNpcIjOy7ll2kt2BXHQe/JNVLzxTf6T43095I47m3t5DHduqAO+4csMcZGRknk4rodV8NR6e0d88SGSVT8sbnZuHIYqep965zxTpljFANeSCU3MCb5oVkxDcyAAKzA8hgOpGM4FUuVk6S13L/wAXfG0dt4f2eH4A7XsotpLowHHPJUdCTgcmuf8ACVxHrFizyRMs6MNoJCmQdNzL6g5FdB8TdLvNQ+F0Wo2213tgJRATwVbgnJ7jOfwrifh+bmB3jMircLCZwcZXamCAR6nNOKXJoRSstF0Pb7LwhbCzAuJZPPYZOwgAZ7Y71wuuaPbrLeWd7aW2pxW77vLk6M2Ov8vyrQuvGc1xpdv9lkeOVsjcB0b/AArm59djsb3ZfNKWkwGdOpLHDfp9aiMZdTSnGpFNzZ5/a2eoz6+ynTpba4V1lEpYKsYXkbR/dxng17t401aXR/BFtqwhEs+xECI+C46rg9jjknmvMdGgvdS1Yq8sksdu74LPxJj+LH+7gYrW+O01yPBlhZaZOkfkL5Tu2QSWAA2nHHfmqmuaSQ7fC/MgB0vxzpe3W1Ns0X79xDKYyeMnnpggHPXitOa30LTtEtL+OeC30dYxsuC37oBjwxPXGT+teY+A7XWQtydauXgsbcEI0TBmHGWQex969aWK21DQrXdaK1lcxHdbv905GBkd+n4dqi7Tsz0J0Y2U4df6/E5zw3qei6RdSat4cudPKxSPu+zoQlw2MYbAz3yO1YdzcXnxG0y6tfCOjz6dctO817HYyiDzz6NI2O+Tg+tdzbeGtL0ezaGKIfM6kwsSwU+oPpjPFVZLuyfVrWw0t5LeSUlkZU2r35YA+3vTT1ujGdOnKGmjfX/LX9H8jzzSdX0Hw9e2mm6xrQs9fS3b7YIZmMYlDYETuBgtgAkdAe/NZvizUoNe8VtPcte2bSvH8q2hRrYx8hlOcAdwM5z7V6TpHg7SLSS7hvr/APtCeWTzLgz2qgEltwOAPvD1rptU0XTL+V2ZlngdduxkJ3Dpg5q+dJ3MUuaNpfkc5J4m0z7FeypdjUblYt/2W1I3lwv6Fup+hqGDxXusYbmDMymMEvCNoxjkEeo6e9aen+G9E0eVBY6Ta2koBVWgjCsO+N3J/Os+6g0y1jYJE0AmHzLGowRk8kdM5zzUKzNtLpp/15f8Ey9L+Ig1e3vJPD+lXOqTWCmS6tnHl7U6ZHc/XtWxol4vxB8L6lpL6bc6eSpBW7QSKh68dM4OMr3Fecz6r4O8I3uviLTdVt7jUIDAJ1ucx7TjLhBzn6mqXhv4f6F4h06CXRdWvVtYmLI0TPFJGCeSc8HkZ4qJSUWkkafV5VouTaXl8/nb59dPM6n4e6X4KstXuNEtLq2n1aOYxOSrRr5q/eA3n1BwP51uTeItIt5YvsWrT6YIGKOrQ5Dc5IyenNTWWh+H579NY1+Bl1vTFMQ1O1+9dJtwGlU8M4H8XU59RXX2ml6VbXVvNGlvc3M6h4pJLcMqp1BbcM5NO8Xq0ZOVal+73tt1VvIrQ3kM1rFcSOCsgBQkBiR60Vznxj8KyeMHtmsdaawu1YGdY4jswqlV2ng/hRVxjFq7Zl7So9VE/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Medium power view of a gastric mucosal biopsy of a patient with eosinophilic gastroenteritis with chronic nausea, vomiting, and early satiety. Gastric biopsy reveals intense infiltration of pink eosinophils in the lamina propria characteristic of eosinophilic gastritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Calman Prussin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_5_21593=[""].join("\n");
var outline_f21_5_21593=null;
var title_f21_5_21594="Childhood lead poisoning: Management";
var content_f21_5_21594=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Childhood lead poisoning: Management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/5/21594/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/5/21594/contributors\">",
"     Richard L Hurwitz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/5/21594/contributors\">",
"     Dean A Lee, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/5/21594/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/5/21594/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/5/21594/contributors\">",
"     Michele Burns Ewald, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/5/21594/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/5/21594/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/5/21594/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/5/21594/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduction of the child's lead exposure is the single most important factor in the management of childhood lead poisoning. Once lead has been ingested or inhaled, it is rapidly incorporated into the skeletal system and becomes an endogenous reservoir of lead exposure that is resistant to elimination. Chelating agents can reduce the immediate toxicity associated with an acute ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/1\">",
"     1",
"    </a>",
"    ], but do not reverse the neurocognitive effects of chronic lead ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of lead poisoning in children varies depending upon the confirmed blood lead level (BLL) and will be reviewed here. Diagnosis, complications, and prevention are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link\">",
"     \"Childhood lead poisoning: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11001?source=see_link\">",
"     \"Childhood lead poisoning: Exposure and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PRIMARY PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because the cognitive and behavioral effects of lead toxicity are not reversible, prevention of further lead exposure (",
"    <a class=\"graphic graphic_table graphicRef56262 \" href=\"UTD.htm?1/30/1515\">",
"     table 1",
"    </a>",
"    ) is the most important aspect of treatment. The identification of a neonate, infant, or child who has been exposed to lead must be viewed as a public health emergency because the only effective long-term treatment is eradication of environmental lead contamination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1099602\">",
"    <span class=\"h2\">",
"     Prenatal exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, blood lead screening is recommended for pregnant women with important risk factors for lead exposure. Providers for pregnant women with elevated blood lead levels should ensure that the maternal lead level is known by the provider managing the newborn infant. Levels of both the mothers and infants should be documented in their medical records. Indications for blood lead screening during pregnancy and postpartum are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link&amp;anchor=H1318049#H1318049\">",
"     \"Adult lead poisoning\", section on 'Pregnancy and breastfeeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    According to the Centers for Disease Control and Prevention, infants of mothers with blood lead levels &ge;5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.24",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    should have cord blood samples sent for blood lead testing at the time of delivery or venous blood lead levels measured soon after birth [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/3\">",
"     3",
"    </a>",
"    ]. Additional testing is indicated for neonates with an initial venous or cord blood lead level &ge;5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.24",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    The frequency of repeated testing and the need for other interventions varies according to the degree of blood lead elevation (",
"    <a class=\"graphic graphic_table graphicRef57426 \" href=\"UTD.htm?7/57/8092\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef75815 \" href=\"UTD.htm?32/29/33236\">",
"     figure 1",
"    </a>",
"    ). These guidelines apply for infants up to age six months. Screening intervals differ for older infants and children (",
"    <a class=\"graphic graphic_table graphicRef74425 \" href=\"UTD.htm?0/61/989\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1099610\">",
"    <span class=\"h2\">",
"     Breastfeeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon estimates of infant blood lead level elevation occurring from breast milk ingestion (",
"    <a class=\"graphic graphic_table graphicRef58503 \" href=\"UTD.htm?32/21/33116\">",
"     table 4",
"    </a>",
"    ) and the proven benefits of breastfeeding in young infants, breastfeeding should be encouraged for all mothers with a venous blood lead level &lt;40",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (1.93",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/3\">",
"     3",
"    </a>",
"    ]. In the United States, infants whose mothers have a BLL &ge;40",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (1.93",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    should not breastfeed initially. The mother should be instructed to pump her breast milk and discard it. Breastfeeding should be instituted if the maternal BLL falls below 40",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (1.93",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    Whether the risks of breastfeeding for mothers with a BLL &ge;40",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (1.93",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    who live in a developing country outweigh the benefits is uncertain.",
"   </p>",
"   <p>",
"    Infant monitoring of blood lead levels during breastfeeding should proceed according to recommendations for follow-up screening of neonates and infants under six months of age (",
"    <a class=\"graphic graphic_table graphicRef57426 \" href=\"UTD.htm?7/57/8092\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef71332 \" href=\"UTD.htm?27/13/27868\">",
"     table 5",
"    </a>",
"    ). Continuation of breastfeeding is based upon whether there is evidence that breast milk is contributing to elevated infant lead levels on the follow-up maternal and infant screening [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infant BLL &lt;5",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (0.24",
"      <span class=\"nowrap\">",
"       micromol/L),",
"      </span>",
"      or has declined by at least 5",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      from the neonatal baseline &ndash; Continue breastfeeding.",
"     </li>",
"     <li>",
"      Infant BLL failing to decline by at least 5",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (0.24",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      from the neonatal baseline, and maternal BLL &le;20",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (0.96",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      &ndash; Environmental and other sources of lead exposure should be evaluated.",
"     </li>",
"     <li>",
"      Infant BLL failing to decline by at least 5",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (0.24",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      from the neonatal baseline, and maternal BLL &gt;20",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (0.96",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      &ndash; Consider interruption of breastfeeding until maternal levels decline.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional monitoring of maternal BLL during breastfeeding depends upon the most recently obtained maternal BLL (immediately postpartum if possible). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=see_link&amp;anchor=H1318049#H1318049\">",
"     \"Adult lead poisoning\", section on 'Pregnancy and breastfeeding'",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1099860\">",
"    <span class=\"h2\">",
"     Environmental exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain measures should be taken in all children with lead levels greater than the United States reference value (5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [0.24",
"    <span class=\"nowrap\">",
"     micromol/L]",
"    </span>",
"    in 2012); the timing, urgency, and setting of the measures vary depending upon the severity of lead toxicity (",
"    <a class=\"graphic graphic_table graphicRef74425 \" href=\"UTD.htm?0/61/989\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The children should undergo a complete history and physical examination that focus on identifying the source of lead exposure, symptoms of lead toxicity, and additional persons at risk. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11001?source=see_link\">",
"       \"Childhood lead poisoning: Exposure and prevention\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link\">",
"       \"Childhood lead poisoning: Clinical manifestations and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The children should undergo a laboratory investigation to determine the presence of concurrent iron deficiency including:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      Reticulocyte count",
"     </li>",
"     <li>",
"      Serum iron",
"     </li>",
"     <li>",
"      Iron binding capacity",
"     </li>",
"     <li>",
"      Ferritin",
"      <br/>",
"      <br/>",
"      A reduced reticulocyte hemoglobin concentration is used in some centers to detect iron deficiency. Unfortunately, the reticulocyte hemoglobin concentration is also reduced in lead poisoning because lead directly interferes with heme synthesis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/4,5\">",
"       4,5",
"      </a>",
"      ]. Measurement of reticulocyte hemoglobin concentration is not helpful in differentiating lead toxicity from iron deficiency and may falsely label iron-replete children as iron-deficient. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=see_link&amp;anchor=H16#H16\">",
"       \"Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The appropriate public health department (eg, city, county, or state) should be notified. Central reporting of lead toxicity helps to identify new risk categories for exposure. In addition, the health department can arrange for inspection of the home and other environments where the child spends time so that remediation can begin. The BLL that triggers a home inspection varies with the municipality, but the Centers for Disease Control (CDC) recommends that the home inspection and environmental remediation should occur for all children with BLLs persistently greater than 15",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (0.72",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Siblings and other children who live in the household or attend the same school or day care that has been identified as a source of lead exposure should be tested for lead poisoning.",
"     </li>",
"     <li>",
"      The child and siblings should have follow-up lead levels. The schedule for these tests varies depending upon the original level (",
"      <a class=\"graphic graphic_table graphicRef74425 \" href=\"UTD.htm?0/61/989\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The family should be educated about sources of lead exposure, prevention of exposure, and ways to decrease intestinal absorption of lead (",
"      <a class=\"graphic graphic_table graphicRef63418 \" href=\"UTD.htm?37/13/38107\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11001?source=see_link&amp;anchor=H16#H16\">",
"       \"Childhood lead poisoning: Exposure and prevention\", section on 'Education and dust control'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with lead poisoning are at risk for developmental delay and may be eligible to receive Early Intervention Services. Appropriate referrals should be made as indicated. Developmental surveillance should continue throughout childhood, particularly at critical transition points (eg, first, fourth, and",
"      <span class=\"nowrap\">",
"       sixth/seventh",
"      </span>",
"      grades) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/7,8\">",
"       7,8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26394?source=see_link&amp;anchor=H18501566#H18501566\">",
"       \"Developmental-behavioral surveillance and screening in primary care\", section on 'When to perform developmental-behavioral screening'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Education",
"    </span>",
"    &nbsp;&mdash;&nbsp;The education of families of children with lead poisoning is one of the most important aspects of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/9\">",
"     9",
"    </a>",
"    ]. Parents should understand the potential sources of lead exposure and the ways that exposure and absorption can be minimized (",
"    <a class=\"graphic graphic_table graphicRef63418 \" href=\"UTD.htm?37/13/38107\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11001?source=see_link&amp;anchor=H13#H13\">",
"     \"Childhood lead poisoning: Exposure and prevention\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular meals and adequate calcium and iron intake may help to minimize lead absorption and prevent pica [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Intestinal lead absorption is increased during periods of fasting [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/12\">",
"     12",
"    </a>",
"    ]. In animals, dietary calcium competitively inhibits active transport of intestinal lead [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/13\">",
"     13",
"    </a>",
"    ]. Whether this also occurs in humans is not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Thus, although adequate calcium intake is recommended, it should not take precedence over environmental remediation or behavior modification, interventions with proven benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/14\">",
"     14",
"    </a>",
"    ]. Adequate intake of vitamin C may increase the renal excretion of lead [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Iron supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adequate iron intake is important in all children because iron deficiency causes neurocognitive deficits whether or not lead toxicity is present [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=see_link&amp;anchor=H20317248#H20317248\">",
"     \"Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the role of iron",
"    <strong>",
"     supplementation",
"    </strong>",
"    in children with lead poisoning is unclear. Like calcium, dietary iron is thought to decrease the intestinal absorption of lead. This theory is supported by epidemiologic studies that demonstrate an increased prevalence of iron deficiency among children with lead poisoning [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. However, the association is not present consistently [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/19\">",
"     19",
"    </a>",
"    ]. Iron supplementation in children with iron deficiency and lead poisoning improves developmental assessment scores independent of BLL [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Evidence for such an effect in",
"    <strong>",
"     iron-replete",
"    </strong>",
"    children is lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Until further data clarify the effect of iron supplementation on lead excretion and the benefit of iron supplementation in iron-replete children with lead toxicity, the decision regarding iron supplementation should be individualized [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SEVERE INTOXICATION (&ge;70 mcg/dL)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe lead intoxication is defined by a venous BLL of &ge;70",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (3.38",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    or having symptoms of encephalopathy (eg, persistent vomiting, obtundation, headache, afebrile convulsions).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2692895\">",
"    <span class=\"h2\">",
"     Initial management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe lead intoxication is a medical emergency, whether or not the child manifests symptoms of lead poisoning. Chelation therapy in these children, particularly those with encephalopathy, can be life-saving [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/1\">",
"     1",
"    </a>",
"    ]. Chelation therapy should be performed in consultation with a toxicologist or other clinician who has experience with the chelating agents (",
"    <a class=\"graphic graphic_table graphicRef59995 graphicRef71832 \" href=\"UTD.htm?6/24/6541\">",
"     table 7A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/7\">",
"     7",
"    </a>",
"    ]. These clinicians can be found through state health department lead programs, pediatric environmental health specialty units (",
"    <a class=\"external\" href=\"file://www.aoec.org/PEHSU.htm\">",
"     www.aoec.org/PEHSU.htm",
"    </a>",
"    ), or by contacting the local poison control center (1-800-222-1222) or American Academy of Pediatrics Committee on Environmental Health. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Children with BLLs greater than 70",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (3.38",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    should be hospitalized immediately [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition to the history, physical examination, and routine laboratory examinations described as part of primary prevention (see",
"    <a class=\"local\" href=\"#H1099860\">",
"     'Environmental exposure'",
"    </a>",
"    above), they should undergo the following studies to identify contraindications to chelation therapy, complications of lead toxicity, and baseline values of minerals that may be affected by chelation therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abdominal radiograph to identify lead paint chips in the gastrointestinal tract (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef81950 \" href=\"UTD.htm?10/14/10464\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Serum electrolytes",
"     </li>",
"     <li>",
"      blood urea nitrogen",
"     </li>",
"     <li>",
"      Serum creatinine",
"     </li>",
"     <li>",
"      Serum calcium",
"     </li>",
"     <li>",
"      Serum magnesium",
"     </li>",
"     <li>",
"      Serum aspartate aminotransferase and alanine aminotransferase",
"     </li>",
"     <li>",
"      Urinalysis",
"     </li>",
"     <li>",
"      Screening for glucose-6-phosphate dehydrogenase (G6PD) deficiency should be performed in patients who will be treated with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/32/26115?source=see_link\">",
"       dimercaprol",
"      </a>",
"      if they are of an ethnicity with high prevalence for the disease (eg, African-American, Mediterranean descent). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13289?source=see_link&amp;anchor=H12#H12\">",
"       \"Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency\", section on 'Epidemiology of G6PD deficiency'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      G6PD deficiency is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=see_link\">",
"       \"Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=see_link\">",
"       \"Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment should be administered to symptomatic (eg, encephalopathic) children who have supportive evidence of lead toxicity even if the diagnosis of lead poisoning has not been confirmed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link&amp;anchor=H14#H14\">",
"     \"Childhood lead poisoning: Clinical manifestations and diagnosis\", section on 'Symptomatic patients'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Performing a lumbar puncture should be",
"    <strong>",
"     avoided",
"    </strong>",
"    in these children unless absolutely necessary to rule out meningitis because lead intoxication can cause increased intracranial pressure. Extreme caution should be exercised if lumbar puncture is attempted, and only a small amount of spinal fluid (less than 1 mL) should be removed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25625?source=see_link\">",
"     \"Lumbar puncture: Indications, contraindications, technique, and complications in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The first priority for treatment in symptomatic patients is to control convulsions. Benzodiazepine administration (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/22/25959?source=see_link\">",
"     lorazepam",
"    </a>",
"    ) is the first-line therapy (",
"    <a class=\"graphic graphic_table graphicRef55368 \" href=\"UTD.htm?29/20/30029\">",
"     table 8",
"    </a>",
"    ). Seizures may be difficult to control. If additional medications are needed,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/63/29689?source=see_link\">",
"     phenobarbital",
"    </a>",
"    is preferred to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    as the second agent because it has greater efficacy for toxin-induced seizures. Clinicians should prepare for airway management including endotracheal intubation for patients with prolonged seizures. Control of seizures should be maintained with maintenance anticonvulsant doses of phenobarbital. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30505?source=see_link&amp;anchor=H34#H34\">",
"     \"Management of status epilepticus in children\", section on 'Initial pharmacologic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The second priority is to establish and maintain an adequate flow of urine, which can be achieved by the administration of intravenous fluids containing dextrose and maintenance amounts of sodium (eg, 5 percent dextrose with half normal saline [77",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    sodium chloride]) at a rate to maintain a minimum daily urine output between 300 and 350",
"    <span class=\"nowrap\">",
"     mL/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    After urine flow has been established, fluids should be administered cautiously: restricted to maintenance requirements with correction for losses from vomiting and dehydration using normal saline. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=see_link\">",
"     \"Maintenance fluid therapy in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The third priority is to decrease the lead burden through administration of chelation therapy. Gut decontamination using whole bowel irrigation should be performed in children with lead flecks demonstrated on abdominal radiographs. However, decontamination is only of value in children with lead flecks in the small bowel since lead is not absorbed from the large bowel. The clinical efficacy of gut decontamination therapy has not been clearly established, however, and therefore should not delay the initiation of chelation therapy in symptomatic children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=see_link&amp;anchor=H21#H21\">",
"     \"Decontamination of poisoned children\", section on 'Whole bowel irrigation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Initial chelation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chelation therapy should be performed in consultation with a toxicologist or other clinician who has experience with the chelating agents (",
"    <a class=\"graphic graphic_table graphicRef59995 graphicRef71832 \" href=\"UTD.htm?6/24/6541\">",
"     table 7A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/7\">",
"     7",
"    </a>",
"    ]. These clinicians can be found through state health department lead programs, pediatric environmental health specialty units (",
"    <a class=\"external\" href=\"file://www.aoec.org/PEHSU.htm\">",
"     www.aoec.org/PEHSU.htm",
"    </a>",
"    ), or by contacting the local poison control center (1-800-222-1222) or American Academy of Pediatrics Committee on Environmental Health. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    We recommend that children with severe lead intoxication receive combined chelation therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/32/26115?source=see_link\">",
"     dimercaprol",
"    </a>",
"    (also called British anti-Lewisite [BAL]) and calcium disodium edetate (CaNa",
"    <sub>",
"     2",
"    </sub>",
"    EDTA). Chelation should occur as part of an overall treatment plan that ensures careful monitoring of lead levels, parental education, and assurance of environmental investigation of the home (",
"    <a class=\"graphic graphic_table graphicRef52132 \" href=\"UTD.htm?28/29/29148\">",
"     table 9",
"    </a>",
"    ). A clinician with expertise in managing pediatric lead poisoning should guide the selection of alternative methods of chelation in settings where CaNa",
"    <sub>",
"     2",
"    </sub>",
"    EDTA is not available. (See",
"    <a class=\"local\" href=\"#H1099860\">",
"     'Environmental exposure'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Education'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The parenteral chelating agents,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/32/26115?source=see_link\">",
"     dimercaprol",
"    </a>",
"    and CaNa",
"    <sub>",
"     2",
"    </sub>",
"    EDTA, are the mainstay of therapy for children with severe lead toxicity (",
"    <a class=\"graphic graphic_table graphicRef52132 \" href=\"UTD.htm?28/29/29148\">",
"     table 9",
"    </a>",
"    ). Na",
"    <sub>",
"     2",
"    </sub>",
"    EDTA (edetate disodium, Endrate) is another chelating agent that has been used to treat hypercalcemia. Na",
"    <sub>",
"     2",
"    </sub>",
"    EDTA should",
"    <strong>",
"     never",
"    </strong>",
"    be used for treating lead or other heavy metal poisoning in children because it causes hypocalcemia, which can lead to tetany and death [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chelating agents remove lead from the blood and soft tissues, including the brain. Thus, chelation can reverse acute encephalopathy and alleviate vomiting, abdominal pain, anemia, and renal insufficiency caused by lead intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/27\">",
"     27",
"    </a>",
"    ]. The use of BAL or CaNa",
"    <sub>",
"     2",
"    </sub>",
"    EDTA as single agents in the treatment of children with acute severe lead encephalopathy was found to reduce mortality from 66 percent to 25 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/28\">",
"     28",
"    </a>",
"    ]. When used together, mortality in this population was further reduced to 1 to 2 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast to the effects on mortality and acute symptoms, chelation therapy does not affect the chronic neurocognitive effects of lead toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link&amp;anchor=H7#H7\">",
"     \"Childhood lead poisoning: Clinical manifestations and diagnosis\", section on 'Neurologic'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Dimercaprol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/32/26115?source=see_link\">",
"     Dimercaprol",
"    </a>",
"    (2,3-dimercapto-1-propanol), also known as British Anti-Lewisite or BAL, was developed in 1946 by the British to counteract German arsenical war gases. It was the first chelating agent found to be useful in the treatment of childhood lead poisoning. Dimercaprol increases the urinary excretion of heavy metals through the formation of stable, nontoxic, soluble chelates. Dimercaprol lacks stability in water and must be dissolved in peanut oil for deep intramuscular injection.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/32/26115?source=see_link\">",
"     Dimercaprol",
"    </a>",
"    is contraindicated in patients with hepatic insufficiency or peanut allergy and must be used cautiously in children with renal impairment or hypertension (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=see_link\">",
"     calculator 1",
"    </a>",
"    and",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=see_link\">",
"     calculator 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients with G6PD deficiency should be monitored for hemolysis during treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/32/26115?source=see_link\">",
"     dimercaprol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Iron therapy should be discontinued during",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/32/26115?source=see_link\">",
"     dimercaprol",
"    </a>",
"    therapy because the combination of iron and dimercaprol forms an emetic compound. Transfusion therapy should be considered as an alternative to iron in children with lead poisoning and concurrent iron deficiency anemia that requires treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/32/26115?source=see_link\">",
"     dimercaprol",
"    </a>",
"    in children with severe lead intoxication is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/32/26115?source=see_link\">",
"       Dimercaprol",
"      </a>",
"      is administered as a deep intramuscular injection at a dose of 75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (or 3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      every four hours (",
"      <a class=\"graphic graphic_table graphicRef52132 \" href=\"UTD.htm?28/29/29148\">",
"       table 9",
"      </a>",
"      ). Pretreatment with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/29/34256?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      (eg, 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV or orally every six hours as needed, maximum single dose 50 mg) is recommended to prevent the adverse effects of dimercaprol that are related to histamine release [",
"      <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The duration of therapy varies depending upon the type and presence of symptoms. Encephalopathic patients are treated for five days; other patients with severe lead toxicity are treated for between three and five days [",
"      <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/31,33\">",
"       31,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A daily urine flow of 300 to 350",
"      <span class=\"nowrap\">",
"       mL/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      or 0.5",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      per hour should be maintained. Intravenous fluids may be necessary to maintain urine output because nausea and vomiting are one of the major side effects of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/32/26115?source=see_link\">",
"       dimercaprol",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Calcium disodium EDTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1950, a second chelating agent, calcium disodium EDTA (CaNa",
"    <sub>",
"     2",
"    </sub>",
"    EDTA, edetate disodium calcium), was found to be clinically useful in the treatment of lead poisoning. Similar to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/32/26115?source=see_link\">",
"     dimercaprol",
"    </a>",
"    , CaNa",
"    <sub>",
"     2",
"    </sub>",
"    EDTA increases the urinary excretion of lead through the formation of a nonionizing, soluble chelate.",
"   </p>",
"   <p>",
"    Because the use of CaNa",
"    <sub>",
"     2",
"    </sub>",
"    EDTA may cause increased lead concentration in the central nervous system (CNS) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/34,35\">",
"     34,35",
"    </a>",
"    ] and consequent increased intracranial pressure, CaNa2EDTA should be administered",
"    <strong>",
"     after",
"    </strong>",
"    &nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/32/26115?source=see_link\">",
"     dimercaprol",
"    </a>",
"    is given in children with severe lead intoxication. Dimercaprol lowers lead levels acutely without causing the elevated CNS levels of lead that are induced by CaNa",
"    <sub>",
"     2",
"    </sub>",
"    EDTA. CaNa",
"    <sub>",
"     2",
"    </sub>",
"    EDTA can be administered four hours after the first dose of dimercaprol and once urine output is established [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/33\">",
"     33",
"    </a>",
"    ]. The use of calcium disodium salt is crucial because the use of the disodium salt alone may result in severe hypocalcemia and possible death [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/26,31\">",
"     26,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CaNa",
"    <sub>",
"     2",
"    </sub>",
"    EDTA can be administered intravenously (IV) as a continuous or bolus infusion in children with encephalopathy but without cerebral edema but should be given intramuscularly (IM) in children with cerebral edema to avoid a potentially lethal increase in intracranial pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/30,36\">",
"     30,36",
"    </a>",
"    ]. Patients with encephalopathy should be managed in consultation with a toxicologist or other clinician who has experience with the chelating agents [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/7,31\">",
"     7,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When administered IV, the dose is 1000 to 1500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day (or 35 to 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) for five days. It can be administered continuously or in two to four divided doses or by continuous infusion (which is the preferred method, given EDTA's ultra-short elimination half-life) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/33\">",
"       33",
"      </a>",
"      ]. If administered in divided doses, each dose should be administered at the slowest rate of infusion that is clinically feasible to avoid precipitation of acute encephalopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/31\">",
"       31",
"      </a>",
"      ]. CaNa",
"      <sub>",
"       2",
"      </sub>",
"      EDTA is not compatible with D10W or lactated Ringer&rsquo;s, and the concentration should not exceed 0.5 percent (5",
"      <span class=\"nowrap\">",
"       mg/mL)",
"      </span>",
"      to avoid phlebitis.",
"     </li>",
"     <li>",
"      When administered IM, the dose is 250",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per dose every four hours for five days. A local anesthetic (eg, procaine) should be used to mitigate the pain of injection if the IM route is to be used. CaNa",
"      <sub>",
"       2",
"      </sub>",
"      EDTA must be administered in a separate syringe and at a separate site from dimercaprol.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the possible elevation of the concentration of lead in the central nervous system, the major side effects of CaNa",
"    <sub>",
"     2",
"    </sub>",
"    EDTA include local reactions at the injection site, fever, hypocalcemia, renal dysfunction (manifest by increasing BUN, proteinuria, hematuria,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    epithelial cells), and the excretion of other essential minerals [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/26,33\">",
"     26,33",
"    </a>",
"    ]. The dose should be adjusted for patients with renal insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hepatic and renal function of the patient must be observed carefully during chelation therapy. Daily monitoring of transaminases (serum aspartate and alanine aminotransferases), serum electrolytes, blood urea nitrogen, and serum creatinine is warranted in severe cases, and on days two, five, and before each treatment course in less severe cases.",
"   </p>",
"   <p>",
"    Frequent urine analysis also should be performed looking for renal epithelial cells, hematuria, or proteinuria that may indicate possible toxicity from CaNa",
"    <sub>",
"     2",
"    </sub>",
"    EDTA. CaNa",
"    <sub>",
"     2",
"    </sub>",
"    EDTA should be temporarily discontinued if the patient becomes anuric; however,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/32/26115?source=see_link\">",
"     dimercaprol",
"    </a>",
"    should be continued [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients receiving CaNa",
"    <sub>",
"     2",
"    </sub>",
"    EDTA and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/32/26115?source=see_link\">",
"     dimercaprol",
"    </a>",
"    should be in a monitored bed so arrhythmias and other nonspecific changes related to hypocalcemia can be detected. Ongoing EKG monitoring may be necessary in some patients depending upon the presence of a prolonged corrected QT interval.",
"   </p>",
"   <p>",
"    Neurologic assessment must be monitored carefully because chelation therapy can cause an increase in intracranial pressure.",
"   </p>",
"   <p>",
"    Blood lead levels should be measured after each three to five day course of therapy in order to assess the need for future chelation therapy and two days later.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2693119\">",
"    <span class=\"h2\">",
"     Additional chelation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The blood lead level (BLL) should be rechecked two days after the completion of therapy. Multiple courses of chelation therapy may be required to reduce BLLs sufficiently to reduce the risk of serious injury and death.",
"   </p>",
"   <p>",
"    A second course of treatment with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/32/26115?source=see_link\">",
"     dimercaprol",
"    </a>",
"    and CaNa",
"    <sub>",
"     2",
"    </sub>",
"    EDTA is administered if the BLL is",
"    <span class=\"nowrap\">",
"     &ge;70mcg/dL",
"    </span>",
"    (3.38",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/22/8548?source=see_link\">",
"     Dimercaptosuccinic acid",
"    </a>",
"    (DMSA) may be used in asymptomatic children who have BLLS between 45 and 70",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (2.17 and 3.38",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    if the child is cooperative, lead safe housing has been obtained, and compliance with therapy can be expected (",
"    <a class=\"graphic graphic_table graphicRef58045 \" href=\"UTD.htm?30/21/31068\">",
"     table 10",
"    </a>",
"    ) as for children with moderate intoxication. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'DMSA'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A minimum of two days without treatment should occur between the first and second courses [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A third course of chelation may be necessary if the BLL remains greater than 45",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (2.17",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    five to seven days after the second course.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;After completion of therapy, the child can be discharged when a lead-free environment can be assured. The family must receive education regarding ways to maintain a lead-free environment and to reduce the absorption of gastrointestinal lead (",
"    <a class=\"graphic graphic_table graphicRef63418 \" href=\"UTD.htm?37/13/38107\">",
"     table 6",
"    </a>",
"    ). Supplementation with iron, calcium, magnesium, and zinc may be necessary depending upon the concentration of these minerals after chelation therapy and can be achieved through the daily administration of a multivitamin with iron and ingestion of 500 to 750 mg of calcium per day (ie, the amount that can be obtained from 16 to 24 ounces of milk in children who are able to drink milk). Iron supplementation should be given with orange juice rather than milk, since ascorbic acid increases iron absorption and milk decreases it. Supplementation with iron and other minerals should not be given during active chelation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;BLLs should be measured periodically (",
"    <a class=\"graphic graphic_table graphicRef52132 \" href=\"UTD.htm?28/29/29148\">",
"     table 9",
"    </a>",
"    ) until the lead level is less than 45",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (2.17",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    Retreatment with chelation therapy should be considered if the BLL rebounds to greater than 80 percent of the original lead level and is greater than 45",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (2.17",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"   </p>",
"   <p>",
"    It is difficult to reduce the BLL to less than 45",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (2.17",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    unless the ingestion occurred acutely because of the large reservoir of lead in bone. Once the BLL is less than 45",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (2.17",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    BLLs should be repeated every three to four months for one year. An acute rise in level may signify a new exposure to lead, and repeated surveillance of the child's environment is advised. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link&amp;anchor=H4#H4\">",
"     \"Childhood lead poisoning: Clinical manifestations and diagnosis\", section on 'Toxicology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MODERATE INTOXICATION (45 TO 69 mcg/dL)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderate lead intoxication is defined by a venous BLL 45 to 69",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (2.17 and 3.33",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    and the absence of symptoms related to lead toxicity. Chelation therapy is indicated for these children and should begin as soon as possible after the BLL is confirmed (",
"    <a class=\"graphic graphic_table graphicRef73145 \" href=\"UTD.htm?23/22/23915\">",
"     table 11",
"    </a>",
"    ). Chelation therapy should be performed in consultation with a toxicologist or other clinician who has experience with the chelating agents (",
"    <a class=\"graphic graphic_table graphicRef59995 graphicRef71832 \" href=\"UTD.htm?6/24/6541\">",
"     table 7A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/7\">",
"     7",
"    </a>",
"    ]. These clinicians can be found through state health department lead programs, pediatric environmental health specialty units (",
"    <a class=\"external\" href=\"file://www.aoec.org/PEHSU.htm\">",
"     www.aoec.org/PEHSU.htm",
"    </a>",
"    ), or by contacting the local poison control center (1-800-222-1222) or American Academy of Pediatrics Committee on Environmental Health. The World Health Organization provides a listing of international poison centers at its website:",
"    <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"     www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Chelation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chelation therapy for moderate lead toxicity may be administered orally or parenterally. Factors to be considered in this decision include [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/37\">",
"     37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age of the child",
"     </li>",
"     <li>",
"      Likelihood of compliance with an oral regimen",
"     </li>",
"     <li>",
"      Duration of lead toxicity",
"     </li>",
"     <li>",
"      Susceptibility to renal or hepatic toxicity",
"     </li>",
"     <li>",
"      Hypersensitivity to sulfa or penicillin drugs",
"     </li>",
"     <li>",
"      Indications for hospitalization",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hospitalization serves two purposes: it permits the monitoring of children for potential adverse effects during chelation therapy and removes the child from the lead-containing environment until the origin of lead exposure can be identified. Additional indications for hospitalization include BLL &gt;50",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (2.41",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    and to ensure compliance with therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/37\">",
"     37",
"    </a>",
"    ]. In most instances, patients should be hospitalized to begin chelation therapy and to ensure a lead-safe environment.",
"   </p>",
"   <p>",
"    We suggest that children with moderate lead intoxication receive chelation with meso-2,3-",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/22/8548?source=see_link\">",
"     dimercaptosuccinic acid",
"    </a>",
"    (DMSA, Succimer&reg;) (",
"    <a class=\"graphic graphic_table graphicRef58045 \" href=\"UTD.htm?30/21/31068\">",
"     table 10",
"    </a>",
"    ) until the blood lead level is &lt;45",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (2.17",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    For children who cannot adhere to treatment with oral DMSA, continuous infusion of CaNa",
"    <sub>",
"     2",
"    </sub>",
"    EDTA may be used instead.",
"   </p>",
"   <p>",
"    The efficacy of intravenous CaNa",
"    <sub>",
"     2",
"    </sub>",
"    EDTA and oral DMSA therapy in the treatment of moderate lead toxicity were compared in a controlled trial of 19 hospitalized children [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/38\">",
"     38",
"    </a>",
"    ]. DMSA was more effective in reducing mean BLL after five days of therapy (61 versus 45 percent) and was well tolerated. BLL 14 days after discharge depended upon outpatient therapy: the mean BLL was 73 percent of pretreatment levels with no additional therapy, 66 percent of pretreatment levels with low-dose DMSA (350",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day), and 50 percent of pretreatment levels with high-dose DMSA (750",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     CaNa2EDTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the treatment of moderate lead intoxication, CaNa",
"    <sub>",
"     2",
"    </sub>",
"    EDTA is administered IV. The dose of 1000 to 1500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day (or 35 to 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) for five days is administered as a continuous infusion as described above.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/32/26115?source=see_link\">",
"     Dimercaprol",
"    </a>",
"    usually is not required at these lead levels unless the child shows signs or symptoms of toxicity. The child should not be discharged until a lead-free environment has been confirmed. The parents or caregivers should be provided with educational and nutritional counseling (",
"    <a class=\"graphic graphic_table graphicRef76197 \" href=\"UTD.htm?0/30/492\">",
"     table 12",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Severe intoxication (&ge;70 mcg/dL)'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If CaNa",
"    <sub>",
"     2",
"    </sub>",
"    EDTA is not available, then Meso-2,3-",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/22/8548?source=see_link\">",
"     dimercaptosuccinic acid",
"    </a>",
"    (DMSA, Succimer&reg;) may be given as described separately. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'DMSA'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22467417\">",
"    <span class=\"h4\">",
"     EDTA mobilization test",
"    </span>",
"    &nbsp;&mdash;&nbsp;CaNa",
"    <sub>",
"     2",
"    </sub>",
"    EDTA mobilization tests, once used as indicators of potential response to chelation therapy in children with moderate lead intoxication, are no longer used by most centers that treat childhood lead poisoning. They are thought to be unnecessary because most patients with BLL greater than 40",
"    <span class=\"nowrap\">",
"     microgram/dL",
"    </span>",
"    (1.93",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    have an adequate response. In addition, they are expensive and difficult to administer [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/31,36,39,40\">",
"     31,36,39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     DMSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meso-2,3-",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/22/8548?source=see_link\">",
"     dimercaptosuccinic acid",
"    </a>",
"    (DMSA, Succimer&reg;) is a water soluble analog of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/32/26115?source=see_link\">",
"     dimercaprol",
"    </a>",
"    that can be administered orally [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/33,41\">",
"     33,41",
"    </a>",
"    ]. Like dimercaprol and CaNa",
"    <sub>",
"     2",
"    </sub>",
"    EDTA, DMSA increases the urinary excretion of lead. It was approved by the US Food and Drug Administration (FDA) for use in children with BLL greater than 45",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (2.17",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in 1991.",
"   </p>",
"   <p>",
"    The advantages of DMSA therapy are that it can be administered orally and has little toxicity. Unlike CaNa",
"    <sub>",
"     2",
"    </sub>",
"    EDTA, it is relatively specific for lead and causes less urinary loss of essential minerals [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/38,42\">",
"     38,42",
"    </a>",
"    ]. Unlike",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/32/26115?source=see_link\">",
"     dimercaprol",
"    </a>",
"    , it may be administered concurrently with iron [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/38,43\">",
"     38,43",
"    </a>",
"    ]. Adverse effects of DMSA include rash, neutropenia, elevation of serum liver transaminases, and gastrointestinal upset [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/37,44\">",
"     37,44",
"    </a>",
"    ]. DMSA has been reported to cause hemolysis in a patient with G6PD deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DMSA is given at a dose of 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or 350",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    (rounded to the nearest 100 mg) three times per day for five days followed by the same dose two times per day for 14 days (",
"    <a class=\"graphic graphic_table graphicRef58045 \" href=\"UTD.htm?30/21/31068\">",
"     table 10",
"    </a>",
"    ). At approximately five years of age,",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    dose and the",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     <strong>",
"     </strong>",
"    </span>",
"    doses are equivalent; for younger children, calculations based on body surface area provide higher doses, which are recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DMSA is supplied in 100 mg gelatin capsules that contain medicated beads. DMSA can be administered by sprinkling the beads onto food or dissolving into juice to help mask the sulfur odor [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/37\">",
"     37",
"    </a>",
"    ]. Juice containing the dissolved medication may be better tolerated if it is taken through a straw from a cup with a lid. During administration in juice, the beads may settle to the bottom and additional juice may need to be added to the cup to ensure ingestion of the entire dose.",
"   </p>",
"   <p>",
"    The child must also be encouraged to drink at least two to three 8 oz glasses of milk per day for calcium supplementation and to use a multivitamin that includes",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/41/1686?source=see_link\">",
"     trace metals",
"    </a>",
"    . Additional oral calcium supplementation sometimes is required if calcium levels cannot be maintained (20 to 65",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of elemental calcium in four divided doses).",
"   </p>",
"   <p>",
"    Blood lead levels (BLLs) may rebound after discontinuation of DMSA therapy because of re-equilibration of lead from other body compartments. The rebound usually plateaus between two to three weeks after completion of therapy and may be as high as 78 percent of pretreatment levels [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/37,42,47,48\">",
"     37,42,47,48",
"    </a>",
"    ]. Thus, a venous BLL should be examined 10 to 14 days after completion of DMSA therapy.",
"   </p>",
"   <p>",
"    Retreatment with chelation therapy should be considered if the BLL rebounds to greater than 80 percent of the original lead level and is greater than 45",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (2.17",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    It is difficult to reduce the BLL to less than 45",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (2.17",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    unless the ingestion occurred acutely because of the large reservoir of lead in bone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link&amp;anchor=H4#H4\">",
"     \"Childhood lead poisoning: Clinical manifestations and diagnosis\", section on 'Toxicology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1655234\">",
"    <span class=\"h3\">",
"     D-penicillamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;D-",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?6/26/6566?source=see_link\">",
"     penicillamine",
"    </a>",
"    is another oral chelating agent. It was developed originally to reduce serum copper concentration in patients with Wilson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/49\">",
"     49",
"    </a>",
"    ]. AAP guidelines for the treatment of lead toxicity describe penicillamine as a third-line agent, indicated only when unacceptable reactions have occurred to DMSA or CaNa",
"    <sub>",
"     2",
"    </sub>",
"    EDTA, and continued therapy is required for moderate intoxication or is desired for children with blood lead levels (BLLS) of 20 to 44",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.96 to 2.12",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/7,31\">",
"     7,31",
"    </a>",
"    ]. Given the potential for significant adverse events (including leukopenia, thrombocytopenia, hematuria, abnormal liver function, urticaria and angioedema), consultation with a clinician with expertise in managing pediatric lead poisoning with D-penicillamine chelation is advised before starting this treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/31,50,51\">",
"     31,50,51",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood lead levels (BLLs) should be measured periodically (",
"    <a class=\"graphic graphic_table graphicRef73145 \" href=\"UTD.htm?23/22/23915\">",
"     table 11",
"    </a>",
"    ) until the lead level is less than 45",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (2.17",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    Retreatment with chelation therapy should be considered if the BLL rebounds to greater than 80 percent of the original lead level and is greater than 45",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (2.17",
"    <span class=\"nowrap\">",
"     micromol/L).",
"    </span>",
"    Lead levels should then be repeated at least every three months for one year. An acute rise in levels may signify a new exposure to lead, and repeat surveillance of the child's environment will be necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     MILD INTOXICATION (&le;44 mcg/dL)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four categories of mild lead intoxication have been defined:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Venous BLL 20 to 44",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (0.96 to 2.12",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Venous BLL 15 to 19",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (0.72 to 0.91",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Venous BLL 5 to 14",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (0.24 to 0.68",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Detectable venous BLL &lt;5",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (&lt;0.24",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     20 to 44 mcg/dL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important interventions for children with BLLs 20 to 44",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.96 and 2.12",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    are parent education, nutritional counseling, and notification of public health authorities for environmental surveillance and remediation (",
"    <a class=\"graphic graphic_table graphicRef61373 \" href=\"UTD.htm?25/58/26539\">",
"     table 13",
"    </a>",
"    ). Removal of the family from the source of lead is critical in preventing further exposure (",
"    <a class=\"graphic graphic_table graphicRef56262 \" href=\"UTD.htm?1/30/1515\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link\">",
"     \"Childhood lead poisoning: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11001?source=see_link&amp;anchor=H13#H13\">",
"     \"Childhood lead poisoning: Exposure and prevention\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Chelation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that children with blood lead levels in the range of 20 to 44",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.96 to 2.12",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    <strong>",
"     not",
"    </strong>",
"    receive chelation therapy. Chelation therapy for children with mild lead intoxication is controversial. Although this regimen has been shown to transiently reduce BLL, there is no evidence that chelation at this level improves clinical outcomes and chelation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/2,31,52-56\">",
"     2,31,52-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, the effects of as many as three courses of DMSA therapy were evaluated in a double-blind, randomized, placebo-controlled trial in 780 children (aged 12 to 33 months) with blood lead levels of 20 to 44",
"    <span class=\"nowrap\">",
"     microgram/dL",
"    </span>",
"    (0.96 to 2.12",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/2\">",
"     2",
"    </a>",
"    ]. Cognitive, motor, behavioral, and neuropsychologic functions were followed over a period of 36 months [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/2\">",
"     2",
"    </a>",
"    ], and again at age seven years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/57\">",
"     57",
"    </a>",
"    ]. The following results were obtained:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mean BLL in the treatment group was 4.5",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (95% CI, 3.7-5.3",
"      <span class=\"nowrap\">",
"       mcg/dL)",
"      </span>",
"      lower than that in the placebo group during the first six months of the trial [",
"      <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The mean IQ score of children in the treatment group was one point lower than that of children in the placebo group [",
"      <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The behavior of the children, as rated by a parent, was slightly worse in the treatment than in the control group. Children in the treatment groups scored slightly better on a battery of tests designed to measure neuropsychologic deficits thought to interfere with learning; these differences were small and not statistically significant [",
"      <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A modest but statistically significant decrease in growth velocity occurred in the treatment group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At seven years of age, no statistically significant differences were observed between treatment and control groups in the areas of cognition, behavior, learning, memory, attention, or neuromotor performance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/57\">",
"     57",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Taken together, evidence suggests that, although chelation therapy in general, and DMSA in particular, is effective in lowering BLLs in children with BLLs less than 45",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (2.17",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    it does not improve scores on tests of cognition, behavior, or neuropsychologic function and thus, is not indicated for children with these BLLs.",
"   </p>",
"   <p>",
"    However, because DMSA therapy can occur in the outpatient setting, many lead poisoning centers (including our own) treat some children who have persistent elevation of BLLs between 25 and 44",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (1.21 and 2.12",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    with DMSA as described above (",
"    <a class=\"graphic graphic_table graphicRef58045 \" href=\"UTD.htm?30/21/31068\">",
"     table 10",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef61373 \" href=\"UTD.htm?25/58/26539\">",
"     table 13",
"    </a>",
"    ). The rationale for this approach is that chronic exposure to elevated lead may result in ongoing toxicity, including CNS damage. Furthermore, chelation may reverse other toxic effects of mild lead intoxication (eg, inhibition of vitamin D and protoporphyrin metabolism) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/58\">",
"     58",
"    </a>",
"    ]. Some centers alternatively treat these patients with D-penicillamine. However, the use of D-penicillamine should only be undertaken after consultation with a clinician with expertise in managing pediatric lead poisoning. (See",
"    <a class=\"local\" href=\"#H1655234\">",
"     'D-penicillamine'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     15 to 19 mcg/dL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with BLLs 15 to 19",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.72 to 0.91",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    should have a confirmatory venous lead level within one month. This should be performed even if the original specimen was a venous sample to make sure that the lead level is not increasing rapidly. Once the elevated BLL is confirmed, the appropriate public health authorities should be notified so that environmental surveillance can be undertaken (",
"    <a class=\"graphic graphic_table graphicRef56262 \" href=\"UTD.htm?1/30/1515\">",
"     table 1",
"    </a>",
"    ). Educational and nutritional counseling should be provided to the family (",
"    <a class=\"graphic graphic_table graphicRef76197 \" href=\"UTD.htm?0/30/492\">",
"     table 12",
"    </a>",
"    ). A repeat lead level should be obtained within two months, and other children living within the household should be tested (",
"    <a class=\"graphic graphic_table graphicRef53709 \" href=\"UTD.htm?5/39/5755\">",
"     table 14",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Education'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'Nutrition'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     5 to 14 mcg/dL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with BLLs 5 to 14",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.24 and 0.68",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    should have a confirmatory venous lead level within one month. This should be performed even if the original specimen was a venous sample to make sure that the lead level is not increasing rapidly. Once the elevated BLL is confirmed, the appropriate public health authorities should be notified (",
"    <a class=\"graphic graphic_table graphicRef56262 \" href=\"UTD.htm?1/30/1515\">",
"     table 1",
"    </a>",
"    ). Educational and nutritional counseling should be provided to the family (",
"    <a class=\"graphic graphic_table graphicRef76197 \" href=\"UTD.htm?0/30/492\">",
"     table 12",
"    </a>",
"    ). A repeat lead level should be obtained within three months, and other children living within the household should be screened (",
"    <a class=\"graphic graphic_table graphicRef70588 \" href=\"UTD.htm?1/24/1419\">",
"     table 15",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Education'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'Nutrition'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Detectable BLL &lt;5 mcg/dL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with detectable blood lead levels (BLLs), 5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.24",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    may warrant monitoring of BLL more often than once per year, particularly if they are younger than two years of age, were tested before the onset of warm weather, are at high risk for lead exposure, or exposure sources have changed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/9\">",
"     9",
"    </a>",
"    ]. Young children are at increased risk for lead poisoning because of their physiology and behavior. BLL tend to be increased during the warm months, perhaps related to increased exposure to lead in dust and soil [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/59-62\">",
"     59-62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Federal regulations in the United States permit laboratories that perform BLL testing to operate with an allowable error of &plusmn;4",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.19",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    or 10 percent, whichever is greater [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/9\">",
"     9",
"    </a>",
"    ]. Thus, a laboratory that meets proficiency standards may report an actual BLL of 5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.48",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    as any value ranging from 1",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    to 9",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.29 to 0.67",
"    <span class=\"nowrap\">",
"     micromol/dL).",
"    </span>",
"    Clinicians should be aware of the performance level of the laboratory they utilize, and where possible, select a laboratory with a routine performance of less than &plusmn; 2",
"    <span class=\"nowrap\">",
"     mcg/dL,",
"    </span>",
"    which is routinely achievable [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link&amp;anchor=H20#H20\">",
"     \"Childhood lead poisoning: Clinical manifestations and diagnosis\", section on 'Lead levels'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with detectable BLL &lt;5",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (0.24",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    are at risk for neurocognitive deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/63-66\">",
"     63-66",
"    </a>",
"    ]. All children should be monitored regularly for developmental and behavioral problems, no matter what their BLL [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, parents of young children should be provided with anticipatory guidance regarding potential sources of lead exposure and promotion of strategies that foster optimal development [",
"    <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/29/19928?source=see_link\">",
"     \"Developmental and behavioral screening tests in primary care\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26394?source=see_link&amp;anchor=H18501566#H18501566\">",
"     \"Developmental-behavioral surveillance and screening in primary care\", section on 'When to perform developmental-behavioral screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lead poisoning is diagnosed when the blood lead level (BLL) is greater than 5",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (0.24",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      on a venous blood sample. Early diagnosis is desirable because most of the effects of lead toxicity are irreversible. Once diagnosed, treatment depends upon the degree of the blood lead elevation and the presence of symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=see_link&amp;anchor=H12#H12\">",
"       \"Childhood lead poisoning: Clinical manifestations and diagnosis\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When indicated as presented below, chelation therapy for lead poisoning should be performed in consultation with a toxicologist or other clinician who has experience with the chelating agents (",
"      <a class=\"graphic graphic_table graphicRef59995 graphicRef71832 \" href=\"UTD.htm?6/24/6541\">",
"       table 7A-B",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/5/21594/abstract/7\">",
"       7",
"      </a>",
"      ]. These clinicians can be found through state health department lead programs, pediatric environmental health specialty units (",
"      <a class=\"external\" href=\"file://www.aoec.org/PEHSU.htm\">",
"       www.aoec.org/PEHSU.htm",
"      </a>",
"      ), or by contacting the local poison control center (1-800-222-1222) or American Academy of Pediatrics Committee on Environmental Health. The World Health Organization provides a listing of international poison centers at its website:",
"      <a class=\"external\" href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\">",
"       www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Severe lead intoxication is defined by a venous BLL of &ge;70",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (3.38",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      or having symptoms of encephalopathy (eg, persistent vomiting, obtundation, headache, afebrile convulsions). Severe lead intoxication is a medical emergency, whether or not the child manifests symptoms of lead poisoning. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Severe intoxication (&ge;70 mcg/dL)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Initial treatment priorities in children with severe lead poisoning include management of seizures (",
"      <a class=\"graphic graphic_table graphicRef55368 \" href=\"UTD.htm?29/20/30029\">",
"       table 8",
"      </a>",
"      ) and establishing and maintaining urine output while avoiding excess fluid administration. Once these objectives are accomplished the lead burden should be decreased by chelation. (See",
"      <a class=\"local\" href=\"#H2692895\">",
"       'Initial management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that children with severe lead intoxication receive combined chelation therapy with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/32/26115?source=see_link\">",
"       dimercaprol",
"      </a>",
"      (also called British Anti-Lewisite [BAL]) and calcium disodium edetate (CaNa",
"      <sub>",
"       2",
"      </sub>",
"      EDTA) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Chelation should occur as part of an overall treatment plan that ensures careful monitoring of lead levels, parental education, and assurance of environmental investigation of the home (",
"      <a class=\"graphic graphic_table graphicRef52132 \" href=\"UTD.htm?28/29/29148\">",
"       table 9",
"      </a>",
"      ). Additional chelation therapy is frequently required because of mobilization of lead from large stores sequestered in the bone. (See",
"      <a class=\"local\" href=\"#H2692895\">",
"       'Initial management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Initial chelation therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2693119\">",
"       'Additional chelation therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Moderate lead intoxication is defined by a venous BLL 45 to 69",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (2.17 and 3.33",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      and the absence of symptoms related to lead toxicity. Chelation is indicated for children with BLLs in this range. We suggest that children with moderate lead intoxication receive chelation with meso-2,3-",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/22/8548?source=see_link\">",
"       dimercaptosuccinic acid",
"      </a>",
"      (DMSA, Succimer&reg;) (",
"      <a class=\"graphic graphic_table graphicRef58045 \" href=\"UTD.htm?30/21/31068\">",
"       table 10",
"      </a>",
"      ) rather than CaNa",
"      <sub>",
"       2",
"      </sub>",
"      EDTA until the blood lead level is &lt;45",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (2.17",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For children who cannot adhere to treatment with DMSA or have contraindications to its use, continuous infusion of CaNa",
"      <sub>",
"       2",
"      </sub>",
"      EDTA may be used.",
"     </li>",
"     <li>",
"      Chelation therapy for moderate lead intoxication should occur as part of an overall treatment plan that ensures careful monitoring of lead levels, parental education, and assurance of environmental investigation of the home (",
"      <a class=\"graphic graphic_table graphicRef73145 \" href=\"UTD.htm?23/22/23915\">",
"       table 11",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Moderate intoxication (45 to 69 mcg/dL)'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Chelation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with detectable blood lead levels (BLLs) &le;44",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (2.12",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      have mild lead intoxication. Management depends upon the degree of blood lead elevation as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Children with BLLs of 20 to 44",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (0.96 and 2.12",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      should receive parent education, nutritional counseling, and notification of public health authorities for environmental surveillance and remediation (",
"      <a class=\"graphic graphic_table graphicRef61373 \" href=\"UTD.htm?25/58/26539\">",
"       table 13",
"      </a>",
"      ). Removal of the family from the source of lead is critical in preventing further exposure (",
"      <a class=\"graphic graphic_table graphicRef56262 \" href=\"UTD.htm?1/30/1515\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       '20 to 44 mcg/dL'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that children with blood lead levels in the range of 20 to 44",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (0.96 to 2.12",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      <strong>",
"       not",
"      </strong>",
"      receive chelation therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Although this regimen has been shown to reduce BLL, evidence indicates that chelating children in this range of BLLs does",
"      <strong>",
"       not",
"      </strong>",
"      improve clinically important outcomes such as behavior or intelligence . (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Chelation therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with BLLs of 5 to 19",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (0.24 to 0.91",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      should undergo a confirmatory venous lead level within one month. Once an elevated BLL is confirmed, the appropriate public health authorities should be notified so that environmental surveillance and abatement can occur. Educational and nutritional counseling should be provided to the family (",
"      <a class=\"graphic graphic_table graphicRef76197 \" href=\"UTD.htm?0/30/492\">",
"       table 12",
"      </a>",
"      ). The clinician should ensure ongoing monitoring of BLLs and screening of other children in the household (",
"      <a class=\"graphic graphic_table graphicRef70588 \" href=\"UTD.htm?1/24/1419\">",
"       table 15",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef53709 \" href=\"UTD.htm?5/39/5755\">",
"       table 14",
"      </a>",
"      ). Chelation is not advised. (See",
"      <a class=\"local\" href=\"#H24\">",
"       '15 to 19 mcg/dL'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H25\">",
"       '5 to 14 mcg/dL'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with BLL approaching 5",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (0.24",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      may warrant monitoring of BLL more often than once per year, particularly if they are younger than two years of age, were tested before the onset of warm weather, are at high risk for lead exposure, or exposure sources have changed.",
"     </li>",
"     <li>",
"      Children with detectable BLL &lt;5",
"      <span class=\"nowrap\">",
"       mcg/dL",
"      </span>",
"      (0.24",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"      are at risk for neurocognitive deficits. Parents of young children should be provided with anticipatory guidance regarding potential sources of lead exposure and promotion of strategies that foster optimal development. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Detectable BLL &lt;5 mcg/dL'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/1\">",
"      Chisolm JJ Jr. The use of chelating agents in the treatment of acute and chronic lead intoxication in childhood. J Pediatr 1968; 73:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/2\">",
"      Rogan WJ, Dietrich KN, Ware JH, et al. The effect of chelation therapy with succimer on neuropsychological development in children exposed to lead. N Engl J Med 2001; 344:1421.",
"     </a>",
"    </li>",
"    <li>",
"     Ettinger, AS, Gurthrie Wengrovitz, A (Eds). Guidelines for the identification and management of lead exposure in pregnant and lactating women. National Center for Environmental Health/Agency for Toxic Substances and Disease Registry; Centers for Disease Control and Prevention, Atlanta, GA, 2010  available at file://www.cdc.gov/nceh/lead/publications/LeadandPregnancy2010.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/4\">",
"      Saxena G, Flora SJ. Lead-induced oxidative stress and hematological alterations and their response to combined administration of calcium disodium EDTA with a thiol chelator in rats. J Biochem Mol Toxicol 2004; 18:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/5\">",
"      Anand S, Pal JK. The haem-regulated eukaryotic initiation factor 2alpha kinase: a molecular indicator of lead-toxicity anaemia in rabbits. Biotechnol Appl Biochem 2002; 36:57.",
"     </a>",
"    </li>",
"    <li>",
"     Roberts JR, Reigart JR. Medical Assessment and Intervention. In: Managing Elevated Blood Lead Levels Among Young Children: Recommendations from the Advisory Committee on Childhood Lead Poisoning Prevention, Centers for Disease Control &amp; Prevention, Atlanta 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/7\">",
"      American Academy of Pediatrics Committee on Environmental Health. Lead exposure in children: prevention, detection, and management. Pediatrics 2005; 116:1036.",
"     </a>",
"    </li>",
"    <li>",
"     Bellinger D, Rappaport L. Developmental Assessment and Interventions. In: Managing Elevated Blood Lead Levels Among Young Children: Recommendations from the Advisory Committee on Childhood Lead Poisoning Prevention, Centers for Disease Control &amp; Prevention, Atlanta 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/9\">",
"      Binns HJ, Campbell C, Brown MJ, Centers for Disease Control and Prevention Advisory Committee on Childhood Lead Poisoning Prevention. Interpreting and managing blood lead levels of less than 10 microg/dL in children and reducing childhood exposure to lead: recommendations of the Centers for Disease Control and Prevention Advisory Committee on Childhood Lead Poisoning Prevention. Pediatrics 2007; 120:e1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/10\">",
"      Hammad TA, Sexton M, Langenberg P. Relationship between blood lead and dietary iron intake in preschool children. A cross-sectional study. Ann Epidemiol 1996; 6:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/11\">",
"      Campbell C, Osterhoudt KC. Prevention of childhood lead poisoning. Curr Opin Pediatr 2000; 12:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/12\">",
"      Mahaffey KR. Nutrition and lead: strategies for public health. Environ Health Perspect 1995; 103 Suppl 6:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/13\">",
"      Sargent JD. The role of nutrition in the prevention of lead poisoning in children. Pediatr Ann 1994; 23:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/14\">",
"      Ballew C, Bowman B. Recommending calcium to reduce lead toxicity in children: a critical review. Nutr Rev 2001; 59:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/15\">",
"      Kristal-Boneh E, Froom P, Yerushalmi N, et al. Effect of dietary calcium on blood lead concentrations in occupationally exposed and nonexposed workers. Am J Ind Med 1998; 34:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/16\">",
"      Wasserman G, Graziano JH, Factor-Litvak P, et al. Independent effects of lead exposure and iron deficiency anemia on developmental outcome at age 2 years. J Pediatr 1992; 121:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/17\">",
"      Bradman A, Eskenazi B, Sutton P, et al. Iron deficiency associated with higher blood lead in children living in contaminated environments. Environ Health Perspect 2001; 109:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/18\">",
"      Wright RO, Shannon MW, Wright RJ, Hu H. Association between iron deficiency and low-level lead poisoning in an urban primary care clinic. Am J Public Health 1999; 89:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/19\">",
"      Serwint JR, Damokosh AI, Berger OG, et al. No difference in iron status between children with low and moderate lead exposure. J Pediatr 1999; 135:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/20\">",
"      Ruff HA, Markowitz ME, Bijur PE, Rosen JF. Relationships among blood lead levels, iron deficiency, and cognitive development in two-year-old children. Environ Health Perspect 1996; 104:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/21\">",
"      Wasserman GA, Graziano JH, Factor-Litvak P, et al. Consequences of lead exposure and iron supplementation on childhood development at age 4 years. Neurotoxicol Teratol 1994; 16:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/22\">",
"      Wright RO. The role of iron therapy in childhood plumbism. Curr Opin Pediatr 1999; 11:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/23\">",
"      Wright RO, Tsaih SW, Schwartz J, et al. Association between iron deficiency and blood lead level in a longitudinal analysis of children followed in an urban primary care clinic. J Pediatr 2003; 142:9.",
"     </a>",
"    </li>",
"    <li>",
"     Piomelli S. Lead poisoning. In: Hematology of Infancy and Childhood, Nathan DG, Oski FA (Eds), WB Saunders, Philadelphia 1993. p.484.",
"    </li>",
"    <li>",
"     Agency for Toxic Substances and Disease Registry. Toxicology Profile for Lead. US Department for Health and Human Services, Atlanta, 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/26\">",
"      Centers for Disease Control and Prevention (CDC). Deaths associated with hypocalcemia from chelation therapy--Texas, Pennsylvania, and Oregon, 2003-2005. MMWR Morb Mortal Wkly Rep 2006; 55:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/27\">",
"      CHISOLM JJ Jr. Aminoaciduria as a manifestation of renal tubular injury in lead intoxication and a comparison with patterns of aminoaciduria seen in other diseases. J Pediatr 1962; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/28\">",
"      Perlstein, MA, Attala, R. Neurologic sequelae of plumbism in children. Clin Pediatr 1966; 5:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/29\">",
"      Janakiraman N, Seeler RA, Royal JE, Chen MF. Hemolysis during BAL chelation therapy for high blood lead levels in two G6PD deficient children. Clin Pediatr (Phila) 1978; 17:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/30\">",
"      Piomelli S, Rosen JF, Chisolm JJ Jr, Graef JW. Management of childhood lead poisoning. J Pediatr 1984; 105:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/31\">",
"      Treatment guidelines for lead exposure in children. American Academy of Pediatrics Committee on Drugs. Pediatrics 1995; 96:155.",
"     </a>",
"    </li>",
"    <li>",
"     Klaasan CD. Heavy metals and heavy metal antagonists. In: The Pharmacologic Basis of Therapeutics, 7th, Gilman AG, Goodman LS, Rall TW (Eds), MacMillan, New York 1985. p.1605.",
"    </li>",
"    <li>",
"     Osterhoudt KC, Burns-Ewald M, Shannon M, Henretig FM. Toxicologic emergencies. In: Textbook of Pediatric Emergency Medicine, 5th, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.951.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/34\">",
"      Cory-Slechta DA. Mobilization of lead over the course of DMSA chelation therapy and long-term efficacy. J Pharmacol Exp Ther 1988; 246:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/35\">",
"      Rahmani R, Dan M, Fishel B, et al. [Fatal encephalopathy due to chronic lead poisoning]. Harefuah 1977; 93:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/36\">",
"      Markowitz ME, Rosen JF. Assessment of lead stores in children: validation of an 8-hour CaNa2EDTA provocative test. J Pediatr 1984; 104:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/37\">",
"      Liebelt EL, Shannon MW. Oral chelators for childhood lead poisoning. Pediatr Ann 1994; 23:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/38\">",
"      Graziano JH, Lolacono NJ, Moulton T, et al. Controlled study of meso-2,3-dimercaptosuccinic acid for the management of childhood lead intoxication. J Pediatr 1992; 120:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/39\">",
"      Kassner J, Shannon M, Graef J. Role of forced diuresis on urinary lead excretion after the ethylenediaminetetraacetic acid mobilization test. J Pediatr 1990; 117:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/40\">",
"      Markowitz ME, Rosen JF. Need for the lead mobilization test in children with lead poisoning. J Pediatr 1991; 119:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/41\">",
"      Friedheim E, Graziano JH, Popovac D, et al. Treatment of lead poisoning by 2,3-dimercaptosuccinic acid. Lancet 1978; 2:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/42\">",
"      Graziano JH, Lolacono NJ, Meyer P. Dose-response study of oral 2,3-dimercaptosuccinic acid in children with elevated blood lead concentrations. J Pediatr 1988; 113:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/43\">",
"      Aposhian HV, Aposhian MM. meso-2,3-Dimercaptosuccinic acid: chemical, pharmacological and toxicological properties of an orally effective metal chelating agent. Annu Rev Pharmacol Toxicol 1990; 30:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/44\">",
"      Mann KV, Travers JD. Succimer, an oral lead chelator. Clin Pharm 1991; 10:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/45\">",
"      Gerr F, Frumkin H, Hodgins P. Hemolytic anemia following succimer administration in a glucose-6-phosphate dehydrogenase deficient patient. J Toxicol Clin Toxicol 1994; 32:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/46\">",
"      Rhoads GG, Rogan WJ. Treatment of lead-exposed children. Pediatrics 1996; 98:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/47\">",
"      Graziano JH, Siris ES, LoIacono N, et al. 2,3-Dimercaptosuccinic acid as an antidote for lead intoxication. Clin Pharmacol Ther 1985; 37:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/48\">",
"      Chisolm JJ Jr. Safety and efficacy of meso-2,3-dimercaptosuccinic acid (DMSA) in children with elevated blood lead concentrations. J Toxicol Clin Toxicol 2000; 38:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/49\">",
"      WALSHE JM. Penicillamine, a new oral therapy for Wilson's disease. Am J Med 1956; 21:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/50\">",
"      Shannon M, Graef J, Lovejoy FH Jr. Efficacy and toxicity of D-penicillamine in low-level lead poisoning. J Pediatr 1988; 112:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/51\">",
"      Sachs HK, Blanksma LA, Murray EF, O'Connell MJ. Ambulatory treatment of lead poisoning: report of 1,155 cases. Pediatrics 1970; 46:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/52\">",
"      Markowitz ME, Bijur PE, Ruff H, Rosen JF. Effects of calcium disodium versenate (CaNa2EDTA) chelation in moderate childhood lead poisoning. Pediatrics 1993; 92:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/53\">",
"      Chisolm JJ Jr. The road to primary prevention of lead toxicity in children. Pediatrics 2001; 107:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/54\">",
"      O'Connor ME, Rich D. Children with moderately elevated lead levels: is chelation with DMSA helpful? Clin Pediatr (Phila) 1999; 38:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/55\">",
"      Liebelt EL, Shannon M, Graef JW. Efficacy of oral meso-2,3-dimercaptosuccinic acid therapy for low-level childhood plumbism. J Pediatr 1994; 124:313.",
"     </a>",
"    </li>",
"    <li>",
"     Roberts JR, Reigart JR. Chapter 3. Medical Assessment and Interventions. Managing elevated blood lead levels among young children: recommendations from the advisory committee on childhood lead poisoning prevention. Centers for Disease Control and Prevention; US Department of Health and Human Services, Atlanta, GA 2002. file://www.cdc.gov/nceh/lead/CaseManagement/caseManage_main.htm (Accessed on July 31, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/57\">",
"      Dietrich KN, Ware JH, Salganik M, et al. Effect of chelation therapy on the neuropsychological and behavioral development of lead-exposed children after school entry. Pediatrics 2004; 114:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/58\">",
"      Shannon M, Woolf A, Binns H. Chelation therapy in children exposed to lead. N Engl J Med 2001; 345:1212.",
"     </a>",
"    </li>",
"    <li>",
"     US Environmental Protection Agency. Seasonal trends in blood lead levels in Milwaukee: Statistical Methodology. Publication EPA 747-R-95-010, US Environmental Protection Agency, Washington, DC 1996.",
"    </li>",
"    <li>",
"     US Environmental Protection Agency. Seasonal rhythms of blood lead levels: Boston 1979-1983. EPA 747-R-94-003, Protection Agency; Washington, DC 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/61\">",
"      Yiin LM, Rhoads GG, Lioy PJ. Seasonal influences on childhood lead exposure. Environ Health Perspect 2000; 108:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/62\">",
"      Laidlaw MA, Mielke HW, Filippelli GM, et al. Seasonality and children's blood lead levels: developing a predictive model using climatic variables and blood lead data from Indianapolis, Indiana, Syracuse, New York, and New Orleans, Louisiana (USA). Environ Health Perspect 2005; 113:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/63\">",
"      Lanphear BP, Dietrich K, Auinger P, Cox C. Cognitive deficits associated with blood lead concentrations &lt;10 microg/dL in US children and adolescents. Public Health Rep 2000; 115:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/64\">",
"      Canfield RL, Henderson CR Jr, Cory-Slechta DA, et al. Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter. N Engl J Med 2003; 348:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/65\">",
"      Lanphear BP, Hornung R, Khoury J, et al. Low-level environmental lead exposure and children's intellectual function: an international pooled analysis. Environ Health Perspect 2005; 113:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/5/21594/abstract/66\">",
"      T&eacute;llez-Rojo MM, Bellinger DC, Arroyo-Quiroz C, et al. Longitudinal associations between blood lead concentrations lower than 10 microg/dL and neurobehavioral development in environmentally exposed children in Mexico City. Pediatrics 2006; 118:e323.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6494 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-AB2AAAC1E4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_5_21594=[""].join("\n");
var outline_f21_5_21594=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PRIMARY PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1099602\">",
"      Prenatal exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1099610\">",
"      Breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1099860\">",
"      Environmental exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nutrition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Iron supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SEVERE INTOXICATION (&ge;70 mcg/dL)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2692895\">",
"      Initial management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Initial chelation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Dimercaprol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Calcium disodium EDTA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2693119\">",
"      Additional chelation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Disposition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MODERATE INTOXICATION (45 TO 69 mcg/dL)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Chelation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - CaNa2EDTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H22467417\">",
"      EDTA mobilization test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - DMSA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1655234\">",
"      - D-penicillamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      MILD INTOXICATION (&le;44 mcg/dL)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      20 to 44 mcg/dL",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Chelation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      15 to 19 mcg/dL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      5 to 14 mcg/dL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Detectable BLL &lt;5 mcg/dL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6494\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6494|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?10/14/10464\" title=\"diagnostic image 1\">",
"      Lead flecks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6494|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/29/33236\" title=\"figure 1\">",
"      Summary of public health actions based on blood lead levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6494|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/30/1515\" title=\"table 1\">",
"      Reducing pediatric lead exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/57/8092\" title=\"table 2\">",
"      Initial blood lead testing of neonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/61/989\" title=\"table 3\">",
"      Management of pediatric lead poisoning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/21/33116\" title=\"table 4\">",
"      Increase in infant blood lead concentration from breast milk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/13/27868\" title=\"table 5\">",
"      Follow-up blood lead testing in infants under 6 months",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/13/38107\" title=\"table 6\">",
"      Reducing absorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/59/20411\" title=\"table 7A\">",
"      Lead chelating agents A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/55/15228\" title=\"table 7B\">",
"      Lead chelating agents B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/20/30029\" title=\"table 8\">",
"      Management of status epilepticus in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/29/29148\" title=\"table 9\">",
"      Treatment for severe pediatric lead poisoning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/21/31068\" title=\"table 10\">",
"      DMSA pediatric lead treatment protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/22/23915\" title=\"table 11\">",
"      Treatment for moderate pediatric lead poisoning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/30/492\" title=\"table 12\">",
"      Reducing lead absorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/58/26539\" title=\"table 13\">",
"      Treatment for mild lead intoxication - lead levels 20 to 44",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/39/5755\" title=\"table 14\">",
"      Treatment for mild pediatric lead poisoning - level 15 to 19",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/24/1419\" title=\"table 15\">",
"      Treatment for mild pediatric lead poisoning - level 5 to 14",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/15/9463?source=related_link\" title=\"calculator 1\">",
"      Calculator: Blood pressure percentiles for boys (2 to 17 years)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/33/9751?source=related_link\" title=\"calculator 2\">",
"      Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/39/12922?source=related_link\">",
"      Adult lead poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/24/394?source=related_link\">",
"      Childhood lead poisoning: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/47/11001?source=related_link\">",
"      Childhood lead poisoning: Exposure and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=related_link\">",
"      Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37913?source=related_link\">",
"      Decontamination of poisoned children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/29/19928?source=related_link\">",
"      Developmental and behavioral screening tests in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26394?source=related_link\">",
"      Developmental-behavioral surveillance and screening in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=related_link\">",
"      Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13289?source=related_link\">",
"      Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22826?source=related_link\">",
"      Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/1/25625?source=related_link\">",
"      Lumbar puncture: Indications, contraindications, technique, and complications in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/20/6470?source=related_link\">",
"      Maintenance fluid therapy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30505?source=related_link\">",
"      Management of status epilepticus in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_5_21595="Results Roche trial NO16966";
var content_f21_5_21595=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F72526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F72526&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Results of Roche trial NO 16966",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Treatment group",
"      </td>",
"      <td class=\"subtitle1\">",
"       FOLFOX + placebo",
"      </td>",
"      <td class=\"subtitle1\">",
"       XELOX + placebo",
"      </td>",
"      <td class=\"subtitle1\">",
"       FOLFOX + bevacizumab",
"      </td>",
"      <td class=\"subtitle1\">",
"       XELOX + bevacizumab",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       N",
"      </td>",
"      <td>",
"       351",
"      </td>",
"      <td>",
"       350",
"      </td>",
"      <td>",
"       349",
"      </td>",
"      <td>",
"       350",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\" colspan=\"2\">",
"       Both placebo groups",
"      </td>",
"      <td class=\"subtitle2\" colspan=\"2\">",
"       Both bevacizumab groups",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       PFS, median (months)",
"      </td>",
"      <td colspan=\"2\">",
"       8.0",
"      </td>",
"      <td colspan=\"2\">",
"       9.4 (p = .0023)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       OS, median (months)",
"      </td>",
"      <td colspan=\"2\">",
"       19.9",
"      </td>",
"      <td colspan=\"2\">",
"       21.3",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Response rate, percent",
"      </td>",
"      <td colspan=\"2\">",
"       38 (49)*",
"      </td>",
"      <td colspan=\"2\">",
"       38 (47)*",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PFS: progression free survival; FOLFOX: oxaliplatin, 5FU, leucovorin; XELOX: capecitabine + oxaliplatin; OS: overall survival.",
"     <br>",
"      * Objective response rates according to independent review committee, followed by investigator-reported rates, in parentheses.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Saltz, LB, et al. J Clin Oncol 2008; 26:2013.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_5_21595=[""].join("\n");
var outline_f21_5_21595=null;
var title_f21_5_21596="Judging quality websites";
var content_f21_5_21596=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F77186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F77186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    How to judge the quality of a Web site",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Who produced the site?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Is the site by a well-known and respected organization or recommended by someone you trust?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Purpose of the site",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Who is the intended audience, and how was the site developed?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Funding sources",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All",
"sites are funded by someone. Do the producers of the site have a",
"financial conflict of interest that might bias the information?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Date",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The evidence base for health care is continually changing. The site should state when it was last updated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        How the information is written",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does the written presentation seem careful and balanced?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Evidence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Do",
"the authors base their recommendations on evidence, explicitly",
"identified (usually as a citation to a published research article)?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Personal experiences",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sharing",
"personal experiences can be useful to patients but should be clearly",
"marked as such and not be the only rationale for recommendations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Communication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        It should be possible to communicate with those responsible for the site.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Links",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If the site is linked to other sites, it should explain how the others were chosen.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Disclaimers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sites",
"should state the limitations of what they have offered, such as",
"conflicts of interest and that the information they provide does not",
"replace contact with a physician.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Interactive facilities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If email lists, bulletin boards, or chat rooms are offered, users should be wary of who the participants are.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from www.judgehealth.org.uk",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_5_21596=[""].join("\n");
var outline_f21_5_21596=null;
var title_f21_5_21597="Generalized cutaneous blistering disorders";
var content_f21_5_21597=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examples of generalized cutaneous blistering disorders",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pathology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Laboratory findings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bullous pemphigoid",
"       </td>",
"       <td>",
"        Tense bullae, urticarial papules and plaques; mucous membrane involvement in up to 30 percent of cases",
"       </td>",
"       <td>",
"        H&amp;E: subepidermal blister with eosinophils; DIF: linear basement membrane zone deposition of IgG and C3",
"       </td>",
"       <td>",
"        IIF: IgG anti-BP antigen 180 and 230",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Pemphigus vulgaris",
"       </td>",
"       <td>",
"        Flaccid vesicles and erosions on skin and mucous membranes, desquamative gingivitis; scalp involvement common",
"       </td>",
"       <td>",
"        H&amp;E: intraepidermal blister formation, acantholysis; DIF: intercellular epidermal IgG deposition involving lower epidermis",
"       </td>",
"       <td>",
"        IIF: intercellular IgG staining of skin substrate, anti- desmoglein 3 IgG",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Pemphigus foliaceus",
"       </td>",
"       <td>",
"        Flaccid vesicles and erosions; no mucous membrane involvement",
"       </td>",
"       <td>",
"        H&amp;E: intraepidermal vesicle and acantholysis (blister is subcorneal); DIF: intercellular IgG deposition in upper epidermis",
"       </td>",
"       <td>",
"        IIF: intercellular IgG staining of skin substrate; anti-desmoglein 1 IgG",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Stevens-Johnson syndrome and toxic epidermal necrolysis",
"       </td>",
"       <td>",
"        Exudative erosions of lips, oral mucosa, eyes, genital mucosa; targetoid papulovesicles of skin, skin sloughing, and skin pain",
"       </td>",
"       <td>",
"        H&amp;E: vacuolar interface dermatitis or epidermal necrosis",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Paraneoplastic pemphigus",
"       </td>",
"       <td>",
"        Targetoid papulovesicles, erythema multiforme like cutaneous lesions; exudative erosions of lips, oral mucosal, eyes, genital mucosa",
"       </td>",
"       <td>",
"        H&amp;E: mixed histology with overlapping features of pemphigus vulgaris, erythema multiforme, and lichen planus; DIF: staining of transitional epithelium (rodent bladder)",
"       </td>",
"       <td>",
"        IIF: antibodies to multiple antigens (desmoplakins, desmogleins, bullous pemphigoid antigen 1, etc)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Dermatitis herpetiformis",
"       </td>",
"       <td>",
"        Grouped papulovesicles on elbows, knees, buttocks, scalp; intense pruritus",
"       </td>",
"       <td>",
"        H&amp;E: subepidermal blister with neutrophils in dermal papillae; DIF: IgA in dermal papillae",
"       </td>",
"       <td>",
"        Elevation of serum IgA anti-epidermal transglutaminase antibodies",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Disseminated HSV/VZV",
"       </td>",
"       <td>",
"        Fever, hepatitis, CNS involvement; grouped and scattered monomorphic vesicles",
"       </td>",
"       <td>",
"        Intraepidermal blister; ballooning of keratinocyte cytoplasm and margination of chromatin to form intranuclear inclusion bodies; mixed inflammatory infiltrate",
"       </td>",
"       <td>",
"        Viral culture, Tzanck smear, DFA, PCR",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Linear IgA bullous dermatosis",
"       </td>",
"       <td>",
"        Annular or arcuate vesicles and bullae; can have mucous membrane involvement",
"       </td>",
"       <td>",
"        H&amp;E: subepidermal blister with predominance of neutrophils; DIF: linear IgA along basement membrane zone",
"       </td>",
"       <td>",
"        IIF: circulating IgA anti-basement membrane antibodies",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Epidermolysis bullosa acquisita",
"       </td>",
"       <td>",
"        Tense blisters and erosions with scarring and milia",
"       </td>",
"       <td>",
"        H&amp;E: subepidermal blisters with mixed inflammatory infiltrate of neutrophils, eosinophils, lymphocytes; DIF: broad, linear IgG along the basement membrane zone; in salt split skin, IgG stains dermal side",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Staphylococcal scalded skin syndrome",
"       </td>",
"       <td>",
"        Widespread erythema, flaccid bullae, erosions, desquamation of skin",
"       </td>",
"       <td>",
"        H&amp;E: subcorneal blister (split within the granular cell layer)",
"       </td>",
"       <td>",
"        Toxin-mediated condition; culture often negative at sites of blistering",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Bullous systemic lupus erythematosus",
"       </td>",
"       <td>",
"        Other skin findings of SLE: nail fold telangiectasias, malar erythema, discoid or subacute cutaneous lupus",
"       </td>",
"       <td>",
"        H&amp;E: similar to dermatitis herpetiformis DIF: mixed features similar to bullous pemphigoid and lupus",
"       </td>",
"       <td>",
"        Antinuclear antibody test",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     H&amp;E: hematoxylin and eosin pathology stain; DIF: direct immunofluorescence; IIF: indirect immunofluorescence; HSV: herpes simplex virus; VZV: varicella zoster; virusDFA: direct fluorescent antibody test; PCR: polymerase chain reaction; CNS: central nervous system; SLE: systemic lupus erythematosus.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_5_21597=[""].join("\n");
var outline_f21_5_21597=null;
var title_f21_5_21598="Pravastatin prevents CHD";
var content_f21_5_21598=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59494&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pravastatin for primary prevention of coronary heart disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 477px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier analysis of the efficacy of pravastatin versus placebo in 6595 middle-aged men with hypercholesterolemia (mean serum cholesterol concentration 272 mg/dL [7.0 mmol/L]). At the end of the study, the men treated with pravastatin (red line) had a 32 percent reduction in definite nonfatal myocardial infarction (MI) or death from coronary heart disease (CHD, top panel) and a 22 percent reduction in death from any cause (lower panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Shepherd J, Cobbe SM, Ford I, et al. N Engl J Med 1995; 333:1301.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_5_21598=[""].join("\n");
var outline_f21_5_21598=null;
var title_f21_5_21599="Positive patch test";
var content_f21_5_21599=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74380&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Positive patch tests",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 403px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Positive epicutaneous (patch) tests on the back of a patient with allergic contact dermatitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William L Weston, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_5_21599=[""].join("\n");
var outline_f21_5_21599=null;
